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Abstract 
This thesis investigates the genesis, knowledge and practice of paediatric bipolar 
disorder (PBD) in the US and England. Using a social representations framework, the 
thesis expands the socio-cultural psychology of medicalisation to elucidate how an 
emergent condition moves across cultures through the interaction, transmission and 
application of multiple forms of knowledge. The research design was comparative and 
multi-method, comprising three empirical studies, each studying key actors in the 
diagnostic process. Study 1 examined the ‘voice’ of the pharmaceutical industry 
incorporating analysis of de-classified internal industry court documents, marketing 
plans, and pharmaceutical advertisements. Study 2 drew on eighteen in-depth interviews 
with clinicians and study 3 was drawn from twenty in-depth interviews with parents, 
both in the US and England. Results show that the pharmaceutical industry uses 
unstable representations of PBD, and childhood itself, to expand market possibilities of 
what mental illness in a child could look like. Clinicians in both contexts struggle with 
pressures to be certain in the face of something unstable, anchoring representations of 
PBD in what they already know. For American clinicians, parents are allies shaping 
PBD as distinct from adult bipolar while the child is in need of early diagnosis and 
management; English clinicians approach PBD as adult bipolar and place the child in 
context, keeping the diagnosis rare. Parents in both the US and England feel frustrated 
and cast aside; American parents channel this into a sense of agency, developing 
‘experiential expertise’, while in England, parents position themselves as amateurs 
,confronting  wider hierarchies within which they feel helpless. Overall, the thesis 
concludes that diagnostic practices are driven by processes of social representation and 
social influence: definitions of PBD, and its emergence as a diagnosis, are extrinsic to 
the condition itself, forged instead at the meeting point in which actors, cultures and 
multiple systems of knowledge and experience interact.  
 
 
 
 
 
 
 
4 
Acknowledgements 
It’s hard to believe I’ve finally reached the point where I’m writing the 
acknowledgements for my PhD thesis, but here I am, and with many people to thank 
for making this four-year journey possible. 
 
First and foremost I would like to thank my supervisor, Professor Sandra 
Jovchelovitch, for taking me on as a student and giving me the confidence to develop 
intellectually. Her wisdom, guidance, and belief in the research have been an 
indispensable part of this experience. I have learned so much from our conversations, 
and those within her lab, which have shaped not only this PhD, but the world outside 
of academia as well. To my Jovchelovitch lab-mates: Natalia Concha, Maria-Cecilia 
Dedios Sanguineti, Sandra Obrodovic and Jacqueline Priego- Hernandez, thank you 
also for your support and interesting discussion over the years…. From Latin-American 
mythology to dialogical methods and back again in one conversation! It was an honor 
to be part of such an engaged group. 
 
I would also like to thank Dr. Alex Gillespie for helping to clarify direction in the early 
days, and providing initial feedback that was kept on board throughout the research 
process. To Professor Cathy Campbell for being so enthusiastic and passionate about 
mental health research, and providing inspiration through the sharing of articles and 
opportunities that fed into the work presented here. To other LSE department 
members: Saadi Lahlou for heading up the PhD students for much of my time in the 
department, and holding us up to a standard. To Steve Bennett, and LSE IT services 
for having such patience. To Daniel Linehan, Terri-Ann Fairclough, Jacqueline Crane 
for being so ready and willing to help with issues big and small (and of course extra 
sandwiches!).  
 
This process has not always been easy, and a massive thank you goes out to my friends 
both here and across the pond who have made it infinitely easier, with a good laugh, a 
night out, or a chat to keep things in perspective: To Kim Sullivan, Paula Bronson, 
 
 
 
 
5 
Joanna Stronach, Marianne Westphal Vincent, Jill Van Buren, Sara Archambault, Gavin 
Hesketh, Maude, Laura Sommerville, Dan Holmes, Julie Bennett, Geetha Reddy, Cathy 
Nicholson, Sara Belton, Jacob Metz, Helen Green, and to Clare Coultas for being such 
a star and top-notch desk-mate/co-conspirator/ choir buddy/all around ace friend. To 
those fellow-PhD students not mentioned here who made the last four years such an 
adventure-I feel lucky to have been part of such a supportive group.  
 
I want to extend an extra special debt of thanks to the families and clinicians who made 
this research possible.  Their willingness and openness to share their stories and 
experiences about a difficult topic was the foundation for this project. I learned so 
much from reflecting on what they have been through. And to Dr. Anthony James who 
provided help and support in contacting parents in England, I am incredibly grateful 
and appreciative of all your help. 
 
To Si for being so proud and such an incredible source of support, especially in this 
final stretch.  Your humour, insight, good conversation and love of good, long wanders 
around London and beyond, kept me going and kept the more difficult moments in 
perspective.  
 
And finally, to my family who has always been so supportive of whatever it is I’ve done, 
and provided such great reasons to come back home as often as possible: Mom, Dad, 
John, Sherry, Dawn, Liam, Cian, Shannon, Joanne, Uncle Tom and Elizabeth, and a 
special dedication to  brother Tom. Thank you, thank you thank you.  
  
 
 
 
 
6 
Table of Contents 
Declaration ......................................................................................................... 2 
Abstract .............................................................................................................. 3 
Acknowledgements ............................................................................................. 4 
List of figures and tables .................................................................................... 11 
Acronyms .......................................................................................................... 12 
1. Outlining the problem: The birth of a diagnosis .......................................... 13 
1.1 Introduction ........................................................................................................... 13 
1.2 A brief history of pediatric bipolar disorder ............................................................ 16 
1.3 The DSM and ICD as cultural artefacts .................................................................... 24 
1.4 PBD in the public sphere: The Bipolar Child, social knowledge and diagnostic 
legitimacy ........................................................................................................... 27 
1.5 Conclusion. ............................................................................................................ 33 
2. Theoretical framework: the acquisition and transmission of medical 
knowledge ............................................................................................. 38 
2.1 Introduction ........................................................................................................... 38 
2.2 The development and construction of psychiatric knowledge................................. 39 
2.2.1 Expanding diagnostic categories into the realm of the child .................................. 44 
2.3 Social representations theory as a framework to explore the genesis of a new 
diagnostic category ............................................................................................. 49 
2.3.1 Making the unfamiliar familiar ............................................................................... 52 
2.4 Encountering the Knowledge of Others .................................................................. 55 
2.4.1 Recognition and perspective taking in knowledge encounters ............................... 59 
2.5 Dialogicality ........................................................................................................... 61 
2.5.1 Modalities of social influence .................................................................................. 65 
2.6 Conclusion. ............................................................................................................ 71 
3. Research design and methodology ............................................................. 75 
3.1 Introduction ........................................................................................................... 75 
3.2 Research contexts .................................................................................................. 78 
3.3 Study 1-The ‘voice’ of the Pharmaceutical industry ................................................ 81 
3.3.1 Internal pharmaceutical industry documents ......................................................... 82 
3.3.2 Pharmaceutical drug advertisements ..................................................................... 83 
3.4 Study 2-Clinicians in the US and England ................................................................ 84 
 
 
 
 
7 
3.4.1 Participants ............................................................................................................. 85 
3.4.2 Interview protocol ................................................................................................... 87 
3.5 Study 3- Parents in the US and England .................................................................. 87 
3.5.1 Participants ............................................................................................................. 88 
3.5.2 Interview protocol ................................................................................................... 89 
3.6 Analysis of data ...................................................................................................... 90 
3.6.1 Internal pharmaceutical industry documents ......................................................... 91 
3.6.2 Pharmaceutical drug advertisements ..................................................................... 93 
3.6.3 Interviews with clinicians and parents .................................................................... 95 
3.7 Ethical considerations ............................................................................................ 99 
4. Pharmaceutical marketing practices and the expansion of a diagnostic 
category ............................................................................................... 100 
4.1 Introduction ......................................................................................................... 100 
4.2 The pharmaceutical industry and the genesis of a diagnosis ................................. 101 
4.2.1 The US as compared to the UK .............................................................................. 103 
4.3 The ‘voice’ of pharma: analysis of internal documents ......................................... 105 
4.4 The organization as ‘Self’ in industry documents .................................................. 105 
4.4.1 Economic pressure ................................................................................................ 105 
4.4.2 Indirect marketing practices to ‘get the word out’ about PBD ............................. 108 
4.5 Competitors ......................................................................................................... 109 
4.5.1 Accommodation of a persistent threat ................................................................. 109 
4.5.2 Need for differentiation from competition ........................................................... 111 
4.6 Industry alliance with clinicians ............................................................................ 113 
4.6.1 Essential to have on board as ‘opinion leaders’ for wider validation of PBD ....... 113 
4.6.2 Responsible for knowing how best to diagnose and treat PBD ............................ 115 
4.7 The Child… ........................................................................................................... 117 
4.7.1 Unmet need and opportunity ................................................................................ 117 
4.7.2 Suffering from a debilitating “constellation of diseases” ..................................... 118 
4.8 Pharmaceutical advertising as external manifestation of industry behaviour ........ 120 
4.8.1 Analysis of advertisements ................................................................................... 121 
4.8.2 ADHD medications ................................................................................................ 121 
4.8.3 Risperdal ............................................................................................................... 123 
4.8.4 Seroquel ................................................................................................................ 125 
4.8.5 Fact versus narrative in pharmaceutical advertising ............................................ 126 
4.9 Discussion. ........................................................................................................... 129 
5. Clinical representations of PBD in the US and England .............................. 135 
5.1 Introduction ......................................................................................................... 135 
5.2 Analytic procedures and findings .......................................................................... 136 
5.3 Reflexive professional Self among colleagues ....................................................... 139 
              American Clinicians .............................................................................................. 140 
5.3.1 Uncertainty alongside increasing recognition ...................................................... 140 
 
 
 
 
8 
5.3.2 Career development and expertise ....................................................................... 142 
              English Clinicians .................................................................................................. 145 
5.3.3 Interdependence and cautious, reflective expertise ............................................. 145 
5.3.4 Independence as positioning in relation to American colleagues ......................... 147 
5.4 Parents…… ........................................................................................................... 149 
              American Clinicians .............................................................................................. 150 
5.4.1 Alliance with parents as co-constructors of knowledge ....................................... 150 
5.4.2 Parent as voice for the child .................................................................................. 151 
5.4.3 Parents as victims ‘held hostage’ to PBD .............................................................. 152 
              English Clinicians .................................................................................................. 154 
5.4.4 Parents as knowledge seekers .............................................................................. 154 
5.4.5 Alignment of parents in dyad with child separate from clinician ......................... 156 
5.5 The pharmaceutical industry ................................................................................ 157 
              American Clinicians .............................................................................................. 158 
5.5.1 Subjective values encounter professional reality .................................................. 158 
              English Clinicians .................................................................................................. 160 
5.5.2 Encroaching threat of vested interest ................................................................... 160 
5.5.3 Trusting the familiar, resisting the unfamiliar ...................................................... 162 
5.6 The child…. ........................................................................................................... 164 
              American Clinicians .............................................................................................. 164 
5.6.1 The child as a cluster of symptoms ....................................................................... 164 
5.6.2 At risk and in need of early intervention and treatment....................................... 166 
              English Clinicians .................................................................................................. 167 
5.6.3 The child as part of a wider social context ............................................................ 167 
5.6.4 PBD not distinct from adult bipolar ...................................................................... 168 
5.6.5 Giving the young person a voice ........................................................................... 169 
5.7 Discussion. ........................................................................................................... 171 
6. Parental representations of PBD in the US and England ............................ 176 
6.1 Introduction ......................................................................................................... 176 
6.2 Analytic procedures and findings .......................................................................... 177 
6.3 Position of Parental Self ....................................................................................... 180 
              American parents ................................................................................................. 180 
6.3.1 Us v. Them: valuing experiential knowledge as expertise .................................... 180 
6.3.2 Proactive advocate wanting what’s best for the child .......................................... 183 
              English parents ..................................................................................................... 184 
6.3.3 Feeling like ‘amateurs’ .......................................................................................... 184 
6.3.4 Ill- informed and cast aside ................................................................................... 186 
6.4 The Child… ........................................................................................................... 188 
              American parents ................................................................................................. 188 
6.4.1 True nature of child obscured by diagnosis .......................................................... 188 
6.4.2 Unpredictability and control ................................................................................. 189 
6.4.3 Medication as an unavoidable necessity .............................................................. 190 
              English parents ..................................................................................................... 192 
 
 
 
 
9 
6.4.4 Lack of certainty over what is normal ................................................................... 192 
6.4.5 Social pressures as triggers ................................................................................... 194 
6.5 Clinicians… ........................................................................................................... 196 
              American parents ................................................................................................. 196 
6.5.1 Feeling ignored, patronized and dismissed ........................................................... 196 
6.5.2 Questioning clinical expertise ............................................................................... 197 
6.5.3 Internalization of clinical expertise ....................................................................... 199 
              English parents ..................................................................................................... 201 
6.5.4 Disappointment and frustration ........................................................................... 201 
6.5.5 Faced with professional reluctance to diagnose ................................................... 202 
6.5.6 Perception of American practitioners as more knowledgable .............................. 205 
6.6 Other parents ....................................................................................................... 207 
6.6.1 Judgment, conflict, and a lack of support ............................................................. 207 
6.7 The School …………………………………………………………………………………. ……………………….210 
6.7.1 Collaborative alliance… ......................................................................................... 209 
6.7.2 …but also a constant struggle ............................................................................... 211 
6.8 Discussion. ........................................................................................................... 212 
7. Discussion and implications ...................................................................... 215 
7.1 Introduction ......................................................................................................... 215 
7.2 Comparison of cultural context: The US and England ............................................ 216 
7.3 The child at the heart of the debates .................................................................... 221 
7.4 Organisational, professional and ‘lay’ knowledge: pharma, clinicians, parents and the 
representations of a new diagnostic category ................................................... 224 
7.4.1 The global influence of the pharmaceutical industry ............................................ 227 
7.4.2 Representations of PBD among American clinicians ............................................ 229 
7.4.3 Representations of PBD among English clinicians ................................................ 231 
7.4.4 Representations of PBD among American parents ............................................... 232 
7.4.5 Representations of PBD among English parents ................................................... 233 
7.5 Social representations, dialogical processes and modalities of influence shape the 
emergence of PBD ............................................................................................ 234 
7.5.1 Anchoring the unfamiliar; objectification via enactment ..................................... 236 
7.5.2 Encountering multiple system of knowledge ........................................................ 237 
7.5.3 Self-Other-object interaction ................................................................................ 239 
7.5.4 Modalities of social influence ................................................................................ 240 
              Norms and frames of reference ........................................................................... 242 
              Steering psychiatric knowledge via persuasion .................................................. 244 
              Integrating the knowledge of ‘Other’ through accommodation ....................... 246 
              Confirmation through validation ........................................................................ 249 
               Vectors of social influence .................................................................................. 250 
7.6 Implications, limitations and future directions ...................................................... 255 
7.7 Study limitations and areas of further investigation.............................................. 257 
Appendices ..................................................................................................... 261 
 
 
 
 
10 
Appendix 1: NHS ethical approval .................................................................................. 261 
Appendix 2: Participant Information sheet- parents, England ........................................ 264 
Appendix 3: Recruitment letters to Young Minds- English Parents ................................. 267 
Appendix 4: Recruitment letter to MD Junction- English parents ................................... 270 
Appendix 5: Participant Information sheet- parents, United States ................................ 271 
Appendix 6: Informed consent....................................................................................... 272 
Appendix  7: Interview schedule- parents ...................................................................... 274 
Appendix 8: Interview schedule- clinicians ..................................................................... 276 
Appendix 9: Coding frame- pharmaceutical industry internal documents ...................... 278 
Appendix 10: Coding frame and sample analysis, pharmaceutical advertisement .......... 281 
Appendix 11: Coding frame, US clinicians ...................................................................... 284 
Appendix 12: Coding frame, English clinicians ................................................................ 286 
Appendix 13: Coding frame, US parents ......................................................................... 288 
Appendix 14: Coding frame, English parents .................................................................. 291 
Appendix 15: Sample excerpt, dialogical analysis ........................................................... 293 
Appendix 16 Excerpt from interview transcript .............................................................. 295 
References ...................................................................................................... 304 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
List of  figures and tables 
Figures 
 
  
Figure 2.1 Knowledge encounter feedback loop………………………………. 61 
Figure 2.2 The ‘cycle of normativity’ as described by Sammut and 
Bauer (2011)……………………………………………………………………. 
 
68 
Figure 3.1 Illustration of overall research design…………………………….. 81 
Figure 4.1 Comparison of Adderall advertisement, Journal of Child 
and Adolescent Psychiatry 2004 and Equasym 
advertisement, British Journal Psychiatry 2004………………. 
 
 
122 
Figure 4.2 Risperdal advertisement, British Journal of Psychiatry, 
2004……………………………………………………………………………….. 
 
123 
Figure 4.3 Risperdal advertisement, British Journal of Psychiatry 
1997………………………………………………………………………………… 
 
124 
Figure 4.4 Seroquel advertisement, British Journal of Psychiatry, 
2011……………………………………………………………………………….. 
 
125 
Figure 4.5 Illustration of the internal v. external voice of the 
pharmaceutical Industry…………………………………………………. 
 
129 
Figure 4.6 Zyprexa marketing strategy presentation to 
pharmaceutical sales reps……………………………………………….. 
 
130 
Figure 5.1 Illustration of themes and significant ‘Others’ among 
American and English clinicians………………………………………..  
 
138 
Figure 6.1 Themes from analysis of American parents, and position 
in relation to significant Others……………………………………….  
 
178 
Figure 6.2 Themes from analysis of English parents, and position in 
relation to significant Others…………………………………………… 
 
179 
Figure 7.1 Pharmaceutical industry anchoring of PBD……………………… 228 
Figure 7.2 Modalities of influence central to the development of 
PBD as a normative frame of reference…………………………… 
 
241 
Figure 7.3 Psychosocial model of diagnostic construction in the US 
and England…………………………………………………………………….. 
 
254 
 Tables   
Table 3.1 Internal pharmaceutical industry documents………………….. 82 
Table 3.2 Medical journals and advertisements accessed January-
June at three points in time: Total ads (unique ads)………… 
 
84 
Table 3.3 Clinician participants and codes: England and the US……… 86 
Table 7.1 The making of a diagnosis 1: Social representations of 
PBD (content)………………………………………………………………….. 
 
224 
Table 7.2 The making of a diagnosis 2: Self-Other interactions 
shaping development of representations of PBD 
(dialogical process)………………………………………………………….. 
 
 
226 
 
 
 
 
12 
Acronyms 
ADHD                Attention deficit hyperactivity disorder 
BD                      bipolar disorder  
CAMHS             Child and Adolescent Mental Health Service (UK) 
DMDD               disruptive mood dysregulation disorder 
DSM                   Diagnostic and Statistical Manual of Mental Disorders  
Dx                       abbreviation, ‘diagnosis’ 
FDA                    Food and Drug Administration (US) 
ICD                     International Classification of Diseases 
NHS                    National Health Service 
OCD                   obsessive compulsive disorder 
ODD                   oppositional defiant disorder 
PBD                    paediatric bipolar disorder 
SI                        social influence 
SRT                    social representations theory 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
1. Outlining the problem: The birth of  a diagnosis 
A word contains a means of classifying individuals, as well as implicit 
theories concerning their constitution, or the reasons for their behaving in 
one way rather than another; an almost physical image of each individual, 
which corresponds to such theories. Once this content has diffused, and 
become accepted, it constitutes an integral part of ourselves, of our 
intercourse with others, of our ways of judging them and interacting with 
them…if the word “neurosis” were to disappear and be replaced with 
“disorder”, such an event would have consequences far beyond its mere 
significance in a sentence, or in psychiatry. It is our inter-relations, and our 
collective thought, which are involved and transformed.  
                                                             (Moscovici and Duveen, 2000, p.26)  
 
1.1 Introduction 
My interest in this research emerged from a curiosity borne of my Master’s dissertation, 
where I became interested in how contested diagnoses catch on in a particular time and 
place. The Master’s was in the field of medical anthropology, and thus included a 
number of readings on the idea of culture-bound syndromes, and the myriad ways 
cultural manifestations of emotional distress were interpreted and acted upon. The 
question of how modern societies understand and respond to emotional suffering is of 
concern to many scholars across the social sciences (See Summerfield 2008; Davies 
2011) who point out the reworking of suffering and dis-ease from something once seen 
as a necessary aspect of the human experience, to something now understood at the 
level of biology and neurochemistry. Societal values shape notions of mental health and 
illness, an idea at the heart of my thesis, acting as a driver motivating my own 
examination of one such illness: paediatric bipolar disorder (PBD). A normative and 
moral component is very much alive in the debates surrounding children’s mental 
health. Conditions such as attention deficit hyperactivity disorder (ADHD), autism, and 
PBD develop in concert with, or in reaction to, prevailing moral standards, not just 
over what it means to be a child, but what it means to be a parent or clinician existing, 
making decisions and developing knowledge within a context that currently favours 
biomedical explanations. Such a context has given rise to the rapid emergence of 
childhood mental disorders and focused attention on seeking out symptoms to fit the 
diagnosis. While many receiving the diagnosis of PBD are no doubt ill, the brisk 
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increase in numbers indicates something happening on a deeper societal level.  In 
looking at conceptualisations of PBD among the pharmaceutical industry, clinicians, 
and parents it is possible to see this process in action, shaping the understandings that 
lead to establishing wider notions of the child and their behaviour, and how these 
understandings are developed. The mere fact of PBD, and the many other diagnoses of 
children’s mental illness, into the realm of academic research, clinical trial, and diagnosis 
has already changed how we think about the child as potentially disordered, lending 
credence to the idea that very young children might experience illness in ways 
previously never attributed to them. While advances in diagnosis and treatment have no 
doubt changed young lives for the better, giving children with mental illness a chance to 
engage with the world in ways that may have been previously limited, this thesis is 
concerned with the zone of ambiguity and uncertainty that remains for a child when a 
diagnosis continues to gain in popularity despite not being grounded in clinical 
agreement. 
PBD does not exist as a diagnostic category in the sense of being reified in 
either of the two diagnostic manuals used in the US and England. As this thesis will 
explore over the course of the following chapters, the diagnosis given to children is 
based on an amalgamation of other subtypes of bipolar disorder, as well as 
schizophrenia, major depression, and conduct disorders such as oppositional defiant 
disorder (ODD). However, an essential starting point for this research is to define the 
subtypes of bipolar disorder as elaborated in both the Diagnostic and Statistical Manual 
of Mental Disorders (from now on, DSM) published by the American Psychiatric 
Association, and the International Classification of Diseases (ICD-10) published by the 
World Health Organization in order to ground initial understanding of PBD. In this 
section, I will outline the diagnostic criteria for bipolar subtype I (BP I); bipolar subtype 
II (BP II) and bipolar not-Otherwise-specified (BP-NOS). 
BP I: This is more serious of the two types of bipolar due to the presence of 
manic episodes in the diagnostic criteria. For a BP I diagnosis, criteria must have been 
met for at least one manic or mixed manic/major depressive episode. A manic episode 
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is defined in the DSM as a persistent elevated, expansive, or irritable mood lasting at 
least one week (American Psychiatric Association, 2000). 
BP II: The presence of manic episodes is not required, instead the BP II 
diagnosis looks to the presence of ‘hypomania’, a less severe type of mania in which 
impairment is not significant enough to cause extensive social distress, psychosis, or the 
need for hospitalization (American Psychiatric Association, 2000). In order to assign a 
BP II diagnosis, criteria needs to have been met for at least one Major Depressive 
episode, one Hypomanic episode, and no history in the patient of manic or mixed-
episodes (American Psychiatric Association, 2000). 
BP-NOS: Bipolar disorder not otherwise specified is a diagnosis of bipolar 
disorder which doesn’t align with the other subtypes of BP I and BP II and is 
characterized by manic, hypomanic, or mixed episodes which are too short in duration 
to meet the criteria in the DSM (Towbin et al 2013). 
The 10th edition of the International Classification of Diseases (ICD-10) 
published by the World Health Organization does not categorise bipolar disorder as BP 
I, BP II and BP NOS, instead defining criteria for Bipolar Affective Disorder, Bipolar 
Affective Disorder with Current Mixed Episode, utilising separate codes for mania with 
and without psychosis, hypomania, major, mild and moderate depressive episodes 
(World Health Organization 1992). A main point of differentiation between the two lies 
in the establishment of the number of episodes needed for a diagnosis to be 
established, with the DSM stating one, and the ICD stating at least two.  Clinicians in 
the US rely on the DSM, while in England both are used in clinical practice, with the 
ICD 10 used more frequently among members of child and adolescent mental health 
service (CAMHS) teams.  
This chapter acts as a foundation for the thesis, grounding the theoretical and 
empirical chapters in what I lay out as the ‘problem’ of PBD; an unstable diagnostic 
category that remains contested even though it continues to expand, now moving 
beyond borders and slowly emerging in a cultural context, England, separate from that 
or its origin, the United States. I begin with a brief outline of the trajectory of the 
diagnosis, which necessarily incorporates a brief history of adult bipolar disorder. This 
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leads into a review of clinical literature on the development of PBD, and the position of 
the diagnostic manuals, the DSM in the US and the ICD-10 in England, as cultural 
artefacts. The final section of this chapter presents examples of PBD as it has emerged 
in both the clinical, specialist, and lay public spheres, changing perceptions of how 
children might fit the diagnosis. This examination of the movement of PBD into the 
public sphere begins with discussion of the highly influential book The Bipolar Child 
which was aimed at parents as a guide for identifying and living with a ‘dysregulated’ 
child, and moves into the articles, editorials and commentary in the popular press, 
where questions began to materialize surrounding the validity and legitimacy of the 
diagnosis and the pharmaceutical treatments being advocated. The chapter concludes 
by grounding what is presented here with the wider project as a whole. 
1.2 A brief history of paediatric bipolar disorder 
The idea that children who manifest extreme moodiness may actually suffer from a 
psychiatric disorder represents a paradigm shift in a field where this sort of behaviour 
was once characterised as a normal part of development (Post 2009). The development 
of the concept of bipolar disorder in children has come as a result of favourable 
conditions taking shape within a particular moment in history. Healy and LeNoury 
(2007) note that the diagnosis of bipolar disorder in children has been made with 
increasing frequency in North America in the last decade “despite a century of 
psychiatric consensus that manic-depressive illness rarely had its onset before 
adolescence” (p.209). This development has taken place against a background of 
“vigorous marketing of bipolar disorder in adults” which has also seen a rise in 
prevalence rates (ibid).  Our modern ideas about bipolar disorders are, as Healy (2008) 
suggests, in some ways conceptually novel, however defining aspects of what was 
commonly known as manic-depressive illness are as old as medicine itself (p.xii). Healy 
writes of mania as a “curious beast, in that the term crops up in antiquity, whereas 
schizophrenia and depression do not” and it is this long lineage of the disorder that has 
been so readily drawn upon by academics and pharmaceutical companies seeking to 
lend weight to contemporary developments around PBD (Healy 2008, xvi). A dramatic 
shift from external behaviour to internal states took place in the nineteenth century 
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marking a departure from early Greek practices basing diagnoses on visual 
manifestation of disorder, and moving towards psychiatrists using words to access 
internal mental states (Healy 2008, 18). Such trends continue in the realm of children’s 
mental illness, in which diagnosis is often based on third party verbal reports (ibid).  
Eisenberg (1986) coined the terms ‘brainless psychiatry’ and ‘mindless 
psychiatry’ in order to describe the swing in thinking from the thought style in which 
‘brain-based’ explanations of mental illness rooted in faltering neurochemistry were not 
yet at the forefront. Psychoanalysis, family psychiatry and the emergence of the 
antipsychiatry movement were at their peak, fading into the background as the move 
was made, in America at least, towards  “excessive biological reductionism” in which 
previous emphasis on ‘the mind’ is cast aside (Parry and Levin 2012, p. 54). In the US, 
1990 represented the beginning of the ‘decade of the brain’ as declared by President 
George W. Bush leading to advances in neuroimaging and genetic studies in search of 
biomarkers for mental illness (Parry and Levin 2012). In questioning whether psychiatry 
can be reduced to neurochemical mechanisms in the brain, there is the related question 
of why psychiatric classification is as behaviouristic and operationalized as it is?  
Evans (2013) notes that after World War II, British and American psychiatrists 
diagnosed in entirely different ways for a given patient. The worry was that these 
judgments lacked any clinical agreement among colleagues. One way of solving this 
problem was to disconnect the idea of diagnosis from as much aetiological or causal 
theory as possible and just describe the behaviour being expressed (Evans 2013). The 
way taxonomy is developed is impacted by social changes. Thus, the increase of 
epidemiological studies and casting of behavioural characteristics associated with 
particular diagnoses had a huge impact on the category being defined. Evans (2013) 
uses the example of autism to illustrate how changing conceptions of mental disorders 
reflects on new conceptions of what is ‘normal’ cognitively of behaviourally. Prior to 
epidemiological studies, autism was described in terms of hallucinations and a loss of 
contact with reality linked to ideas advanced by Bleuler and Freud (Evans 2013), 
however the idea transformed into one of autistic children have no fantasy life at all. It 
has now become a diagnosis characterised by logical thinking. Measures being applied 
 
 
 
 
18 
have changed the meaning of that particular category, reflecting more general 
perceptions of infant thought and cognition (ibid). As I will illustrate in the following 
chapters, the change in meaning of bipolar disorder has occurred in the United States, 
and is still being negotiated in England. Rather than epidemiological studies 
transforming the nature of how we categorise this new breed of children, I will argue 
that it is a range of psychosocial processes taking shape in response to institutional and 
cultural cues which allow for a re-categorization and reconceptualization of a once rare 
diagnosis found only in adults, into a more common and treatable disorder found in 
very young children. 
The concept of bipolar disorder (BPD) was initially extended in the 1970’s with 
the introduction of the subtype of Bipolar 1, characterised mainly by depressive 
episodes accompanied by occasional minor episodes of mania. This was not widely 
accepted outside the United States, however, and thus not featured as a major diagnosis 
in the 10th edition of the ICD (Moncrieff 2014). The view that mania could exist in 
children was first suggested in a paper by Carlson et. al. (1983) in which the possibility 
was presented that mania in preadolescent children could present as irritability and 
emotional instability, as opposed to the more ‘classic’ presentation of elevated mood 
and grandiosity found in adults. Geller et. al. (1995) extended this idea to argue that 
children with rapid-cycling mania/irritability could actually have bipolar, however 
researchers hesitated to use irritability as a characterization of BP because it also 
commonly appears in ADHD (Parens and Johnson 2010).  
The birth of the controversy surrounding the current conception of PBD came 
with its initial unveiling by a group of influential clinicians affiliated with Harvard 
Medical School. Prior to 1995 there was very little mention or public awareness about 
the diagnosis, but the publication of a series of papers (Wozniak et. al 1995; Beiderman 
et. al 1996) brought the conception of the disorder to life.  The group had been focused 
on ADHD in children until it was proposed that those who weren’t responding 
appropriately to Ritalin and other medications for ADHD might have a version of 
bipolar disorder. This early research utilised a child behaviour checklist to confirm the 
bipolar diagnosis in children who met the criteria for mania because they were showing 
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evidence of chronic irritability, and suggested that children with ADHD were also at an 
increased risk of developing PBD (Beiderman et. al., 1996). Something in the research 
resonated with the larger audience of psychiatrists and, shortly after, the lay public, as 
Wozniak’s (1995) paper quickly became one of the ten most cited papers ever published 
in the Journal of the American Academy of Child and Adolescent Psychiatry (Finkel 
2012).  
Disagreement surrounding how best to characterise PBD is based on differing 
approaches to diagnostic criteria. Early research (Wozniak et. al 1995, Beiderman et. al 
1996) suggested a much more broad spectrum approach to diagnosis of the disorder in 
children in which the well-accepted classical presentation, or ‘narrow phenotype’,  
found in adults with the illness (recurrent episodes of mania, defined as elevated mood 
and grandiosity, were followed by severe depressive episodes also lasting weeks or 
months) was readapted and applied to young children, where the criteria now allowed 
for “rapid cycling”, in which young children could have several episodes per day 
(Washburn, West and Heil, 2011). Episodic changes in mood, and the marked euphoria 
which previously characterised mania, was replaced by chronic irritability for the 
presence of mania in children (Carlson and Meyer 2006). 
Pavuluri et.al. (2005) produced an early review the literature on PBD finding 
that the disorder is increasingly recognised by clinicians, however, as mentioned above, 
differing clinical perspectives on how the disorder manifests in children remains the 
rule.  Pavuluri et.al. (2005) use this as the motivation to push for future research that 
focuses on “the external validation” of PBD in the form of more longitudinal studies 
using genetic, neuroimaging and neurochemical methods to increase understanding of 
PBD’s origins (p.867). The high rates of co morbidity with ADHD were suggested as 
one reason why proper identification of children is difficult. It is this desire to find 
something to observe, some physical manifestation of a phenomenon that remains a 
vague collection of competing definitions, that is central to the development of PBD in 
the US as diagnosis and treatment are steered towards something that can be ‘fixed’. 
Pavuluri et.al. (2005) play down disagreement among clinical colleagues about PBD, 
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suggesting that there is in fact consensus that PBD exists, but more research is needed 
to determine whether the ‘broad’ phenotype actually falls within the bipolar spectrum.  
Faedda et al. (2004) note that the differentiation of PBD from other disorders 
remains challenging due to high comorbidity with other childhood disorders and lack of 
similarity of the episodic nature of childhood bipolar as is found in adult BPD. Their 
study examined children meeting DSM IV criteria for bipolar disorder (with the 
exception of episode duration criteria) analysing clinical records to evaluate age of onset 
and other factors. Of the 82 young people diagnosed PBD, psychopathology was 
recognised before age 3 in 74% of the children, presenting as mood and sleep 
disturbances, hyperactivity, aggression and anxiety (Faedda et. al. 2004). The study 
concluded that PBD is often mis- or undiagnosed although it often manifests with 
mood lability and sleep disturbances in young children. Parens and Johnston (2010) 
seek to distinguish between the small number of children who do fit the criteria for 
bipolar disorder in the DSM and the much larger group of children who have been 
given the diagnosis despite not conforming to the criteria. In outlining the controversy, 
they argue in favour of the development of a new diagnostic category of ‘severe mood 
dysregulation’ in order to cut down on the number of children being misdiagnosed, and 
thus mistreated (Parens and Johnston 2010). 
In contrast, Post (2009) supports the idea that PBD is an early manifestation of 
what is seen in adults, arguing that there is not enough recognition of the disorder in 
young people, resulting in inadequate treatment. These assertions are drawn from a 
study examining retrospective assessments among adults with bipolar in which they 
recollected the age of onset of their symptoms. Post (2009) is a proponent of early 
diagnosis and treatment (and maintains professional links to the pharmaceutical 
industry as a paid consultant) singling out analysis revealing that the length of the delay 
between a child’s diagnosis and the first treatment is a predictor of more serious on-
going illness into adulthood. Proposing that childhood onset illnesses would have a 
better outcome with earlier, more appropriate, interventions, Post (2009) concludes that 
intensive investigations should be undertaken into the more controversial variations of 
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PBD spectrum, such as BP-NOS or conduct disorder with ADHD, in order to define 
their optimal treatment strategies, including in very young children (p. 884).  
Despite the controversy over this relabelling, rates of PBD have continued to 
increase. Moreno et al (2007) found a 40-fold increase in the number of outpatient 
visits reported in the US between 1994 and 2003. The rise of PBD in outpatient settings 
was also illustrated by Blader and Carlson (2007) who reviewed records from the annual 
National Hospital Discharge Survey finding that the rates of children given a diagnosis 
of bipolar increased from 1.3 per 10,000 US children in 1996 to 7.3 per 10,000 in 2004. 
A diagnosis of bipolar was the least frequent diagnosis recorded for children admitted 
as in-patients for psychiatric reasons in 1996, however it was the most common in 2004 
(Blader and Carlson 2007). 
Further shaping debate around PBD is the influence of the pharmaceutical 
industry, which played a major role in funding the initial research that was meant to 
provide results which would benefit the company (Harris 2009b). As a result of its 
contentious introduction, there remain distinct sides of the debate. Those in favour of 
diagnosis argue against turning childhood mental disorders into polemics. Timimi and 
Taylor (2004) cite a lack of evidence for social factors as the cause of certain disorders, 
however others have argued that leaving children untreated leads to greater risk of 
social problems including incarceration, substance abuse, fractured families (Volkmar et 
al 2002), and mistreatment with the wrong medications (Wozniak et al 1995; Beiderman 
et al 1996). Others suggest it is not a new problem at all, but rather follows the lead of 
other previously overlooked mental illnesses in childhood which can be successfully 
treated (Pavuluri 2005; Danner et al 2009), thus cutting down on potential 
neurocognitive deficits as a result of missed diagnosis. Those supporting a diagnosis of 
PBD say more research into the underlying causes is needed via neuroimaging, as the 
identification of biomarkers and genetic insight will lead to greater understanding of 
PBD as a developmental illness (Leibenluft 2008). 
While much of the literature on PBD remains in the clinical realm, Parry and 
Levin (2012) discuss the rise of the diagnosis in terms of wider systemic influences at 
play. They express concern that trauma, attachment and other psychosocial factors are 
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not as given as much consideration when making the diagnosis, owing to what they 
consider and overemphasis on neurochemical and biological explanations. Instead of 
being viewed as a previously overlooked disorder, Parry and Levin (2012) argue that 
PBD is reflective of several factors associated with a wider paradigm shift within 
psychiatry. Diagnosis is a product of an American system that prompts diagnostic 
‘upcoding’ as a result of pressure to assign a diagnosis in order to get reimbursement 
for treatment from insurance companies, potentially leading to increase in diagnosis of 
PBD and the influence of the pharmaceutical industry (ibid). Corcoran and Stubbins 
(2015) have also sought to understand broader systemic factors at play in the rise of 
PBD in the US. They have found that a lack of child psychiatrists to assess children 
properly, combined with insurance restrictions limiting the amount of time a clinician 
can spend with a child leads to children being assessed by medical professionals not 
trained in child psychiatry (Corcoran and Stubbins, 2015). In contending that PBD is a 
phenomenon confined mostly to the US, Parry and Levin (2012) offer that it is best 
understood via a “broad, systemic perspective”, which thus warrants moving beyond 
the clinical academic literature and the focus on mediations and neuroimaging (p. 53). 
There is a clear need to explore the “broader paradigmatic shifts in psychiatry” (ibid. p 
55) to fully grasp what is at play in the genesis of a diagnostic category that counts very 
young children among its members. This is something this thesis is setting out to 
explore. 
While PBD is still very much aligned with the US, a central question of this 
thesis is how understandings of what makes the diagnosis are moving and establishing 
themselves in a different cultural context, and what bearing context has in how such a 
diagnosis catches on or remains in the background. I suspect it goes beyond the 
statement of one prominent American psychiatrist who suggested “Europeans are 
biased against recognizing psychiatric disorders in children… US rates of diagnosis 
reflect a deeper understanding of the disorder among US psychiatrists” (Parens and 
Johnson 2010, 5). Literature exploring international comparisons in the understanding 
of PBD remains rare, while epidemiological international comparisons into prevalence 
rates are only slightly more common. Soutullo and colleagues (2005) sought to address 
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scepticism surrounding PBD by gauging international perspectives on the epidemiology 
and phenomenology of PBD in non-US samples. They noted often overlooked 
divergent approaches to defining bipolar disorder in the ICD-10 as compared to the 
DSM IV leading to methodological differences in epidemiological studies which could 
help explain international prevalence rates. Among their conclusions, it was suggested 
that different levels of recognition of child and adolescent psychiatry as a true speciality 
in Europe, combined with clinician bias against bipolar disorder internationally, over-
diagnosis in the USA and/or actual higher prevalence of PBD in the USA may explain 
their results (Soutullo et al. 2005).  In a study exploring how British clinicians apply the 
diagnosis of bipolar disorder to children, Chan et al (2011) found that the diagnosis was 
rarely made by clinicians working in Southern England, and out of 3586 children in the 
study, only 35 participants (1.0%) were diagnosed as having bipolar disorder. Of those, 
only 9 children (0.3%) were under the age of 13 (p. 75).  Contrast this with rates of 
diagnosis in the US where, according to Kaplan (2011), the rise of outpatient office 
visits for children and adolescents with bipolar disorder increased 40-fold from 20,000 
in 1994–95 to 800,000 in 2002–03, with number no doubt having increased since then. 
More recently, a study comparing hospital discharge rates for children in the US 
and England with a diagnosis of PBD suggests that by the age of 5 years old, the rate of 
discharges of American children have already exceeded that of their English 
counterparts, where the peak occurs at 19 years of age (James et al. 2014). Also 
significant is a 114- fold difference in rates found in adolescence with a peak age in the 
US of 342 per 100,000 at age 16, versus England at 3.0 per 100,000. Does this suggest a 
US propensity to diagnose adolescents exhibiting adolescent behaviour as ill, or an 
English reluctance to pay attention to warning signs? Crossley (2006) suggests that the 
self-image of British psychiatry “emphasises eclecticism and open-mindedness” noting 
the contribution of a number of professionals, not just psychiatrists, to the care of one 
individual. Clacey, Goldacre and James (2015) conducted and international comparison 
of hospital discharge rates for children diagnosed with PBD using national data sets. In 
the US the discharge rates per 100,000 population for those under the age of 20 were 
95.6 as compared to 0.9 in England, noting that the most significant diversions 
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occurred among those aged 5-9 years old. The authors describe how American 
authorities maintain that PBD is characterised by non-episodic, chronic, ultra-rapid 
cycling, mixed irritable states. In the UK, such cases would be conceptualised not as 
paediatric bipolar disorder but as oppositional defiant disorder, conduct disorder 
and/or ADHD with emotional dysregulation. (Clacey, Goldacre and James, 2015). This 
was also proposed by Dubicka et al., (2008) in a study presenting five standardized 
vignettes illustrating complex scenarios of mania in children in which four represented 
incidents in which the diagnosis would be controversial, and one ‘classic’ case of mania 
in an older child in which it was thought there would be easy agreement. The vignettes 
were shown to child psychiatrists in both the US and UK and provided evidence that 
PBD is more readily diagnosed in the US.  
 
1.3 The DSM and ICD as cultural artefacts 
The entry of PBD into the public domain has not been without controversy. A main 
point of contention lay in the fact that PBD as a diagnosis doesn’t exist in either the 
DSM 5, which is used in the US, or the ICD-10 used in Europe, leading to accusations 
of the misapplication of adult criteria to children. And it is not only borrowing criteria 
from adults which is at issue, but also the redefinition of criteria in order to make sense 
of what clinicians might actually see in children, given that many classic bipolar 
symptoms are rare to non-existent in pre-pubertal young people. Central among these 
redefinitions is the use of irritability as a way of identifying both mania and depression 
in children. In the US, where there is already a long-held familiarity in diagnosing 
children with behavioural disorders, this notion of mania has gained more traction. Not 
so in England, where there is a desire to stay aligned with more established, 
conservative definitions, as well as a desire to maintain distance from what is widely 
seen as an American fondness for over diagnosing and medicating children. This will be 
explored more in chapter five when considering the development of clinical 
representations of PBD in the US as compared to England. 
In discussing disorders of childhood as they relate to cultural psychopathology, 
Lopez and Guarnaccia (2000) note that it is a “rich field of inquiry for those interested 
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in culture” (p. 572). The position of the child in a particular context speaks to how 
those around the child give rise to new understanding about childhood and what 
constitutes ‘normal’ conduct. Weisz et al. (1997) suggest that child psychopathology 
requires attention be given to the behaviour of children as well as the view of those 
adults- particularly parents, teachers, and mental health practitioners- for it is the adults 
who usually decide whether a problem exists. The fact that others determine whether 
children’s behaviour is problematic indicates the importance of the social world in 
defining mental illness and disorders of children and adolescents (cited in Lopez and 
Guarnaccia 2000, p.584). 
The cultural background of a child is present both in how the child’s behaviour 
is interpreted by others, as well as in how their psychological distress is expressed. For 
example, Lopez and Guarnaccia (2000) discuss a cultural propensity to foster either 
internalizing manifestations of distress, such as depression and anxiety, or more 
external manifestations, such as acting out, or aggressive behaviours. A culture that 
values self-control and emotional restraint, or one valuing achievement and success, 
leads to children expressing psychological distress in a way that doesn’t violate cultural 
norms (p. 584). The question arises, why is there such international variation in 
discharge rates for paediatric bipolar disorder, even allowing for the overall differences 
in the total discharge rates between countries, and are they warranted? (Clacey, 
Goldacre and James, 2015).  
Both the DSM and the ICD are cultural artefacts reflective of, and shaped by, 
current conceptions of what counts as scientific evidence, and what makes up a “real” 
disorder (Summerfield 2008). New assumptions about what is normal versus what is 
disordered are incorporated into common sense beliefs about the world and a person’s 
own relationship to psychological norms (Offman and Kleinplatz 2004), which then 
contribute to the construction of new diagnostic categories reflective of such societal 
trends (Summerfield 2008; Jutel 2011). Bipolar Disorder Not Otherwise Specified (BP-
NOS), is the most commonly seen subtype in paediatric psychiatric clinics, and is not 
clearly defined in the DSM IV. The symptoms of mania in a child had to have lasted at 
least 4 hours within a 24-hour period for at least 4 "cumulative lifetime days” (National 
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Institute of Mental Health, 2006).  In this description, it appears that even children 
having a severe temper tantrum could fit the diagnosis, an issue leading the British 
Psychological Society (2012) to voice concern over the validity of diagnostic categories 
for PBD, noting that “assumption, rather than hard evidence from empirical research 
are driving development of diagnostic criteria” (p. 3). Clacey, Goldacre and James 
(2015) suggest that in the United States, PBD is a diagnosis of inclusion of children 
with symptoms of ADHD, irritability and fluctuating moods, whether or not there is 
clear evidence of a manic episode, raising the possibility that severe adolescent mood 
dysregulation is being diagnosed as bipolar. 
The most recent edition of the DSM, DSM 5, requires only one such manic 
episode before a diagnosis of bipolar can be made. To receive the BP-NOS diagnosis, a 
child does not need to meet the criteria for any of the other subtypes of BPD. For 
example, a child may have an unstable mood and rapid movement between more manic 
and depressive symptoms, however those symptoms do not meet the “minimal 
duration criteria for a Manic or Major Depressive Episode” (Parens and Johnson 2010, 
6). Compare this criterion for mania to the classification in the ICD-10 in which more 
than one manic episode is required (Clacey, Goldacre and James, 2015). Moreover, the 
UK National Institute for Health and Care Excellence (NICE) clinical practice 
guideline advocates a more conservative approach to diagnosing bipolar I in children, 
and urges against bipolar 2 diagnoses for young people (ibid.). According to Healy 
(2007), the DSM makes it easier to diagnose bipolar disorder in children than does the 
ICD while Wang (2012) identifies the DSM as something of a road map reflecting rapid 
revision of scientific views on mental health.  
Among British psychiatrists, there is a concern that PBD is a “catch-all 
category, which will broaden the rates of diagnosis of such conditions…and result in 
significant side effects due to the unnecessary medication prescribed as a result of false 
positive diagnoses” (British Psychological Society 2012, p.11). In a 2006 report 
outlining clinical guidelines in the management of bipolar disorder, NICE stated their 
position as acknowledging that while children can “present with many features 
suggestive of a diagnosis of bipolar disorder”, they remained unconvinced that there 
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was enough clinical evidence available to support the everyday clinical use of the 
diagnosis” (NICE 2006, p. 526).  
1.4 PBD in the public sphere: The Bipolar Child, social knowledge and 
diagnostic legitimacy 
The emergence of PBD in academic literature was followed soon after by the 
introduction of the diagnosis to the wider public. Perhaps the most significant shift in 
understanding came with the publication of The Bipolar Child: The Definitive and Reassuring 
Guide to Childhood’s Most Misunderstood Disorder (Papolos and Papolos, 2000), a book that 
led to a swell in the number of parents asking for the diagnosis. The publication of the 
book was the most salient indicator of a shift in thinking about PBD (Healy and 
LeNoury 2007) and suggested, among other ideas, that PBD could actually emerge in 
infancy, or even in-utero (Papolos and Papolos 2000, p. 8). I first heard about this book 
when conducting my initial review of literature for this research, as it was mentioned in 
a number of popular articles expanding on the increasing prevalence of PBD in the US. 
The importance of the book’s influence was further cemented once analysis was started 
on the interviews conducted with American parents for this project. It became apparent 
that each one had mentioned the book as being an essential resource in their 
understanding of the diagnosis.  An indication of the level to which The Bipolar Child 
caught on can be seen in its sales trajectory, as it was initially published in January 2000, 
was in its 10th printing by May, and sold 700,000 copies in its first six-months (Healy 
and LeNoury 2007). 
The knowledge about PBD perpetuated in The Bipolar Child suggested that the 
disorder is not new, nor is it uncommon. Rather, the authors suggest that PBD 
represents a neglected public health problem, citing research that up to one third of 
American children given the diagnosis of ADHD likely have PBD instead (Papolos and 
Papolos 2000, p. 4). The book goes on to tell parents that bipolar disorders have 
“probably been conserved in the human genome because it confers great energy and 
originality of thought” thus equating having the diagnosis with being intellectually or 
creatively gifted. Indeed, in speaking to American parents, each one also mentioned the 
gifted status of their child, suggesting that the label of the diagnosis obscured the true 
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nature of their child, but perhaps finding comfort in the idea that the fact that the child 
was exhibiting certain behaviours was to be equated with heightened abilities. Thus, 
many children with PBD are described as: 
…extremely precocious and bright-doing everything early and with gusto. 
They seem like they are magical children, their creativity can be astounding 
and the parents speak about them with real respect, sometimes even awe 
(Papolos and Papolos 2000, p. 8) 
 
In presenting the diagnosis in this light, the authors make the idea of PBD more 
palatable to parents who may be worried enough about their child to seek professional 
help, yet sceptical about the label ‘bipolar’. The push for increased individuality that is 
so central to the American mentality has been manifested in how diagnostic categories 
are introduced to the public who may be responsible for their wider acceptance, in this 
case parents. A diagnosis, however difficult, marks a child as different or special, and 
thus attempts are made to locate positive associations of the illness in history, or 
characteristics of genius, creativity, and gifted intelligence, perhaps as a means to soften 
the blow for some, or providing a sense of increased comfort with the idea of seeking 
out the diagnosis for others. The characterisation of the bipolar child presented in the 
book is also a manual for parents in terms of presenting a new way to shape responses 
to the child by aligning potentially disturbing behaviours with brain chemistry:  
Bipolar children seem to be out of sync. …they seem to have great 
difficulty making shifts from one context to another. When the demand to 
do so is made- and it may only be a request to stop watching television and 
join the family in the kitchen for dinner- he or she may not be able to 
brook the transition and the change in the state of mood, attention, or 
motor response required. The child may become easily frustrated and 
irritable, and a repeated demand may provoke the child’s angry outburst or 
rage. The limbic system (the emotional brain) seems to be involved with 
the integration of sensory experience, and we will explore this more closely 
in chapter 7 (Papolos and Papolos 2000, p. 17) 
 
Of interest is the way the authors immediately follow up the vignette of a rage set off 
by being asked to come to the dinner table with something beyond the control of any 
of the actors involved: the limbic system. Thus the context is removed from how 
behaviour should be interpreted and placed squarely within a disrupted neurochemistry. 
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The power in the vignette above is given to the child, however the book places 
power in the hands of the parents by presenting information on such topics as “How to 
Judge a Doctor’s Ability to Diagnose and Treat Bipolar Disorder in Children”. The 
authors lay out a series of ten bullet points as to what parents should look for, including 
the need for an aggressive physician who is not afraid to initiate treating with 
medications as soon as possible, as “taking too much time to give a diagnosis and 
initiate treatment hurts the child and the family” (Papolos and Papolos 2000, p. 60). 
Parents are then advised which questions to ask the physician, and which clinical 
responses they should take on board: 
If the doctor mentions that most children who have bipolar disorder 
cannot be diagnosed according to current diagnostic criteria, and he or she 
knows that the duration of cycling is much shorter in children, and then 
treats this form of the condition as bipolar anyway, the parents should breathe a 
sigh of relief (Papolos and Papolos 2000, p. 69. Emphasis added) 
 
Parents are being actively encouraged to challenge clinicians who don’t subscribe to the 
more controversial broad-spectrum approach to diagnosis advocated by the authors, 
instead being told to “breathe a sigh of relief” when they find someone willing to 
diagnose bipolar in a child despite the fact that the child may not meet traditional 
diagnostic criteria. Papolos and Papolos (2000) suggest that parents have to abandon 
the idea of traditional parenting practices involving consistency and authority, as the 
idea of the parent establishing control in order that the child feels safe, doesn’t stand a 
chance in the family with a bipolar child. They note that:  
Any assertion of authority is viewed by the child as the parent dominating 
him or her, a domination to be resisted at any cost. Something goes off in 
the child’s brain and a rage gathers. A simple “no” triggers a nuclear 
explosion (Papolos and Papolos 2000, p. 253). 
 
Again, it is the child’s brain that is responsible, thus the parent isn’t necessarily reacting 
to their child’s behaviour as much as they are responding to something separate within 
the child. The popular dissemination of this idea that parental authority won’t work, 
and in fact can make a bad situation worse, is an approach that has been implicated in 
the critique of the expansion of mental illness diagnoses in children. The degree to 
which The Bipolar Child caught on and became a significant, if not unique source of 
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information for parents seeking answers provides an indication of how in the 
development of the concept of PBD, representations of acceptable parenting practices 
are given almost as much weight as representations of the child. This supports Harris’ 
(2005) assertion that telling parents their child has a biologically based mental illness, 
although difficult, is easier than examining family interactions that provoke such 
behaviours, something that is sure to cause a certain level of parental guilt. Thus, a new 
dynamic is created between parent and child, in which the parent sees child as ill and in 
need of nurturance, and the parent feels relief that the child’s conduct is not their fault 
(Harris 2005, 531). Physicians are also able to gain a positive sense of their own 
position as a fighter for what’s best for the misunderstood child who has labelled as 
‘bad’, but who actually suffers from chemical imbalance that can be treated (ibid.). 
Books like The Bipolar Child, and the many of its ilk which followed over the following 
decade, not only increased awareness about PBD, but provided some insight into how 
the “enormity of the problems faced by many children makes the simplicity of a 
biological explanation incredibly appealing” (ibid). 
Parry and Levin (2012) note the dearth of studies in the psychiatric literature 
being openly critical of PBD, proposing that “contrary views about PBD are seen as 
opinion based and lacking in data” in a field that holds quantitative research in higher 
regard than qualitative. Following on from the publication of the book, a series of in-
depth media reports, commentaries and editorials presented details about the lives of 
young people living with a diagnosis of bipolar. The tenor of the articles was more 
questioning and critical of the diagnosis however, with several highlighting instances of 
the diagnosis and its treatments gone horribly wrong. Most significant among these is 
the story of Rebecca Riley, a Boston toddler diagnosed with PBD at age two after her 
mother became concerned that she seemed hyperactive and wasn’t sleeping well. The 
diagnosis led to the prescription of a cocktail of medications, including the 
antipsychotic Seroquel, which ultimately led to her death from overdose at the age of 
four. The story was one of the first to bring PBD into the mainstream, and highlighted 
the fact that Riley’s ten-year old brother and four-year old sister were also being treated 
for PBD as well, by the same psychiatrist. (60 Minutes, September 28, 2007).  
 
 
 
 
31 
One year later PBS aired a documentary on ‘The Medicated Child” (PBS 
Frontline, 2008.) which profiled four-year old DJ Koontz who was given the diagnosis 
of PBD after his parents noted his temper tantrums became more frequent and 
uncontrollable, leading to him being prescribed powerful antipsychotic medications. 
The story quotes DJ’s mother as saying she was concerned about the use of 
medications but that without it they wouldn’t be able to function as a family. The lack 
of a link between PBD and the adult manifestation of bipolar was highlighted by 
Thomas Insel, then the director of the National Institute of Mental Health, noting that 
there was no indication that adults with the illness started with what is now being called 
PBD, nor was it certain that these kids would grow into the more classical manic-
depressive type illness on which its name is based. 
Similarly, a Time Magazine cover story highlights a single mother with three 
children, two of whom have BPD, a son aged five, and a daughter aged two asking the 
question of why so many children are being diagnosed with a disorder previously 
known as manic-depression? The boy at the heart of the article, Ian Palmer, began 
treatment with stimulants and Prozac, responding inadequately to both, and 
subsequently put on antipsychotics (Kluger and Song 2002). The article suggests that 
the most serious symptoms for children may appear just when the academic challenge 
of grade school starts to be felt, and doctors who recognize BPD and know how to 
handle it are in critically short supply. As Healy and LeNoury (2007) observe, the Time 
Magazine piece, and other popular articles, cite surveys suggesting that 20% of young 
people in the US have some sort of diagnosable mental illness. A more recent 
Newsweek story written by a well-known child psychiatrist (Kaplan 2011) denounced 
the “unwarranted enthusiasm” for PBD. The article noted that despite practicing for 
three decades and seeing faddish illnesses come and go, the momentum behind PBD 
was unprecedented. No scientific evidence exists to support PBD, instead Kaplan 
(2011) suggests that PBD is “almost always a case of severe ADHD combined with 
severe oppositional defiant disorder” (ibid). This is echoed in a New York Times story 
which sheds light on the fact that psychiatrists often disagree over what is wrong with a 
child (Carey 2006). A Boston Globe article in which psychiatrists interviewed noted that 
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the question of whether or not to give a diagnosis of bipolar can be an agonizing 
decision for clinicians who are at the mercy of both conscious and unconscious 
pressures to medicate such children. However, the article cites one psychiatrist as 
stating that central to making progress in understanding PBD is to understand better, as 
a field, which pre-schoolers warrant increased attention and need to be treated 
aggressively (Goldberg 2007). 
In England there has been much less attention to PBD in popular media 
outlets; however, that is beginning to change. A CAMHS mental health nurse writing in 
a blog for the UK-based mental health charity MIND questioned whether small 
children can get bipolar disorder, noting that her professional colleagues are taking sides 
in the debates, suggesting what is happening around PBD is similar to the debates that 
took shape around ADHD years ago. While some argue it is “the new big thing”, others 
insist it is the American link to the vested interests of Big Pharma at play (Zarathustra 
2010). The blog cites the example of a young girl in the CAMHS caseload who had 
been diagnosed with ADHD in Britain and prescribed a stimulant, methylphenidate, 
but was promptly diagnosed with PBD (and prescribed antipsychotics) when her 
parents took her to America. On return to Britain, the child was reassessed by CAMHS 
and not found to have any of the signs or symptoms of bipolar, and switched back to 
the treatment with a stimulant (Zarathustra 2010). While most of the popular media 
attention in England has been focused on ADHD, a 2014 article in The Sunday Times 
entitled ‘Can a Child be Diagnosed with Bipolar Disorder?” in which readers were 
introduced to the types of children profiled over the years in US media (Glass 2014). 
This article in particular featured the perspective of a frustrated parent in England, 
desperately seeking the diagnosis for their daughter, but meeting resistance within the 
NHS. The parent is driven to seek advice from American experts (ibid). Such articles, 
and the comments they receive, act as an indicator for where popular knowledge about 
PBD lies. One comment to the blog posted on the MIND website in the UK illustrates 
an issue common among many in England, that there is something of an opposite 
problem to America’s perceived over-diagnosis taking shape, in which there is a sense 
that doctors believe one’s brain suddenly changes once a young person turns 18, and 
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prior to that point any signs of mental illness are not taken seriously enough 
(Zarathustra 2010).  
It has been argued that differing diagnostic practices are responsible for higher 
rates of PBD in the US as compared to England (Stringaris 2010; Clacey, Goldacre and 
James, 2015). The question that is central to this thesis is why? What is shaping these 
practices beyond mixed use of diagnostic manuals and the level of influence of 
insurance systems and socialized medicine? There is no doubt that such ingrained, 
systematic differences are central in how diagnostic practice is manifested, however this 
project is concerned with what lies behind these systems, how these systems are 
internalized and enacted at the level of interaction between individuals and groups. I 
argue that one way to understand these differences is to look at psychosocial processes 
taking shape within the interactions of those most involved in perpetuating the 
diagnosis: clinicians, parents and the pharmaceutical industry. Current research in the 
clinical literature necessarily focuses on clinical issues, while acknowledging that more 
needs to be done to understand conceptual differences and wider political, social and 
economic factors shaping diagnostic practice around PBD. We are all embedded in 
social environments in which traditions and practices come equipped with previously 
constructed meanings, norms and expectations that only carry on to the extent that they 
are able to orient to new circumstances (Linell 2009). It is within these situations, or in 
the case of this research, the cultures of diagnosis allowing for knowledge to evolve in a 
particular way, that the meaning of the child is negotiated among professionals and 
parents, acting within spheres of influence in which top-down pressures continue to 
operate in the background.  
1.5 Conclusion 
In this chapter, I have briefly outlined the early trajectory of PBD, reviewed key 
literature on the diagnosis, and presented the problem of PBD as it exists in the public 
sphere in terms of the knowledge presented to the wider public in the form of an 
influential book, as well as more critical voices coming out of popular media. The 
controversies remain despite twenty years of development of the concept of PBD. 
Although there is a fair amount of clinical research on PBD since it was popularized in 
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1995, and no doubt significantly more on bipolar disorders in history, the present 
emphasis on investigations into neurochemical explanations leaves a gap for more 
research pursuing explorations concerned with the psychosocial development of the 
diagnosis and the role processes of social influence and social representation have on 
the development of such a category. Much of the current literature on PBD focuses on 
clinical understanding of the disorder, however less evident are more qualitative 
explorations of how PBD is conceptualised by those most involved in treating, and 
caring for those living with the diagnosis. There is a significant amount of literature on 
the related, often overlapping, diagnosis of ADHD (see for example Singh 2002, 2007, 
2011; Timimi 2003; Edwards and Howlett 2013), which this current research builds on, 
however as an area of study, PBD is unique in that it is a diagnosis that is still seeking to 
be understood and defined.  
Childhood mental disorders such as ADHD and autism spectrum disorders 
come equipped with all of the controversy, contestation and debate that surrounds 
PBD, however those illnesses have succeeded in solidifying their place in the realm of, 
as Fleck (1979) would say, scientific fact, or at least public understanding. The exact 
position of PBD continues to be negotiated making it a valuable point of departure to 
understand how and why a controversial diagnosis catches on or gets discarded. How 
does the interaction between different knowledge systems in two different cultural 
contexts - in the case of this study professional biomedical knowledge, the experiential 
knowledge of parents and the political economy of the pharmaceutical industry - come 
together in the cultural production of a contested diagnosis? How do these different 
groups conceptualise the diagnosis of bipolar in children, and how does this shape the 
ways in which the diagnosis is accepted or rejected as a valid diagnostic category? There 
are a number of ideas presented here, which may be taken as already established givens. 
For example, as will be discussed in chapter two, the medicalisation of children has been 
well-researched and forms the backbone of my own interest in developing this thesis, as 
is the notion that these processes of medicalisation are more often found in America. 
What this thesis aims to contribute, however, is a better understanding of what is at 
play in these processes of medicalisation, how a diagnosis in children which has 
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remained controversial for the whole of its existence is understood by those most 
directly involved in its perpetuation, and how (and why) this might differ in the US as 
compared to England. The fact that PBD remains so contentious is a testament to the 
fact that socio-psychological research is warranted. What happens in the US with 
regards to diagnostic understanding does tend to migrate to England, and as the 
English healthcare system becomes increasingly fractured, threatened by privatisation, 
and the consumer-driven ethos potentially takes hold, an understanding of how 
knowledge around PBD has developed would support clinicians, parents, and young 
people in a more holistic knowledge of what is being communicated and asked of them.  
This thesis focuses on interaction as a means to explore knowledge 
construction. Healy (2008) talks about disease as being a “social, linguistic and 
biological entity, now increasingly part of a world of bureaucratic categories and 
pharmaceutical practice” (p. xi). Given the multiplicity of ways in which to understand 
mental illness in children, braking down practices into interactive and representational 
components allows a fuller picture of something unstable and constantly changing, or at 
least to capture a particular moment in its trajectory towards becoming a new entity. 
Language shapes understanding, thus communication between actors central to a 
phenomenon meaning becomes restrained if reduced to, or overly focused upon, a 
particular vocabulary of diagnosis (Parry and Levin 2012, 62). To build on this point, 
Alderson (2013) discusses the ways in which children can be implicitly blamed for 
things in which the cause actually lies in adult hands (Alderson 2013). In this thesis I 
argue that while it might not come down to ‘blame’ as such, the construction of PBD is 
borne of adult assumptions of how children should behave, or the parent child 
mismatch in which parenting style causes reactive effect in the child, leading the child to 
be on the receiving end of resulting ramifications. Tied up in this are the 
institutionalization of cultural norms and assumptions subtly dictating how not only a 
child should be, but what a clinician should know, how they should practice, how 
parents should parent and what childhood should be. My research hones in on what it 
is that has shaped the knowledge of those above. It is a small piece of the whole puzzle, 
but seeing how this diagnosis has developed, and now catching it as it moves into a 
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different social context, met with localized resistance, provides a way to shed light on 
psychosocial processes accompanying PBD diagnosis.  
This will be further unpacked in the following chapters. Chapter two presents the 
theoretical framework guiding this thesis in which the development and construction of 
psychiatric knowledge is approached via a social representations framework 
emphasizing the anchoring of the unknown in the known, knowledge encounters 
among and between competing perspectives, and the modalities of social influence and 
asymmetries on knowledge that make up a dialogical approach to interaction. Chapter 
three illustrates the research design and methodology grounding this project, including 
the rationale for undertaking research with the particular groups and contexts that were 
ultimately chosen. Chapter four presents the first of the three empirical chapters, focusing 
on the voice of the pharmaceutical industry, which plays such a central role in the 
genesis of this diagnosis. An analysis of the organisational perspective of the industry 
communicating PBD is represented via internal documents, de-classified court 
documents, marketing, and continuing education materials, while the ‘external voice’ of 
the industry is explored through pharmaceutical advertisements. Chapter five unpacks 
clinical representations of PBD, comparing what, and who, clinician’s talk about when 
discussing PBD in the US as compared to England. The position of the clinical ‘Self’ in 
relation to significant Others, including parents, clinical colleagues, and the child at the 
centre of the debates, sheds light on how the representations that shape diagnostic 
understanding and practice are developed. Chapter six, the final empirical chapter, turns 
attention to parents in the US and England in order to see what factors shape the 
development of their knowledge about PBD. The final chapter, chapter seven, presents a 
discussion tying in theory and context to provide a model for how psychosocial 
processes shape the emergence and resistance of a contested diagnosis. 
As will be discussed in the following chapter, the guiding theoretical framework 
of this thesis relates to social representations, and the particular concern with the 
transmission, diffusion and transformation of scientific knowledge, and relationship 
between scientific and common sense thinking. In the case of this project, an 
exploration of these processes can be seen in the transmission of knowledge about 
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PBD through encountering knowledge of often competing knowledge systems, which 
allow for new associations upon which to crystallize opinion and attitudes about PBD; 
diffusion through media and pharmaceutical advertising, as well as communication 
between colleagues, peers, professionals and the lay public; and the transformation of 
knowledge about PBD, the stage I argue we find ourselves in at the present time. By 
attempting to catch a diagnosis as it is transforming, this project contributes to debates 
surrounding children’s mental health and the medicalisation of childhood. I propose 
that incorporating these frameworks alongside social psychological contributions 
including social representations, social influence and ideas of dialogicality will lead to a 
social psychology of medicalisation that, in addition to examining practices leading to 
medicalising childhood, will also look at the knowledge processes behind this 
increasingly dominant paradigm in the debates around children’s mental health.  
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2. Theoretical framework: the acquisition and 
transmission of  medical knowledge 
Controversies are fascinating social processes because they make apparent 
all of the normally silent and hidden activities that regularly produce our 
taken-for-granted everyday world- shows us competing voices, fractious 
voices, contradictory facts and uncertain compromises in the world of 
knowledge production  
                                                                                          (Dumit 2012, 32) 
 
2.1 Introduction 
Conrad and Barker (2010) suggest that what gets labelled as disease or qualifies as 
biological is often socially negotiated. Central to this negotiation is the acquisition and 
transmission of medical knowledge through which attitudes and beliefs of 
organizations, professionals and the lay public are shaped and put into practice. It is this 
notion of paediatric bipolar disorder as being the socially elaborated product of 
different spheres of knowledge coming together that is the fundamental concept 
driving this thesis. It is informed by theories related to how illness is constructed. As 
Barker (2010) explains, illness and disease exist as phenomena shaped by experiences, 
interaction, and shifting frameworks of knowledge as opposed to fixed realities. When 
it comes to mental illness in particular, everyday meanings may differ from more 
scientific and clinically based understanding (Dixit 2005) thus, an exploration of the 
relationship between how individuals conceptualize a diagnosis such as PBD in a wider 
social context made up of myriad implicit social knowledges is warranted. This chapter 
is therefore concerned with the social and psychological genesis of PBD as being made 
up of both representational and dialogical processes. The chapter begins with by 
grounding my socio-psychological exploration in selected literature on the social 
construction of illness, and more specifically the development of psychiatric knowledge 
and the expansion of diagnostic categories into the realm of the child. The next section 
explores social representations theory (SRT) as an overarching framework of the thesis, 
concerned as it is with the movement of knowledge within and between groups and 
contexts, and the processes involved in anchoring and objectification, rendering the 
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unfamiliar familiar, ultimately finding a home in a new object, in this case a new 
diagnosis. The chapter then moves on to discuss the use of a model of knowledge 
encounters to explore the role of recognition and perspective taking when coming up 
against the differing, often contentious, knowledge of Others. The final section 
introduces the idea of dialogicality as it coincides with knowledge encounters, focusing 
on the interaction between Self, Other, and Object, the tensions present when such 
interactions are asymmetrical in terms of power positions or knowledge held, and the 
role modalities of social influence including persuasion, conformity, and minority 
influence play in shaping such interactions. The chapter concludes with a summary of 
the chapter and brief discussion of how what is presented here relates to the wider 
contribution of this thesis. 
2.2 The development and construction of psychiatric knowledge  
A psychosocial analysis of the construction of scientific, medical, or psychiatric 
knowledge needs to address questions regarding what is already known about a specific 
object or phenomenon, and the social factors upon which this knowledge depends 
(Flick 1998). It is at the point between subjective and socially shared understanding that 
diagnostic boundaries are contested and reshaped. Categories of disease are contingent 
on a particular time and cultural context, existing as reflections of wider social attitudes, 
values and social mores. Psychiatric diagnoses in particular are often seen as vehicles of 
absorption for social and cultural circumstances, arising not just from the introduction 
of various diagnostic technologies and new options for treatment, but also wider socio-
political ideas at play within a given context, in which what is culturally valued becomes 
objectified in the form of a diagnosis (Summerfield 2001). Harré (1998) noted that 
“psychological phenomena do not just happen in response to environmental 
contingencies, they are brought about” (p.137). The development of medical 
knowledge, and the construction of illness categories that happens a result, is a circular 
process involving multiple actors invested in whatever potential benefit a diagnostic 
label might provide. Explanatory frameworks designed to understand pathological 
behaviour have shifted. Where once explanations for the eccentric or the peculiar might 
have been explored within a religious structure, the language of biomedicine, and a 
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concurrent “vocabulary of distress” have become the modern source of everyday 
explanation (Summerfield 2004; see also Davies 2011). Biological explanations leading 
to diagnosis and pharmacological treatments are now applied to “problematic 
behaviours” including those related to low achievement and underperformance (Davies 
2011), a phenomenon reflective of the increased prevalence of, and trust in, biomedical 
knowledge. The availability of certain types of knowledge is a central concern of this 
thesis, and one that is highlighted by the child psychiatrist Leon Eisenberg, the so-called 
“father of ADHD”, in a paper constructing an argument in favour of the idea of mental 
illness as a social construction. Eisenberg (1988) includes a quote from Einstein who, 
reflecting on methods in the development of theoretical physics, suggests: 
To the discoverer…the constructions of his imagination appear so 
necessary and so natural that he is apt to treat them not as the creations of 
his own thought, but as given realities (p. 2). 
 
What constitutes a given reality, especially with regards to a diagnosis in children for 
which there is no agreed upon diagnostic criteria? Who decides what is valid to draw on 
in order to make definitive diagnostic decisions? The influence of social factors on the 
development of scientific and medical knowledge has been explored across disciplines, 
most notably in the philosophy of science (Fleck 1934/1979; Kuhn 1962; Hacking 
1998, 1999) and sociology (Berger and Luckmann 1966; Abraham 1995, Brown 1995; 
Conrad 2007, Conrad and Barker 2010; Rose 2004, 2006, 2010).  The starting point for 
this thesis, and its consideration of how a diagnosis is constructed in two separate 
cultural contexts lies in Fleck’s (1934/1979) exploration of the development of the 
modern concept of syphilis, in which the objectivity of scientific knowledge is 
questioned Fleck (1979) argues that even in the face of ‘hard’ science and medical 
technologies, illness remains a culturally conditioned object.  
The epistemology developed by Fleck didn’t ask what science should be, but 
what it actually is, and the ways in which “historical processes and social institutions are 
related to the emergence of scientific facts” (Lowy 1988, 137). Kuhn (1962) advanced 
Fleck’s perspective, proposing that it is the adjustment of scientific belief and alteration 
of theory on the part of professionals seeking to “eliminate any apparent conflict with 
evidence” which provides an illustration of the relativistic nature of scientific “truth” 
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(cited in Abraham 1995, p. 4). Such “shifts” can be seen in not only in science, but 
medicine as well in which clinicians change how they see behaviours in order to fit with 
what is expected within a dominant paradigm. This point will be subsequently 
supported in this thesis though findings among American clinicians to be discussed 
further in chapter five. In the US and England, societal norms dictating how a child 
should be inevitably play into how psychiatrists and other practitioners expand their 
understanding of pathological behaviours. These paradigms fall under what Fleck 
(1934/1979) termed a ‘thought style’ in which groups form, often unconsciously, into 
‘thought collectives’ allowing for the development and survival of a scientific 
explanation only if it conforms to the prevailing habits of thinking.  A central point of 
Fleck’s thesis that is relevant here as well is the idea that scientific exploits “can prevail 
only if they have a seminal effect by being performed at a time when the social 
conditions are right” (Fleck 1979, 45).  
The acceptance or rejection of a diagnostic category, and all points in between, 
need favourable conditions in which to grow and expand, as well as to be discarded. In 
the case of a diagnosis still in the process of attaining a stable definition, an exploration 
into what shapes diagnostic practice, parental understanding, and how the child is 
represented on a broader scale are all central in grasping why here and why now? 
Would the diagnosis of PBD be able to expand in a culture that was more comfortable 
with children who lacked a certain level of focus, were perhaps less sociable, and not as 
achievement oriented? Fleck (1979) suggests that ideas do not arise spontaneously, but 
rather “are determined by their “ancestors” thus “a field undergoing development 
should always be investigated from the viewpoint of its past development” (p. 20). The 
development of PBD is the latest in a long line of diagnoses applied to children, and 
with each new category comes an increased familiarity with the language of diagnosis, 
and a reification of representations of the behaviours that shape its manifestation. 
As an early proponent of the idea of cognition taking shape not as an individual 
process, but rather as the product of social activity, Fleck’s case study illustrates the 
ways in which a stock of scientific or medical knowledge exceeds the range of any one 
individual (Fleck 1979, p. 38). As expanded upon by Fleck, the individual is hardly ever 
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conscious of the dominant paradigms guiding their thinking. In the current climate, 
such thought styles veer towards the biomedical, with neurochemical explanations for a 
child’s behaviour seen as more valid than those emphasizing social or environmental 
rationales. Key actors central to the development of PBD belong to different thought 
collectives, with General Practitioners working at the community level in England 
holding a different set of beliefs from those practicing in specialist research centres. 
Similarly, parents in the US maintain a perspective that perhaps differs from their 
English counterparts.  Differing spheres of knowledge, yet all are responsible for 
holding and perpetuating awareness about the same object, often appropriating and 
advancing knowledge across boundaries, as will be discussed throughout the remaining 
chapters.   
For Brown (1995) the construction of medical knowledge is based on the origin 
of professional beliefs and diagnosis, described as “ways of knowing that are shaped by 
the dominant biomedical paradigm, as well as ethical and moral values, the professional 
and institutional practices of the health care system, and the larger social structures of 
society” (p. 37). The construction of a new diagnosis is a dynamic process, constantly 
changing based on what those involved in its construction find necessary or 
meaningful. This looping effect of knowledge systems as revealed in Fleck’s study 
provides an illustration of popular ‘lay’ knowledge feeding expert knowledge, which 
then translates back into a generally accepted knowledge simplified for the masses 
(Lowy 1988, 146). The diffusion of theories of mental illness into popular culture, or via 
direct communication to the patient by “the authority of the physician” have the ability 
to shape how symptoms are defined, as well as the wider course of the illness 
(Eisenberg 1988, 6). However, findings in the present research, which will be illustrated 
in the coming empirical chapters, and discussed in chapter seven, suggest an increasingly 
circular process in which the vectors of influence move both ways, with “lay” 
knowledge playing a central role in the development of professional knowledge about 
mental illness. 
A significant insight of Fleck’s (1979) thesis is the idea that attention initiates 
the development of knowledge and ideas, thus he elaborates on the “capacity of 
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observation acquired through learning process” explaining differences in the perception 
of medical specialists to the differences inherent to their training (p. 2). They are being 
educated to “see the right picture” (Lowy 1988, 142). As will be seen later in section 
5.3.1, the “seeing is believing” mentality is very much a part of diagnostic practice 
among clinicians, but why should this seem less valid and more contentious for mental 
illness? Fleck is arguing that even things that can be “seen” under a microscope are 
constructed, as what is seen is an interpretation steered by training in a particular 
thought style which then clouds one’s ability to see the same object from a different 
perspective (ibid). In the development of knowledge around a particular diagnostic 
category, the question remains as to why a particular set of behaviours or physical 
sensation becomes identified as pathology in a particular place at a particular time. Such 
questions are of concern to Brown (1995) who asks questions relevant to this thesis as 
well: 
Why was action taken or not taken? Who benefits, or at least avoids 
trouble, by identification and action? How did the divergent perspectives 
on the phenomenon merge or clash? How does the person's experience of 
the illness affect the course of the disease, as well as the social outcome of 
the illness? (p. 37) 
 
A more critical view suggests that all diagnoses, not just those of a more contested 
nature such as PBD, are social constructions designed as a means of social control, 
segregating those deemed uncontrollable, and medicalising their deviance (Foucault 
1971) or as a myth “providing professional assent to popular rationalization” (Szasz 
1974, 262). Diagnostic categories are put forth as the product of lobbying and advocacy 
(Seale and Pattinson 1994) or social circumstances leading certain behaviours to be 
labelled problematic, and thus included in a diagnostic framework (Jutel 2011) all of 
which suggests the validity of Fleck’s early notions of what constitutes a scientific ‘fact’. 
There is always a process of social elaboration at play in terms of what gets picked up, 
and what gets discarded. Illness emerges as unique product of unique societal 
understandings of Self and resultant established norms (see for example Kleinman 
1988; Littlewood 2002), a concept taken up by Hacking (1999) in his inquiry 
surrounding the act of classification as mechanism responsible for reshaping the way 
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individuals experience themselves. The ‘looping effect’ Hacking describes involves the 
evolution of an individual’s feelings and behaviours in concert with a ‘Self’ that has 
been newly classified as somehow disordered. The more knowledge people have about 
which behaviours constitute a particular diagnosis, the more the classification alone will 
cause those who fall within its boundaries to behave accordingly. Thus, categories of 
thought about people actually leads to the existence of those kinds of people, 
suggesting that there are expectations for what someone classified as having a particular 
illness will look like, filing away what behaviours are indicative of a specific diagnosis, 
and “what is believed to be true about behaviour affects the very behaviour which it 
purports to explain” (Eisenberg 1988, 1).  
2.2.1 Expanding diagnostic categories into the realm of the child 
Ever changing societal attitudes shape the way individuals define what it means to be 
healthy or ill, as well as ways in which they seek treatment for what they perceive to be 
wrong (Summerfield 2004). Sociological perspectives such as those related to the 
medicalisation of the everyday (Conrad and Leiter 2004; Barker 2010; Conrad and 
Barker, 2010), the effects representations of health in the media have on our sense of 
Self (Seale 2003), and the consequences of an increased societal comfort in using 
psycho pharmaceuticals as a psychic cure-all (Rose 2004, 2006, 2010) shape “how 
individuals and groups contribute to producing perceived social reality and knowledge” 
(Conrad and Barker 2010, p. 67). Cultural standards of behaviour, and related notions 
of what it means to be “normal” continue to assert themselves, most visibly in the 
current debate surrounding children’s mental health. The medicalisation of distress and 
emotional unease now being imparted on children leads to the question of unknown 
consequences. What are the consequences of imposing new social norms and values 
attributed to the fast-paced, neo-liberal economic climate, giving rise to values related to 
maximizing profit? Or as will be discussed throughout this thesis, what are the 
consequences of multiple systems of knowledge interacting with one another in 
reference to a child unwittingly thrust into the centre of political and moral discourse? 
Distraction, a less-than-upbeat mood and low productivity have become pathological 
(Davies 2011), a set of circumstances leading Verhaege (2014) to argue that in the 
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struggle for identity in a market-based society, new norms are being created, where 
different contexts push different definitions of what constitutes deviance, leaving 
children and young people on the receiving end of a new moral model.  
It is in light of this wider market-based context that Timimi (2006) advances the 
idea of how “ childhood often represents a central arena through which we construct 
our fantasies about the future and a battleground through which we struggle to express 
competing ideological agendas” (p. 35). In presenting a socio-cultural account of the 
development of the ADHD diagnosis in children, Timimi (2006) expands on the early 
post-war construction of childhood as we now know it, seeing it as a springboard for 
the eventual medicalisation that has become increasingly common for this stage of life. 
In grounding the development of childhood in the shift in parenting practices after 
World War II from those emphasizing discipline and authority, to more modern 
incarnations privileging guidance, compassion and consideration of the rights of the 
child, Timimi (2006) makes a compelling argument for the origin of medicalisation 
among young people as stemming from the reshaping of family life, and the 
accompanying “renegotiation of power” within the family resulting from shifting 
economic structures,  and mothers now able to go off to work (p. 36). Such a familial 
restructuring led to more professional ‘ownership’ of tasks once relegated to the role of 
extended family, such as child-rearing and parenting advice (ibid.). For Timimi, this is 
the point at which a more “child-permissive” culture takes shape, and children become 
socialized into a wider cultural ideology promoting ‘freedom’ through individualism, 
competitiveness and the rejection of authority (Timimi 2006, 36). With this socialization 
comes a blurring of boundaries between childhood and adulthood, between power of 
the parent versus power of the child; a power that is increasingly given stature via the 
child’s introduction into a world that seeks to identify them as small adults, drawing on 
the child as a new consumer, increasing parental anxiety in the meantime and leading to 
an increased reliance on professionals (Timimi 2006). The construction of this type 
childhood is then open to forces of medicalisation in which: 
…economically and politically powerful groups, such as doctors and the 
pharmaceutical industry, have enabled Western medicine to push back its 
frontiers of influence. In the sphere of children’s mental health this has 
resulted in the creation, not only of new diagnostic categories, but whole 
 
 
 
 
46 
new classes of disorder such as ‘developmental neuropsychiatry’ (Timimi 
2006, 38).   
 
The definition of new diagnoses comes as a result of reshaping expectations of 
children, drawing on ideas which position emerging problematic behaviours in the 
realm of the biomedical, thus allowing for targeted treatment. The broader cultural 
context is then “relegated to that of triggers or modifiers of the disease” and it is the 
market forces that shape psychiatry’s response (Timimi 2006, 40). The construction of 
psychiatric knowledge and the development of new ‘conditions’ of childhood then 
become validated as established medical conditions alongside requisite pharmaceutical 
treatment, via inclusion in official guidelines for practitioners (Timimi and Moncrieff , 
2013). Wider conditions surrounding the child that could account for changes in 
behaviour, such as poverty, abuse, or an unstable upbringing are then cast aside in 
favour of the immediate and treatable biomedical explanation.  
Singh (2006) suggests that there are multiple factors that have supported the 
development of the ADHD diagnosis, not least of which are the institutional and 
professional contexts surrounding the child, what is referred to as the child’s 
“ecological niche” (2011; 2012).  Citing schools as a major player, Singh positions their 
role as “mechanisms to produce and embed socio-cultural knowledge about children’s 
behaviour and approaches to treatment” as evidence of their integration with a wider 
medical agenda (p. 451). The need for inclusion of the world around the child is 
essential in order to better understand the diagnosis as it stands now, and future 
directions for diagnosis and treatment. The institutionalization not only of practices, 
but beliefs about what ADHD means and the justification of psycho-stimulants as 
treatment, illustrates the depths to which socio-cultural and socio-historical context 
plays a role. It is through acknowledging these contexts that Singh advances the moral 
dimension of ADHD by seeking to understand the experiences of young people 
themselves. Through an exploration comparing children in the US and UK, Singh 
(2014) illustrates the context dependent nature of diagnostic categories, and the 
differing representations children themselves have of their diagnosis and its meanings. 
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The representation of ADHD as the product of a child’s “ecological niche” is 
part of a broader picture suggesting that a lack of motivation with regards to schooling 
and education is a symptom of a culturally ingrained lack of social mobility present in 
the UK context. While the lack of social mobility may provide the child with an 
increased sense of community in the form of family and friends close by, it is the 
ingrained nature of these social patterns that remain difficult to shift (Singh 2006) 
leading to Singh’s finding that for kids in the UK, ADHD becomes a problem of 
“behaving well” as opposed to their American counterparts for whom ADHD is about 
achievement and a problem of “doing well” (Singh 2006, 892). Singh proposes that 
comparisons between the US and the UK point to cultural context emphasizing 
competing ‘ecological niche’ related to conduct versus performance. Such an ecological 
view allows for “more relevant judgments about impact of drug treatment on children’s 
moral capacities, and informed views about those drugs, more informed ethical 
judgments” (Singh 2014) 
If we are to support Murphy’s (2006) assertion that “biology produces the 
impairment and society its manifestation” (p. 274), then we must acknowledge that how 
we choose to label such manifestations leads to how it is treated and understood by 
individuals, and represented on a wider social scale. The construction of a particular 
diagnosis is then the result of factors such as increased professional concern with a 
particular disorder, which provides a narrative guide on which to base thinking about 
the condition. With regards to PBD, Parens and Johnson (2010) acknowledge that rates 
of the diagnosis are much higher in the US than anywhere else in the world, leading to 
the suggestion that it is the redefinition of what mania looks like in children that is 
responsible for the recent increase. This redefinition comes as a result of American 
diagnostic practice, as opposed to just genes or environment, with American clinicians 
using lower thresholds for identifying symptoms than their European counterparts 
(Parens and Johnson 2010). Discussing what they term a “zone of ambiguity” between 
children who clearly do and do not suffer from a mental disorder, Parens and Johnson 
(2010, 2) elaborate on the complexities involved with identifying and beginning the 
proper course of treatment.  
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The expansion of a symptom such as mania, which has a very clear and defined 
meaning in the realm of adult bipolar makes diagnosis difficult when it becomes aligned 
with children. A clinician is no longer faced with a clear set of diagnostic boundaries, 
but is now required to draw on more subjective representations of what a ‘manic’ child 
should look like, and increasingly, the available explanation is that a manic child looks 
angry and irritable. Healy (2006) argues that Big Pharma is uniquely responsible for 
creating bipolar disorder in children through disease-mongering tactics, whereby the 
push to normalize notions of adult bipolar disorder and its treatment through direct-to-
consumer advertising has shifted the possibility for such illness into the domain of 
children. In an analysis of medical advertisements promoting the use of psycho-
stimulants in children, Singh (2007) traces the pharmaceutical construction of the 
‘problem child’, an issue taken up by Healy and Le Noury (2007) in their exploration of 
the emergence of PBD. Their contention that it is an industry reliance on Other key 
actors, such as academic experts, parental advocacy groups, diagnostic measurement 
tools that spreads recognition of the disorder is a concern for this thesis as well.  It is 
important to consider the multiple sources disseminating this particular brand of 
knowledge, as Healy and Le Noury (2007) have done; however, in order to explore the 
wider phenomenon of why it has stuck, it is necessary to have the space to consider 
what drives individual and intergroup meanings surrounding PBD, something a socio-
psychological approach is well positioned to explore; moving beyond what is being 
constructed and how, to get at the why. How are ideas being borrowed and re-
appropriated?  To what end?  
Berger and Luckmann (1966) suggest that it is through the accumulation of 
different perspectives that an object of thought becomes ever more crystallized. The 
meeting of multiple perspectives, and their associated knowledge systems, forms the 
core of my own exploration into the development of PBD in the US as compared to 
England. The development of a new diagnostic category, and the shifting knowledge 
surrounding how it should be defined, is a process that is always in a state of flux, 
especially with regards to mental illness, and particularly mental illness in children where 
moral and ethical considerations are brought to the fore in a way that allows 
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perspectives regarding diagnostic criteria and prevalence rates to never remain 
unchallenged. This chapter has illustrated so far some socio-historical and socio-cultural 
reasons for the rise in children being deemed mentally ill, but the remaining sections 
will focus on frameworks for studying psychosocial processes which are this thesis’ 
central contribution.  
2.3 Social representations theory (SRT) as a framework to explore the genesis 
of a new diagnostic category 
How does one actually know what one is seeing when witnessing a child acting out with 
a certain set of behaviours?  How can one be so certain that this particular constellation 
of behaviours are actually ‘symptoms’ and should equated with a particular diagnosis?  
How we acquire knowledge happens via direct, lived experience, or that which comes 
via indirect experience, drawing on ideas we come into contact with and relying on 
what we trust to be true (Moscovici and Duveen 2001). In studying the emergence of a 
new diagnosis, it is this indirect social knowledge that is important to explore. What 
becomes of a new diagnostic category as it moves from the domain of specialists into 
that of the public, and the adoption, resistance, or reshaping of such a category is a 
question addressed in this thesis. The clinician and parents making decisions on behalf 
of the child are not usually basing their assumptions and actions on first-hand 
experience, so what is it that guides them, and what role does the wider cultural context 
have on how they come to ‘know’ the child and potential ‘pathological’ conduct? Social 
forces at play, manifested via communication and discourse, contribute to how new 
phenomena are understood by different groups. This is a central concern of SRT as a 
social constructionist approach, particularly those phenomena related to the ever 
present tension between scientific knowledge (or medical and psychiatric knowledge in 
the case of this thesis) and more common sense knowledge (Kronberger 2015). 
Moscovici’s (1961) original development and application of SRT considered 
knowledge in relation to the context in which it is produced, taking into account the 
impact of scientific knowledge on everyday perception and thinking (in Farr 1998), a 
central component of the theory that makes it especially relevant to this thesis. Social 
representations are defined as: 
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systems of values, ideas and practices with a two-fold function: first to 
establish an order which will enable individuals to orientate themselves in 
their material and social world and to master it; and secondly to enable 
communication to take place among the members of a community by 
providing them with a code for social exchange and a code for naming and 
classifying unambiguously the various aspects of their world and their 
individual and group history. (Moscovici 1973, p. xiii) 
 
As a theory concerned with how meanings are produced and propagated, exploring 
how knowledge about health and illness moves from the more reified domain of clinical 
knowledge and expertise into that of the lay public, SRT provides valuable tools for 
how wider forces, both historical and cultural, impact an individual’s understanding and 
behaviour surrounding health and illness (Joffe 2002). Wagner et al., (1999) suggests 
how “in contrast to theories of attitudes, beliefs and values, which study phenomena 
only in terms of evaluations or as cognitions, the approach of social representations 
allows us to capture macro social phenomena in their historical totality and dynamics” 
(p.99). Such an approach allows for a more all-encompassing analysis of the 
multifaceted nature of groups in context, which is necessary given the complex, layered 
problem such as the emergence of a contested childhood mental disorder. As one 
aspect of socially shared knowledge, Linell (2009) considers social representations as 
“potentialities to evoke particular types of discourses, actions, and attitudes” (p. 242). It 
is those social phenomena arising from such discourse, especially those that tend 
towards remaining contested and of concern to the wider public, which produce 
tension and thus incite action through communication (Marková 2003). 
Theories of medicalisation have focused on external factors shaping the 
construction of illness, but the strength of a socio-psychological approach in general, 
and the use of SRT in particular, lies in opening up the ”black box” of medicalisation 
and paying attention to the role of representations, dialogicality and social influence 
shaping subjective and social reality. Exploring the tension between individual and 
societal knowledge, and understanding where the conflicts lie, or ways in which a 
diagnosis might be beneficial, and why it makes sense to have this particular category of 
behaviour, can all be better understood by thinking about the way PBD is discussed. 
Bauer and Gaskell (2008) write that the theory of social representations illustrates the 
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“process of transformation as ideas move in society” with such movement producing 
meaning through contact with the ‘Other’ (p. 339). In their contribution to Moscovici’s 
original theory, Bauer and Gaskell (2008) take as their central question what happens to 
ideas when they become part of common sense in particular contexts?  When a new 
medical phenomenon emerges, different groups make sense of it in different, 
sometimes oppositional, ways. Bipolar began as a rare adult affliction that has gradually 
expanded to include children. Even among those expressing concern about the 
expansion of diagnostic categories there is often acceptance that this is a ‘new normal’. 
According to Duveen (2000), two central functions of social representations are 
that they serve to both conventionalize the objects we encounter, locating them within a 
specific category allowing a starting point for interpretation, as well as acting as a 
prescriptive, becoming a guideline for thought and action. Such a combination enacts a 
structure “which is present before we have even begun to think, and of a tradition 
which decrees what we should think” (p. 23). Such structure is helpful in considering 
the psychosocial processes shaping how a new diagnostic category comes to pass, and 
can be seen in findings discussed in later chapters in which clinicians and parents 
realign what is seen in the behaviour of children they interact with what they feel they 
should seeing. How do ideas of what should be seen as representative of a diagnosis of 
PBD become integrated into wider thinking?  Social representations function by “giving 
form to objects, people and events that one may encounter by locating them within a 
given category”, thus providing a point of reference with which to communicate with 
one another (Moscovici 1984, 7). We are then able to draw on representations that are 
most useful and make the most sense when attempting to account for new phenomena.  
There is a tension that exists between prevailing psychiatric descriptions of 
disorder and a growing critique over the increase and expansion of psychiatric 
classifications. Looking at how PBD is constructed, produced and objectified by 
parents, clinicians and the pharmaceutical industry inevitably brings such contradictory 
representations to the fore. It is during periods of questioning, upheaval and change in 
which individuals are most motivated to apply meaning to experience in order to 
understand their increasingly uncertain world. Instead of focusing solely on the social 
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structures shaping how certain behaviours end up being labelled as pathological, SRT 
provides a framework to understand why and how this might happen, and additionally, 
why and how at multiple levels and across different spheres of knowledge. In focusing 
on how knowledge of PBD is constructed by different groups, SRT moves beyond the 
surface of the debates to examine the ways in which the diagnosis might be useful (see 
Cornish and Gillespie 2009) in the context not just of culture, but of daily lived 
experience. Representations of a powerful few have significant effects on what becomes 
accepted as fact. This legitimization is a circular process in that mutual influence and 
negotiation that comes into play with PBD, in which parents and clinicians view 
themselves, and one another, both as experts and as lacking full knowledge of what the 
diagnosis of PBD means. In writing of the role of social representations in the 
construction of social reality, Herzlich (1973) explains the fusion of individual 
experience with social phenomena that takes place through encounters with numerous 
values and models within a culture. It is through channelling the resultant knowledge 
into shared conceptual categories that Herzlich suggests results in the production of “a 
unique entity within which communication, consensus and social norms become 
possible” (p. 11). It is this space, this shared entity between three different spheres of 
knowledge production, that SRT is well positioned to explore in relation to the 
development, acceptance and resistance of a contested diagnosis such as PBD. 
2.3.1 Making the unfamiliar familiar  
Societies necessarily contain points of tension and disjunction. In considering the 
development of social representations within a culture that loathes uncertainty and 
absence of meaning, Duveen (2000) proposes that it is “around these points of cleavage 
in the representational system of a culture that new social representations emerge…in 
these points of cleavage there is a lack of meaning, a point where the unfamiliar 
appears” thus initiating the representational work to “familiarize the unfamiliar so as to 
re-establish a sense of stability” (p. 8).  Social representations exist as a means to make 
sense of the unfamiliar. Anchoring and objectification are two social psychological 
processes central to the formation of new social representations proposed by Moscovici 
(1961, 1984) in which individuals and groups construct and make sense of new 
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phenomena by linking up new, potentially threatening knowledge and realigning it with 
previously understood concepts and understandings, thus, the unknown is now 
included in an already established category. In his original examination of the concept 
of psychoanalysis, Moscovici (1961) noted the myriad ways different groups made sense 
of the idea by suggesting how the social group to which one belongs is central to 
shaping which aspects of socially embedded knowledge are drawn upon, and provide a 
map on which to base perceptions, comparisons and in the case of an emerging mental 
disorder, understandings of what constitutes normal versus pathological behaviour.  
While anchoring leads to the creation of the mental map with which to make 
unfamiliar phenomena familiar, objectification renders the abstract, unknown concept 
into something concrete, reducing “the mental to the physical and the unknown to the 
known by means of the creation of a figurative nucleus, words into images, or the 
transformation of images into elements of reality that can be concretely observed in 
people and things” (De Rosa 1987, 51). Objectification comes in the form of a physical 
symbolic object, for example a diagnostic label providing a set of behaviours into 
something tangible that can be assessed, acted upon and treated, a fact which provides 
comfort when faced with symptoms or behaviours less easily explained in terms of 
physical causes. In this sense, objectification of symptoms into diagnosis “saturates the 
unfamiliar concept with reality, changing it into a building block of reality itself” 
(Moscovici 1981, 198). Duveen and Lloyd (1990) propose that objectification is 
impossible unless a representation is already anchored (p. 2), however as I will show in 
later chapters, one of the theoretical contributions of this study will be to show that it is 
possible to have both happen simultaneously, in a way reminiscent of ‘build it and they 
will come’. In the case of a new diagnosis such as PBD, the idea of what it should be, or 
how it should look is introduced in the form of a diagnostic label, with individuals and 
groups then use as a point of reference with which to anchor new representations; 
representations which then make sense in terms of the object. The physicist James 
Maxwell captures the relevance of these processes noting that: 
what seems abstract to one generation becomes concrete to the next- what 
is unfamiliar and unperceived on one generation becomes familiar and 
obvious in the next (quoted in Moscovici 1984, p. 37) 
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Knowledge thus becomes objectified by virtue of the fact that it is passed on, whether 
among individuals, groups, or as in the excerpt above, generations. As a diagnosis, PBD 
is itself the direct result of the anchoring process, based as it is on a series of borrowed 
representations, rather than possessing any clearly defined diagnostic criteria of its own. 
PBD doesn’t exist as a category in the DSM 5 or ICD-10. Instead, its establishment as a 
diagnosis has happened as a result of drawing on adult criteria for bipolar disorders, 
realigning the symptoms and presentation with what is seen in children who show up in 
clinics with behaviours that lack a clear diagnostic home. More established illnesses 
such as ADHD and schizophrenia are repeatedly used as reference points by academics 
and clinicians in order to make sense of the children they see, adapting and reshaping 
adult criteria to try and fit with the new label that has been introduced. It becomes a 
circular process at that point, in which the anchoring of PBD in more established 
diagnoses creates the conditions for a new disorder to be reified as fact.  
Anchoring extends beyond the realm of diagnostic criteria to include treatment 
options as well. Healy (2006, 444) writes of how psychotropic medication for treatment 
of bipolar disorders was “based on analogy with epilepsy, rather than on 
demonstrations of proven clinical benefits” suggesting that even the choice of what 
medication to use is based on what has been used with other conditions. As it stands 
now, the most frequently used pharmacological interventions for PBD have never been 
the subject of clinical trials with children, but are instead used in smaller doses based on 
what has been known to work in adults, and as Healy (2006) has pointed out, adults 
with conditions other than bipolar disorder. Such choices are not made in isolation, 
however. What is required for anchoring and objectification to take place is a 
subscription to collective thought through which communication transpires. Whether in 
the form of newspapers, television, or research journals, turning the unfamiliar familiar 
necessarily requires interaction and engagement with others in order to establish a point 
of reference. The importance of a point of reference comes into play in further 
discussion of social influence in section 2.5.1 below, in which the development of new 
norms of childhood, and the definition, diagnosis and treatment of pathological 
conduct is shaped by these processes. 
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Moscovici (1984) suggests that a consequence of the classification that comes as 
a result of seeking to generate meaning and understanding about the unfamiliar is that it 
provides a set of characteristics on which individuals can form interpretations, base 
opinion and initiate action. These interpretations and opinions can only go so far on 
their own, as the true development of new knowledge and social objects is necessarily 
contingent upon interaction. As will be explored in the following sections, interactive 
processes shaping the social negotiation of what constitutes a new diagnosis in children 
stems from the clash and alignment of perspectives multiple individuals and groups 
encountering one another’s knowledge, as well as the dialogical interactions between 
one’s self, the other, and the object of PBD. Processes of perspective taking, 
recognition of the other, social positioning and influence are all involved in shaping the 
development of new social representations, and thus the acquisition and transmission 
of new knowledge. 
2.4 Encountering the Knowledge of Others 
This chapter began by highlighting Fleck’s epistemology in which the development of 
thought collectives stemmed from an examination of the changing concept of syphilis 
over time. The definition of what we have come to know about syphilis developed 
through interaction among and between these ‘thought styles’, through the meeting of 
ideas both in opposition and cooperation (Fleck 1979, 3). It is this encounter with other 
knowledge systems that is a central focus of a socio-psychological understanding of the 
development of a diagnosis. Without consideration of the perspective of the Other, 
there is nothing to come up against, react to, move on from or make sense of. 
“Knowledge” as explained by Linell (2009) is “socially generated, socially sustained, 
socially negotiated, transformed, confirmed and censored, and socially distributed” (p. 
241), brought about, reshaped, maintained, often rejected and rendered obsolete by 
virtue of communication between individuals and groups. For Jovchelovitch (2007) 
these aspects of knowledge production are necessarily interconnected with, and rooted 
in, the wider social and cultural context.  
In developing a framework to examine issues of communication for different 
groups, Jovchelovitch (2007) defines a knowledge encounter as “the meeting between 
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two or more representational systems, expressing different subjective, intersubjective 
and objective worlds” (p. 129), proposing a social psychology of such exchanges in 
which different representations, and the knowledge systems they enable, meet and 
communicate in public spheres. As defined by Jovchelovitch (2007), interactions: 
involve meeting points between knowledge of Self and knowledge of 
Others, between competing representations, practices and views of the 
world that both recast the communicative dynamics between Self and 
Other and bring to the fore the nature of the dominant representations Self 
holds about the knowledge of Other (p. 128) 
 
The use of the knowledge encounter framework is relevant for this thesis as 
knowledge about new disorders does not come out of nowhere, but rather through 
interactions between multiple actors, each with their own representational systems, 
both collective and social, that provide the context in which to develop understanding 
of a child’s behaviours, push specific agendas, engage in diagnostic practice, and 
position oneself as clinician or parent in the face of something so poorly understood. 
The construction of a diagnosis takes place through such interactions, and the variable 
nature of subjective and social knowledge and representations held within one 
individual or group, and the ways they can be reshaped through interacting with the 
perspective on the ‘Other’, makes this a compelling model for exploring the emergence 
of PBD.  
The diagnosis encompasses not only the child who carries the label, but also 
institutions and industry who have a vested interest, parents who both contribute to, 
shape and internalize such research, and the mental health professionals who find 
themselves negotiating all of these spheres, in addition to external pressures from a 
wider institutional framework in the form of social services, schools or the 
pharmaceutical industry. Notions surrounding behaviours making up PBD, or concerns 
related to prevalence, options for treatment, or even whether or not it exists as a 
biological entity, are acquired, consciously or not, via processes of negotiation. Within 
groups, there are those who will seek out knowledge in line with a desired outcome, and 
others who find themselves in receipt of a new set of terminology and behavioural 
categories that they were previously unaware of. Accepting and recognizing knowledge 
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held by another as legitimate is shaped directly by a participant’s existing knowledge of 
themselves and others (Jovchelovitch 2007, p. 139) as well as representations they may 
have regarding the source of information they are receiving, for example an innate 
mistrust of doctors, or a belief in the veracity of anything proposed in an academic 
medical journal. 
Instances of knowledge encounters can be seen in research related to social 
representations, such as Marglin’s (1990) examination of globalised (logocentric) versus 
localised (non- logocentric) conceptions of the smallpox vaccine brought from England 
to India in the 19th century. In highlighting competing meanings of illness both as an 
enemy to be prevented, controlled, conquered, or destroyed, and as part of a wider 
holistic system, Marglin (1990) explores attitudes towards vaccination through religious, 
political and naturalistic discourses. It is the battle between the scientific and the 
supernatural, in which one form of knowledge is presented as superior. 
Studies looking at representations of health and illness have also provided 
examples of knowledge encounters in action. In focusing on representations of mental 
illness specifically, Jodelet (1991) cites such explorations as “an ideal vehicle for the 
study of social thinking and its functioning” given how unstable and up for debate 
many ideas and assumptions about the nature of many mental health diagnoses 
continue to be (p. 8). In addition, the health sector more generally provides salient 
examples of the emergence not just of lay and professional knowledge systems, but the 
development within those areas for new forms of knowledge to enter the fray, such as 
that of experiential knowledge (Jodelet 2013). Jodelet’s (1991) study of representations 
held by members of a French community towards mentally ill lodgers living among 
them investigated ways in which the idea of ‘Otherness’ is constructed.  In this case, 
representations of madness linked with fear and contagion led to a “belief in the 
transmission of insanity” which was at the heart of conceptions of madness (p. 21).  
The concept of feeling threatened and afraid of the Other is also of concern to Foster 
(2001; 2003) in seeking to understand representations of mental illness constructed and 
maintained by both the lay public and mental health service-users. Proposing 
differentiation as a means through which  ‘healthy’ individuals hold up particular 
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ideological positions and strengthen identity, Foster (2001) suggests the emphasis on 
‘Otherness’ becomes much less straightforward and more complex when examining 
representations held by the service users themselves. Knowledge encounters between 
both lay and professional systems emerges in Morant’s (1998) comparative study of 
mental health professionals in the UK and France, suggesting that professional 
common sense is rooted in constant debate surrounding the many competing types of 
social and cultural knowledge, as well as institutional agendas (p. 834). Morant (1998, 
2006) argues that position of mental health practitioners as intermediaries between 
professional and non-professional worlds come as a result of their being called upon to 
translate knowledge between the scientific and lay spheres rendering it “compatible 
with and integrated into ‘common sense’ (ibid. 819).  
Beliefs about mental health and illness are not the result of a lack of knowledge 
or misunderstanding, but rather they are actively constructed to make sense of the 
frequently confusing and often contradictory experiences that people have (Zani 1995). 
In proposing that strategies developed for confronting illness are shaped by culturally 
specific health care systems, Zani (1995) suggests that it is the immediate need to assign 
a meaning to an illness that leads to an incompatibility with “slow, progressive advance 
of knowledge” producing “a continuum in which different interpretive planes co-exist” 
(p.145). Such a ‘quick-fix’ mentality can be seen in American diagnostic practice, where 
clinicians themselves experience tension between top-down and bottom-up systems of 
knowledge to create certainty in the face of an unstable, newly emerging diagnostic 
category, forced by virtue of professional reality to quicken the pace of knowledge 
advancement in the name of innovation.  
While the above review illustrates ways in which encounters between knowledge 
systems can be at odds, such meetings can also lead to fruitful dialogue between 
individuals, their wider community and context (Aveling and Jovchelovitch 2013). The 
idea of knowledge as produced from lived, situated action provides the means towards 
knowledge encounters developing into partnerships between all stakeholders shaped by 
institutional and sociocultural contexts (Aveling and Jovchelovitch 2013). Thus, 
knowledge encounters can be seen as overcoming necessary conflict to arrive at a 
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moment of joint action leading to positive intervention (ibid). Encountering the 
knowledge of others involves struggles over both content of representations, as well as 
identities and group projects that a system of knowledge expresses (ibid., p. 36). 
2.4.1 Recognition and perspective taking in knowledge encounters 
The knowledge encounter approach draws on interrelated concepts of perspective 
taking and recognition (Jovchelovitch 2007, 129), with different outcomes produced by 
Self and Other which depends on whether “interlocutors can communicate and 
mutually recognize one another as legitimate partners in interaction” (ibid. 132) The 
emergence of PBD can be seen as an illustration of what Jovchelovitch (2007) refers to 
as a “hierarchical representation of knowledge” in which imbalances in status and one’s 
power position link to the perceived worth of different types of knowledge and has a 
direct influence on the way that knowledge is communicated, received and legitimated. 
In this sense, the way in which a disorder is first presented to the public, or rather who 
is responsible for the introduction contributes to a social construction of meaning in 
which knowledge is often linked to specific interests and agendas, where problems such 
as those related to legitimation of certain knowledge systems by groups with powerful 
interests come to the fore (Campbell and Jovchelovitch 2000). The process of acquiring 
and diffusing knowledge about PBD is not a straightforward, top-down progression. 
Rather, there is an element of knowledge appropriation taking place in which 
boundaries between knowledge systems are blurred.  
Of particular interest is how individuals and groups use the new knowledge, for 
it is only in its usefulness that it may cross boundaries between institutions, 
professionals, parents and young people.  The development of a new medical 
phenomenon is reliant on different groups making sense of it in different, sometimes 
oppositional, ways. Gillespie (2012) suggests that it is by holding on to one’s own 
perspective, while simultaneously considering and adapting to those of others, despite 
the possibility of significant differences in attitude, opinion, or understanding that 
allows action to take place. The integration of perspectives allows individuals to move 
between their own perspective and that of the other leading to processes of 
representing. A central question to address in approaching a socio-psychological 
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analysis of the construction of knowledge relates to the question of what individuals or 
groups know about a particular domain or object, in this case diagnostic criteria for 
PBD, and on which social factors this knowledge depends (Flick 1998, p.45). 
Diagnostic boundaries are perpetually being reshaped, and with that reshaping comes 
the need to recalibrate representations. Whether this happens through overt dialogue, 
or less obvious, more subjective mechanisms, it is an area where looking at different 
types of knowledge produced via knowledge encounters is useful. Names, symptoms 
and treatment of specific conditions, are communicated in conversation or through 
media, shaping representations of what is normal versus disordered, shifting and 
changing shape as other knowledge systems are encountered. Thus, members of a 
group or similar social context develop different representations from one another or 
even within themselves. Conversely, a controversial diagnosis has the power to bring 
together people from different backgrounds in their collective identification with the 
struggles that go along with having experience with the disorder, demonstrating “how 
transformations in the public spheres of communities relates to the transformation of 
knowledge” (Jovchelovitch 2008, p. 129).  
Bauer and Gaskell (1999; 2008) suggest that the knowledge output of groups is 
not static. Over the course of the development of a disorder what begins as a sphere of 
knowledge made up only of professionals begins to open up to parental knowledge as 
well, creating new knowledge, which then may morph over time into a different 
representation of an object, or perhaps a different object all together. When it comes to 
a battle of meanings, not all ideas are equal (Castro 2014), and the clash of ideas and 
knowledge systems taking place in the development, adaptation and resistance of PBD 
as a diagnostic category can be seen as indicative of this. Of interest is the 
multidirectional flow of information and social influence, changing as it moves among 
groups. Perhaps a reference point is established within an organisational knowledge 
system, framed in terms of making a profit. Moving into the realm of those who mark it 
as such by virtue of their professional affiliation, it becomes reified as professional 
‘expert’ knowledge, finally being made sense of on the practical level of a parent who 
attempts to put such understanding into action through parenting the child. But often 
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what is put forth doesn’t make sense in a way that aligns with experience, so the lay 
knowledge is then fed back into the world of the professionals, who perhaps take it on 
board to reshape how they understand the object, which in turn feeds back to the 
institution, who looks at these knowledge systems as a means to further customize what 
they are putting out (fig. 2.1). So the knowledge encounter becomes a feedback loop, in 
which the encounter is never complete, and the knowledge is in a constant state of 
being added to.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Knowledge encounter feedback loop 
 
The following section elaborates on this looping effect to understand the dialogical 
interrelation between Self-Other-Object. As social representations are understood as 
socially embedded knowledge stemming from an individual’s membership and 
positioning within social groups, what people know and the way they come to know it 
is dependent upon the social groups to which they belong  (Flick 1998; see also Fleck 
1979). Recognising and taking another’s perspective necessarily requires interaction, and 
it is the dialogue that takes place, or is shut down, that forms the point at which a new 
object in the form of a contentious diagnosis in children takes shape. 
2.5 Dialogicality  
Social knowledge is made up of multiple voices, which take up fluid subjective positions 
in relation to actual or perceived others. A dialogical framework seeks to account for 
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how people relate to and understand the world, acquiring knowledge in divergent ways 
and proposing a way to understand human beings as not fully autonomous, but rather 
highly interdependent and reliant on one another’s perspective to shape our own (Linell 
2009). Thus, the development of knowledge, and resulting social representations, are 
socially elaborated via debates in which multiple perspectives come together to 
transform abstract information into more concrete meanings based on their own 
unique points of view (Clémence 2001). How these new social realities are devised, 
generated, understood and communicated are of concern to Marková (2003), who 
argues that such processes are necessarily take up between Self, or Ego, and Other, or 
Alter. The capacity of the human mind to relate and communicate, acquiring, 
appropriating and making sense of different forms of knowledge, grounds Marková’s 
explanation of the ontological nature of dialogicality, in which it is through 
communication that the Ego-Alter “intersubjectively co-constitute one another: one 
does not exist without the Other” (Marková 2006, 126). The knowledge generated as a 
result of these interactions is captured as a triangular relationship between Ego-Alter-
Object in which the object can exist as both external and internal to the Self (ibid. 128).  
In considering the importance of interactions between Ego-Alter, the question 
of what is actually meant by the Self and the Other is significant. Who exactly is the Self 
being referred to? And who is the Other? Linell (2009) discusses the possibility for 
“multiple abstract dialogues” that may take place within oneself such as internal 
dialogue, dialogue between competing ‘I’ positions, between ideas, paradigms or even 
cultural artefacts (p. 6). All represent aspects of what Hermans (2001) refers to as a 
‘dialogical Self’ in which such internal positions contribute to a ‘multivoiced Self’ (p. 
250). This is echoed by Linell (2009) elaborating on the multiple ‘Others’ a dialogical 
Self comes into contact with: those who we communicate with directly (concrete 
Other), and those who might be considered a more ‘generalized Other’ coming in the 
form of peripheral third parties who may shape how we think and position ourselves. 
Such ‘third parties’ often become aids to, or partners in communication, allowing us to 
move beyond expressing ourselves “only with regard to the immediate addressee, but 
also with respect to, and in respect of, absent third parties that:  
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must be made relevant by the primary participants, in spite of the fact that 
they may be silent in the interaction, play more peripheral roles than 
primary participants, and are sometimes even only virtually present (Linell 
2009, 100) 
 
These insights regarding multiple voices coming together in an individual Self stem 
from Bakhtin’s notion of ‘heteroglossia’ which, as Marková (2003) emphasizes: 
 
…saturates all aspects of dialogicality: ambivalence, hidden and open 
polemics, collisions and quarrelling. All of these are ridden with tension in 
which different points of view clash and languages overlap exposing them 
to new interpretations (p. 113). 
 
The tension brought about by interacting with competing perspectives, either internal 
or external, allows for one’s position and intention to be solidified. Of relevance to this 
thesis is the idea that dialogue does not only take place within interpersonal exchanges 
between Ego-Alter, but also simultaneously on the level of wider sociocultural practices 
within communities and institutions, orienting towards the wider “sociocultural and 
historical belongingness “ of the interaction, a level that Linell (2009, p. 54) terms 
‘double dialogicality’. This dialogue “at two levels” suggests one mechanism at play in 
the process of anchoring (cf 2.2.2), as in the case of imparting information or 
developing knowledge about a new diagnostic category with an unknown aetiology, 
paying attention to what is said about behaviours as symptoms is viewed in light of how 
it makes sense with a) what came previously, and b) acceptable explanations to draw 
upon to determine origins of illness, such as neurochemical explanatory frameworks 
that may filter how information about a child is processed. 
Dialogicality as a theory of social knowledge takes as its point of departure the 
“dynamics of social action” which, according to Marková (2003) provides a more 
robust model than those such as social cognition which tend towards regarding 
knowledge as somehow stable, not accounting for the dynamics of interaction between 
Self and Other (p. xii). This approach to dialogicality does not suggest a fusion of Self 
and Other. Instead, Marková (2003) allows that while communication can bring the 
position of Ego-Alter closer together, there remains room for independence as 
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individuals, despite a “dialogical interdependence” highlighting the role of perspective-
taking and intersubjectivity as a means to orient oneself in respect to another (p. 155). 
There is space for a ‘dialogical Self’ to emerge via multiple ‘I’ positions within an 
individual, and the reflexivity that comes through assessing the relationship between 
internal feelings and external events (Valsiner and Han 2008). This dialogical Self is thus 
positioned both personally and culturally, internalizing what takes place externally and 
becoming subjected to ‘position’ leaps in response to uncertainty and anxiety (Hermans 
2001). Shifting contact with multiple Others necessitates a recalibration of one’s ‘I’ 
position in response to the position of one’s interlocutor. In referencing Bakhtin’s 
position that the Self does not become one with another over the course of dialogue, 
rather what is at play is a development of understanding the strangeness that is the 
perspective of the Other (Marková 2003, 103).  Such processes to understand and 
access ‘the strange’ are what drive communication in the first place. It is the encounter 
between the Self and the strangeness of Other that leads to the imposition of meaning 
onto what is not known, as well as the appropriation the Other’s knowledge in a way 
that facilitates and supports making sense and rendering the unfamiliar familiar  
(Marková 2003, 104). Bakhtin (1981) expresses the interplay between Self and Other, 
and the process of taking on board another’s words and with it, it could be argued, 
aspects of their perspective: 
The word in language is half someone else’s. It becomes ‘one’s own’ only 
when the speaker populates it with his own intention, his own accent, when 
he appropriates the word, adapting it to his own semantic and expressive 
intention. Prior to this moment of appropriation, the word does not exist 
in a neutral and impersonal language…but rather it exists in Other people’s 
mouths, in Other people’s concrete contexts, serving Other people’s 
intentions: it is from there that one must take the word, and make it one’s 
own. (Quoted in Linell 2009, p. 76)  
 
This idea of appropriation is central to the construction of diagnosis. Researchers 
collaborate, ideas are borrowed and readapted for a different context, clinicians look to 
both pharmaceutical representatives, colleagues, parents, and their own subjective sense 
of expertise to shape diagnostic practice, and parents take on board academic and 
popular research, clinical advice, aligning that knowledge with their own experience as 
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parents of a “dysregulated” child. In all of these cases, the development and 
perpetuation of a diagnosis comes as a result of taking what is “half someone else’s” 
and making it one’s own, a process requiring reflection on how what is taken in makes 
sense, and is useful, in light of what is outside. 
2.5.1 Modalities of social influence  
While social influence represents its own core field of study within social psychology, it 
is included here as a subsection of dialogicality as, for the purposes of this thesis, 
modalities of social influence are considered as a communicative practice. In building 
on what has been laid out as the guiding framework for this thesis so far, the 
construction of diagnosis is seen as social and psychological processes dependent on 
the nature of the encounter between multiple stakeholders. Dialogical theory enabled an 
in-depth exploration of the interactions between Self-Other-Object involved in the 
construction of the diagnosis. These, I will argue here, are all guided and shaped by 
social influence, specifically the modalities of persuasion, conformity, accommodation, 
assimilation and resistance through minority influence, which this thesis will show to be 
key drivers in the development of PBD. 
Revisiting Fleck’s work, we are reminded of the trajectory of a new idea, 
beginning as hazy and lacking necessary proof for validation, but becoming more 
“precise and substantial” as evidence is culled from multiple points of view (Fleck 1979, 
p. 23). It is the pressure stemming from public opinion that steers scientific knowledge 
towards accepting the ‘correct’ hazy ideas and moving away from those that don’t 
belong (ibid). How an idea is deemed correct however, and why there may be several 
versions of what ‘correct’ looks like, is bound to how established a system of opinions 
has become, and how powerful the position of those advocating a particular system 
continues to be.  As a diagnosis given to children, there is a conspicuous moral 
component built into the establishment of diagnostic criteria and the assignment of 
behavioural symptoms. The question of what is normal is the natural counter-question 
to the push for pathology, thus exploring the evolving frames of reference and 
maintenance of norms giving rise to PBD is necessary starting point for further 
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understanding of the role of social influence in shaping wider representations, not only 
of the diagnosis, but the child as well.  
Sherif (1936) notes that rather than existing as absolutes, social norms develop 
over the course of relationships between individuals (p. 17). In this respect, the role of 
perceived social consensus in the development of knowledge about PBD then becomes 
central to the establishment of normative frames of reference, as well as its 
development as a diagnostic category. Moscovici (1976) postulates that consensus has 
two socio-psychological functions. The first refers to the validation of opinion and 
judgment. The confirmation that one’s social reality corresponds with the wider 
“socially endorsed” reality is essential in order to remove any doubt when encountering 
the perspective of another that may contradict one’s own. Conflict is a necessary 
condition of influence, stirring uncertainty and ambiguity and leading to the second 
function of consensus, Self-affirmation through making one’s private reality a public 
reality  (Moscovici 1976, p. 152). In externalizing our private reality, we are asking 
others to join us in seeing what we see to be true. Consensus is a central consideration 
of this thesis, as it is a lack of consensus surrounding what bipolar disorder in children 
should look like that shapes how clinical representations of PBD are formed. The lack 
of agreement opens up space for a clinician’s own subjective doubt, as well as sidelong 
pressure from colleagues, institutional pressures from above, and parental anxiety from 
below, all of which create multiple “socially endorsed realities” that the clinician must 
then make sense of and choose from. Both of the above functions of consensus- 
validation and endorsement- become part of the influence process. However that which 
dominates, and therefore shapes interaction, is determined by social norms (Moscovici 
1976). 
Social norms remain unstable entities, however Sherif (1936) posits that there 
can be a collective decision among individuals faced with an ambiguous object to 
perceive order by developing a frame of reference among themselves, thus lending 
some temporary stability (p. 90). As a practice, psychiatry is built on an individual 
clinician’s subjective appraisal of a situation and set of behaviours, however as a 
profession positioned within the field of medicine, objective measurements and 
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empirical evidence are seen as being essential for credibility. Thus, the need for 
validation that one’s opinions are correct and in line with prevailing norms of the 
group, what Festinger (1954) refers to as ‘subjective validity’, becomes a driver shaping 
understandings of PBD. The issue lies in the uncertainty surrounding the diagnosis, 
both in terms of diagnostic criteria, as well as clinical agreement over how best to define 
the disorder. The more ambiguous a situation or phenomenon, the more likely one is to 
depend on social reality, and collective consultation with a reference group, for 
orientation (Moscovici 1976, 31). The reference groups with which one aligns is 
significant in this respect, as it is this group that provides the norms and values against 
which on evaluates and compares one’s own opinion (Turner 1991), supporting 
Festinger’s assertion that an opinion is only valid to the extent that it is aligned with a 
group of people holding similar beliefs, opinions and attitudes (ibid, p. 19). 
In examining how such norms are developed, Sammut and Bauer (2011) 
present a model of the cycle of normativity as a mechanism through which influence is 
put into practice in the development and maintenance of norms. The cycle presents 
normalization as resulting from the accommodation and assimilation of new 
knowledge, perspectives and ideas. The starting and end point of the cycle is the notion 
of a frame of reference, which provides a structure against which one might measure 
how well aligned their (or another’s) perceptions, judgements, and attitudes actually are 
(fig. 2.2).  
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Figure 2.2: The ‘cycle of normativity’ as described by Sammut and Bauer (2011) 
 
Thus, the success of a frame of reference is necessarily dependent upon how members 
of a group are able to abide by them, and provide a means against which to judge 
newcomers (Sammut and Bauer 2011). A central modality of influence involved in the 
development of a frame of reference is that of persuasion. Within social psychology, 
multiple socio-cognitive models exist to elaborate on how and why people change 
attitudes as a result of persuasive techniques of communication. The Yale Group, 
established by Hovland and colleagues researching at Yale University Sought to identify 
effects of persuasion on attitude change, paying particular attention to power and 
characteristics of the source of a communicative message, the nature and particular 
features of the message itself, and a consideration of the audience receiving the 
message, and how different audiences might be receptive to such changes (Hovland, 
Janis and Kelley 1953). This was expanded upon by Petty and Cacioppo (1986) in 
developing the elaboration likelihood model of persuasion (ELM) proposing a more 
cognitive, dual-process route to persuasion via central processing (slower and more 
deliberative, however likely to lead to lasting change) and peripheral processing (more 
immediate, but fleeting). While this thesis emphasizes the multiple directions of 
influence, the ideas laid out in the ELM model provide an understanding of how, for 
Norm
Assimilation of 
newcomer
Accomodation
Normalization
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example, the position of a clinician as a respected expert might make for a credible 
source, sought out by pharma as an influential ‘opinion leader’ (cf 4.6.1) or trusted by 
parents who may feel they have no other point of information, as with those living in 
England (cf 6.3.3). Sammut and Bauer (2011) discuss the notion of soft-power tactics as 
a means to persuasion, seeking to resolve conflict through communication by 
attempting to convince another that one’s own perspective is right, with the intended 
outcome that the recipient of persuasive communication ultimately shifts their position 
to align with that of the source of the communicative act (p. 88).  
 The accommodation and assimilation of new individuals, ideas and 
understandings is central to the cycle of common sense laid out by Sammut and Bauer 
(2011) as well. In this thesis, it is the presence of conformity pressures, minority 
influence, and the challenging of consensus in shaping the level to which knowledge of 
the Other is accommodated, or rejected, that is of concern. As will be discussed in later 
chapters, the assimilation of a new ‘broad spectrum’ idea of PBD is not taking place in 
England, while in the US it is the challenging of previous consensus in psychiatry 
stating bipolar cannot exist in young children that is being challenged. Adapting, or 
conforming, to group norms allows for a sense of group orientation and increased Self-
esteem via social validation, as discussed in the previous section. However the presence 
of one group’s version of reality existing as the version of reality to be held as ‘correct’ 
leads to shutting down the consideration of alternative options in favour of maintaining 
some illusory form of consensus (see for example Janis 1972). The strength of a 
dominant perspective that others may unwittingly conform to thus has the power to 
change what is morally desirable as well, as in the case with the increasing 
medicalisation of children’s behaviour. Normative influence exerts powerful force in 
shaping conformity, as illustrated in classic studies by Asch (1952) showing the degree 
to which errors in estimation of objective truth can quickly become biased towards an 
objectively incorrect view held by the majority (Sammut and Bauer 2011) leading to a 
new frame of reference. Once a system of opinions has been established, it offers on 
going resistance to anything that may contradict it (Ng 2001) however those who find 
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themselves in a minority position still have the power to reshape such systems, as long 
as there is consistency (Moscovici 1976). 
Social representations are co-constructions produced by different groups, with 
“executive producers” changing over time as the representation develops (Breakwell 
1993, p.183). These representations held by a powerful few are significant in the way 
they affect the views of those with less status, legitimacy or recognition who may have 
less recourse to influence the development of the representation (Breakwell 1993, p. 
188) and indeed it is through such patterns of influence processes that specific 
representations become stabilized (Duveen 2001). However, as will be shown in this 
thesis, a characteristic of minorities suggesting a desire for recognition and belief in the 
necessity of influencing the dominant social order to come around to see its own 
perspective as valid is what drives persistence and innovation (Moscovici 2001). The 
power of the minority lies in its ability to challenge consensus and resist conformity 
pressures, as will be illustrated in the discussion of clinicians and parents in chapters five 
and six.  
The exercise of social influence via normalization acts as a powerful system 
fostering the accommodation of new ideas, a model of which proves particularly 
relevant to this thesis as it pertains to modalities of persuasion, soft-power, conformity 
and minority influence as significant mechanisms at work in shaping norms dictating 
the development of knowledge and practice around PBD. While I draw on this ‘cycle of 
normativity’ to explore the role of influence as a communicative practice shaping the 
development of representations, my own approach moves away from seeing the 
assimilation of newcomers and accommodation of dissenting views as being based in 
Piagetian ideas of socio-cognitive development and a schema/environment interaction 
as proposed by Sammut and Bauer (2011), instead focusing on it in terms of 
challenging consensus, conformity pressures and validation shaping accommodation of 
the knowledge of Other, and the establishment of a new norm. The salience of these 
particular processes as they relate to the development of a diagnostic category will be 
illustrated in chapters four, five and six, and discussed in depth in chapter seven when looking 
empirically at the role of the pharmaceutical industry, clinicians and parents in the US 
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and England in the development of representations of PBD. The modalities, and 
interactions themselves, need not only to be considered as mechanisms driving social 
influence, but also as processes with multiple vectors. The myriad directions of these 
modalities of influence, whether they are unidirectional, or exist multi-directionally as a 
feedback loop via interaction with Others, is central to the degree at which an idea may 
be taken on board or discarded. 
In discussing the need for the temporal and cultural context to be open to a 
new idea or object, it is influence through the power of language and dialogue that 
emphasizes how a new idea might be useful through both revealing and reflecting the 
power behind it (Ng 2001, p. 90). Thus, in looking at the way in which the 
pharmaceutical industry, clinicians and parents in the US and England discuss PBD, 
paying attention to who’s terminology and perspectives are adopted, and the processes 
guiding this adoption (or rejection as the case may be) sheds light on where the power, 
and thus influence, lies. 
2.6 Conclusion 
A diagnostic category such as PBD is more than a mental illness. Rather it is a set of 
expectations surrounding what constitutes normal behaviour, made up of contrasting 
representations surrounding the meaning of childhood that collide in local (family), 
institutional (medicine, education, pharmaceutical industry), and societal knowledge 
systems, becoming more powerful and reified the more institutionalized they become. 
Fleck (1979) writes of the necessity of a concept to be “sufficiently intertwined or 
interwoven within the fabric of contemporary knowledge in order to be considered 
finally established as an undoubtedly “real fact”’ (p.6). This project, through closely 
examining the construction of a new diagnosis by multiple actors in two separate 
cultural contexts, provides insight into why certain disorders take hold, while others 
continue to be resisted. The positioning of clinicians (see chapter five) negotiating a wider 
social and institutional hierarchy, in which they may exist as majority or minority 
players, are faced with top-down political and economic pressures from local medical 
systems, as well as bottom up psychological pressures which directly influences clinical 
approaches to diagnosis and treatment. Parents (see chapter six) face their own battle for 
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recognition of their experiential knowledge, wanting not to be blamed for poor 
parenting, but to be heard, understood and accommodated. Always in the background 
is the influence, however camouflaged, of the pharmaceutical industry (see chapter four) 
who has relied on persuasion via mechanisms of soft power to influence interaction 
with those deemed useful in order to shape new representations, and thus norms, of 
childhood.   
Exploring multiple modes and levels of knowledge production is where a socio-
psychological approach to the problem of changing definitions of healthy versus ill can 
provide a more dynamic account of how and why this happens than might be found in 
other socio-scientific approaches. It is the role of representations as modalities of 
knowledge in the construction of social, and psychiatric, reality that makes it a useful 
framework in which to study how such a disorder is constructed and taken up by 
different groups. Gaskell (2001) advocates a social representations perspective noting 
that it allows room for the dynamism present in cultural, scientific and technological 
developments to be considered, as different knowledge bases represent differing 
realities, each with their own concerns, enthusiasms and agendas. Thus, social 
representations of PBD may actually play a central role in the development of the 
wider, continuously developing reality of PBD, pointing to the co-constitutive 
development of medical knowledge. Jaspers notes that “more than the physicians’ 
judgment, it is the dominant ideas of the social context, which determine what is called 
“disease”’ (quoted in Canguilhem 1989, p. 121). It is precisely this idea that can be 
brought forward through an exploration of dialogical processes and representations 
held by members of the wider social context, and modalities of influence as 
communicative practice underlying their development.  
Central to how this thesis has been approached theoretically is the question of 
the function and motivation of particular discourses, and in particular the quest for 
validation and legitimisation of particular knowledges, whether they are institutional, 
professional or lay knowledge systems. The appropriation of language and ideas related 
to PBD points to the strategic action of dialogue, as well as the presence of 
asymmetrical knowledge and power dynamics influencing which understandings of 
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PBD are taken up. Vaughan (2011) brings to the fore power dynamics that can shape a 
more ‘strategic’ approach to communication. Strategic action:  
…may involve appearing to accommodate the Other’s perspective, but this, 
importantly, is not for the purpose of developing new knowledge and a 
mutually derived communicative goal. Rather, the purpose is effective 
achievement of the speaker’s ‘I’ intention (Vaughan 2011, 51)  
 
One’s subjective opinion within a wider collective determines how one makes sense of 
and communicates information about a particular object. PBD has developed as a result 
of interactions between the very powerful, and those who may be perceived by 
themselves or others to be less powerful, but they have all had a stake in the 
development of the diagnosis on some level. All have produced knowledge, 
accommodated the knowledge of the Other and contributed to redefining 
representations of the child at the centre of the diagnosis. The strategic action of 
dialogue in order to maintain one’s power position, as elaborated in the excerpt above, 
allows for a deeper understanding of social processes, such as medicalisation, by 
highlighting intentions and goals present in communication. The generation of meaning 
and redefinitions of problematic conduct can be found in an exploration of the 
function and motivation surrounding what is said.  The multiple ‘voices’ playing a part 
in developing knowledge of what behaviours should be deemed pathological for 
example, introduces a way of considering why there is an increased comfort with 
identifying certain aspects of childhood as being worthy of medical study, diagnosis and 
treatment.  
It is this focus on representational processes of anchoring and objectification, 
combined with knowledge encounters, dialogical processes, the personal positioning of 
Self and Other within those interactions, and the role of social influence shaping those 
interactions that form a central contribution of this thesis, one which will be explored 
in further detail in the remaining chapters. The following chapter, chapter three, will 
present an overview of the methodology involved, followed by analysis of the ‘voices’ 
of the pharmaceutical industry on a global scale (chapter four), clinicians in the US and 
England (chapter five), and parents in the US and England (chapter six). A final discussion 
chapter will bring the empirical analysis together with the theoretical frameworks that 
 
 
 
 
74 
have been presented here in order to advance a socio-psychological understanding of 
the construction of knowledge around a diagnosis, which remains controversial, 
contested and uncertain, and what impact cultural context has on the development of 
this knowledge. 
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3. Research design and methodology 
 
3.1 Introduction 
This thesis is concerned with the diagnosis of PBD and the psychosocial processes at 
play shaping how a new and emerging condition is constructed in the US as compared 
to England. The availability of particular assumptions and ideas circulating in the public 
sphere are very much a product of a unique set of circumstances that make up a cultural 
‘present’; one in which notions of health and illness are formed out of established and 
newly emergent social norms, as well as the wider political economy of groups and 
organisations with interests in how the wider society understands and acts upon notions 
of health and illness. The purpose of my research builds on this idea to explore how 
and why a new mental illness in children, PBD, has taken hold in a particular time and 
place, and how differing perspectives have contributed to acceptance or contestation of 
the diagnosis. In order to address this, the current study utilises a grounded-theory 
(Glaser and Strauss 1967) qualitative approach to analysis in which the voice of the 
pharmaceutical industry, clinicians and parents in the United States and England is 
explored, allowing theory to develop from the data.  A qualitative comparative research 
design using document analysis, image analysis and semi structured in-depth interviews 
was chosen in order to develop an understanding of the multiple perspectives in their 
particular social contexts, and in relation to this specific disorder (see fig. 3.1 below). 
PBD remains controversial, as there is still no firmly established, agreed upon set of 
criteria objectified in any diagnostic manual. The United States and England represent 
two different ‘cultures of medicalisation’ in which societal values and social norms feed 
into how emotional distress in a child is interpreted. The diagnostic debates taking place 
around PBD acts a vehicle to understand how these different systems of knowledge 
operate in order to develop an understanding around diagnosis and practice. Thus, 
context is central to understanding PBD, making a qualitative approach useful in 
exploring the multiple perspectives, knowledges and interactions taking shape in the 
establishment of the diagnosis. 
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In what follows, the methodological framework for the thesis is presented, 
beginning with an outline of the research contexts. I will then present the procedures 
involved in the three empirical studies that make up this thesis: the ‘voice’ of the 
pharmaceutical industry as accessed via the analysis of internal documents and 
pharmaceutical advertising; clinicians in the United States and England; and parents of 
children with the bipolar diagnosis in the United States and England. The analytic 
procedures for each study will be described in more detail in the associated empirical 
chapter. My aim with this chapter is to present the empirical component of the thesis 
and offer the reader a full methodological account of the research. The overarching 
question guiding the research has been how is the diagnosis of PBD constructed in the 
US as compared to England. The three studies were guided by the following sub-
questions: 
 
1) What are the social representations of PBD held by the pharmaceutical 
industry, and how has the industry contributed to wider understandings of 
PBD as a diagnostic fact? 
 
1a) What factors shape such representations within the pharmaceutical 
industry?  
 
2) What are the representations of PBD held by clinicians in the US and 
England, and what psychosocial processes have shaped those 
representations? 
 
3) What are the representations of PBD held by parents in the US and 
England, and what psychosocial processes have shaped those 
representations? 
 
4) What do the content and processes of representations of PBD among 
Pharma, clinicians, and parents suggest about the construction of the 
diagnosis in the US as compared to England? 
 
An important factor when considering a research project related to a contested 
mental illness in children, a sensitive topic where strong opinions, moral and value-
based assumptions are necessarily brought to the fore, is my own position as a 
researcher. I bring up the idea of reflexivity here, before detailing the methodological 
approach taken in the research, as it was my position as investigator, but also as an 
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outsider in most respects, that was on my mind at every stage of the research process. 
Robson (2011) asks what responsibility investigators have for the knowledge they have 
acquired as a result of the research they have conducted (p.199). This was something on 
my mind constantly, both while conducting the interviews and analysis. While speaking 
with parents, for example, I was conscious of the fact that I was not a parent myself, so 
how could I possibly know what it was like to be a parent in the situation my 
participants were in, and make assumptions about what it is they were really saying or 
thinking? While I don’t doubt that my attention might have been directed differently 
had I been in a closer position to my participants, I believe my distance from the 
immediacy of their experience was important for the sake of attempting to maintain 
objectivity. Qualitative research necessarily involves interaction between the researcher 
and the data and thus interpretation and presentation of findings always involves some 
part of the researcher (Cutcliffe 2000). As such, individual researchers act based on the 
meaning the object of their research has for them as opposed to any outside scholar, 
determining what is taking place in interaction rather than imposing a subjective set of 
expectations and assumptions (Blumer 1969).  As a researcher, I agree that an 
awareness of preconceptions, beliefs and any prior knowledge being brought to the 
study needs to be maintained, however I disagree that it should be cast aside all 
together, as that would be impossible. Instead, I agree with Stern (1994) in the assertion 
that it is the creativity in the act which qualitative research allows that “brings the truth 
of a social situation into being” (Cutcliffe 200, p. 1479). This is not to say that as a 
qualitative researcher I was giving myself free-reign to pull concepts and theories out of 
nowhere, rather I sought, through a deep familiarity with the data, to respect what was 
said and continued attention to the research questions.  My awareness of my position 
hopefully allowed me to approach the interviews and analysis with a sensitivity to the 
fact that I was on the outside, while at the same time keeping the research questions 
and theoretical frameworks close. 
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3.2 Research contexts 
This thesis is generally concerned with questions surrounding how a medicalised 
condition becomes a globalised diagnosis, moving across cultures by virtue of 
construction, transmission and application of medical knowledge. The United States 
and England were selected as two cultural contexts representing two ends of the 
spectrum: expansion versus resistance of a new diagnosis. As discussed in chapter one, 
PBD is still very much rooted in the US context, with literature suggesting differing 
diagnostic practices as the reason for cross-cultural discrepancies in prevalence rates 
(see Stringaris 2010; Clacey, Goldacre and James, 2015). As mentioned earlier, the 
rationale for a comparison with England rests on a number of factors:  the broader 
institutional cultures of medicine in the two contexts (consumer-driven versus 
socialised), the use of different diagnostic manuals and related reliance on insurance 
codes, variations in lay- familiarity with the language of diagnosis, arrived at via 
exposure to self-help manuals and direct-to-consumer marketing of medications and 
the conditions they treat,  and finally the role of health care users in steering clinical 
practice. An exploration into how those practicing or parenting within these systems 
provides insight into whether the genesis of PBD is something of a modern-day ‘culture 
bound’ syndrome, or if there is in fact another way to understand why the diagnosis, 
how it comes to be conceptualised and enacted, has thrived in the US while remaining 
rare elsewhere in the world. 
Chapter two introduced the conceptual framework guiding this research in which 
a social representations approach is drawn on as a means to understand the movement 
of knowledge about PBD, something which is still very much in-progress and affords a 
unique research opportunity on the emergence of a psychiatric condition.  Given the 
concern of social representations theory with the transmission, diffusion and 
transformation of medical knowledge, and particularly the way it is held and rendered 
useful by non-professionals, a comparison not just among individuals, but also across 
cultural boundaries, allows for a way of understanding diagnostic construction as it 
continues to take shape. England was seen as an appropriate comparative context in 
that it has gradually seen an increase related diagnoses, such as ADHD. Additionally, 
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PBD has been recognised, though not fully accepted, as a diagnosis both clinically (See 
Dubicka et. al 2008; James et. al 2014, Chan, Stringaris and Ford 2011) and in the most 
recently updated NICE guidelines (NICE 2014). Thus, comparison between the 
birthplace of the diagnosis and a place where it continues to be negotiated allows for an 
exploration of what social psychological processes are at play in the development, 
acceptance, or rejection of a particularly controversial diagnostic category. 
In seeking to understand this condition in particular, the US is an obvious 
starting point given its position as the birthplace of the diagnosis. The consumer-driven 
nature of the US healthcare system, and questions surrounding broad systemic and 
institutional practices leading to increasing medicalisation and treatment on mental 
health conditions, provides the backdrop out of which PBD emerged and continues to 
be contested even as the diagnosis continues to become more common. The healthcare 
context of the US is made up of a combination of government programs such as 
Medicare and Medicaid and for-profit private insurance programs all of which provide 
health coverage for approximately 260 million Americans, with about 49 million 
remaining uninsured (Sillup and Makowska 2013, 6). The majority of Americans are 
privately insured (195 million) with the majority of that population covered through 
their employers (ibid.). The importance of access to insurance matters when it comes to 
discussion of PBD, as the link between insurance and the pharmaceutical industry 
dictates how the disorder is diagnosed, who is diagnosed, and how it is treated. A 
related aspect of the US context which will be discussed in chapter four of this thesis is 
the presence of the direct-to-consumer advertising of pharmaceuticals, permeating the 
public sphere with a familiarity of myriad health conditions, as well as their 
pharmacological treatments. Such advertising does not exist in England. 
England provides an interesting comparison in that there is significant overlap 
with regards to research, the use diagnostic tools such as the Diagnostic and Statistical 
Manual of Mental Disorder (DSM), and the acceptance of several formerly contested 
diagnoses, for example Attention Deficit Hyperactivity Disorder (ADHD). However, 
ideas about children and mental illness continue to be secondary, where the national 
health system is less prepared to ‘see’ such illnesses in very young children, and as a 
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result the diagnosis of PBD remains rare, with an element of resistance to the 
possibility of existence as defined by broader diagnostic criteria coming out of the US. 
The differences in the debates surrounding children’s mental health in these two 
cultural contexts provides a fertile ground on which to explore how such a diagnosis 
comes to be accepted or rejected on multiple levels. Several years ago the diagnosis of 
ADHD went from being seen in England as virtually non-existent “American problem” 
to something diagnosed not just in children, but now adults as well.  There is a sense 
that a similar cultural shift is taking place with the diagnosis of PBD, however the 
degree to which it is recognised by professionals and the general public depends on the 
extent to which knowledge about the disorder circulates, and is understood, in a wider 
societal context.   
The English healthcare delivery system is the responsibility of the central 
government (Grosios, Gahan and Burbridge 2010) which designates a healthcare 
budget generated from tax revenues for the National Health Service (NHS), which is 
the main employer of medical staff and one of the largest healthcare systems in the 
world (Sillup and Makowska 2013, 6). Although the NHS represents the fifth largest 
pharmaceutical market in the European Union, it continues to control the majority of 
drug prescriptions, signifying that the UK is “the highest user of generic drugs and the 
lowest user of new drugs in Europe” (ibid., 8).  
This research is especially timely given the most recent publication in the US of 
the latest version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
in 2013, a publication recently dismissed by The National Institute of Mental Health 
(NIMH) in the US, who called into question its legitimacy as a diagnostic tool (Insel 
2013). Its publication has reignited debates in the US and beyond surrounding what 
constitutes mental illness, how best to approach expanding diagnostic categories for 
children, and the potential medicalisation of childhood behaviours.  A comparison with 
England provides a compelling angle in that the UK, by virtue of the way the NHS is 
set up, is less bound to the rules and codes of the DSM (using the ICD-10 in 
conjunction) and the influence of the pharmaceutical industry and its related marketing 
practices in the US.  
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Figure 3.1: Illustration of overall research design  
 
3.3 Study 1-The ‘voice’ of the Pharmaceutical industry  
The first study explores the ‘voice’ of the pharmaceutical industry as a key actor in the 
development of PBD as a diagnostic category on a global scale (see Chapter Four). 
Medical and scientific knowledge is generated through social processes made possible 
by myriad institutional practices including political decision-making, research funding, 
collaborations between researchers and institutions (Pickersgill 2010). The 
pharmaceutical industry sits at the intersection of these practices, where research, 
marketing and dissemination of medications and the conditions they treat shape wider 
understandings of what it means to be ill, and what pathology can look like. For this 
reason, the inclusion of the pharmaceutical industry as one of the three ‘key’ voices was 
deemed necessary to provide a more complete picture of the genesis of this particular 
diagnosis. 
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3.3.1 Internal pharmaceutical industry documents  
Documents are a useful source of data as they provide a level of understanding of the 
social realities and representations taking place within particular institutional contexts 
(Flick 2006). Internal industry documents are used here for their role as communicative 
devices that were designed to fulfil a practical purpose, thus illustrating the existing 
knowledge systems within the industry at the time, reflecting the industry’s own agenda 
in developing a wider understanding of children’s mental illness. In total, fifteen 
documents were chosen for analysis to represent a range of perspectives from within 
the industry (see table 3.1).  The documents were selected based on the most prescribed 
medications to children for PBD and include Risperdal (Johnson and Johnson), 
Zyprexa (AstraZeneca) and Seroquel (Eli Lilly). The documents were previously 
confidential, but are now found in the public domain, and included court transcripts 
from a former CEO of a pharmaceutical company, a former pharmaceutical sales 
representative who would make sales calls to clinicians, marketing plans for 
medications, internal emails, and slide presentations used to educate clinicians and sales 
representatives.   
 
Table 3.1 
Internal pharmaceutical industry documents 
              Document Name Pharmaceutical 
affiliation 
Year 
 
1
1 
Seroquel strategic plan, 1997-2001 AstraZeneca 
Seroquel 
1
1996 
2
2 
Drug evaluation letter from US Food and drug 
Administration 
Johnson & 
Johnson (Janssen) 
Risperdal 
1
1997 
3
3 
Zyprexa Marketplace Strategy Eli Lilly 
Zyprexa 
2
2000 
4
4 
Business Plan Summary, Risperdal Johnson & 
Johnson (Janssen) 
Risperdal 
2
2000 
5
5 
Minutes of meeting with FDA to discuss pediatric 
exclusivity and development program for conduct disorder 
Johnson & 
Johnson (Janssen) 
Risperdal 
2
2000 
6
6 
PCP (primary care physician) Discussion Guide Eli Lilly 
Zyprexa 
2
2000 
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7
7 
2001 Integrated Product Plan, Zyprexa product 
Team 
Eli Lilly 
Zyprexa 
2
2001 
8
8 
Zyprexa Global Marketing Plan, 2003-2004 Eli Lilly 
Zyprexa 
2
2002 
9
9 
Zyprexa primary Care Sales Force Resource Guide Eli Lilly 
Zyprexa 
2
2002 
1
10 
Proposal/Budget: trial 99, 104, 105, 104+105 
Abstract preparation and submission, USPMHC 16th US 
psychiatric & mental health congress 
AstraZeneca 
Seroquel 
 
2
2003 
1
11 
Zyprexa Retail Resource Guide Eli Lilly 
Zyprexa 
2
2003 
1
12 
Internal email AstraZeneca 
Seroquel 
2
2004 
1
13 
Risperdal litigation trial, Bentley vs. Janssen. 
Transcript of Pharmaceutical sales rep Tony Jones 
Johnson & 
Johnson (Janssen) 
Risperdal 
2
2012 
1
14 
Risperdal litigation. Transcript of videotaped 
deposition of Alex Gorsky, former CEO Janssen 
Johnson & 
Johnson (Janssen) 
Risperdal 
2
2012 
1
15 
Civil action court document, United States in 
Complaint Intervention, including sales call notes from 
pharmaceutical sales reps 
Johnson & 
Johnson (Janssen) 
Risperdal 
2
2013 
 
 
Sources: Documents 5, 13-15 from Brill, S. (2015). All Others from 
University of California San Francisco Drug Industry Document Archive 
(https://www.library.ucsf.edu/db/drug-industry-document-archive-dida) 
 
Documents were drawn from two sources. Eleven came from the University of 
California San Francisco online drug industry document archive, which is a collection 
of documents “created by major pharmaceutical companies related to their advertising, 
manufacturing, marketing, sales and scientific research” 
(https://industrydocuments.library.ucsf.edu/drug/). The search focused on three 
medications, using childhood/paediatric/bipolar as search terms. The remaining four 
documents, all related to the drug Risperdal, came from an interactive article published 
by the Huffington Post (Brill 2015).  
3.3.2 Pharmaceutical drug advertisements  
The second data source in the study of pharmaceutical representations of PBD was the 
external manifestation of the industry’s ‘voice’ in the form of drug advertisements. In 
citing McCluhan, Farr (1995) suggests that advertisements are “part of the folklore of 
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an industrial culture. It is quite literally, possible to read the signs of the times” (p. 15). 
In conducting an analysis of pharmaceutical drug advertisements, it is possible to get an 
illustration of which ideas about mental health are being perpetuated (Foster 2010. 
Advertisements are designed not only to influence, but also to reflect existing 
professional ideas and to support professional identity (Foster 2010) thus contributing 
to wider implications for how treatment is perceived. Thirty-two unique advertisements 
(there were multiple ads repeated) were drawn from paper copies of the Journal of 
American Child and Adolescent Psychiatry (N=12) and the British Journal of 
Psychiatry (N=20) at three points in time: 1997; 2004; and 2011 to reflect any potential 
growth in familiarity with PBD after it was introduced in 1995 (see table 3.3). 
 
Table 3.2 
Medical journals and advertisements accessed January-June at three points in time: Total ads (unique 
ads) 
Journal Timeline  
1997 
 
2004 
 
2011 
British Journal of Psychiatry 19 (7) 19(11) 9(2) 
Journal of the American Academy of Child and Adolescent Psychiatry 5 (1) 14 (6) 14(5) 
 
Advertisements selected excluded those for anti-depressants, instead focusing on 
medications exclusively indicated for childhood mental disorders (ADHD) or were used 
off label for PBD (antipsychotics such as Risperdal). An initial scan of the ads was done 
to get a sense of what stood out visually and in terms of text, size of ads, which journals 
they were found in before undertaking a semiological and thematic content analysis 
discussed in section 3.6.2 below 
3.4 Study 2-Clinicians in the US and England 
The second study focuses on clinical representations of PBD, comparing health 
professionals practicing in the US and those in England (see Chapter Five). Clinicians in 
the US and England play a significant role in communicating the disorder to parents 
and recommending treatment options. Clinical professionals, particularly those working 
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in children’s mental health, are working amidst what Galanter and Patel (2005) refer to 
as the “variability and inaccuracies in diagnosis” (p. 675) in which the risk of a child 
being misdiagnosed as a result differing clinical perspectives can result in inappropriate 
or harmful treatment. This diagnostic inconstancy is central to the debates around 
children’s mental illness, thus the inclusion of clinicians allows not only for an 
understanding of professional opinion and personal struggles regarding the existence of 
the disorder, but also what drives diagnosis, especially in the realm of third party 
(parents, teachers) pressures, and their subjective positioning in relation to these. The 
decision to use semi-structured in depth interviews was one of both practicality and 
theoretical considerations. Gaskell (2000) writes how “the social world is not an 
unproblematic given. It is actively constructed by people in their everyday lives, but not 
under conditions of their own making” (p. 39).  Thus, the usefulness of depth 
interviews lies in their potential to explore how ideas and meanings are developed in the 
course of a conversation, through shifts in thinking and the choice of how other 
perspectives are represented. Exploring clinical discourse, or by extension that of the 
pharmaceutical industry and parents also present in this thesis, is of interest as an 
approach as it acts as a behaviour in its own right, as well as “the virtually unique 
window that it opens on what lies behind our actions” (Robson 2011, 280). 
3.4.1 Participants 
Semi structured interviews were conducted with mental health practitioners in the 
United States (n=8) and England (n=10). In the US, child and adolescent psychiatrists, 
and one psychiatric nurse, were sampled from both private and public health services 
and interviewed in June and July 2013. The sample comes from university clinics and 
community hospitals four urban areas on the East Coast (n=4) and in the Midwest 
(n=4). In England, the sample is made up of clinical psychiatrists and psychiatric nurses 
who were contacted via Child and Adolescent Mental Health Services (CAMHS) and 
specialist clinics in in Greater London (n=7), Gloucestershire (n=2) and Oxfordshire 
(n=1) and interviewed March-December 2013.  All clinicians, including those who were 
affiliated with research, were practitioners involved in the daily assessment and 
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treatment of children with behavioural disorders (see table 3.3 below for participant 
information. 
 
Table 3.3                                                                                                     
Clinician participants and codes: England and the US 
English 
participants  
 
Position 
US  
participants 
 
Position 
UKC 1 Child and adolescent psychiatrist: 
practitioner/research 
USC 1 Child and adolescent psychiatrist: 
practitioner/research 
UKC 2 Child and adolescent psychiatrist: 
practitioner/research 
USC 2 Child and adolescent psychiatrist: 
practitioner/research 
UKC 3 CAMHS nurse USC 3 Child and adolescent psychiatric 
nurse 
UKC 4 Child and adolescent psychiatrist: 
practitioner/research 
USC 4 Child and adolescent psychiatrist: 
practitioner/research 
UKC 5 Clinical child psychiatrist USC 5 Clinical child psychiatrist 
UKC 6 Clinical child psychiatrist, CAMHS USC 6 Child and adolescent psychiatrist: 
practitioner/research 
UKC 7 Clinical child psychiatrist, CAMHS USC 7 Child and adolescent psychiatrist: 
practitioner/research 
UKC 8 CAMHS mental health nurse USC 8 Child and adolescent psychiatrist: 
practitioner/research 
UKC 9 Clinical child psychiatrist- CAMHS   
UKC 10 Child and adolescent psychiatrist: 
practitioner/research 
  
 
This project takes a theoretical approach to sampling, which Gobo (2008) describes as 
constructing a sample, meaningful through building in certain characteristics or criteria, 
which helps to develop and test the proposed theory and explanation. Gobo (2008) 
notes that groups are selected on the basis of relevance to research questions, 
theoretical position and analytical framework, analytical practice and explanation being 
developed. The sample was constructed in order to access perspectives of those 
working with children with PBD in order to enable specific questions to be answered 
related to the development of knowledge around the diagnosis. It provided a set of 
clinical and parental voices on PBD, allowing for a comparison of how these different 
groups contribute to the construction of the condition, illustrating socio-psychological 
mechanisms at play in the construction of diagnosis. 
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One limitation with this aspect of the study, however, was that the inclusion of 
more ground-level community psychiatric practitioners in the US would have provided 
a broader perspective, but as a testament to the shortage of services available, it came as 
little surprise that they were over-subscribed and unable to speak to me.  Clinicians 
were contacted initially via phone or email and provided a brief description of the 
project. Information sheets and consent forms were sent via email to those who 
expressed an interest in learning more. Those who agreed to participate were 
interviewed in their office where all interviews were audio recorded with permission 
and lasted from sixteen minutes to one hour and a half for a total of 18 hours of 
interview data.  
3.4.2 Interview protocol 
In-depth individual semi-structured interviews were conducted with all participants. 
The aim of the interviews was to explore clinician’s own conceptualizations of bipolar 
disorder in children, and to discuss the diagnosis in relation to a number of dimensions, 
which included the children, parents, school and the pharmaceutical industry. The 
interview explored three levels: (i) description of PBD, (ii) sources of knowledge about 
the disorder and (iii) personal feelings about diagnostic practice. Questions raised 
concerned each of these levels.  Additionally clinicians were asked about their 
interactions with parents and children, what their ideas were regarding how best to treat 
the symptoms, and broader questions related to changes they may have seen in 
children’s mental health over the course of their careers. The questions served as a 
guide, and interviews were open to move into territory not formally laid out in the topic 
guide. For the full topic guide of interviews, see Appendix 8. 
3.5 Study 3- Parents in the US and England 
The final study seeks to understand representations of PBD held by parents in the US 
and England (see Chapter Six). Carugati and Selleri (1998) write that parents “find 
themselves daily at the crossroads of salient and socially value laden experiences of 
differences, for which both experts and parents have no ultimate exhaustive 
explanations” (p. 178). Tied into this are dominant social ideas regarding “normal” 
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childhood behaviour, and moral judgments over parenting skills. Thus, the perspective 
of parents, and an awareness of the way PBD is understood and communicated by 
those living within different cultural and medical cultures, is central to understanding 
the construction of a diagnosis. 
3.5.1 Participants 
Participants interviewed included 15 American parents drawn from regions, both rural 
and urban, across the US, and 5 in England, specifically Greater London, (n=2) 
Oxfordshire (n=1), Gloucestershire (n=1), and the West Midlands (n=1). As it can be 
noted, the number of parents interviewed in England was considerably smaller than in 
the US. Parents selected had children aged 4-16 who had been formally diagnosed with 
PBD, and there were difficulties in establishing a more symmetrical data set. It was 
extremely challenging to gain access to parents in the UK. This is itself indicative of the 
differences between the two contexts, and will be discussed further in chapter seven. In 
the US, diagnostic criteria is often applied to pre-school aged children, while in 
England, the age is typically young people who have reached adolescence. Thus, the age 
range was chosen in an effort to capture possible cultural differences in age of 
diagnosis, allowing for younger children and older adolescents to be represented. 
Parents are not included if an official diagnosis had not been made.  
In the US, parents were recruited via an organization devoted to paediatric 
bipolar disorder called The Balanced mind Foundation, based in Chicago, Illinois. After 
making initial contact with Balanced Mind, information sheets about the research were 
submitted, which they then disseminated to their mailing list of families located all 
across the US, in both urban and rural areas. Those parents who were interested then 
contacted the researcher, and a phone or Skype interview was arranged.  
English parents proved to be much more difficult to access as participants, as 
will be discussed at greater length below. I began my search by contacting an online 
forum that was based out of the US.  There were several parents from England on this 
website, however only one who responded to my request for an interview. In the 
context of the forum, this parent mentioned they had self-diagnosed with bipolar 
disorder, and now felt they were seeing the same thing in their eight year old daughter. 
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Noting that in England it was impossible to get her daughter assessed and treated for 
bipolar disorder at such a young age, they sought advice from other parents in this 
forum. I then contacted a number of mental health charities in the UK, including those 
specifically for children’s mental health, and those for bipolar disorder. When asking 
about the potential for speaking to parents of children with bipolar disorder, I was told 
on a number of occasions that the diagnosis didn’t exist in England, and that I would 
have better luck focusing on ADHD. Never the less, an advertisement was posted on 
the Re-Think website, and from this I had a second parent contact me agreeing to 
participate.  
The rarity of the diagnosis in England, combined with the stigma that remains 
around mental illness, meant that acquiring a snowball sample for this population 
wasn’t materializing. A final attempt to access parents via local CAMHS teams resulted 
in an involved process applying for ethical approval through the NHS Integrated 
Research Application System (IRAS), a process which ultimately took close to two years 
to finalize. An initial application was made to work with a group in one particular 
council who had agreed to put me in touch with parents. At the last minute, this fell 
through due to short staffing. A new application was made, and a new sponsor found 
with a consultant child and adolescent psychiatrist at the Highfield Unit at Warneford 
Hospital, Oxford. With this psychiatrist’s assistance, three more parents were found 
who were interested in participating. We were unable to access any more than this 
however, leading to a very small sample size for this population. 
3.5.2 Interview protocol 
In-depth individual semi-structured interviews were conducted with all participants. 
The aim of the interviews was to explore parents’ own conceptualizations of bipolar 
disorder in their children, and to discuss the development of their understanding of the 
diagnosis, from their initial knowledge up to the present. The interview explored three 
levels: (i) early understandings and sources of knowledge about PBD (ii) navigating the 
search for support and treatment and (iii) definition of PBD and how parents believe 
Others think about PBD, including those in England (asked of US parents) and those 
in the US (asked of English parents). The questions served as a guide, and interviews 
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were open to move into territory not formally laid out in the topic guide. Most parents 
seemed eager to share their experiences, and often “began at the beginning”, 
communicating their trajectory into the world of PBD in a manner suggestive of a 
personal/familial narrative. Interviews lasted from forty minutes to over two hours in 
some instances and resulted in 24 hours of recorded data: 15 hours for American 
parents and 9 hours for those in England.  For the full topic guide, see Appendix 7. 
 
3.6 Analysis of data 
As stated previously, a qualitative approach to analysis was taken in this study. Analysis 
of pharmaceutical industry internal documents and interview data with parents and 
clinicians all involved both thematic (Attride-Stirling 2001) and dialogical (Sullivan 
2012; Gillespie and Cornish 2010) analyses, while analysis of advertisements 
incorporated a semiological analysis (Penn 2001) combined with a qualitative content 
analysis (Bell 2000) in order to fully explore and appreciate the visual elements so 
important in shaping how illness is represented in this format. The use of thematic 
analysis allows for flexibility in organizing and analysing the data, as it is free from any 
one theoretical or epistemological stance it can be applied using a number of 
approaches (Braun and Clarke 2006) and allows for the identification of significant 
themes coming up in discussion. Here it was used as a constructionist method 
examining how realities, experiences and meanings surrounding the emergence of PBD 
as a diagnostic category are shaped by multiple, often competing, discourses taking 
place in the wider cultural contexts of the US and England.  
A dialogical approach to analysis was pursued as a second order level of analysis 
as it allows for a more nuanced exploration of subjectivity (Sullivan 2012). As I will 
show in the three empirical chapters that follow, these theoretical drivers inform 
analysis in that a consideration of who is being addressed in an exchange, and the 
‘multiple voices’ that are present are central shaping individual perspectives, as it grants 
a level of understanding of explicit and implicit views and reference points (Gillespie 
and Cornish 2010). Drawing on notions of the ‘dialogical Self' as proposed by Herman 
(2001) the struggle for dominance that multiple subjective I-positions experience at 
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different times, depending on the context and the relationships being addressed, is of 
interest methodologically for the purposes of this thesis. Such attention shifts a 
researcher’s attention to the ‘personal position’ of a speaker, which involves identifying 
the varying ‘positions’ that the Self assumes, whether internal or external (Sullivan 
2012). The significance of these positions become salient when looking to see which 
‘Others’ coming up in conversations, and how the speaker positions both themselves 
and the Other, and in what capacity. The steps taken in the analysis of the data sets 
making up this project are now presented in the following sections.  
In approaching the analysis of interviews, attention to what people say, but also 
what is not being said, helps access representations held without witnessing an actual 
physical interaction (Flick, Foster and Caillud 2015, 68). As it was not possible to 
arrange focus groups as part of this research due to clinician schedules, and the far 
reaching logistics of parent-participants, this approach proved valuable as a tool to 
explore the function and motivation of participants’ discourse as it related to those with 
whom they are interacting, addressing, echoing, and thus constructing knowledge about 
PBD.  
3.6.1 Internal pharmaceutical industry documents 
The steps taken in the analysis of internal pharmaceutical industry documents are listed 
below. As with the interview data, the documents were analysed at two levels: a first 
order thematic analysis in order understand what was being said by those voices within 
the industry, followed by a second order dialogical approach to analysis in order to 
understand who was being addressed in the documents and how. This analysis helped 
answer research question numbers 1 and 1a:  
•What are the social representations of PBD held by the 
pharmaceutical industry, and how has the industry contributed to 
wider understandings of PBD as a diagnostic fact? 
 
•What are the factors shaping such representations within the 
pharmaceutical industry? 
 
From the beginning it was determined that the documents would be analysed according 
to notions of Self and Other, thus, these classifications were assigned as global themes, 
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perhaps beginning at for what is often the end point of a thematic analysis. With this in 
mind, documents were read in order to familiarize with the data, and coded based on 
initial descriptive dialogical coding to identify who was being discussed as ‘Other’ and 
In Vivo coding in which words and phrases from participants own language in the data 
(Saldana 2013). Coding methods were chosen based on the nature of the research 
questions, which sought to explore the phenomenon of PBD from the myriad 
perspectives involved in shaping its construction. Central to the research design was a 
desire to understand the processes and interactions taking shape within pharmaceutical 
industry discourse, thus allowing for an exploration of what was being said about PBD, 
the dynamics of the wider industry culture, who the central players were, and how they 
were being discussed. Codes were refined and merged before then being grouped into 
what became ‘basic themes’ (see Attride-Stirling 2001). For example, a number of codes 
for the internal documents related to profit-motives, economic pressures, and 
competition from other pharmaceutical companies, and threats to the business 
marketing model. Codes of this type were grouped into a basic theme 1.1.1: ‘Pressure to 
expand indications for medications in the face of competition and economic pressure’.  See appendix 9 
for coding framework.  
These ‘basic themes’ were based on the content of the data, however at this 
stage a dialogical approach to analysis was introduced in which the themes pulled from 
the data were analysed and grouped according to who’s ‘voice’ was coming through in 
the text. On the most basic level, the voice was a question of whether it was the 
multiple actors making up the pharmaceutical industry speaking as an industry-wide 
‘Self’, or whether the content of discourse focused on, echoed, or referred to various 
‘Others’, and if so, who those Others might be. These ‘Others’ showing up in 
pharmaceutical industry discourse were then positioned as ‘organizing themes’ as 
follows: 
• The voice of pharma (‘I’ position) 
• Industry competitors 
• Clinicians 
• The child 
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While parents are central to this thesis, they were not a significant point of discussion 
within the documents so were thus left out of the framework. Once it became clear 
who was being discussed in relation to the development of PBD, these actors were 
aligned under the appropriate global theme of Self (in the case of the industry talking 
about its own position) or Other (incorporating competitors, clinicians and the child).  
Coded excerpts were then revisited and analysed paying more attention to how 
significant others were being discussed in order to report the basic themes for 
discussion. 
3.6.2 Pharmaceutical drug advertisements 
Analysis of pharmaceutical drug advertisements also set out to answer research 
questions 1 and 1a as above. The idea was to have an internal voice of the industry 
represented through documents, followed by the analysis described here, representing 
the external voice of the industry that is presented to clinicians and the consumer 
public. Ferner and Scott (1994) propose that:  
Science requires the unambiguous description and logical analysis of facts. 
This is not the purpose of advertising, which shares with art the use of 
oblique visual and verbal images to convey the message it wants us to 
receive. The advertiser tries to influence our visual and verbal images to 
convey the message it wants us to receive” (p. 1734).   
 
In the analysis of pharmaceutical advertisements, my concern lay in the intention of the 
ad. What is the discourse being put forth? What debates does it enter into?  A 
semiological analysis of these images allow for an understanding of how images make 
meaning and how they work within a broader system of meanings (Rose 2001). Penn 
(2000) notes that the act of viewing image or reading text is a constructive process, thus 
an analysis of pharmaceutical advertisements employing a process combining 
denotative semiological analysis (outlined by Penn 2000) sought to identify what was 
happening in the image and what level of knowledge was needed to “grasp” the 
signification at this level. An initial scan of the images to see what stood out at first 
glance was combined with a qualitative content analysis following Bell (2001) in which 
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the variables and values present in each advertisement were coded. The final 
connotative level of the ad was concerned with more dialogical associations such as 
what knowledge is required to see the image a certain way, and who might the intended 
audience be? The steps involved in analysis of the advertisements are as follows: 
Step 1: An initial scan of the full sample of ads was undertaken to get a sense of 
what stood out visually and in terms of text, size of ads, which journals they were 
appearing in, and any difference in prevalence or type of ad over the course of the 
years. 
Step 2: The second step in analysis of the advertisements involved performing 
what Penn (2000) refers to as a “denotational inventory”  (p. 232) in which elements in 
the image and text were coded to identify what is being said in the text, where text and 
image is positioned, how it is represented visually. The purpose of this stage was to 
capture the literal meaning of what was being presented in the advertisements, a 
systemic approach which Penn (2000) suggests is necessary to ensure that analysis is not 
“selectively Self-confirming” (ibid). This stage of analysis followed Bell’s (2001) 
approach to visual content analysis in which codes were assigned by attributing values 
to variables (such as image type, pictorial elements, gender, role represented and 
setting). For example pictorial elements might include that the advert was muted and 
dark, covering two full pages, while the text suggested a “mind in turmoil” presented in 
blurred text emerging out of the obscured profile of a middle aged-woman in an 
unknown setting. Coding at this stage also considered what appeals were present in the 
ad, what normative values were being perpetuated, who the ad was addressing, and 
how. This added an element of dialogicality in seeking to get beyond the literal image, 
allowing for a broader understanding of how the ads were being used, and what cultural 
knowledges were required of the viewer. 
Step 3: The final stage built on the denotational inventory to analyse what 
associations are brought to mind in the image and text, what is absent, how the 
elements relate to each Other. The wider context of the ad was considered at this stage 
as well, considering whether it was found in a US or UK based medical journal. See 
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appendix 10 for a full coding frame and sample of analysis notes for a selected 
advertisement. 
3.6.3 Interviews with clinicians and parents  
Analysis of interviews involved a combination of an inductive approach in which 
interview transcripts were coded openly to see what patterns developed in data, and a 
more deductive approach in which data and developing themes were viewed with a 
socio-representational framework in mind. This analysis helped answer research 
questions 2 and 3: 
•What are the representations of PBD held by clinicians in the US 
and England, and what psychosocial factors have shaped those 
representations? 
 
•What are the representations of PBD held by parents in the US and 
England, and what psychosocial factors have shaped those 
representations? 
 
Applying a socio-representational approach to the data builds on notions surrounding 
how illness is constructed by moving beyond looking wholly at external social factors 
shaping diagnosis, and adding the dynamic of constructive processes at play which 
allow individuals and groups to produce, objectify and make sense of a new disorder. 
As discussed in section 3.4 above, analysis of interview data was broken down into two 
levels with a first order thematic analysis following Attride-Stirling (2001) followed by a 
dialogical analysis (Gillespie and Cornish 2010; Sullivan 2012).  The steps taken in 
analysis are presented below. 
 
Step 1. Becoming familiar with the data 
In order to become familiar with the data, I transcribed all interviews, taking informal 
notes as I did so in order to catch potential areas of interest coming up in discussion. 
This, along with reading and re-reading the interview transcripts, allowed for a 
reflection on the data, serving as a sort of preliminary analysis to begin thinking around 
not just what was being said, but how it was being said. Interview transcripts from 
clinicians and parents were then uploaded into NVivo 10 in order to begin coding.  
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Step 2. Generating initial codes                                                                                         
The process of coding began in an exploratory fashion, with an initial coding frame  
created using open codes generated inductively from all interviews, beginning with 
clinicians, combining the US and England data sets. Excerpts of the data coded 
included text segments relating to meanings, assumptions and interpretations of PBD 
(for example “unstable” or “neurochemically based”) as well as specific actions or 
practices around the diagnosis (such as the tendency elaborated by clinicians for 
American parents to “shop around” for a doctor willing to consider PBD as a 
diagnosis). This initial coding frame was then revised to approach analysis of the groups 
separately so as to compare themes and dialogical processes coming out in data. Coding 
was then expanded beyond open coding to a more theoretical ‘axial’ coding (Robson 
2011) to interconnect the previous open codes, and approach the data with a renewed 
approach to relationships and interactions being depicted or discussed in the data.  
It was decided that as the focus of my research questions narrowed, and themes 
emerged from the initial descriptive coding, that the coding framework should be 
expanded to allow for the uncovering of knowledge encounters and dialogical processes 
taking shape in the interviews. Thus, the most significant ‘Others’ to come up in 
discussion with clinicians and parents, including the parent and clinician’s subjective 
positioning of their ‘reflexive Self’ were taken as the basis for NVivo’s ‘parent- nodes’ 
(global themes according to Attride-Stirling, 2001) forming the structure of the coding 
framework. For clinicians this was as follows: 
• Position of the clinical Self 
• Clinicians on professional colleagues 
• Clinicians on parents 
• Clinicians on the pharmaceutical industry 
• Clinicians on the child 
• Clinicians on the US/England 
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As the clinician data set was the first to be analysed, it acted as a template for how to 
develop the subsequent coding frames. Once it was decided that the inclusion of a 
dialogical perspective was going to be central to the analysis, the coding framework for 
parents began by laying out the global themes of parent as Self, identifying who the 
significant Others were in their discussion, and then coding and clustering into themes 
according to what was being said with regards to a specific Other.  The framework was 
refined and reflected these ‘Others’ coming up in conversation:  
• Position of the parental Self 
• Parents on clinicians 
• Parents on schools 
• Parents on the pharmaceutical industry 
• Parents on peers/colleagues 
• Parents on the child 
 
For parents, the first round of descriptive coding resulted in initial themes that were 
then sorted into whom this content was referring to. For example the code of ‘feeling 
ignored’ came about in how parents discussed their interactions with clinicians, so was 
placed as a child node under the global theme ‘Parents on clinicians’. All of the codes 
coming under this heading were then grouped together to form organizing themes 
making up what parents were saying about clinicians with regards to PBD, and how 
they were saying it. Excerpts in which parents or clinicians were talking about these 
significant others were then isolated and interpreted in order to bring out themes 
emerging to further explore what message was being communicated and why it was 
being communicated in a particular way.  
 
Step 3. Identification of themes                                                                                           
Once coding was complete, the text segments were then analysed to pull out salient 
themes. The themes were grounded in the data, however were based on decisions 
shaped by the theoretical approach chosen and were clustered together. All of the 
excerpts falling under the headings outlined above were re-read, sometimes reworked 
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and moved or deleted as part of an iterative process where the data was revisited, 
followed by analysis, followed by revisiting the data, and so-on until it was determined 
that a valid set of themes could be established, and compared within their networks. 
The coding frameworks for clinicians and parents can be found in appendices 11 
through 14. 
 
Step 4: Dialogical analysis of representative quotes                                                       
After pulling out themes in the interviews with parents and clinicians, representative 
quotes were selected for a more in depth dialogical analysis to contribute to the final 
interpretation and summary outlined in the following section. Quotes that made up the 
basic themes were carefully read to identify subject position, paying particular attention 
to what/who was being quoted directly. Questions asked of the data at this stage follow 
recommendations from Gillespie and Cornish (2010) and include the following:  
• What is the context? 
• Who is being addressed and how? 
• Who is doing the talking and how? 
• What are the responses, actual or anticipated? 
 
In approaching selected excerpts this way, I sought to illustrate not just how clinical and 
parental discussion about significant Other plays into their own understanding of PBD, 
but also how they positioned themselves in relation to these various Others, and what 
that might suggest about why they conceptualize PBD the way that they do. An 
example of dialogical analysis can be found in appendix 15. 
 
Step 5:  Interpretation and summarization of themes and dialogical processes taking shape in the data 
The final step involved the fine-tuning of the global theme Self and Other into 
expansive organizing themes of who the Self (e.g. the ‘clinical Self’) and who the others 
were (e.g. ‘the child’), and finally into basic themes for discussion (how the clinician was 
discussing the child, for example as ‘a cluster of symptoms’). Throughout analysis, I 
maintained a focus on the interactive threads present in the data, and how the thematic 
elements (content) coincided with the dialogical elements (process) when parents and 
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clinicians were free to elaborate on PBD, from the very practical definitions and 
symptoms, to more abstract ideas and meanings about perceptions of pressures shaping 
the development of thinking around PBD, or the crystallization of a perspective on a 
significant Other. 
3.7 Ethical considerations 
The ethical review board at the London School of Economics and Political Science 
approved the study and informed consent was obtained for each interview. In addition, 
approval for the English parent-participants was obtained from the NHS via the 
Integrated Research Application System as discussed in section 3.5 above.  In 
considering ethical issues with regards to the research I am engaged in, there is a risk 
that when parents are asked to reflect on their experiences negotiating their child’s 
diagnosis they may become upset. It was not my aim to ask such personal, probing 
questions, however if it edged towards this in the course of conversation, I responded 
asking if the participant wanted to move on to a different topic. This was never taken 
up, however. I was able to provide web addresses and phone numbers for support 
groups for parents of children with bipolar as part of my information sheet provided to 
parents so that there was an awareness of outside support as being available. 
Additionally there is the issue of confidentiality. In order to ensure confidentiality is 
maintained, all interview data was anonymised at the point of transcription, with 
participants given unique codes instead of using names. I was the sole transcriber of 
this data, and as I transcribed I was also in a position to remove any identifying details 
such as the location or institutional affiliation of participants. Informed consent sheets 
were sent out alongside information sheets explaining the research, were discussed and 
signed prior to beginning the interview. Participants were also offered the opportunity 
to view the anonymised transcript once it had been transcribed.  
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4. Pharmaceutical marketing practices and the expansion 
of  a diagnostic category 
 
4.1 Introduction 
The aim of this chapter is to understand the role of the pharmaceutical industry in 
shaping representations of paediatric bipolar disorder (PBD). Medications used to treat 
the diagnosis feature prominently in the analysis that follows, which leads to the 
question of why a study focusing on a representation of a particular diagnosis includes 
analysis of representations of medications. The answer lies in the genesis of PBD as a 
diagnostic category, and how closely bound its emergence was, and continues to be, 
with the production of medications in need of something to treat. From its inception as 
a diagnostic category, PBD has been rooted in controversy as a result of its attachment 
to a pharmaceutical marketing model, something not as salient in other childhood 
mental illnesses such as unipolar depression or autism spectrum disorders. This chapter 
focuses on the organisational ‘voice’ of the pharmaceutical industry as communicated in 
marketing practices for the medications used to treat bipolar disorder. The decision to 
have a chapter focusing on medication grounding a wider project concerned with 
conceptualizations of the diagnosis itself is rooted in the fact that PBD as a diagnosis is 
directly related to the development of the medications which could act as a treatment. 
The expansion of disease categories as a means to justify new uses for medications, or 
revamp the indications for existing drugs is central to the debates surrounding PBD as a 
diagnostic category and will be shown in my analysis of internal documents related to 
the marketing and promotion of the medications used to treat PBD (Risperdal, Zyprexa 
and Seroquel), as well as the advertisements used to market these medications, in the 
following sections. 
The research questions guiding this chapter are as follows: 
•What are the social representations of PBD held by the 
pharmaceutical industry, and how has the industry contributed to 
wider understandings of PBD as a diagnostic fact? 
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•What factors shape such representations within the pharmaceutical 
industry? 
 
The chapter is broken down into three sections. Section one is a background to 
contextualize the role the pharmaceutical industry has played in the development of the 
diagnosis so far. This is followed by section two, an analysis of internal industry 
documents and finally section three, and analysis of advertisements ending with a 
chapter conclusion. 
 
4.2 The pharmaceutical industry and the genesis of a diagnosis 
In their exploration of how the concept of paediatric bipolar emerged out of a once-
rare diagnosis of manic-depressive psychosis, Healy and LeNoury (2007) present a 
narrative history of the diagnosis applied to children as being borne out of the 
aggressive marketing of bipolar in adults, illustrating how “company strategies in one 
domain can resonate in another, in this case the paediatric domain” (p. 209). Central to 
their argument is the idea that the construction and expansion of this diagnostic 
category can be directly linked to pharmaceutical marketing practices. In seeking to 
expand the market for the new breed of ‘atypical’ antipsychotic medications, a process 
takes shape in which “a new and flexible notion of the condition that bears little 
resemblance to the classical representation of bipolar can then be applied to ordinary 
variations in temperament” (Moncrieff 2014, 582). This link has become common 
knowledge as a result of lawsuit in which the pharmaceutical company Johnson & 
Johnson was forced to pay $2.2 billion in criminal and civil fines for improperly 
promoting the antipsychotic Risperdal to children, including those with PBD (Thomas 
2013). A relationship between Johnson & Johnson and a leading child psychiatrist at 
Harvard Medical School, Doctor Joseph Biederman was exposed, as the company had 
paid Rd. Biederman to act as a “Key Opinion Leader” and provided over $700,000 to 
establish a centre for the study of paediatric psychopathology. Doctor Biederman and 
his group began generating studies suggesting that children suffering from ADHD 
could actually be suffering from Bipolar Disorder, thus fuelling a 40-fold increase in the 
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diagnosis, and the expensive, risky antipsychotic Risperdal as its treatment, from 1994-
2003 (Harris 2008). 
A 2014 report from The Agency for Healthcare Research and Quality (AHRQ) 
shows that mental health conditions are repeatedly found to be the largest expenditure 
for children’s health (Express Scripts, July 10, 2014) with roughly 41.5% of mental 
health expenditures coming from prescription medication (Soni 2014).  In a recent 
study comparing hospital discharge rates for paediatric bipolar in the US as compared 
to England between 2000 and 2010, James et al. (2014) found a 72-fold difference in 
discharge rates for young people with a diagnosis of PBD (US: 100.9 per 100,000 
population versus England: 1.4 per 100,000 population).  Overall, hospital stays for 
bipolar disorder for all children aged 1-17 increased 434% (O’Meara 2013), while from 
2005 to 2009, disruptive behaviour disorders were the most common diagnoses in child 
and adolescent visits resulting in the prescription of antipsychotics, accounting for 
63.0% and 33.7%, respectively (ibid.). 
The growing use of antipsychotic medications in this age group, coming from 
both off-label and FDA approved uses, has greatly expanded both the range of mental 
disorders treated with these medications (Olfson et. al., 2012) as well as the ages of the 
children receiving the medications, with some being prescribed to preschool children 
aged 2-6 years despite little understanding of their long term effects (Harrison, Cluxton-
Keller and Gross 2012). These statistics demonstrate the reality of how the link 
between medication and diagnosis comes into play, with antipsychotic medications that 
once existed solely in the realm of treatment for serious psychotic disorders in adults 
now being used to quell disruptive behaviour in young children. Parents, providers, and 
policy makers are “eager for quick, effective, and inexpensive treatment to stop 
children’s disruptive behaviours, as children with emotional and conduct-related 
disorders are more likely to be expelled from preschool, require special education and 
healthcare services.” (Harrison, Cluxton-Keller and Gross 2012, 139). 
Fortune 500 drug companies have emerged as the most dominant influence in 
the US healthcare system due to the powerful economic sway they hold (Diller 2008). 
The field of child and adolescent psychiatry is especially open to influence owing to the 
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uncertainty surrounding children’s mental illness, an openness that sees drug company 
research funding, professional medical education and direct to consumer advertising 
contributing to wider explanatory frameworks emphasizing neurochemical explanations 
for behaviour, and pharmaceutical solutions, as opposed to approaches such as 
education or parenting skills (ibid). The disease model of psychiatry has drastically 
reshaped how we view behaviours in light of what is considered normal versus 
pathological, and nowhere is this more apparent than in the field of children’s mental 
health. The pursuit of medical facts “is increasingly dominated by considerations of 
marketing from start to finish” (Kirmayer and Raikhel 2009, 9).  
Medications play a direct role in the process of diagnosis when illness is 
diagnosed with a specific course of treatment in mind.  Norms for behaviour end up 
being associated with a specific illness organized around medicines available to treat the 
problem as much as symptoms that may be present (Vuckovic and Nichter 1997), thus, 
a situation is created in which the process of defining a diagnostic category comes not 
via objective and agreed upon criteria, but rather the medications which are available to 
potentially provide treatment (Wedge 2015). Increasing clinical acceptance of 
antipsychotics for problematic aggression in disruptive behaviour disorders may have 
increased the number of children and adolescents being prescribed antipsychotics, while 
the growth in clinical diagnoses of bipolar disorder for children and adolescents may 
have further increased antipsychotic use in young people. This is especially the case for 
boys and racial minorities (Olfson et. al., 2012) leading some to suggest that 
pharmaceutical companies are “abusing kids by treating behaviour like a disease” 
(Azerrad  2016) and blurring the boundaries of where health ends and disease begins, 
redefining undesirable behaviours as potentially risky symptoms (Tone and Siegel-
Watkins 2007).  
4.2.1 The US as compared to England 
In the United States there exists free market approach to access to medications while in 
England, a voluntary scheme keeps access to medications affordable while also leaving 
room for industry profit (Collins 2015).  Although EU countries have different 
healthcare systems, there are European directives concerning pharmaceutical marketing 
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in member countries that must be obeyed. In the US, however, regulation comes not as 
a result of federal law, but rather guidelines that the pharmaceutical companies trade 
association, PhRMA, developed for member companies to follow and avoid 
government regulation (Sillup and Makowska 2013, 14). The Medicines Act in the UK 
prohibits the pharmaceutical industry from promoting unlicensed medications, such as 
those prescribed off-label for children with PBD.  As a result, the conflict of interest 
generated by influence of relationships between doctor and industry is not as salient in 
England (Rani et al, 2007).  
A British Psychological Society report on understanding psychosis and 
schizophrenia suggests that antipsychotic medications may be useful, but they hold fast 
to a lack of evidence suggesting such medications correct any “biological abnormality” 
(Luhrmann 2015).  The report goes on to emphasize that for any severe mental illness, 
the risks of taking antipsychotic drugs for years may outweigh the benefits, and more 
needs to be done to make services available allowing people to discuss their experiences 
and what it means to them, a radically different approach from that held by most 
Americans (ibid.) The use of antipsychotics in children is not licensed in the UK, and 
parental training is often favoured as a first line approach when children are involved 
(James 2010).  In response to the growing literature out of the US on the use of atypical 
antipsychotics in very young children (under 5 years of age) for the treatment of bipolar 
disorder, James (2010) suggests that there is limited evidence for the effects these 
medications have on children, thus the practice of prescribing these medications is not 
licensed or recommended in England, as the risk then becomes about antipsychotics 
becoming the go-to first line treatment for PBD as they have done in the US, especially 
if psychological treatments are not readily available (ibid). 
Dumit (2012) makes the assertion that “each kind of knowledge produces more 
needs, more actions” (p.31), something which can certainly be seen in the connection 
between an organisational desire for profit and the development of a diagnostic 
category as a means to satisfy that desire. The controversy surrounding the inclusion of 
children in this equation illustrates the ways in which controversies are “fascinating 
social processes” in which “all of the normally silent and hidden activities that regularly 
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produce our taken-for-granted everyday world show up in competing voices, 
contradictory facts and uncertain compromises” making up the production of new 
knowledge (ibid., p. 32). The process of an industry coming to see children as potential 
patients, and communicating this to clinicians, allows the verification of new identity 
for the child through marketing practices elaborating new norms for how a child should 
be.  
4.3 The ‘voice’ of pharma: analysis of internal documents 
Healy and LeNoury (2007) have highlighted the pharmaceutical industry mechanisms 
involved in the development of PBD, working around regulations that prevented direct 
marketing of the illness itself to clinicians and the wider public. In attempting to 
understand the influence of pharma in the genesis of PBD when the obvious routes to 
construction are so heavily veiled, this analysis builds on Healy and LeNoury’s (2007) 
assertions beginning with an analysis of internal industry documents as a means to 
access the organisational perspective that was shaping representations about children’s 
behaviour, leading to the development of a new diagnostic category. This section 
presents the findings from an analysis of the documents in which the focus is on what 
those inside the industry were saying in the early days just prior to, and just after, the 
idea of PBD came about. Specific attention was paid to who was speaking in the 
document, what was being said about PBD, and who was being addressed. Of note was 
the fact that the presence of parents didn’t feature strongly within industry discussion 
of the child, suggesting the further isolation of the child as more of a target as opposed 
to an individual in the process of developing as part of a wider context of family, school 
and societal expectation. Details of the analysis are outlined in detail in chapter three (cf 
3.4.1). 
4.4 The organization as ‘Self’ in industry documents 
4.4.1 Economic pressure  
The subjective ‘voice’ of the pharmaceutical industry is articulated through the words of 
pharmaceutical representatives, key executives in the industry, and an anonymous, more 
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generalized voice that is responsible for the development of educational materials and 
presentations that are then communicated to sales representatives and clinicians. When 
examining internal industry documents related to the marketing of medications used to 
treat bipolar disorder in children, one thread that remains consistent is the role external 
economic pressures and an increase in competition play as a motivator for the 
development of new diagnoses for old treatments. The process of reshaping 
perceptions of a child’s behaviour as pathological begins here, with the pressure to stay 
afloat as a business in the face of increasing additions to a very specific market. This is 
illustrated in the words of a sales representative discussing the move to expand the 
prescription of the antipsychotic medication Risperdal from adults with schizophrenia 
into children: 
So this over here, when you look at hostility, aggression, agitation, this was 
a -- I mean, a significant opportunity for growth for Risperdal, because we 
weren't really winning in this area here; our competitors were. That's in a 
nutshell what our sales aid would look like; and when we would go in to 
talk to physicians, we would talk about these symptoms with the focus 
here; thus, yeah, I have, you know, the younger population has hostility, 
aggression, those type of symptoms; and thus, they would use Risperdal for 
those (Testimony of pharmaceutical sales representative, Document 13, 2012, p. 140)  
 
The excerpt above illustrates how a voice within the industry is openly 
acknowledging the persistent presence of competitors as being a force in how they 
position their own marketing practices. The speaker is presenting the push to recognize 
hostility and aggression as a matter of necessity in a world where opportunity for 
growth and a desire to come out on top take precedence over the reality of what the 
sales representative is proposing when he goes in to make a sales call to the clinicians. 
The child at the centre of the push for expansion is not present Other than as a 
representation of a market that remains, at that time, untapped. 
The subjective positioning of the pharmaceutical industry in the face of 
increasing economic pressure illustrates a concern with marking the symptoms of 
hostility and aggression, mentioned above, as part of a wider legitimate diagnostic 
category. The need for validation, which is seen here as coming in the form of a 
blessing form the US Food and Drug Administration (FDA), comes from a larger 
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discussion surrounding key factors identified in reifying PBD as a diagnosis through 
acquiring the FDA label that would render Risperdal as an exclusive treatment 
legitimate in the eyes of the US government. The following quote comes from a 
deposition of the former CEO of Janssen Pharmaceuticals, a subsidiary of Johnson & 
Johnson responsible for marketing Risperdal, the medication that gave rise to the 
diagnosis of PBD initially. In recounting his reading of an early marketing plan for 
Risperdal, the importance of official validation is conveyed: 
 
                      
 
 
(Doc. 14. deposition of former CEO for Janssen Pharmaceuticals, p.80) 
 
The importance of having PBD officially endorsed as an identifiable mental disorder in 
order to justify prescribing practices acts as a starting point from which a new 
diagnostic entity is shaped. The speaker above anticipates that without official 
acknowledgement, they are likely to lose out to the competition. Thus it becomes a race 
to see who can succeed in establishing evidence in favour of the diagnosis first. The 
point is made by this CEO later in the deposition that "because parents, patients and 
clinicians are exposed to a media that frequently questions the validity of childhood 
disorders, genetic and brain imaging studies are needed to show the validity of these 
disorders as brain disorders that respond to medication." (Document 14, 2012, 99). The 
notion of validity as being rooted in something scientific, and thus objective and 
trustworthy, is perpetuated to counteract the industry’s own understanding of a wider 
public perception surrounding their practices. There is an organisational Self-awareness 
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at play in which those on the inside responsible for communicating new criteria for a 
new diagnosis do so strategically, in full consideration and expectation of potential 
critique.  
4.4.2 Indirect marketing practices to ‘get the word out’ about PBD 
The ‘Self’ awareness of how those on the outside, whether government regulatory 
agencies, practicing clinicians, or the more general public, are likely to meet with the 
recommendation for a new diagnosis of PBD, drives early strategic marketing practices 
in the development of PBD. The need to ‘get the word’ out among potential early-
adopter clinicians who would be likely to influence their colleagues is evidenced by how 
the industry talks about the process of going about this: 
 
(Doc. 13.  Risperdal rep call notes, p. 27) 
 
The above reference to industry practice illustrates the move away from attempts to get 
psychiatrists on board, manoeuvring instead into the realm of general practice 
physicians who have little training the diagnosis or treatment of mental illness. By 
expanding the marketing of the condition and its treatments into a less specialized field 
of medicine, the industry begins the process of building alliances among those who will 
be useful in further legitimizing the diagnosis. Of particular importance for steering the 
building of these alliances is the sales force team responsible for interacting with the 
clinicians. An internal resource guide for those on the sales force for the medication 
Zyprexa highlights how the industry builds up the importance of their mission using 
emotional appeals: 
The Primary Care sales force will be a major part of helping to improve 
these statistics, and behind every statistic is a patient and their family 
struggling with mental illness. Years from now, as Lilly is launching new 
revolutions in neuroscience, you can look back and say that ZYPREXA 
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changed the way bipolar disorder was viewed, diagnosed, and treated by 
primary care physicians. (Doc. 9. Zyprexa primary care sales force resource guide, p. 
4) 
 
The motivational tone of the excerpt encourages commitment to the cause, 
emphasising the positive, life-changing role the sales rep can have on an individual level. 
The industry recognizes the sales team as being their public face, on whose shoulders 
the responsibility of convincing a potentially sceptical professional field of the 
importance of their mission. The incongruity of a young sales representative with no 
medical training convincing a medical professional how to diagnose and treat an 
unstable, yet-to-be-legitimated diagnosis is not lost on those at higher levels within the 
industry.  Thus, their interaction with sales representatives, and the way directives to 
carry out less overt marketing practices in order to ‘get the word out’ about bipolar, are 
all driven by elevating the representatives’ sense of their own power to ‘help a 
struggling family’. Included in this is the power of the representative, as proxy for the 
industry as a whole, to completely reshape representations of bipolar disorder from 
something once rare and only seen in adults, to something more chronic and treatable, 
seen in young children. Ultimately such a push comes back to economic pressure and 
competition leading to justification of the expansion of diagnostic categories through 
reshaping understandings of what bipolar looks like, and how clinicians think about the 
medications used to treat them. 
4.5 Competitors 
4.5.1 Accommodation of a persistent threat 
The most significant ‘Others’ to come from analysis of industry documents were 
pharmaceutical companies all vying for similar markets. The Big Three with regards to 
PBD include Johnson & Johnson/Janssen (makers of Risperdal), AstraZeneca (makers 
of Seroquel) and Eli Lilly (makers of Zyprexa). Viewing the industry’s subjective 
perspective put forth in their own documents, the presence of other companies is 
keenly felt, and often overtly referred to in terms of how competitive intelligence about 
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what one another are up to shape which opportunities are pursued, as is evidenced in 
the following excerpt from one company’s strategic plan: 
SEROOUEL will face considerable competition at launch given its timing 
to the market relative to olanzapine and sertindole, as well as the 
formidable presence of Janssen, Lilly, Abbott, and Pfizer in the psychiatric 
marketplace… The strategic positioning statement for SEROOUEL at 
launch is:   
 
"The atypical antipsychotic agent for first line treatment, with proven 
efficacy against positive and negative symptoms plus no EPS or prolactin 
liability compared to placebo across the SEROOUEL dose range."  
 
Risperidone's positioning has been "The only first-choice serotonin-
dopamine antagonist" ... emphasizing efficacy against both positive and 
negative symptoms, and "EPS comparable to placebo at doses 
<I0mg/day". This positioning will be weakened by the new entrants, 
including SEROQUEL. (Doc. 1. Seroquel Strategic plan, p. 4) 
 
Here, the positioning of the other is taken on board and willingly accommodated into 
this company’s objective, and this is not unique. While other companies within the 
industry are viewed as a threat, their presence is also recognised as a necessary, 
galvanizing force crystallizing a company’s own objectives and steering pursuit of a 
share of the market in a new diagnosis such as PBD: 
Competitors will become increasingly creative and look for new 
opportunities within the current market to steal ZYPREXA share. To 
remain competitive, ZYPREXA will have to increase marketing spending 
levels and also recognize that the incremental return per dollar may 
decrease. Aripiprazole and risperidone depot are the two most significant 
short-term threats to ZYPREXA. (Doc. 8. Zyprexa Global Marketing Plan, 
p.25) 
 
As illustrated above, competitors function as a presence to position oneself (on an 
industrial scale) against. Threat is not articulated here as something negative necessarily, 
rather the tone of the marketing plan suggests this as the reality of the industry, and that 
the ever present risk of others stealing market share is a positive, providing a catalyst to 
stake out a unique corner of the market- a process discussed in the next section. 
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4.5.2 Need for differentiation from competition 
Dissonant thinking in terms of maintaining inconsistent positions appears 
commonplace at the organisational level within the pharmaceutical industry. As 
discussed in the section above, the threat posed by other companies is a significant 
driving force that is not entirely negative in terms of how it is understood by those 
within the industry, however at the same time there exists a sensed of forced 
differentiation, with different companies employing different tactics to perpetuate their 
definition of PBD. One mode of differentiation which served as an early attempt to 
shape representations of the new diagnosis was the push from within one company to 
focus on symptoms instead of a specific diagnosis thus ensuring that a clinician didn’t 
automatically rely on previous understandings of ‘schizophrenia’ or ‘psychosis’ when 
considering how best to treat a patient:  
 
 
 
 
   
 
    
 
 
(Doc. 15.  Janssen sales call notes for Risperdal, P. 28) 
 
A focus on how to steer clinical attributions of behavioural symptoms allows for a 
readjustment of how clinicians conceptualise PBD by changing what is available and 
acceptable to draw on when faced with an unstable young patient. By using this focus 
as a tool, a company sets itself apart from the competition by indicating these 
behaviours as problematic and warranting their company’s specific medication as the 
recommended treatment. In the excerpt that follows from a young pharmaceutical sales 
representative, threat and need to stand out and form a unique niche in the face of 
 
 
 
 
112 
competition can be sees as a central motivating factor shaping marketing practices and 
thus the early shaping of how to understand PBD. Additionally, two vectors of 
influence are at play: the industry influencing the sales representative, and the sales 
representative influencing the clinician. 
                                                      
                      
 (Doc. 13.  Testimony of pharmaceutical sales representative, p. 138) 
 
Here, education is used as a means of informational influence in which the sales 
representative was encouraged by the national office to focus on excitement, irritability 
and aggression when making calls to clinicians who treat children, thus pushing those 
clinicians to remember children they may have just seen in their office, and align their 
behaviours with what is being presented by the representative. Such behaviours are 
presented as normal indications warranting treatment with Risperdal. An emergent 
norm effect begins to take shape in which, as in the example above, the push to view 
symptoms as pathology has done more than provide a unique selling point for an 
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individual company, but has also succeeded in normalizing aggression and irritability as 
symptomatic of a new definition of bipolar disorder in children. Through differentiating 
themselves from competitors, the industry has successfully taught key clinicians what to 
see and how best to interpret what they see.  
4.6 Industry alliance with clinicians 
4.6.1 Essential to have on board as ‘opinion leaders’ for wider validation of PBD 
While the pharmaceutical industry ‘Self’ and the role of competitors as ‘Other’ illustrate 
the development of marketing practices related to PBD, the clinician plays a central role 
in terms of putting those practices into action. It is through the clinician that a company 
communicates and legitimates the understandings it has sought to develop regarding 
PBD. The clinician becomes responsible for perpetuating the message, influencing 
colleagues, and reifying the concept of PBD as being defined by certain behaviours, 
which are best treated through the use of specific medications. The development of a 
strategic alliance between the industry and clinicians becomes of central importance, 
resulting in a common industry-wide practice of establishing ‘opinion leaders’ in the 
field. 
The table presented below from a marketing plan illustrates the consideration 
taken in targeting clinicians, with the notes in the margins highlighting industry views of 
physician type 1, one who has a demonstrated expertise in treating mental illness, 
requires certainty about what is being treated before acting, and is uncomfortable with 
the idea of prescribing medications off-label, beyond their indicated range. This 
clinician is seen as “panic bound”, yet likely to be influenced by physician type 2, the 
“high flyer” who is more experimental in their approach to diagnosis and treatment and 
has a high level of ‘Self-perceived’ expertise. Clinician 2 is labelled as likely to be an 
opinion leader, suggesting the industry seeks to target clinicians and nurture alliances 
with those who are giving signals of being open to influence. 
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(Doc. 8. Zyprexa Global Marketing Plan, p. 22) 
 
Once a clinician has been identified as being developed as a key opinion leader, the 
sales representative may then go about putting a reward system in place, in which the 
clinician is put in a position of power, authority and expertise, but only in exchange for 
delivering what is expected from the company: 
 
 
 
 
 
 
115 
 
 
 
 
 
 
 
 
 
 
(Doc. 15. Risperdal sales representative call notes, p. 26) 
 
Here the desire to get the word out is driven by a mutually beneficial arrangement that 
has little to do with how these medications might be used, and on what populations. Of 
interest is the fact that it is not only psychiatrists being sought out as opinion leaders in 
the development of PBD, but the emphasis placed on educating and influencing those 
primary care physicians who, due to different fields of expertise and training, would not 
have previously been known to diagnose or treat the mentally ill- let alone be familiar 
with antipsychotic medications used for treating severe mental illness. 
4.6.2 Responsible for knowing how best to diagnose and treat PBD 
The reliance on clinicians by the pharmaceutical industry is twofold. On the one hand 
they are courted or encouraged to lend their position to the act of influencing 
colleagues and the wider public about the existence and validity of PBD, as well as 
acceptable ways of treating the disorder. Simultaneously, in developing an affiliation 
with clinicians on the level of their expertise and opinion, the responsibility also shifts 
away from the industry (still very much at work behind the scenes) to the public face 
that the clinician provides. Strategically, this allows the industry to fend off criticism of 
practices related to perpetuating increased diagnoses of children with mental disorders, 
and their treatment with antipsychotic medications, by reinforcing the understanding 
that it is the clinician that is ultimately making the decision, that it is their competence 
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of judgement that leads to diagnosis and treatment of a child as evidenced in the 
following excerpts from a former pharmaceutical CEO: 
                       
                                       
 (Doc 14. Risperdal Litigation, CEO deposition, p.163) 
 
                                                   
(Doc. 14. Risperdal Litigation, CEO deposition, p.215) 
 
In the quotes above, the CEO defends the position of the company’s practice by 
shifting the focus onto the experienced clinician, first reiterating the uncertainty 
surrounding the diagnosis of PBD, and the fact that clinicians were facing not just the 
unfixed diagnosis, but the fact that none of the most suitable treatments (as defined by 
the industry) were allowed to be prescribed for children. Clinicians are presented as 
being bound by restrictions, but solely in control of how they diagnose and prescribe. 
Here, the industry seeks to remove any residue of perceived influence they may have 
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held over the clinicians by rooting clinical practice in a reliance on diagnostic manuals 
such as the DSM to help them do what they thought was best for the patient. The 
industry here is positioning itself as an outsider, standing by while the clinician does 
what they will do, thus attempting to distance themselves from the controversy and 
their role in perpetuating the diagnosis of PBD. For the industry, the function of 
clinicians is to legitimate and validate the diagnosis for the industry through practices 
such as signing their names to ghost written papers, presenting at conferences, and 
influencing their colleagues as knowledge leaders, but also as a scapegoat when 
controversy arises.  The expertise that renders them so valuable in advancing notions of 
PBD also becomes an asset in separating the industry from any perceived liability that 
may result. 
4.7 The Child 
4.7.1 Unmet need and opportunity 
The child in pharmaceutical industry documents is presented as an opportunity to move 
into new territory previously untapped in the prescription of antipsychotics. Most of 
the documents covering the testimony of those voices from inside the industry (CEO, 
pharmaceutical rep), as well as the marketing plans and educational materials all refer to 
children as the next frontier: 
If the paediatric indications for schizophrenia and bipolar disorder are 
approved, the ZYPREXA patent will be extended by six months in the US. 
(Doc.8. Zyprexa global marketing plan, 2002, p. 15) 
 
There is no attempt to hide the fact that the move into paediatrics would be beneficial 
in terms of profit, as it would allow for the extension of patent protection giving 
exclusive license to, in this case Zyprexa, to be prescribed for PBD. Opening up the 
possibility of bipolar in young children in this context has nothing to do with what is 
happening within the child, rather it is the process of coming up with a diagnosis to 
meet the treatment that takes precedence, trumping any further consideration of how a 
child might be affected by the untested medications, or whether a new diagnosis such as 
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PBD is warranted. The child is simultaneously at the centre of, and removed from, the 
cold, hard business of profit margins and staying ahead of the competition.  
The representation of children as an opportunity to expand a market provides a 
basis for widening the more general assumptions about which behaviours may 
ultimately be deemed pathological: 
There are significant unmet needs in these populations and there are 
significant opportunities for therapies that go beyond symptom control 
(e.g. improved attention). Bipolar Disorder represents a huge market 
potential and it is currently in the early stages of development. Treatment 
for Bipolar Disorder will grow dramatically if a solution to under- and 
misdiagnosis is created. (Doc. 8. Zyprexa global marketing plan, 2002, p. 13) 
 
The idea of “unmet need” perpetuated by the industry suggests that clinicians have 
been missing something in these children all along, that they have a need that is not 
being provided for and which the industry is in a position to facilitate the clinician 
taking action. A problem has been created so that a solution may follow, and what is 
presented here is a solution not only to the problem of dwindling profits, but to clinical 
uncertainty as well. Validating the possibility that these disorders can exist in children, 
and framing it in terms of ever expanding criteria (such as the need now for improved 
attention) provide clinicians with an explanatory framework that is broad enough to 
make sense of many of the children who will likely be showing up in their offices, and a 
new category under which to interpret their behaviours.  Clinicians are thus provided a 
mechanism allowing them to have a sense of fulfilling their obligation to patients as 
knowledgeable clinicians, while moving the industry into new territory whereby 
childhood conduct is redefined in order to satisfy a marketing opportunity. 
4.7.2 Suffering from a debilitating “constellation of diseases” 
The blatant proposition of children as an unmet need is not how the industry presents 
the development of PBD to the outside world, however. Instead, the external 
representation is not of children as an opportunity, but rather that they are suffering 
from a debilitating illness which, if left untreated, can ruin their lives as well as the lives 
of those around them. It is the notion of the greater good which is communicated 
when the voice of pharma enters the public sphere: 
 
 
 
 
119 
                                     
(Doc. 14, pharmaceutical industry CEO deposition testimony, p. 77) 
                         
  (Doc. 14, pharmaceutical industry CEO deposition testimony, p. 137) 
 
The excerpts above communicate a message of a desire for understanding on the part 
of the industry, to make sense of the debilitating illness causing the suffering of an 
increasing number of young people. PBD is presented as existing in uncharted territory, 
where a clinician was faced with something new, with no template to follow in terms of 
how best to treat. There is a sense of retrospective urgency as the speaker depicts the 
child at the centre of the discussion as in distress over a lack of clarity surrounding what 
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is happening to them, and that a push for objective diagnostic certainty to help these 
children is what motivates off-label prescribing of antipsychotics, as opposed to callous 
profiteering. The inclusion of a child’s suffering into the discussion of marketing 
practices has the effect of justifying convention while at the same time giving pause to 
various others who may attempt to position the industry as caring little for a child’s 
welfare. 
4.8 Pharmaceutical advertising as external manifestation of industry behaviour 
Physicians often deny the relative importance of commercial sources influencing their 
prescribing (Avorn et. al., 1982) but studies have shown that drug advertising does 
influence prescribing patterns (Quinn et. al., 1997, citing Hemminki 1975). Drug 
advertisements are “an important part of a drug company’s persuasive arsenal used to 
‘educate’ doctors and the general public and shape attitudes about health and well-being 
as part of a campaign to create desire for pharmaceutical product” (Singh 2007, 133) 
and act as useful window into ideas and representations about health and illness that are 
held, and disseminated, within the health industry (Foster 2010).  While some messages 
are intended, others are less obvious in the perpetuation of views through the choice of 
images and text used in the ads (ibid, 27).   
By using advertisements to market their medications, companies normalise the 
notion of disorder through presenting the pharmaceutical solution. Goldman and 
Montagne (1986) note that pharmaceutical advertising campaigns are often based on 
abstract visual metaphors so as to generate cognitive connections between the meaning 
of the images and the medications being advertised, encouraging the viewer to “infer 
connections between multiple meaning systems” (Goldman and Montagne 1986, 1047). 
In the case of the advertisements in the section that follows, the medications are those 
prescribed to children with PBD, so there is an interesting contrast present in how the 
medications are discussed internally, versus how they are represented here and how 
those representations might be generalised into wider pharmaceutical representations 
not of the medications, but the conditions they are advertised to treat; conditions which 
provide the meaning anchors for PBD: ADHD and Schizophrenia. 
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4.8.1 Analysis of advertisements 
Farr (1995) notes the importance of linking up the image with the text when 
interpreting advertisements, as there is often a relationship between them, which should 
be considered.  Analysis of the images here thus incorporated a semiological analysis 
following Penn (2000) and qualitative content analysis (Bell 2001) (cf 3.4.2) which aimed 
to interpret the image and text to understand how the visuals were being used to 
communicate a message about the medication. Analysis was made up of three steps 
involving an initial scan of the images to see what stood out in terms of text and image, 
followed by a “denotational inventory” where the elements of the advertisements were 
coded according to a ‘variables and values’ framework outlined by Bell (2001) in which 
attributes such as image type, social distance, the type of appeal being used to persuade, 
and the normative values communicated were coded. Once coded for values and 
appeals, a dialogical approach was employed which explored the type of knowledge the 
ads are presupposing, the debate is the ad entering into in terms of wider institutional 
and cultural frameworks, and who is being addressed in the ads. The findings of the 
analysis of ads are presented below. For full details of the sample and coding frame see 
chapter three and appendix 10. 
 
4.8.2 ADHD medications 
It is interesting to note that in the medical journals surveyed, those in the US were 
dominated by medications for ADHD as opposed to the antipsychotic medications 
which were more common in the UK. What this suggests is the level to which norms of 
childhood are perpetuated and constructed in these ads, making the idea of comorbidity 
between ADHD and PBD make sense. A clinician’s perspective in thinking about 
mental illness in children is consistently brought back to how a child ‘should’ behave, 
thus when confronted with an aggressive child in the office, these representations will 
never be far off. These are images of what constitutes normal boyhood in a particular 
cultural context. Engagement, achievement, and social adeptness are highly valued, thus 
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the one interpretation might be that if they are lacking in your child, this can be seen as 
pathological.   
The advertisements in figure 4.1 below are text heavy and factual, 
communicating statistics on efficacy, improvement ratios, and performance. 
 
                                                                            
 
Figure 4.1. Comparison of Adderall advertisement, Journal of Child and Adolescent 
Psychiatry 2004 and Equasym advertisement, British Journal Psychiatry 2004 
 
Also included in the ad are specifics on how the medications work- extended release 
tablets, information in the main text on dosage etc. A common theme in ADHD 
advertisements is the notion of performance, with math tests often cited as evidence of 
how effective the medication is. The school day constantly referenced as a point of 
measure (eg.“improves attention and behaviour throughout the school day” or 
“Equasym, with the school day in mind”). Advertisers and the pharmaceutical industry 
are not hiding the fact that this is being marketed as a performance-enhancing drug. 
The representation of this as a mental illness has fallen by the wayside. The ad is 
addressing clinicians, however the content of the text suggests a sense of asking the 
clinician to become the parent. The Adderall ad on the left tells the viewer to “reveal 
his potential” before noting that the medication improves academic performance, citing 
a trial in which patients completed 26 more math problems correctly as opposed to 
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those not taking the medication. The Equasym ad plays into the innocence of a child’s 
aspirations, including a “spring school year plan” penned in the child’s hand that 
include “becoming part of the theatre group, making a card for mother’s day and 
making a costume for the Easter parade”. Aspirational appeal for a wholesome, 
‘normal’ childhood is made to the clinician presenting an image to contrast with those 
children they might be seeing in their office.  
4.8.3 Risperdal  
As discussed in the previous section, the desire to expand the market for Risperdal was 
what gave life to the diagnosis of PBD. As one of the most prescribed medications for 
children with both ADHD and PBD, it is particularly interesting to see how this 
medication is marketed externally, after getting a sense in the previous section of how it 
was discussed internally. The off-label indication for Risperdal means that it cannot be 
actively marketed for children, so what is presented here provides an indication of how 
they are being represented. The ad presented in fig. 4.2 below is dramatic in its 
presentation, presented almost as a work of art. The text at the top of the ad, reading 
“Amelia, virtually housebound through fear, believes that when she goes out she’s 
followed by a menacing black dog. And that the dog and her coalesce.” is presented in a 
very small font, inviting the viewer in, perhaps suggesting they get close to her delusion- 
an invitation to share her fear. 
 
                 
         Figure 4.2. Risperdal advertisement, British Journal of Psychiatry, 2004 
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The premise of this ad is that relapses are a living nightmare, though it’s never specified 
what the relapse refers to. There is an ambiguity felt in the absence of a specific 
diagnostic indication, allowing space to for the clinician-viewer to consider that the 
medication can be used for any number of conditions. The overall tenor of the ad is 
unsettling, going deep into wild delusions of a living nightmare. The woman appears to 
be young, her expression one of remove, perhaps lost in her delusion, unaware of the 
world around her, providing a window for clinicians into her mind. The appeal of the 
image is emotional, while the size and content of the text attempts to bring viewer in to 
a shared experience.  
 
             
Figure 4.3.  Risperdal advertisement, British Journal of Psychiatry 1997 
                                       
In contrast to the first Risperdal image, the advertisement above again hits first with an 
emotional appeal suggested by the image of a woman staring off into the distance with 
a soft, calm gaze. Her profile emerges out of a red fog of blurred, swirling text 
symbolizing the turmoil she is experiencing in her head. The face is semi-obscured by 
this red fog suggesting without the medication, a sense of identity is lost. There is 
minimal text, instead the peace of the ad is preserved through muted colours, the 
reddish brown leading into a soft blue indicating hope and healing, while the crystal 
clear text advises the clinician-viewer that ‘peace at last’ can be achieved. Risperdal 
equals power, but a soft power here. The medication has the power to relieve 
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symptoms, as indicated in the first bullet point, while the slogan reminds viewers that 
Risperdal is “power you can trust”.  Power is the central theme here, with a sense of 
mastery and control over the diagnosis reminding clinicians that the power to calm the 
mind in turmoil lies in their hands. Assumed cultural knowledge in the form of norms 
emphasising turmoil and chaos as negative and treatable, while peace is sought as a 
desired outcome. Unlike the previous ad, this specifically indicates that Risperdal 
relieves symptoms of schizophrenia without specifying what those might be.  This ad is 
also from 1997, as opposed to the first, which was from 2004, perhaps suggesting an 
increasing desire to stay vague on specific indications in keeping with increasing off-
label prescription practices. In addition to the overall emotional appeal, the text citing 
studies alluding to the power and efficacy of treatment suggests factual, scientific 
appeal.  
4.8.4 Seroquel 
This ad for Seroquel, another of the atypical antipsychotics indicated for treatment of 
PBD, presents the medication as an ‘add on’ for the treatment of depression- a much 
more benign characterisation of the medication given its severity. 
 
 
Figure 4.4. Seroquel advertisement, British Journal of Psychiatry, 2011 
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The clinician-viewer does not need to be immediately reminded of the seriousness of, 
or stigma surrounding the medication they will be prescribing. But what does the 
viewer see? The muted, mustard yellow tone of the illustration suggests something stale, 
stagnant, and depressing. On the left, we see a slumped individual who appears to have 
just come home, or rolled out of bed, perhaps getting ready to go out, gathering bag 
and computer, but they are stopped in their tracks, unable to continue on. The roll of 
tissues close at hand illustrates the depth of the sadness in the tears that keep flowing. 
The position suggests weight, the inability to move from this place. The single/twin 
bed, half unmade, suggests loneliness. There is a small sense of chaos and searching, as 
thought something has been lost, in the way the belongings are scattered about on the 
floor, but also behind, the dresser drawers are opened. On another table next to the bed 
lie boards of some sort, suggesting taking something apart, or an unfinished project. 
These things also barricade the bed, and the individual from the window, and the light. 
The window appears to be open, ushering in a breeze, a shift, a wind of change into this 
stale, dormant environment. A camera lies in disuse, a life and interests left behind. 
However there is hope to the right of the page, with the warm glow of light that bathes 
the name of the medication. The association with creativity in the presence of the 
camera, and also the way the ad itself is illustrated stirs an association about the creative 
temperament who may also veer towards sadness and madness. The emotional appeal 
here lies in the loneliness conveyed, the life put on hold.  
4.8.5 Fact versus narrative in pharmaceutical advertising 
In PBD, the findings presented in this chapter suggest that a disorder of adulthood has 
been reconfigured as a disorder of childhood, grounded in representations of both the 
behavioural problems associated with ADHD, and the severity and future risk 
associated with schizophrenia. Both become ‘meaning anchors’ on which to ground a 
new interpretation of childhood behaviour as potentially pathological.  These 
advertisements could be seen as visual representations of what the industry 
communicates internally, seeking to expand the idea of who or what types of 
individuals can be a candidate for these medications and their related diagnoses. 
Elements of ADHD incorporated in to diagnosis of PBD include chronicity, 
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treatability, and value judgements as to how a child ‘should be’, while element of 
schizophrenia in PBD include the desired link to neurochemical imbalance, risk, 
urgency, and a need for treatment that can’t be ignored- this despite the fact that in the 
US, psychosis need not be present as a symptom. The ads for ADHD medications are 
cantered on the child, reinforcing norms of childhood, while the child is absent 
antipsychotic ads. The presence of such absence begs the question of deliberate absence 
or ambiguity utilised as a means to support the expansion of diagnostic categories, 
thereby leaving space to attribute ever-more symptoms to PBD in children, possibly 
resulting in more off-label prescribing of antipsychotics.   
The common sense understanding of ADHD grounds new notions of how a 
child might come to be identified with a new diagnosis of PBD. Early marketing 
practices sought to anchor the new conceptualization of PBD within ADHD by 
suggesting both a high co-morbidity between the two, as well as the potential 
misdiagnosis of ADHD instead of PBD due to overlapping symptoms. The 
antipsychotic medications continue to be grounded in Schizophrenia, where the images 
presented are much more orientated towards creating an emotional narrative as 
opposed to grounding the medication, and associated conditions in factual text.  The 
images are darker, murkier and more intense, incorporating elements of the delusions 
experienced by the isolated individuals depicted. Of interest is that often time a specific 
diagnostic indication is not made clear in the ad, or if it is, there is the suggestion that 
what is presented in the images represents ways of being that could be attributed to 
multiple diagnoses, and thus the medication is a treatment not for one condition only, 
but for a more generalized representation of a clinician’s sense of what it means to be 
disordered. The images allow the viewer to get inside the experience of the individual, 
or the position of a parent in the case of the ADHD advertisements, but also to remain 
objective knowing what’s wrong and how best to treat. The power and control lies with 
the clinician viewing the advertisement. 
Ferner and Scott (1994) remind us that “science requires the unambiguous 
description and logical analysis of facts”, a process at odds with the purpose of 
advertising, which they suggest “shares with art the use of oblique visual and verbal 
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images to convey the message it wants us to receive” (p. 1734). In the case of marketing 
medications used in the development of PBD as a diagnostic category, the textual and 
visual images simultaneously create an explicit sense of social norms on which to draw 
in diagnostic practice, while at the same time allowing for ambiguity, leaving it up to the 
viewer how a medication should be used, and for which treatments. Both normative 
and informational influence are at play within the advertisements, with the use of 
emotion (in the case of antipsychotics) acting as a tool perpetuating descriptive norms 
which visualize the current state of mind within sufferers, in need of clinical 
intervention. Within the advertisements for ADHD, a more factual presentation 
indicates the level to which injunctive norms are utilised in an attempt to align notions 
of childhood with what should be (as opposed to what is) providing a sense of possibility 
through correct diagnosis and use of a specific treatment.  
The persuasive power of a message, visual or otherwise, lies not only in the 
message itself, but the education designed to align with the content of the message. As 
this chapter has shown, the education of clinicians by the pharmaceutical industry has 
been a key aspect in building a particular understanding of PBD. That education 
ensures aspects of the message are internalised, thus, when coming across an 
advertisement for a medication which a clinician has recently learned can be used to 
treat a more broad range of conditions, and may also be sanctioned for the treatment of 
children, both informational and normative processes are drawn on to absorb the 
message as a whole. Medications themselves can be seen as representations that:  
carry meanings and shape social relations as they evolve in conjunction 
with individuals and collectivities…and are intertwined to form ‘social 
facts’ that are highly responsive to culture, history and social context” 
(Cohen et al 2001, 442).  
 
It is at this level of interaction, between the development of a diagnosis to expand the 
market of a medication, and how this is communicated via image and text, that 
contributes to a wider exploration of the role of pharmaceutical advertising as one 
aspect of the ‘voice’ of the pharmaceutical industry as it relates to shaping 
understandings of PBD. 
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4.9 Discussion  
This chapter has explored how pharmaceutical industry marketing practices shape 
representations of PBD in the US and England via the internal and external 
perpetuation of narratives found in documents and advertisements. Findings are 
illustrated in figure 4.5 below, and suggest the centrality of economic pressures and 
fierce competition in the development of PBD as a diagnostic category. Rather than 
seeing competitors as a threat, their developing understanding of PBD is 
accommodated and applied towards further development and perpetuation of what the 
disorder should look like. As a result, children are represented in terms of their market 
potential, reflecting ‘an unmet need’ who need to be positioned as suffering and at risk 
in order to campaign for their treatment with severe and untested medications.  
 
 
Figure 4.5: Illustration of the internal v. external voice of the pharmaceutical industry 
 
Encounters between industry representatives and clinicians steer processes of 
anchoring PBD in an already established diagnosis of ADHD, emphasising the 
chronicity and treatability, while steering away from previous associations with more 
severe, psychotic presentations such as schizophrenia. Thus the objectification of a 
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more ‘broad spectrum’ PBD as discussed in chapter one begins to take shape. The 
education of clinicians taking place via office visits from pharmaceutical representatives 
leads to a variation of bipolar disorder now anchored in rage, excitability and aggression 
as symptoms. The interpretation of such behaviours as pathological is driven by 
mechanisms of soft-power via financial incentive, for both the industry itself, as well as 
the clinician prescribers it seeks to influence. Clinicians are rewarded for their ‘expertise’ 
in the form of being designated opinion leader, and reminded of the role they hold for 
their patients as trusted, respectable, and knowledgeable. The overt use of persuasion as 
a tactic is illustrated in figure 4.6 below, in which a PowerPoint presentations shown to 
sales representatives reminded them of their role in getting clinicians on board. Central 
to the industry’s construction of PBD as a valid diagnostic category lies in changing 
previously, potentially well-entrenched, long-held beliefs about what bipolar means. 
 
                            
Fig.4.6 Zyprexa marketing strategy presentation to pharmaceutical sales representatives 
               
 
For the external voice of the industry as manifested in drug advertisements, it is not the 
diagnosis represented specifically, but rather norms and appeals, both rational and 
emotional, which are used to elaborate and make sense of this condition. There appears 
a deliberate ambiguity in what is absent from these ads, allowing clinicians to see these 
medications as existing for multiple uses, not just what may be indicated by official 
 
 
 
 
131 
regulating bodies- something which is emphasized in the education they receive from 
industry representatives, as discussed previously. Gervais et al. (1999) suggest that ‘as 
much theoretical attention needs to be paid to what is not there as to what is there, not 
least because the former shapes the latter (p. 420). In this case, the idea perpetuated as 
seen in the internal documents, in which clinicians are encouraged to abandon previous 
notions of what ‘bipolar’ stands for, adopting a new perspective which suggests rage, 
irritability and inappropriate conduct can be indicative of disorder is thus born into the 
way the medications are marketed as a diagnosis comprised of elements from many 
other diagnoses.   
For the pharmaceutical industry, bipolar disorder in children need not solely 
associated with manic-depressive psychosis anymore. Instead, what we see in the 
analysis of the pharmaceutical industry ‘voice’ are the industry behaviours acting as 
mechanisms of influence which drive the move beyond only using these medications 
for Schizophrenia, as on its own this is not lucrative enough.   We see how uncertainty 
combined with pressure and the promise of prestige is used to reshape how one thinks 
about this disorder, but more importantly, how knowledge of what makes up this 
diagnosis is realigned to make sense in children. A previously objectified psychotic 
disorder becomes re-objectified as behavioural through persuasion and conversion of 
clinical thinking, the soft power of economic incentives, validation of the diagnosis 
through alliance with ‘expert’ clinical professionals, and the perpetuation of risk in 
order to maintain a level of uncertainty and ambiguity in need of frequent re-validation.  
Both normative and informational influence can be seen in the way ads visualize the 
tension between how things are versus how things ought to be, a presentation that is 
enhanced by the steering of clinical perspective through education.  
Playing on risk, fear, confusion and comparing this with a future possibility that 
incorporates achievement and sociability, the pharmaceutical industry engages in 
persuasive techniques in which the clinician’s position as trusted expert is played into as 
target-audience. Prescription decisions made by a clinician can be influenced by a 
number of factors including diagnostic uncertainty (Cohen et al 2001) and have been 
identified as a “symbol of doctors’ control and power to heal” (Vuckovic and Nichter 
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1997, 1296) both of which are present in the ads. Medications inform the interpretation 
of illness “to the extent that explanatory models for illness may be framed in terms of 
the type, strength and quantity of medication consumed. The severity of the illness is 
inferred from how powerful the medication is perceived to be” (ibid.). Thus, the 
alignment of antipsychotics as an acceptable treatment for PBD simultaneously 
communicates a lack of stigma in the treatability of an increasingly common diagnosis, 
with the urgency stemming from the association of antipsychotics with severe mental 
illness. PBD is thus severe enough to warrant these strong medications, yet not so 
severe that clinicians shouldn’t be seeing more and more cases in their offices. This 
exemplifies ways in which psychiatric knowledge and diagnostic practice can be shaped 
by the interests the pharmaceutical industry, as well as broader social and cultural 
attitudes toward medication (Kirmayer and Raikhel 2009).   
Dumit (2012) introduces the concept of “pharmaceutical witnessing” as a type 
of “biomedical informing” in which “facts are passed on embedded in stories or images 
in which the viewer is put in the position of having to make sense of the story or ignore 
the risk it portrays all together” (p. 75). In the context of what has been discussed here, 
this suggests that clinician-viewers of advertisements, participants in direct interactions 
between sales representatives and physicians, or indirect actions the result of being on 
the receiving end of targeted education and marketing campaigns, it is they who 
become responsible for making a diagnostic or prescriptive choice and thus being 
responsible for the outcome. This level of informing is illustrated in the marketing 
mechanisms used by the industry as knowledge is passed from top levels of the industry 
down to the sales representatives, who then have a tremendous amount of power in 
shaping what clinicians should be seeing, how they should be defining what they see, 
and how it should be treated. Stories come in the form of personal profiles of 
hypothetical patients presented in education seminars or sales calls, or those implied by 
top level executives to the sales representatives doing the groundwork, that their work 
is important, they are contributing to the greater good through the reduction of 
childhood suffering. 
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The ‘pharmaceutical witnessing’ is present in the narratives suggested in the 
advertisements, in which instead of a condition being marketed directly, social norms 
are reinforced and space left open for wider notions of what this particular diagnosis 
might look like in a child. These are ways the voice of the pharmaceutical industry tells 
its story and shape representations of PBD as a diagnostic fact. 
As will be discussed in the remaining empirical and discussion chapters, the way 
this discourse has been internalised by clinicians and parents in the US and England will 
show the pharmaceutical industry as a unidirectional vector of influence, establishing 
very direct presence within American practice, and even among American parents, 
while remaining less overt in England. Among English clinicians, the influence of 
pharma with regards to contested treatments for unstable diagnostic categories serves as 
a force to collectively resist as much as possible. Central to the differences between the 
two contexts is the conflict that exists in England, where the field of psychiatry, and 
families of children living with bipolar disorder, pull between competing 
representations of the diagnosis; one as illustrated here as stemming from an industry 
seeking to make a profit, and a more stable, long-term representation of bipolar which  
remains a highly stigmatized life-long illness aligned with prior representations of 
bipolar disorder as manic depressive psychosis.   
The conceptualisation of PBD taking shape in the US as an uncertain and 
unstable diagnosis comes as a result of the way the diagnosis came to be; the product of 
a pharmaceutical company seeking to extend its patent on an antipsychotic medication, 
seeing children as marketing opportunity, and deliberately expanding and confusing the 
behaviours that can be seen to be indicative of the diagnosis so that just about any 
undesirable childhood conduct could be included in the pathology. This conflicts with 
the representation of PBD in England where the notion of bipolar in young people is 
still in the process of migrating from the US, a second-hand diagnosis one step 
removed from its beginnings as a US based marketing strategy. Thus professionals and 
parents in England still hold on to the idea of PBD as the same as bipolar in adults, 
usually involving psychosis, and not occurring in very young children.  The presence of 
the pharmaceutical influence in shaping representations in England is placed as 
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something to either rally against, reaffirming expert knowledge in traditional definitions 
of bipolar disorder, or else slowly adopting what is perpetuated in the US, seeing an 
expanded idea of bipolar in children as something useful and worthy of attention. 
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5. Clinical representations of  PBD in the US and England 
 
5.1 Introduction 
While the previous chapter (chapter four) focused on the role of the pharmaceutical 
industry, illustrating how processes of anchoring, objectification, and social influence 
succeeded in reshaping how bipolar disorder in children is defined, the aim of this 
chapter is to explore how these new representations may have been internalised in the 
understanding of clinicians, and how a clinician’s own knowledge combines with the 
new ‘broad spectrum’ conceptualization of PBD.  The results suggest that clinicians in 
the US and England have differing ideas over what counts as ‘disordered’ behaviour, as 
well as which other knowledges are being relied upon to generate representations of 
both the diagnosis, as well as the child at the centre of it. The questions guiding this 
chapter are as follows: 
 
 What are the representations of PBD held by clinicians in the US and England  
 What psychosocial processes shape the development of these representations? 
 
The data presented in the following sections address my research questions by 
exploring the significant others coming up in conversation about PBD for clinicians in 
both contexts, beginning with the clinician’s positioning as a ‘reflexive Self’, followed by 
how clinicians in both the US and England discuss, or take on the ‘voice’ of the parents 
they interact with, the pharmaceutical industry influence that in both subtle and not so 
subtle ways, and finally the child at the centre of it all.  
The findings in this chapter connect to the overall thesis as it presents one set 
of three key actors whose knowledge is involved in the construction of PBD as a 
diagnostic fact. Clinicians hold a significant and unique place in three knowledge 
systems explored, as they exist as a point of reference between top-down institutional 
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processes and bottom up anxieties of parents and pressures making their understanding 
of the diagnosis central to how it is perpetuated on a wider, more common sense level. 
In looking at how American and English clinicians differ in whose knowledge they take 
on board, who they see as allies, and how they discuss the child, it is possible to get a 
sense of the wider culture of practice in which their knowledge takes shape. The 
purpose of the analysis presented in the following sections is to provide empirical 
evidence for how clinicians in the US and England develop an understanding of PBD, 
and how this knowledge is taken up in clinical and diagnostic practice. Such evidence 
provides a contribution to understanding the wider mechanisms shaping how the 
diagnosis has come to be, in particular why it has expanded in one cultural context 
while remaining rare in another. 
5.2 Analytic procedures and findings 
The purpose of the analysis discussed in this chapter is to provide an empirical 
grounding as evidence for the development of clinical representations of PBD. The 
findings presented here are the result of thematic and dialogical analyses, which is 
discussed in further detail in section 3.4.3.  In conducting separate analyses on US and 
English clinician data, I sought to develop a coding framework that reflected both the 
content and processes involved in the development of knowledge of PBD; what was 
being said about PBD, and how it was being said.  After early initial round of coding 
each set of interviews for the US sample of 8 clinicians and the English sample of 10 
clinicians, it was decided that Self and Other would be made global themes. The data 
was then re-approached with this organizing framework. An initial identification of who 
the significant others were coming up in conversation acted as organizing themes under 
the global heading of ‘Self-Other’. For American participants, this resulted in organizing 
themes of the clinical-Self- ‘I’ position followed in frequency by significant others in the 
form of colleagues, parents, the pharmaceutical industry and the child. For English 
clinicians significant others coming up in conversation were the same, but the degree of 
presence in discussion differed. Discussion of colleagues took precedence, followed by 
the child, parents and pharma, with talk of their own history or trajectory into working 
with PBD minimal in discussion. Each group of participants was coded separately so as 
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to allow for comparison. Coding was an iterative process in which data was read with 
the positioning of the Self and mention of Others in mind, but allowing space within 
those broader headings to develop basic themes specific to what was being said in 
relation to PBD. Basic themes then reflected what was being said about these 
significant others. Coding frameworks can be found in appendices 11 and 12. . It was in 
the final interpretive stage of analysis, once the coded segments were in place, that a 
dialogical approach to selected segments was undertaken. While the coding and 
resulting thematic framework developed identified the ‘who’ and the ‘what’, the 
dialogical analysis of those coded segments addressed the ‘how’. For an example of 
dialogical analysis, see appendix 15. 
The most significant others among both American and English participants was 
the pharmaceutical industry, clinical colleagues, parents and the child. Analysis of the 
data resulted in often overlapping themes, as discussion about the wider diagnosis often 
contained issues related to more than one isolated group or theme. Discussion of a 
child’s behaviour for example, is relevant to how clinicians are discussing the child, but 
also how parents interpret present that behaviour to the clinician, and how it is then 
viewed as a symptom to be medicated. Thus, themes and subthemes could be seen as 
intertwined when discussing this diagnosis.  In the final stage of analysis I explored 
what came out in the basic themes, identifying how clinicians positioned themselves in 
relation to others, noting who had more of an influence on their thinking and why, 
what representations were generated as a result of interactions described. This allowed 
me also to see how clinicians positioned others as well, and how their reflections on the 
knowledge held by these others was responded to with acceptance, wariness, or flat out 
rejection. An illustration of the themes that came out of analysis, as well as the 
positioning of US and English clinicians in relation to significant others coming up in 
discussion can be seen in figure 5.1 below. The presentation of these themes are 
discussed in detail in the remaining sections of the chapter.   
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Figure 5.1:  Illustration of themes and significant ‘Others’ among American and English 
clinicians. 
 
As illustrated in figure 5.1, for American clinicians, the role of parents is central to their 
development of representations of PBD, relying on their experiential knowledge in the 
early days of the diagnosis to validate their own professional trajectories. Equally, as the 
diagnosis expanded, clinicians sought to perhaps justify their own approaches to 
diagnosis and treatment, which they may not have been entirely comfortable with. As a 
result, a dyad is formed alongside parents in which both are able to legitimate one 
another’s decisions for the child. In this sense, the child remains peripheral, despite 
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being central to the conversation at hand. The way clinicians position themselves in 
relation to professional colleagues and the pharmaceutical industry is also central to 
how PBD is understood, and professional knowledge developed, suggesting the role 
sidelong and top-down influence can have on the way the clinician ultimately 
approaches the child. Among American clinicians, PBD is seen as a parent-driven 
diagnosis, unstable and still in-flux, requiring a high level of expertise to truly 
understand, and a potential risk for the child, thus warranting early intervention for 
pharmaceutical treatment.  
Among English clinicians, it is their position within a collective field of mental 
health practitioners that governs the development of representations about PBD. 
Parents are not as influential as they appear to be in the US, and they are positioned 
alongside the child in discussion suggesting that parents are seekers, rather than holders 
of knowledge. There is still a hierarchy in place in which clinicians are seen as holding 
the expertise, however there is a sense of the responsibility of working with young 
children that weighs on these practitioners, thus there is a caution present that steers a 
desire to understand the wider context of the child, of which the parent is a part.   
 
5.3 Reflexive professional Self among colleagues 
What is meant by a ‘reflexive Self’?  In referring to the work of Hermans, Sullivan 
(2012) suggests that one’s Self is actually made up of multiple ‘I-positions’ which are 
constantly struggling for dominance, activated or deactivated depending on context and 
relationship to Others being addressed directly, or more indirectly through presence in 
conversation (cf 2.4). For US clinicians, the dialogical self is situated as ‘I’ in relation to 
significant others to illustrate interactions taking shape in the world of the clinician, 
with an emphasis of incorporating a personal narrative trajectory into current opinion 
and practice around PBD. Among English clinicians, the subjective clinical ‘Self’ is 
discussed less in terms of the clinician as individual practitioner, but rather in 
conjunction with the wider professional field of psychiatry in the UK. In paying close 
attention to how professionals were positioning themselves in relation to the diagnosis 
of PBD, and when the choice was used to refer to ‘I’ as a practitioner versus ‘we’ as 
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clinicians, the wider influence of clinical colleagues became apparent, and the impact 
that influence had on clinical practice.  
American Clinicians 
5.3.1 Uncertainty alongside increasing recognition 
When asked to define bipolar disorder in children, clinicians responded in terms of 
visible signs of the disorder, using the way children presented with various symptomatic 
behaviours as their point of departure for discussing PBD on a broader scale. 
Symptoms and presentation of children are at the heart of the debate, and drives the 
controversy surrounding PBD by virtue of the fact that there is so little clinical 
agreement on what this disorder looks like. Clinicians openly questioned their own 
application of the diagnosis to something so poorly understood, suggesting an 
acknowledgement of their own internal conflict when presented with children whose 
behaviours seemed unclassifiable. There was a very real sense of both internal and 
external pressure to find them an appropriate ‘diagnostic home’. Analysis of data found 
that the lack of specific criteria leads clinicians to fend for themselves in terms of how 
exactly to define the disorder, leading to multiple ways of interpreting behaviours: 
So my opinion on this, and this is purely an opinion, is that you had a lot of 
clinicians looking at the same behaviour and calling it different things, and 
again, influenced by the literature. I call it evidence-based practice gone 
awry. (USC2) 
 
In acknowledging the lack of consensus among colleagues, the speaker above suggests 
diminishing confidence in just what it is they, as a collective field, are seeing. It as if this 
clinician is accepting as a reality the fact that when dealing with this particular diagnosis, 
the state of the field in which he practices remains diffuse in its approach to defining 
PBD. American clinicians find themselves navigating between two beliefs about the 
nature of PBD: 
There’s a lack of consensus on what the criteria’s gonna be. Do we use new 
broader criteria, or do we use the traditional old timey criteria where they 
were manic for days in a row, staying awake all day with all this energy, and 
a euphoric or explosive mood that goes along with decreased need for 
sleep for signs of psychosis? (USC5) 
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The clinician above questions the two polarities available to draw from; the ‘broader 
criteria’ which includes rage, irritability and is at the heart of the controversy, or the 
more classic approach to PBD prioritizing psychosis, the latter seeming to fall out of 
favour among US clinicians. There is a sense of resignation, ambivalence and conflict in 
assessing the context in which they practice, but also an acceptance of responsibility in 
perpetuating this state of affairs as this clinician aligns with his colleagues in the use of 
the term ‘we’. When there is no clear, agreed upon set of criteria to look for, and 
clinicians have different opinions on whether PBD is a stand-alone diagnosis, or 
something related to adult bipolar, the circumstances are favourable to begin 
realignment of what should be seen to match what actually is being seen. This can be 
seen in a clinician interviewed elaborating on the early diffusion of knowledge among 
clinicians over how to ‘see’ bipolar disorder in children, despite it not have ever been 
seen before: 
So a lot of adult bipolar researchers, and then also child and adolescent 
psychiatrists mostly started to say ‘well, wait a second. If they’re reporting 
this, and we’re seeing some behaviour that may be like this, what’s going 
on? We should see this. So if everybody’s saying these things are starting 
when I’m a child or early adolescent, why aren’t we seeing it? Why do we 
have rates of BPD that are extremely low in children?’ (USC1) 
 
The tone of the speaker suggests the urgency with which clinicians in the early days 
sought to make sense of what they were seeing that was in line with what colleagues 
were seeing. When reports of this new ‘broad spectrum’ approach to PBD began to 
trickle down from more prominent members of the field, there was a sense of not 
wanting to miss out on something potentially important, but also perhaps a desire not 
to be deemed uninformed or lacking in expertise. This presents an illustration of how 
the uncertainty surrounding diagnostic criteria began to impact the action and 
behaviours of the field of psychiatry as PBD was just beginning to emerge as a 
phenomenon. Awareness and increased recognition of PBD is shaped not by a new set 
of behaviours emerging out of nowhere, but rather as a result of seeing what is 
presented in a different way, a view articulated by one clinician involved in the early 
diffusion of knowledge about the diagnosis:  
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I will tell you that between the time I was training in 1991 and 1995, there 
was not a dramatic increase in our clinic. It was that I saw what was in front of 
me in a different way. The same children were right in front of us, but when 
you started to say, ‘well could this be a diagnosis of mania? Why did I never 
call it mania before?’ Because I was told that children don’t get mania, so 
I’d read the same symptoms through a different lens. (USC7, emphasis added) 
 
Here the idea of ‘seeing is believing’, where a lack of belief leads to a lack of 
recognition, allows for a specific set of behaviours to be assigned ‘manic’ when 
previously they may have been considered within the normal spectrum of childhood 
experience.  This comes not as a result of something changing within the child, but 
rather a clinical perspective that chooses to see those behaviours as pathological, 
suggesting the wider representations being established and perpetuated.  More common 
sense beliefs about the rise of ‘new’ disorders such as PBD position them as being 
modern afflictions-the product of a unique set of environmental or societal stressors 
impacting directly onto the child, but what comes out of discussion here is that their 
own role as diagnostician, and thus perpetuators of diagnosis, plays a significant role in 
its expansion. Seeing “the same symptoms through a different lens” is an example of 
how such negotiations also involve changing the interpretation of a child’s conduct by 
clinicians. Reshaping how behaviour is viewed as normal versus pathological is central 
to the current paradigm shift that is taking place as a battle is fought over whose 
knowledge matters. The open acknowledgement of clinicians that it was their own shift 
in thinking, positioned in reaction to others, that brought the diagnosis to the fore as 
opposed to something innate in the child is of interest, and yet it is this shift in thinking 
that now drives a deeper search for more children who meet the poorly defined criteria 
for the diagnosis. 
5.3.2 Career development and expertise  
The development of expertise, and the related positioning that entails, in one that is 
earned. The importance of early career trajectories, and the influence of mentors on the 
evolution of their thinking about PBD, was a point of departure for wider discussion 
about the diagnosis with US clinicians. As one recalled:  
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I was like, I don’t really totally understand [the diagnosis of PBD] and knew 
that it was a very new area of research, so in many ways kind of ripe for 
people to come in and make it their specialty and study it. So it seemed like 
an exciting opportunity that way. (USC1) 
 
The ambiguity proved intriguing and the induction into a new world where more 
established colleagues will clarify this practitioner’s own thinking about what can be 
seen as symptomatic of PBD. The influence of education and knowledge sharing, in 
which a medical student or trainee psychiatrist is open to being steered and thus 
converted to a way of thinking is central in establishing how professionals came to 
understand PBD. Where a clinician was trained, and whom they trained under 
determine what type of knowledge is being assimilated. The necessity of developing a 
career thus becomes central to how open a young clinician may be in shaping their 
interpretations of behaviours leading to PBD.  
The desire to establish a refined and discreet diagnosis and find a diagnostic 
home for children who no one knew how to label or what to do with is deemed 
necessary to create certainty in place of the discomfort that comes with ambiguity. A 
realm of expertise is created, so that the ability to ‘see’ PBD in a vague mass of 
symptoms is represented as being an acquired skill, where awareness is equated with 
experience. Clinicians position themselves against apprehensive and sceptical colleagues 
who are seen as a barrier to their own advancement and thus discredited in 
conversation. This drive for advancement, couched in innovation, suggests the level of 
autonomy clinicians in the US strive for in their practice. Such representations lead to a 
further identification of the Self as the voice of reason in a sea of criticism, as the 
following example of a clinician re-enacting interactions with colleagues illustrates: 
Other researchers were quite nasty in their responses to me: “I’ve been 
working 20 years in this field, I’ve never seen a case!”…“well you must be 
looking at this funny, you must be making this up”. Accusations. “It can’t 
be true. You can’t be competent, because if it existed, I’d be seeing it”. 
(USC7) 
 
Failure to recognize PBD is seen as risky potentially leading to a loss of esteem among 
colleagues, as well as a sense of one’s subjective sense of expertise. In order to facilitate 
a search for what ‘should’ be seen, it becomes necessary to establish fields of expertise 
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and specialized clinics; tangible evidence of a process taking shape, a diagnosis 
objectified, with a ‘build it and they will come’ phenomenon contributing to the 
evolution of exactly what is being sought out to treat. In the excerpt above, the clinician 
positions themselves as a fighter, giving a sense that their belief in pursuing PBD was 
for the greater good and came at a great personal cost.  
While clinicians working in children’s mental health operate as part of a wider 
collective of specialists, when discussing their own professional position among 
colleagues, there was a sense of operating independently of one another, maintaining 
opposing views and proposing contrasting approaches. There was little unity or 
cohesion evident, instead the way clinicians themselves in relation to their colleagues 
was oriented towards reiterating their expertise in the face of controversy, as is evident 
in this recounting of an interaction between two child and adolescent psychiatrists: 
I had a child under my care who I had diagnosed with PBD. And I was 
treating him with medications for PBD, and…was hospitalized at a local 
psychiatric hospital. The doctor there said “well, this is a boy that’s 
depressed, but I don’t see the bipolar” and I said, “well he’s not manic 
now. He’s depressed now. He has a history of mania”. (Doctor:)”I heard 
that history and I don’t think it sounds like bipolar disorder”. And so the 
doctor told the patient and the mother “I don’t believe Rd. USC7 has the 
correct diagnosis. I think you should take an antidepressant. Here’s 
Prozac.” And they discharged him on Prozac. That was February. It’s now 
July. I decreased the Prozac dose because after several months he started to 
seem more agitated and irritable, and so he went to the emergency room. 
He wanted help, because he goes nights without sleep, he’s very agitated, 
he’s exploding with his mother, he’s been making odd sexual comments to 
her. Well what is that? He’s got bipolar disorder. So, they tried to re-
hospitalise him, he didn’t want to stay, so he left after a day, and the doctor 
there said “I don’t think you have bipolar disorder, I think you have 
depression” Well how - aren’t they hearing these same facts?! (USC7) 
 
The way the speaker presents this scenario above illustrates the multiple systems of 
knowledge coming up against one another in a quest for validation. The sense of the 
speaker feeling undermined is offset by positioning themselves as the expert trying in 
vain to do what’s best for the child in the face of a misinformed colleague. The 
colleague as ‘Other’ is represented as out of touch, a source of confusion for the 
parents and oblivious to the ‘facts’ of PBD. The tone is almost conspiratorial with the 
listener, inviting us to take a position as well. The interpretation of clinicians of 
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colleagues as a threat is tied to competition for legitimacy when engaging with an 
unstable diagnosis.  
The notion of expertise is a fundamental aspect in the development of clinical 
thinking about PBD. In positioning themselves as experts in relation to this very murky, 
ill-defined diagnosis, professionals are forced to crystallize their ideas about what the 
diagnosis means, holding their opinions close in order to maintain the sense of mastery 
in the eyes of their colleagues: 
I: How can you be certain that when you do give the diagnosis of PBD that 
that’s what it is? 
 
R: Oh it’s a matter of going with your diagnostic skill. Years and years of 
experience. Scores and thousands of children over the years that have come 
through our threshold, and so we could tell them from a mile, which 
spectrum where they are, because that’s something that you develop very 
well over time, but if you’re not used to that, it’s very hard. (USC4) 
 
The above quotes indicate the beginning of a thought process in which “recognition” 
of behaviours as being pathological is calibrated with the clinician’s own well-developed 
proficiency in diagnosing. There is no questioning on the part of the speaker that they 
would get it wrong, or not know what they were looking at. The certainty present in 
this quote is indicative of having decided what children with PBD look like, and if that 
differs from what other experts see, then that must come down to a lack of experience. 
Diagnoses such as schizophrenia, childhood depression, and ADHD don’t always elicit 
the same discussion surrounding the need for a well-trained eye to make the call. The 
overlap and comorbidity of PBD with these other disorders illustrates the ongoing 
negotiation involved in positioning PBD alongside other mental illnesses. 
 
English Clinicians 
5.3.3 Interdependence and cautious, reflective expertise 
Among English clinicians, the Self was positioned as cautious, often deferring to what 
one clinicians referred to as “the culture of second opinions” that seems to govern 
practice in England.  There was an overarching sense of wanting to see as complete a 
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picture of the child’s life beyond presenting symptoms, and a hesitancy to stand alone 
in making a diagnosis: 
I think just in thinking about it without really having thought about it, you 
know to diagnose a child of 3 or 4, we would be very cautious and 
concerned, I mean, we get a lot of children with ADHD or referred for 
ADHD at very young ages, and again we’re very um…because you can’t 
diagnose, or you’re not meant to diagnose before the age of 6 anyway. You 
know we’re very cautious, and we’d want to know what else is going on 
with the family, so I think we’d be, I’m guessing that we still feel the same 
if we had a referral that said ‘we have a 3 year old and we’re concerned 
about him or her having a bipolar disorder’ to a certain extent. (UKC 3) 
 
Diagnostic instability creates a space for influence at multiple levels. Normative 
pressures illustrate the conflict among clinicians over the interplay of their sense of 
themselves as independent practitioners, as well as members of a wider collective field 
of practice. There may be an assumption that a certain level of expertise solidifies 
positions and shields clinicians from doubt, however as the following excerpt illustrates, 
when it comes to facing a murky and contentious diagnosis such as PBD, maintaining a 
set position without regard for the beliefs and approaches of colleagues if difficult to 
sustain: 
The proper manic depression, everybody would recognize that, even the 
taxi driver can make that diagnosis you see. But for these other cases that 
are kind of-- we are very inconsistent in our practice, and as I say the 
diagnosis will be anything from stroppy adolescent to something with the 
parents to proper bipolar, you see. In between you have these other 
differentials, you see, and I think we are still...I mean, the ADHD and 
bipolar is a very sensitive area, yeah? And there are people who say they 
have ADHD and bipolar, and people who say its ADHD but present with 
bipolar, and others say it’s bipolar and present as ADHD. That is a very 
controversial. There are some political elements to these things where you have the kind 
of view that make you unpopular with peers and things like that. You’re judged by peers, 
and if peers are not tolerant of something like that, you probably will not maintain it. 
(UKC6, emphasis added) 
 
Here the inconsistency lies within the collective ‘we’. The clinician above doesn’t make 
an attempt to distance himself, rather there is a sense of surrendering to the realities of 
the profession in which sometimes being part of a wider collective results in one’s own 
subjective perspective being subsumed by the politics of the broader field of practice. 
Conformity pressures from peers point to a wider trend towards building consensus, 
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going along with the dominant ideas of psychiatric practice even if it may not align with 
an individual clinician’s perspective.  In alluding to the uncertainty over how to label 
children presenting with ADHD who may be given a diagnosis of bipolar, or vice-versa, 
prevailing norms among this clinician’s peers suggest how a set of behaviours is 
diagnosed is significantly shaped by how professional colleagues think about and 
attribute those behaviours. The power of the beliefs of one’s peers is internalised, 
indicating the ongoing tension between remaining separate and going along with 
dominant practice, and the possible realignment of what clinicians are seeing, with what 
they may feel they should see. As much as they may practice as individuals, it is the 
continued association and acceptance by fellow practitioners that take precedence in the 
face of the uncertainty and controversy surrounding PBD. 
5.3.4 Independence as positioning in relation to American colleagues          
For English clinicians, American colleagues were central to discussion in a way that 
suggested the level of influence the US has in the genesis of PBD in England. As such, 
the conception of an independent clinical Self situated within, and identifying with, a 
wider collective field was reinforced by a sense of clinicians in England position 
themselves in relation to the Americans, crystallizing aspects of their own practice as a 
form of resistance to the potential future impact of US influence. As one clinician 
noted, philosophical issues are one core difference between the two cultures: 
Some of it I think is just that there’s a stronger emphasis on theory and 
tradition here, and in Europe in general, whereas back in the US it’s about 
innovation and moving forward. (UKC2) 
 
While for others, resistance goes beyond deep-rooted notions of tradition versus 
innovation into a feeling that what is being proposed by American psychiatry is not to 
be taken seriously: 
So there have been some American researchers who have come over, and 
we’ve listened and gone “no I don’t believe you. I just plainly don’t believe 
you at all” when they’ve gone on about 5 year olds with Bipolar, and you’re 
going ‘this is ridiculous, you’re in stupid territory here’. And actually even 
peddling this stuff is stupid. And there isn’t that discourse around. There 
isn’t enough of that discourse within the people feel to kind of challenge to 
that orthodoxy. (UKC9) 
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In the quote above, the idea of such young people being given such a severe diagnosis 
is ludicrous. The clinician is positioning themselves, and the field as a whole, in 
response to this by noting that the collective ‘we’ has listened to this and dismissed it as 
out of line with the values held by practitioners in England; values which include the 
ability and willingness to challenge the orthodoxy. Tied up in this resistance is an 
awareness of, and perhaps ambivalence about, the very direct influence American 
psychiatry has had on the genesis of PBD as a diagnostic category in England: 
R: I suppose we all heard about it as the diagnostic rates in the States went 
up, and we collaborated very much with (institution X) and we visited and 
went along and you know, I spent some time just sitting in clinics there, 
and picking up some of their thinking about bipolar disorder. ..I remember 
some American child psychiatrists saying, “oh, this is so old hat, please 
don’t tell us anymore about the differences, we know, we know, we think 
we’re on the right track”  
 
I: Did you feel they were trying to convince you their approach was better? 
 
R: No, I think they felt that they had the research to support what they 
were identifying and diagnosing and um, and as the years have gone by I 
think that they have always felt that we haven’t been as acutely aware about 
some of the issues, although the pendulum’s swung back a little in the 
States as well, hasn’t it? (UKC 1) 
 
The exchange above illustrates the tension present between top down and bottom up 
influences in dialogue with American colleagues. On the one had there is the 
recognition of American colleagues as being influential in steering knowledge and 
development of PBD, but alongside this is a need to assert professional independence. 
The inclusion of the clinician’s assumption that US psychiatry believes practitioners in 
England are somehow naïve with regards to understanding this new diagnosis functions 
as something UKC1 can rally against. What is suggested in how this clinician is 
discussing the American psychiatrists is perhaps some level of resentment in assuming 
England is behind the times with regards to research, which when internalised on the 
collective whole can act as a motivating factor to act on the thinking that this clinician 
‘picked up on’ while visiting colleagues in the US. Another clinician illustrates this 
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tension through reference to cultural stereotypes as an explanation for why PBD has 
become much more common in America: 
this is totally speculative now, but national stereotypes, what might’ve 
happened in America was, you know people are very solution focused, so 
‘we’re going to give it a different name now, we want to treat it now, we 
want to get it better’. People are less cynical, so they just want to do 
something about it (UKC4) 
 
Here the speaker is acting on the need to articulate differences beyond diagnostic 
cultures, instead looking to cultural disposition as a mechanism to distance the 
collective (more cynical, process oriented) field in which he himself practices from the 
less considered approach articulated as he takes on the voice of an American 
counterpart. Tension between admiring American colleagues for doing what they do 
well, being at the forefront in advancing new theories, treatments and practices, while at 
the same time providing a reminder of elements that English clinicians proudly distance 
themselves from, defining their own practice and position as a clinical Self,  in relation 
to how it differs from their American colleagues. 
5.4 Parents  
Parents figure strongly in discussion with American clinicians, where they are 
positioned as co-constructors of knowledge about PBD, their experience of living with, 
and caring for the child central to how they are seen by clinicians as contributing to 
validation of the diagnosis. Among English clinicians, parents were present in 
discussion of PBD, but not to the same extent as their colleagues in the US. English 
clinicians interviewed indicated a desire to understand fears a parent may have on how 
they are perceived by others, however their experiential knowledge is not automatically 
taken as truth, instead they are viewed as seekers, rather than holders of knowledge, 
aligned with their children in that they are seen as part of the wider context of the child 
that needs to be considered when evaluating disruptive behaviours.  
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American Clinicians 
5.4.1 Alliance with parents as co-constructors of knowledge 
American clinicians portrayed parents as collaborative allies, noting a parent’s 
experiential knowledge achieved through living with a ‘dysregulated’ child as a form of 
expertise that contributed to the early establishment of American specialist PBD clinics. 
As one clinician who had previously specialized only adult bipolar disorder described 
his reasons for moving into working with children: 
 
One factor was, the factor was, parents complaining about this. (USC8) 
 
Parents are strongly present in clinical discourse surrounding PBD among clinicians in 
the US, and are presented as in a dyad with the clinician, while he child often remains 
peripheral to discussion.  American clinicians discussed parents as often, if not more, 
than their young patients, and frequently described them in a way that suggested how 
intertwined with their child’s diagnosis they were. For clinicians involved in early 
investigations, seeking parental involvement was necessary as a means to direct their 
own research in a way that would allow it to be taken up by a targeted population, while 
at the same time achieving credibility for taking into account parental needs and 
consideration of their experience. In finding themselves faced with something they are 
unable to understand, clinicians look to parents to shape their own clinical 
understanding through defining what they see and what they need. Collaboration and 
negotiation between these two groups thus proves beneficial, where parents see the 
legitimation of what they have been seeing in the establishment of a diagnosis that 
makes sense to them, while clinicians find something to grasp in parental experience, 
and upon which they justify the establishment of clinics and research groups. Thus, 
parental need and demand presents an acceptable explanation for clinicians to explain 
increased diagnostic rates, rather than something suggesting vested interest or career 
advancement.  
In seeking to get parents ‘on board’, they become something of an ally for 
academic clinicians who come up against resistance from fellow researchers. By 
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providing first-hand vignettes of behaviour, and legitimizing clinical claims based on 
their experience, parents become useful to set the course for acceptance by clinical 
colleagues who may have otherwise been dismissive:  
The research community was very sceptical. Some of the clinicians were 
too. And the parents were immediately on the bandwagon. “Finally you’re 
describing my child. This is what I’ve been experiencing. I’ve been trying to 
tell the doctor for years.” And sometimes parents who had bipolar 
themselves who were dismissed. “Well, you have bipolar disorder Mrs. 
Smith, so maybe that’s how you see the world, and why you’re so worried 
about it”. And in fact you see these moms who either had bipolar 
themselves or in their families were often the best reporters, because they 
were knowing what to look for and were able to describe it in ways that I 
thought were especially articulate and insightful. So parents were 
immediately big fans, and believers, and relieved. And then I watched 
researchers get on board. (USC7) 
 
Here the power bestowed on the parent lies in backing up the clinical agenda, in which 
a parent’s first-hand experiential knowledge of the child as valuable in convincing 
others that PBD should exist as a diagnosis. The interaction between this clinician’s 
Self, clinical colleagues and parents come together in a narrative which suggests that it is 
the clinician following the parents lead. On the one hand this can be useful in 
influencing colleagues to ‘get on board’ with the idea that PBD exists as a real 
diagnostic entity, but on the other hand there is a sense that imparting this level of 
capacity onto the parent removes responsibility from the shoulders of the clinician, 
allowing them a sense of justification in the face of controversy.  
5.4.2 Parent as voice for the child 
Parental representations occupy a position as important as a clinician’s own direct 
observation and interaction with the child.  A frequent refrain among American 
clinicians was the idea that a young child doesn’t have the language to articulate mania 
and depression, thus necessitating the heightened role of parental involvement. 
The depression sometimes is easier, but even the depression you have to 
take into account the age of the kid. The kid is not going to come at 7 or 8 
years old and tell you they’re depressed, and so the parents have to come 
in. (USC8) 
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Clinicians are seeking out parent’s subjective judgments about their child’s behaviour 
and basing their own clinical notions of PBD on this, as much as what they actually see 
in front of them when the child visits their office. In this way, ideas about what PBD 
looks like in a child are co-created by parents and in a circular process of interaction in 
which parents are encouraged to pay attention to certain behaviours, and as a result are 
trained to see such behaviours as pathological, which is then fed back to clinicians, 
reinforcing clinical expectations while legitimating and perpetuating the diagnosis.  
Parental demand, based on lived experience with their children, initially focused clinical 
attention on specific behaviours, which clinicians have then adopted into their 
representation of a disordered child. The behaviours thus become reified as ‘symptoms’ 
through the process of negotiation with parents tutored to view certain conduct as 
symptomatic of this illness. Parents direct clinical attention, which clinicians then direct 
back at parents and, by proxy, onto the child.  
5.4.3 Parents as victims ‘held hostage’ to PBD 
Conflicting clinical representations of parents are evident in the way parents are 
discussed by professionals as both co-constructors of knowledge about the diagnosis as 
well as co-patients alongside their child and victims in need of support themselves. 
Parents at the mercy of such out of control children need their own training to ‘manage’ 
the child at home. The idea clinicians have of parents being intertwined with their 
child’s diagnosis leads to a conflicting representation in which, in addition to being 
victimized by their child, they are also partly responsible for exacerbating the 
behaviours leading to the child being deemed ill: 
Now, back 12 years ago, I think a large part of the evolution of this 
disorder was from a clinical standpoint we were struggling with ‘what do 
we call it?’ but what we heard from parents was that oftentimes they were 
almost like the victims of an illness that didn’t have a name… If the parents 
are so beaten up and worn down and trounced upon and have no energy to 
really interface with a highly intense kid, it doesn’t matter what you do with 
the kid. I mean, you can help with their intensity, but their parent still needs 
some skills. (USC3)  
 
The clinician above admits the possibility that parents and family dynamics are 
responsible for the child’s behaviour, however responsibility is removed by aligning 
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approaches to parenting with a lack of support, both within their immediate social 
sphere as well as on a wider societal level, in the face of an uncontrollable child.  When 
it comes to addressing the problems in a therapeutic setting, children are often left out 
of the picture: 
Oftentimes we feel our parents probably get even more benefit [from 
therapy] than the kids do…parents can start to feel a sense of mastery again 
over the illness. (USC1)   
 
The representation above depicts a child in need of management, and the parent’s need 
for clinical help to learn how to ‘master’ the illness, and thus the child. The diagnosis of 
PBD here is as much about parents as the child actually given the diagnosis and 
subjected to treatment. The perception is one of parents as victims, at the mercy of 
their unruly children, and in need of support, and thus becoming patients alongside 
their child, with one clinician likening the parent experience as being “held hostage” to 
the disorder- an association that indicates an omission of the child’s experience. The 
child becomes viewed as a threat, capable of beating down their parents and taking 
control through aggressive behaviour.  
By removing the child from the equation and instead focusing on parents and 
‘the disorder’, the child is kept at a distance and left open to the portrayals that make 
the most sense for clinicians and parents. In questioning why this might be the case, it 
becomes necessary to consider once again the role of what interests are at stake in 
favour of advancing the diagnosis. By presenting parents as victims, a powerful 
mechanism is created in which the potential for further expansion of PBD is grounded 
in lived experience, albeit not the experience of the child at the centre of the diagnosis.  
The notion of parent as victim, held hostage to the out of control child is directly 
related to the push for establishment of the diagnosis. Clinician’s positioning of parents 
in this way allows for the inclusion of something concrete, in the form of a parent’s 
experiential knowledge, to counteract the uncertainty. Additionally, a space is opened 
up for further encounters between parents and clinicians as a result of working 
alongside parents to manage their child. 
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English Clinicians 
5.4.4 Parents as knowledge seekers 
Interviews with English clinicians stood out for the note of caution expressed regarding 
over-reliance on parental accounts of a child’s behaviour. While they noted that parents 
were a key part of solving the puzzle, they were not viewed as a central source of 
information. In describing the level of knowledge about the diagnosis that parents show 
up with to the initial consultation, one clinician noted that: 
Um, the level of knowledge isn’t deep, or the level of information that they 
have, rather, so even if they come to us with a potential diagnosis of BPD, 
they often don’t know what the implications are. When we give them a 
diagnosis of potential, possible BP, we call it not- otherwise –specified, 
spectrum or whatever, you can qualify it in a number of ways, then they 
really need some help with that, so what we do is give them some of our 
papers that are written for a more general audience, and spend a lot of time 
explaining to them what it means, and the reason this question is 
important. (UKC4) 
 
The parent here is seen as being in need of some helpful education, lacking the same 
level of expertise as the clinician. While there was a theme of alliance with parents for 
American clinicians, among the English sample, there was distancing from the parent in 
which the clinician used influence and education to shape parental thinking about the 
diagnosis and associated behaviours. The relative absence of parental influence on 
clinicians in England can also be seen in the deliberation involved in ascertaining 
whether a child meets the criteria for PBD. The experiential knowledge possessed by 
parents is not enough. The clinician in this case requires more than one source of 
information about the child: 
When there’s a discrepancy between what the parent is telling you, and 
what you see in front of you don’t match. So we’ve had a couple of parents 
come in and say “he’s bipolar, he’s restless, he’s stomping all over the place, 
he’s rude” and you see a child who’s sitting quietly during the assessment 
for an hour or so, being very polite, and you think this is not- something 
doesn’t match up. Particularly when there’s only one source of information, 
so in CAMHS, we try to get as many multiple sources of information as we 
can, mainly from schools, parents and the young person themselves 
(UKC7) 
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The tone of the excerpt above appears to negate the parental account, suggesting that 
they are almost not to be believed. The clinician notes the importance of the child’s 
own perspective in trying to get a holistic picture of what is going on. The child is kept 
at the heart of discussion, and the overall sense is one of collaboration among multiple 
groups, bringing together myriad perspectives, to ensure that once a diagnosis is made it 
has the backing of several professional frames of reference. Here there is the 
impression of caution that goes along with the idea of England as being a “culture of 
second opinions” as one clinician allowed. In contrast with the US, clinicians in 
England, as the above examples suggest, acknowledge the position of parents in clinical 
discourse as being one of many sources of knowledge about the child as opposed to the 
key holder of information. 
Understanding parents is central to attempts by English clinicians to interpret 
what is going on in the mind, and wider context, of a child presenting with behavioural 
issues: 
One of the things that’s really hard for parents is when you come to 
services like CAMHS, the worry in the back of your head is that the fingers 
are going to be pointed at you as a parent. In some ways that’s where 
diagnosis can seem like an effective option because you sort of go from 
being a failed parent to a heroic parent struggling with a disabled child. But, 
in my experience worry and that sense of guilt doesn’t disappear when they 
get a diagnosis. Different sorts of guilt start to appear… and if you don’t 
have those conversations they sit there in the background and they 
continue to worry what you think about them. (UKC5) 
 
The parent in the above quote is integrated into the experience of the child, where the 
parent is no longer able to think of adolescence in ordinary terms. For the speaker, the 
parent’s inability to see beyond the particular illness framework is problematic, however 
there is a sense of understanding the role diagnosis can play for an anxious parent, 
acknowledging feelings of guilt and inadequacy and the lure of being recast as a 
struggling, heroic parent. The clinicians’ own complicity in shaping parental 
representations of ‘normal’ childhood behaviour is evident in the admission that it 
becomes difficult to think of them as anything other than disordered after having been 
encouraged to view them this way. The position of parents and the family as seekers of 
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information elicits sympathy in the form of a clinician’s desire to understand parental 
experience: 
Somewhere in the back of their head they’re going ‘is this normal 
adolescence, or are we dealing with something qualitatively quite different 
from that?’ And that obviously has not only a kind of rather personal 
overlay, but also has a cultural one. So, what people expect in different 
cultures is hugely different of their kind of kids. (UKC9) 
 
Taking on the voice of a parent here, the clinical insight opens up to wider cultural 
factors influencing perceptions of behaviour, suggesting a level of understanding that 
no two parents will see behaviour in the same way. In demonstrating an openness to 
parental perspectives, the clinician is taking on board more than just the child being 
brought in for consultation, but also the wider context from which the child comes, 
allowing for a fuller picture, and perhaps more considered, reflective path to diagnosis. 
5.4.5 Alignment of parents in dyad with child separate from clinician 
In discussion with English clinicians, the same sense of separation between the parent 
and child isn’t present in discussion as it is with American clinicians. Instead, parents 
are aligned with the child, positioned as a piece of the broader contextual puzzle in 
which a ‘mood-dysregulated’ child exists. The sharing of familial context is a key 
component to a clinician’s perspective that the two exist parallel to one another: 
With PBD, you have to do a lot of work with parents. There’s no point just 
working with the young person, because they live in their families, they are 
part of their families, and the families are crucial in identifying if things are 
breaking down again, and are crucial in supporting their recovery, so if the 
parents don’t really understand what’s going on then nothing’s gonna work, 
really. (UKC8) 
 
Families are crucial, valued as a source of support and structure for the child. Parents 
are also seen as unified with the experience of their child in terms of motivation for 
seeking a diagnosis of PBD is discussed. The previous section discussed the clinical 
perspective outlining parents as seekers of information, thus for English clinicians faced 
with parents showing up assuming knowledge of PBD, there is often inherent suspicion 
related to ulterior motives for seeking the diagnosis: 
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Another example of somebody I had where the child didn’t have PBD, he 
had, for example conduct disorder, and he was getting into all sorts of 
fights and criminal activity and shoplifting and so on, and being aggressive 
at school, but both mom and the young person were invested in having a 
medical explanation of their difficulties. So they would read on the Internet 
and read what BP is, and then come and tell you, almost word for word, 
“Oh he has elated grandiose mood, or he’s…” and I’m like, these aren’t 
even your own words. These are coded words, because there’s an 
investment in having that diagnosis because it sort of takes the 
responsibility of his and mom’s actions (UKC7) 
 
Here, parent and child are seen as one, evident via references to the “mom and young 
person” and “their” difficulties. Allusions to the parent and child as an interrelated 
micro-collective suggests a level of clinical distancing, allowing for the incorporation of 
parental dynamics to be viewed by the clinician seeking to make a diagnosis in direct 
line with the young person’s ‘symptoms’. There is a wariness in approaching those who 
seem over-invested in a diagnosis: 
I don’t want to be too damning and judgmental, but it tends to be the 
personality disordered families who are like that, so they’ve got a very, very 
troubled teenager in the family, but the whole family is troubled, and 
they’ve had- they’re the ones who when they come to us they’ve got three 
CAMHS files already, and it’s like…they’re desperate for you to say “this is 
this, and have this medicine and make it all go away and make it all be 
better” And it’s always that they’re the ones who aren’t anything like manic 
depressive. (UKC8) 
 
Motivation is a key factor considered by clinicians in England, often approached with a 
degree of apprehension and an attribution of interrelated behaviours among both 
parents and their children. Parents are seen not as separate entities, but rather very 
much at the centre of  what clinicians consider when considering whether a diagnosis of 
PBD is warranted for the young person or not. 
5.5 The pharmaceutical industry 
Despite the overt influence of the pharmaceutical industry in the US, both in terms of 
the early development of PBD, as well as continued presence in diagnostic practice, the 
presence of pharma in clinicians talk was stronger among clinicians in England, perhaps 
suggesting the power present in a less obvious influence. Among American clinicians 
interviewed, the dominant theme related to a sense of feeling stuck, pulled between 
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subjective values coming up against professional realities, which involve the use of 
medications on oftentimes very young children. In England, the role of pharma remains 
tied with debates surrounding medication practices not only on a practical level, but 
also in the perception of trust, which underscores discussion about how to approach 
medicating children. Several English clinicians noted that medication is not thought of 
as a first-line treatment, and articulated reluctance in going along with US led research 
that has been financed, and thus influenced, by the pharmaceutical industry, suggesting 
a subjective conflict surrounding putting the research into practice via approaches to 
medicating.  
American Clinicians 
5.5.1 Subjective values encounter professional reality 
The presence of pharmaceutical industry influence is tied up with debates surrounding 
medication practices and shapes clinical understandings of the diagnosis. There is 
reluctance in having to go along with research that has been financed by pharma 
resulting in inner conflict that comes with top-down pressure to put the research into 
practice via approaches to medicating. Many who work in the field have been on the 
receiving end of criticism for perpetuating a diagnosis many believe was created in 
order to sell certain medications: 
Pharma has had a big role in getting some of the early science up off the 
ground that’s how in America, well I don’t know what it’s like in the UK, 
but to get studies up off the ground, it’s very difficult without pilot data 
which requires money, so back in the day there was no way to get things up 
and going without some relationship with pharma, so I see how the 
criticism [of PBD] could be put into play. (USC3) 
 
Here there is an acknowledgement of the necessity the industry plays in early research 
on PBD, while also maintaining an awareness of how this is perceived by those who are 
critical of the diagnosis. In the course of conversation clinicians revealed ways in which 
they reconciled their conflicted feelings regarding having so little control over how 
children given a diagnosis of PBD were supposed to be treated. Several professionals 
positioned themselves as caught in the middle, uncomfortable with prevalence of 
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medication and their place in perpetuating the diagnosis, and expressing discomfort 
with how they have been knowingly complicit in the expansion of PBD: 
How do you justify giving an unstudied medication to children and 
teenagers? Well, you do it by saying they’ve got bipolar disorder, and so if 
they’ve got PBD, I’ve got a drug that treats PBD. And those are the 
second- generation antipsychotics. So, that I believe is the reason why we 
have such an expansion of BPD in this population, because it justifies our 
treatment for them. (USC5) 
 
Clinicians are forced to reconcile their positions within the wider social and cultural 
hierarchy in which they practice with their personal values in any way they can by 
finding ways to make sense of how they practice. As discussed in chapter three, this 
excerpt presents an illustration of how ingrained the tension that exist between existing 
normative pressures and injunctive norms suggesting how a clinician should practice. 
Here we see a desire to rally against the system, but the reality is that this clinician will 
conform to prevailing standards while recognizing their own role in the perpetuation of 
the diagnosis.  In presenting more personal and value laden accounts, US clinicians 
imply that while the culture in which they practice emphasizes the use of medication as 
being a necessary component of treating this disorder, no matter what the age of the 
child, they are not always entirely comfortable with the idea: 
The sad piece, in my opinion, people often have too blind a trust in our 
medical system. Again, I feel that the majority of people the medical 
system…are doing what they think is right, but that doesn’t mean that it is 
right. I just think our system, for whatever reason, maybe it’s the influence 
of pharmaceutical companies, but we have such a drug centred health care 
system. Everything is about ‘what medication, how can we treat you?  
(USC1) 
 
As the above quote reveals, internal conflict and pressure to be responsible and fulfil 
professional duty in the face of uncertainty encounters an external pressure to 
prescribe. The trajectory of the conversation with the speaker above kept coming back 
to the role of pharma and the emphasis on medications, suggesting this was a source of 
inner strife. As with several professionals interviewed, there was talk of feeling trapped 
in a system: 
Why do I put a kid in the hospital? Well, if I’m going to justify it to an 
insurance company, I get, it’s easy to get the insurance to cover Bipolar 
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disorder. It’s easy to get treatment authorized for BPD….sometimes it puts 
me in ethical dilemmas where a government agency is requiring me to do 
one treatment like a stimulant, which I feel is going to be worse for the 
patient, and I’ll lose sleep over that. Should I fight the system? Fight the 
bureaucracy to do what’s right, or just go along with it, and it puts me in a 
difficult position. (USC5) 
 
A lack of control and feeling trapped in the middle drive an agentic shift away from the 
clinician themselves, and towards the broader context in which the presence of Pharma, 
and it’s influence on the process of insurance reimbursement, were responsible for why 
younger and younger children were being treated with such strong medications lacking 
clear clinical evidence for efficacy. The speaker above faces a more direct dilemma in 
confronting very real top-down pressures from higher-ups who have significant 
influence over diagnostic practice, despite the fact that knowledge drawn from this 
clinician’s daily experience directly contradicts the pharmaceutical suggestions being 
made.  
The fatalism present in conversations with American clinicians suggests the 
pharmaceutical influence is seen as something unavoidable, controversial and necessary 
for research funding, and thus a force to be worked around. The top down influence 
extends beyond clinical trials shapes policies of government agencies responsible for 
dictating prescription practices of doctors on a more localised level. The process of 
reconciling beliefs with actual circumstances is not always successful, however, and 
often clinicians live in a constant state of limbo that never gets fully resolved. A sense 
of resignation and justification reigned as clinicians sought to align personal values with 
the realities and pressures of their profession, practicing in a healthcare system where 
insurance practices are closely linked with pharmaceutical influence.   
English Clinicians 
5.5.2 Encroaching threat of vested interest 
One repeated theme to come out of discussion with English clinicians was a desire to 
maintain a level of scepticism and resistance, instead of blindly accepting the treatment 
approaches to PBD normalised in the US: 
 
 
 
 
161 
So people are quite worried. When research is being sponsored by a 
pharmaceutical company, people have a knee-jerk response, particularly in 
this country. It implies in some way, not that they’re necessarily in cahoots 
or anything, or being paid to lie, but that they’re somehow biased…that has 
played a role in the resistance here I think. And the other one is perhaps 
latent anti-Americanism (laughs), so I shouldn’t say anti-Americanism, but 
saying ‘oh well, it comes from America, let’s be very sceptical about it’.  It’s 
a very interesting- it’s a funny attitude because in other matters its ‘oh its 
American, it’s got to be good’ do you know what I mean?  But in these 
matters, people are very sceptical. (UKC4) 
 
The above excerpt illustrates the core of resistance to the expansion of PBD in the 
form of distrust of US led research. The American influence is simultaneously reviled 
and appropriated in that the US leads the way for English clinicians (‘it must be good’) 
while also representing what they as a group don’t necessarily want to become (at the 
mercy of vested interest). Here, a desire for recognition comes up against an inherent 
distrust. The ingrained scepticism in the tone above stems from widespread 
understanding that the promotion of PBD in the US has been the result of a very small, 
extremely influential group in receipt of enormous pharmaceutical funding: 
So there was a very successful influence coming down from a few people 
who became very key individuals in promoting this concept [of PBD], and 
basically increasing the sale of antipsychotic, or atypical antipsychotic 
medication to young people. (UKC5) 
 
The link between understanding a diagnosis and medication as an initial response is a 
multi-tiered process in England. Thus, the idea of a condition predicated on the 
existence of a pharmaceutical treatment is one that leaves many practitioners in 
England wary. Perhaps there is a sense that the field of psychiatry in England may 
become increasingly influenced by practices taking shape in America, as some have 
suggested it already has with the arrival of ADHD going from rare to common in a 
matter of  a few short years. By staying alert to pharma led research emerging from the 
US, alongside prescribing trends of antipsychotics to children, clinicians in England are 
able to maintain a level of questioning remove in an attempt to keep the diagnosis of 
PBD from becoming reconfigured as something assumed to be much more common 
than they believe that it is. 
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5.5.3 Trusting the familiar, resisting the unfamiliar 
The tension present between English clinicians and how they view the potential for 
pharmaceutical influence to shape the knowledge about PBD disseminated by their 
American colleagues leads to a desire to try and focus on home-grown research and 
practice as much as possible. This allows for the reinforcement of their own 
positioning, forcing a redefinition of what they as individual practitioners within the 
wider field value in terms of professional autonomy. As will be discussed further in 
chapter seven, it is the point at which a gap in knowledge takes shape that allows for a 
level of trust to fill in. In this sense, a lack of trust, or wariness, of American-led 
research becomes objectified as something against which to position oneself and resist. 
In the case of a psychiatric nurse within a CAMHS team quoted below, these values 
extend to where professional attention is paid: 
I mean we don’t really have much contact with the reps, the drug reps, so I 
suppose we don’t, we’re not that, we don’t really get influenced by it all. We 
are really only working on the criteria because that’s the criteria if you see 
what I mean. We’re not thinking well, and our first line isn’t medication, so 
we wouldn’t be thinking we’ve got to look at this in terms of whether we’ve 
got to medicate or not, we’re looking at it as whether they meet the criteria. 
(UKC3) 
 
Medicating is not seen as the first option, and the specific reference to pharmaceutical 
representatives and the influence they wield indicate the fact that they are a force to be 
contended with, despite this nurse saying they are actively not influenced, preferring to 
focus exclusively on the behaviour they see, and what that means for treatment, as 
opposed to the other way around. Resistance to increasingly strong influence of the 
pharmaceutical industry is presented as the result of lively debate, and again, as 
something coming from the outside that clinicians in England can position themselves 
against: 
There has been a very lively debate in this country about the influence of 
the Pharma industry, and much more vigorous attempts by the medical 
community in this country to get to grips with the pernicious influence of 
the pharma industry, so there is that, a much bigger community of people 
within the medical profession who are trying to do something about it. But 
their influence [pharma] is strong. Very strong. (UKC5) 
 
 
 
 
 
163 
Here the clinician indicates a collective refusal to go along with the increasingly 
pernicious attempts of the pharmaceutical industry to sway practice in this country, 
actively resisting a perceived imposed consensus coming from the US. While there may 
be a sense of a critical perspective here, the speaker is at one with the wider field, 
expressing a sense of pride in the culture of questioning and debate, as opposed to just 
accepting recommendations at face value. It is an active resistance that stems from 
distrust of US research and practices, where several clinicians interviewed stated a 
greater level of trust in ‘home-grown’ knowledge, as it is perceived as being less heavily 
pressured by vested interest.  
Having the presence of pharma to come up against leads strength to 
identification with one’s own colleagues, a perspective expressed in several instances by 
way of the introduction of cultural stereotypes into conversation: 
I think there is a cultural split between the UK and US. There is a view that 
a lot of American psychiatry…well, you become stereotypes…and the 
American stereotype is that its drug company led, and over reliance on 
medication rather than psychotherapies. (UKC10) 
 
It is not just the mention of stereotypes, but the idea that when faced with a contested 
diagnosis, with controversial beginnings such as PBD, one becomes the stereotype. 
American psychiatry on the whole becomes a metaphor for a focus on solutions, quick-
fix treatments and an emphasis on conquering the illness and getting better. Such 
perspectives allow for a greater sense of what clinicians in England are up against when 
learning more about PBD, navigating the terrain of a rapidly shifting diagnostic 
category. 
Clinicians interviewed in England proved to be more outspoken in their 
thoughts about the level of influence maintained by the industry, and the implications it 
may have on the future of how they practice. A common feeling among clinicians was 
that of Pharma as an encroaching threat to their understanding of PBD. As one 
clinician stated: 
 
The developmental stream in the States for bipolar? Money” (UKC9) 
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An awareness of the origins of this particular diagnosis as rooted in American 
controversy led those interviewed in England to reiterate this as central to their 
resistance to the idea of expanding the diagnosis into younger and younger children.  
5.6 The child 
It is the child who ultimately bares the weight of diagnosis, thus clinical representations 
of PBD shaping diagnostic practice largely come down to the position of the child in 
discussion, a position that is shaped by interactions with the three significant others 
highlighted in this section so far: clinical colleagues, parents and the wider influence of 
the pharmaceutical industry. Interviews with American clinicians revealed the child on 
the periphery of discussion, which tended to focus most heavily on the clinical Self, 
colleagues and parents. The child figures more prominently among English clinicians 
for whom a more holistic approach to diagnosis and treatment is favoured, with the 
child often consulted for their own feedback. Clinicians in the US may desire this as 
part of their own professional practice as well, but it remains uncommon due to a lack 
of space within the wider diagnostic culture to explore these options. How a child’s 
behaviours are assigned the category of PBD, and deemed pathological or not, is central 
to the way in which the ‘voice’ of the child was accessed in interviews. 
American Clinicians 
5.6.1 The child as a cluster of symptoms  
The child is largely absent from conversations with US clinicians, who tend to be more 
parent-centric in discussions surrounding PBD. When the child is present, they are 
largely portrayed as a collection of symptoms and behaviours in need of management: 
It’s very important to think about the symptoms of the children, and the 
domains that are affected, and I think it’s the functioning that I care about, 
and children, it’s a little bit like a sculpture as they’re growing up, and it’s 
very fluid, and we need to shape this carefully, and there are many 
problems sometimes, and they overlap, because just like a circuitry 
dysfunction, with multiple circuits being entangled, if one is affected, three 
or four that are attached to it might be affected, so you need to think 
carefully. (USC4) 
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The quote above positions the speaker in a place of remove, evoking in the listener a 
mechanistic impression of children with PBD as malleable and in need of shaping by 
the clinician. Such statements are indicative of the elevated importance the clinician 
places on their role, and the child as ‘Other’ becomes something distant and somehow 
objectified. Perhaps in thinking about children this way, emphasizing how much they 
suffer as a result of living with PBD, is a way for clinicians to distance themselves from 
potential moral concerns associated with such a contested diagnosis. Focusing on 
children as a collection of symptoms renders the emotional clinical, and removes the 
clinician from direct engagement with the actual individual at the heart of the symptoms 
they seek to treat. A framework is then created in which the child is lost to the 
behaviours that come to define him or her, as is evident in discussion of several of the 
co-occurring diagnoses that come with PBD: 
I’ll have the parents track mood changes. If it’s something where you don’t 
see a lot of mood lability per se except in an instrumental way, where 
Johnny starts screaming and shouting because he knows that’s going to get 
mom to change behaviour, and that I can actually manipulate that, I can 
actually modify his mood lability through consequences, well, then I’m 
probably going to move away from that and probably just look at ODD 
[oppositional Defiant Disorder] so those are the things that I start to look 
at. Is there mood lability that is unrelated to a child getting what they want? 
(USC2) 
 
The child is described not as part of a wider social context, but rather as a collection of 
potential diagnoses. Nowhere in the above quote is there a suggestion that the child 
may not actually need to be diagnosed with anything. The clinician is so trained to see 
sets of behaviours as representative of disorder that there is no way to see otherwise, 
thus, a child who cries in response to not getting what he wants is given the diagnosis 
of ODD. And once again, the perception is mediated by the parent who is asked to pay 
attention to, and track, mood changes. While parents may have been instrumental in 
getting the disorder off the ground, clinicians are now training parents to see their child 
as they do, with just about any behaviour suggesting something pathological. Multiple 
factors have come to shape clinical thinking of children with PBD to the degree that it 
becomes so entrenched that they must see something that any behaviour becomes a 
symptom. 
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5.6.2 At risk and in need of early intervention and treatment 
A common theme among American clinicians was a conceptualisation of the child as a 
potential risk to be recognised early on before any questionable behaviours had even 
emerged (“prodromal diagnosis”). Every American clinician interviewed was in favour 
of prodromal diagnosis with many suggesting that such ‘problem behaviours’ can be 
seen in children as young as three years old. Clinicians in favour of early intervention 
repeatedly point out that PBD is a serious diagnosis not only to give, but also not to 
give, suggesting the cumulative disadvantages bestowed on a child with PBD, 
everything from doing poorly in school, to a later life of criminality and social deviance, 
warrants treatment as early as possible: 
The reason to treat is that in the here and now, it’s causing tremendous 
disruption in everyone’s life- the child’s life, first and foremost... And then 
[the symptoms of PBD] leads kids to do reckless things, leads them to take 
a different path in life, to find different peers, they get arrested, they get 
involved in drugs and alcohol, there’s a lot of terrible outcomes from PBD, 
so if you can help detour somebody from that terrible course, and give 
them some relief in the here and now. (USC7) 
 
For the speaker above, PBD represents a present disruption, and a future risk not only 
for the child, but those around them. By framing the diagnosis this way, clinicians’ 
justification for prodromal diagnosis is driven by their perceived need to ‘catch’ 
something before it can do any real damage, whether neurobiological or social. But who 
ultimately benefits from this practice? The assertion that clinical concern lies with the 
symptoms, not the diagnosis, is in direct contrast to prodromal diagnosis in which 
you’re not treating actual symptoms, rather the future risk of getting the disorder. This 
ties into a need for clinical mastery, again suggesting the role of professional interest in 
the expansion of PBD. Discussion with American clinicians also highlighted the very 
prominent position the medicating of children held within the practice of prodromal 
diagnosis:  
In the old days, ten years ago, if a kid was out of control, but the parent 
was like “I don’t want to do medicine” I was like, “ok that’s fine. If you can 
handle it and you can deal with them, we’ll try without medicine.” But now, 
if you wait, you’re just letting their brain deteriorate and become more 
severe, so in those cases I would try to get them to agree to medication… 
So PBD and Schizophrenia we’ve had studies in the last few years showing 
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you can have significant nerve deterioration and atrophy if the brain if its 
untreated, so that kinds of changed my perspective on how soon I give 
medicine. (USC5) 
 
Here, the clinician’s idea of PBD has shifted based on discourse surrounding early 
diagnosis and treatment. New knowledge has taken shape in practice which emphasises 
the neurochemical explanation for behaviours, validating the use of medication, and 
instilling the importance of catching and treating PBD early as essential to the future of 
the child. The clinician above uses early intervention as a tool in order to get parents to 
come around to the idea of medicating, this from the same clinician who had earlier 
expressed discomfort with the pressures to medicate in a certain way that left him 
losing sleep at night.  Again, in the quote above, we can see the anchoring of PBD in 
schizophrenia, despite the fact that in the US much of PBD is seen as rooted in rage 
and irritability, rather than the concrete psychosis of schizophrenia. However when it 
offers an explanation that makes sense and backs up clinical intentions, this clinician 
puts into practice in order to position the child at risk and push the idea for early 
diagnosis and treatment. The position of the child in clinician’s discussion about PBD is 
a reflection of the wider system in which they practice. In the case of those in the US 
where the dominant social representation is that of a collection of problematic 
behaviours, they are working within a culture that has normalised the medicalisation of 
children, and the emphasis is on prevention alongside the push for innovation. 
 
English Clinicians 
5.6.3 The child as part of a wider social context  
The wider social context of the child was of great importance in discussion with 
English clinicians.  There is a greater resistance among this cohort to label too soon 
before grasping the wider systemic understandings of the behaviours they’re seeing. The 
child is represented as being a product of their environment in which wider contextual 
factors such as family dynamics are considered alongside parental accounts, teacher 
accounts and the clinician’s own observations. A notable finding to come from analysis 
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of the data was the fact that every clinician interviewed in the English sample 
referenced the conditions making up the wider word of the child as necessary to 
understand in conjunction with whatever their presenting behaviours: 
You’ll have the psychiatric diagnosis there, but it will always include the 
whole child in terms of the child’s cognitive functioning, medical, 
physiological functioning, and finally the context. So, for instance, if you 
see that a child’s disturbed because the parents have just got divorced 3 
months ago, or there’s a new baby sister, or they’ve all been in some huge 
house fire, you don’t ignore that context. That’s terribly important to be 
included any sort of formulation. (UKC1) 
 
Common among English professionals was a sense of caution and a need to know what 
else is going on with the family before landing on any type of diagnosis for the child: 
The African girl I saw for example, I will not stop her father from drinking 
alcohol. I am going to make a diagnosis of the child and a factor 
precipitating the behaviour is the fact that her father’s not available, and he 
has a 24 year old as a girlfriend. That’s when things are not clean. That’s 
when people like myself or others will say look, we need to sort out the 
social adversity before we start working with a diagnosis. I think it’s a 
chicken and egg, you see. (UKC6) 
 
Acknowledging the challenge of diagnosing a condition when ‘things are not clean’ is 
indicative of the unstable nature of PBD. Here, a number of social factors are listed as 
being reasons why a girl might show up with disordered behaviours. What the clinician 
suggests through this example is a sense of how much one should draw conclusions 
from dominant ideas circulating in the public sphere. In this instance, there is an 
understanding and acceptance that a clinician will get behind what is presented at face 
value to access underlying causes for unfamiliar or threatening actions on the part of 
the child, as well as an understanding of the tenuous nature of the diagnostic process as 
being very circular in ideas about cause and effect; a fact which shapes how behaviours 
may or may not be defined as pathological in the first place. 
5.6.4 PBD not distinct from adult bipolar 
Defining the diagnosis and deciphering what a child with PBD looks like was a 
significant point of contrast with colleagues in the US. Where in the US context, the 
child was discussed as a collection of symptoms, English clinicians have more space 
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built in to their practice to explore multiple contextual causes for problematic 
behaviour. There was a wariness of slipping into characterizing PBD as rage and 
irritability. Instead, there was a tendency to discuss the diagnosis, and symptoms, as 
something extremely rare, as well as in line with a manic-depressive, psychotic episode 
requiring in-patient treatment:  
So with PBD it would be something that looked much more similar to a 
kind of chronic relapsing psychotic picture, so something that you would 
see in a diagnosis of schizophrenia. (UKC9) 
 
According to this clinician, a diagnosis of PBD is not one to be given lightly. The 
alignment with schizophrenia suggests the child with PBD is in fact very ill in a way that 
can’t be contested as easily as a child characterised by rage and irritability. Despite the 
representation of children with PBD as psychotic, however, discomfort and uncertainty 
remain, with several clinicians acknowledging the act of giving the label of PBD as 
making them nervous. The severity of the diagnosis is central to this clinician’s 
interpretation of how a child is presenting. Their reluctance to give the label of PBD, 
the fact that it makes them nervous, reveals a concern for the child that moves beyond 
the immediate treatment into future implications for what this particular diagnostic 
label would mean.  
5.6.5 Giving the young person a voice 
English clinicians attempt to take on the perspective on the young person with PBD, as 
made evident when providing specific examples in discussion of young people in their 
care. Clinicians sought to take on the voice of the child, unpacking what the diagnosis, 
and the requisite treatments, means to them. There was a sense of wanting to move 
beyond the diagnosis itself with the child in order to start to work on the core problems 
rather than the controlling symptoms: 
Get them to think about what’s going on at school, what’s going on at 
home, what they’d like to achieve, what activities are they doing, helping 
them recast their image of themselves away from being sort of disabled 
towards what are their strengths, what are things that they’re interested in, 
and so on and so forth, (UKC5) 
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This speaker sees their position as one who can help the child reshape their identity in 
line with how they see themselves, as opposed to allowing the diagnosis, or other 
individuals, to define it for them. The notion of a feedback loop in which those given a 
particular diagnosis of mental illness can learn to reshape their sense of themselves in 
response to external expectation, is especially salient for young people still in the 
process of finding out who they are. Clinical consideration of these processes is helpful 
in allowing the child to make attempts at healing in whatever way possible. The 
challenges for adherence to medication is highlighted by another clinician, but again 
there is compassion in understanding just what that might mean for a young person: 
One of the main difficulties with psychiatry in general I think, and 
particularly BP is that when you’re high, you are feeling amazing, you’re 
feeling invincible, you feel that you are witty and clever and funny and so 
on, and the medication brings you back down, which is very boring for 
people with BP to be on a stable level on an even keel, that’s very boring, 
so one of the main problems I think in general is non-compliance with 
medication. (UKC7) 
 
In England, the youngest PBD patients clinicians are likely to see are aged 13 and 14: 
So here people wouldn’t even dream of calling, or many wouldn’t, a child 
below the age of 16 as having BP. (UKC4) 
 
Developmentally they are at a stage where they are trying to manage a number of 
different changes, from school and exams, to hormones and changing relationships. 
Thrown into this adolescent sea change is the uncertainty of what is happening on a 
behavioural level, and in the responses those around the young person may be having 
to their new behaviours. Negative responses can cause the young person to feel that 
their already fragmented world is becoming less stable, and as clinicians with a more 
psychoanalytic grounding to their practice, clinicians in England illustrated these issues 
as shaping how they view the child: 
So a lot of these kids will say ‘well I’m not taking meds’…alright. And I’m 
not there to- I can tell them about the risk factors that show this, that and 
the Other, but at the end of the day, part of the subtlety is not exactly- and 
I don’t think it’s about persuading, it is something about laying out the lay 
of the land, and to then slightly unpick what their narrative is in the midst 
of all of this. So is it about not being controlled, because mom and dad do 
enough of that. Is that because their mates at school are going to go ‘well 
you’re a spaz aren’t you’, because you can’t, for whatever reason. Is it 
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because of the side effects of the medicine, they feel sick on it and what 
have you, which is a big reason why people stop taking meds. So there’s all 
kinds of little bits you need to kind of pull out in this. (UKC9) 
 
The excerpt above shows an attempt to access the child’s own narrative. The clinician 
here even looks to the power of the young person’s peer group, and the impact that has 
on how the child views themselves. They recognize their unique position in the life of 
the child- one that is not teacher, or parent, or Other figure of traditional authority; 
rather the clinician here, in discussion how the child is perceiving the world around 
them, illustrates a desire to move beyond symptoms and help the child retain a sense of 
their own identity in the midst of diagnostic uncertainty. 
5.7 Discussion 
This chapter has focused on clinicians in the US and England, and how their 
interactions with significant others shape the development of their representations of 
the diagnosis. The questions guiding this chapter asked about the representations of 
PBD held by clinicians in the US and England, as well as the psychosocial processes at 
play in shaping the development of these representations.  
For American clinicians interviewed, representations of PBD are anchored in 
associations with ADHD, and represented as something murky and unstable, clouded 
by uncertainty and ambiguity, yet continuing to expand, encompassing more and more 
children with disparate sets of ‘symptoms’. PBD is thus objectified and enacted as a 
diagnosis, which is more common in the young than previously thought. The analysis 
of data from interviews with American clinicians has shown how PBD exists as an 
unstable diagnosis based ever-changing criteria, which has been borne out of the 
influence of parents and clinical colleagues, as well as external pressure from the 
pharmaceutical industry, all of which shape representations of the child at the heart of 
the diagnosis. Representations of the child held by American clinicians tend towards 
seeing the child as being at risk, thus initiating the need for prodromal diagnosis and 
treatment. Professional perspectives outweigh any more personal considerations in 
seeing the child as a cluster of symptoms in need of management suggesting the need to 
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separate a more holistic feeling about the child and their behaviour with more clinical 
distancing that allows the clinician to practice in delicate and controversial territory. 
Dialogical processes shaping American clinical representations of PBD point to 
a sense of uncertainty combined with the development of expertise, which leads to an 
increased “recognition” of behaviours indicative of PBD. Among colleagues, clinicians 
seek to stand alone. Unlike their colleagues in England, there is no sense in discussion 
with American participants that the dominant view of the wider field of practice in the 
US is influencing their thinking. Instead, there is an acknowledgement of how fractured 
the discipline is, with each clinician subscribing to a different school of thought with 
regards to PBD. As there is no central force to react against, American clinicians 
practice as “islands” in a sense, developing knowledge of PBD within a context that 
valorises autonomy and the push for innovation as the norm. Innovation here comes in 
the consideration of PBD as risky to overlook, thus in need of a definitive explanation 
and course of early treatment. While on the one hand there is a normalization of 
independent practice, there is at the same time a desire to build consensus as a field, yet 
the differences appear too deeply ingrained, the multiple schools of thought within 
American psychiatry too divergent, for any real consensus around how best to approach 
PBD to be achieved. 
Parents play a pivotal role in the development of clinical understanding of what 
they are seeing, acting as co-producers of expertise and thereby exerting minority 
influence, which is accommodated by clinicians in that it functions to validate an 
uncertain and unstable diagnosis.  Parental demand, based on lived experience with 
their children, initially focused clinical attention on specific behaviours, which are then 
adopted into their representation of a disordered child. Rage and irritability thus 
become reified as ‘symptoms’ through the process of negotiation with parents to log 
certain aspect of a child’s conduct as symptomatic of this illness. Parents are the voice 
for the child, and among American clinicians there is a sense of the parents as victims 
of the disorder. An alliance between clinician and parent paves the way for the 
perpetuation of new knowledge and understanding of PBD, however the child becomes 
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almost peripheral. Thus, this chapter has shown how parents directed clinical attention, 
which clinicians then direct back at parents and, by proxy, onto the child.   
The presence of pharma forces an examination of subjective values in the face 
of professional realities, leading American clinicians to negotiate a wider social and 
institutional hierarchy, in which top-down political and economic pressures from the 
local medical and pharmaceutical systems encounter bottom up psychological pressures, 
such as from anxious parents, directly influences clinical approaches to diagnosis and 
treatment, by incentivizing early and rapid diagnosis. In summary, the interaction 
between clinical knowledge, and their presentation of the knowledge of others, namely 
colleagues, parents and the pharmaceutical industry, lead to a representation of the child 
as defined by the symptoms they exhibit, and thus a risk in need of early intervention.  
In England, PBD is represented as a rare diagnosis, anchored in more classical 
bipolar presentations not seen in very young children, and often involving marked 
periods of mania and psychotic behaviour, often associated with schizophrenia, and in 
need of multiple sources of information and perspectives to arrive at a proper 
diagnosis. The objectification of PBD as a separate entity from adult bipolar is rejected, 
thus traditional understandings of bipolar are adhered to, keeping the diagnosis rare in 
young people. The child is central to clinical discussion and is seen as part of the wider 
social context of family, school and peer groups. Interpretation of the data suggest 
desire to understand PBD from the perspective of the child. 
Dialogical processes shaping English clinical representations of PBD include 
the redefinition of the clinical Self in reference to various Others and positioned within 
a wider collective field. This can be seen as an illustration of greater interdependence 
among colleagues, however such interdependence, while positive in that it suggests a 
level of unity, indicates conformity pressures to local system of knowledge (e.g. UK 
practice) leading to social validation from colleagues of how what is seen clinically 
should be interpreted. In contrast to their American counterparts, the unspoken 
pressure to conform steers the accommodation of knowledge from one’s clinical 
colleagues over parents. For English clinicians, parents are seen as aligned with the 
child, a distanciation which favours a view of parents less as co-constructors of 
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knowledge, or victims, and instead as seekers of information which the clinician is in a 
position to provide. Parents are part of the wider social context of the child, an 
understanding of which is a key part of the diagnostic process in England, with 
clinicians hesitant to give such a severe diagnosis young people without a full picture of 
familial context backed up by concurrent perspectives of Others in the life of the child, 
such as teachers or care workers.  
Minority influence comes into play when considering the positioning of English 
clinicians against the imposing, yet often indirect, dominance of American colleagues. 
English participants interviewed expressed conflicted feelings about accepting some 
aspects of US-led research and innovative perspectives on children’s mental health, 
while at the same time wishing to maintain professional distance in response to a feeling 
that American psychiatric practice tends towards the over-diagnosis and over-
medication of children. Alongside this is the interaction with the pharmaceutical 
industry, depicted as an encroaching threat, warranting scepticism and generating a 
propensity to place increased trust in more ‘home-grown’ research perceived to be less 
influenced by vested interest. In representing a unified field of practice consistent in 
their resistance to external American influence, there is a sense that further 
development of the ‘broad spectrum’ approach to PBD in England will remain rare. 
Much depends on the degree to which a few influential clinicians in England push the 
idea in the future, however. Also potentially challenging their strength as a minority and 
influencing future clinical thinking and practice around keeping PBD rare will be the 
degree to which parents adopt ‘broad spectrum’ thinking. This, in conjunction with a 
healthcare system in which many who are able decide to pursue private care, thus 
increasing patient power as a consumer.   
The particular vectors of influence for American and English clinicians also 
drive the development of representations of PBD.  In America there are multiple 
vectors, with the pharmaceutical industry and parents chief among them. In England, 
however, regulatory practices unique to the UK ensure more limited, disrupted, vectors 
of influence, in which the pharmaceutical industry and parents are less salient. The 
indirect pressure form America as a ‘generalized Other’, however, combined with the 
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desire to maintain unity with the wider collective field of practice in the UK, means that 
modalities of influence are present in clinical thinking, however on a different level than 
that of their American counterparts. 
The chapter has shown how social representations of PBD held by clinicians in 
the US and England encompass not just the diagnosis itself, but also representations of 
the child in relation to frames of reference suggesting a cultural standard. Knowledge is 
constructed via encounters between multiple systems of knowledge which shape these 
representations, as well as through modalities of social influence including conformity 
pressures, minority influence, subjective and peer validation and the accommodation or 
resistance to developing notions of PBD. A more in-depth discussion of the findings 
can be found in chapter seven, where the role of cultural context will be expanded upon to 
understand what role this plays on similarities or differences shaping the development 
and maintenance of knowledge about PBD, how it is communicated, diagnosed and 
treated. The following chapter, chapter six, is the final empirical chapter and presents the 
analysis of parents in the US and England. 
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6. Parental representations of  PBD in the US and England 
 
6.1 Introduction  
The previous chapter, chapter five, focused on the development of clinical knowledge 
shaping representations of PBD coming as a result of interactions between themselves 
as individuals operating as part of a wider professional collective, the influence of the 
pharmaceutical industry, and their positioning of parents as either central (US) or 
peripheral (England) framing their view of the child and diagnosis. The aim of this 
chapter is to explore how parents in the US and England develop understandings of 
PBD, and who else is involved in shaping these representations. The results suggest 
that parents in the US have many more sources of influence in their thinking, 
particularly parental peers and the school who don’t figure as prominently among 
parents in England. American parents have found a sense of purpose and advocacy as a 
result of their struggles with their children, allowing for a sense of expertise to develop. 
In England, parents continue to feel cast aside and in the dark regarding what the 
diagnosis of bipolar disorder means for both their child and their family, maintaining a 
position of themselves as amateurs, unsure where exactly to turn for information and 
support. The questions guiding this chapter are as follows: 
 
 What are the representations of PBD held by parents in the US and England? 
 What psychosocial processes shape the development of these representations? 
 
The data presented in the following sections address my research questions by 
illustrating that for parents, interaction with key actors involved in the life-world of the 
child is central to shaping how parents view their own child’s behaviour in light of the 
diagnosis, as is the process of reflecting on their own position in relation to these 
others. For American parents, the development of their own sense of expertise is 
necessary in order to feel a sense of mastery over their child’s behaviour, and the world 
of professional interaction that they enter into as part of the trajectory of their child’s 
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diagnosis, while the child is seen as being at the mercy of the diagnosis, not in control 
of their emotions or actions. Other parents and the school are also significant others 
for American participants, while among English participants representations of the 
diagnosis stem from feeling like they have no control or agency themselves, that they 
are in the position of amateur, reliant upon clinical expertise to provide guidance that, 
more often than not, proves unreliable. Parents are at the mercy of a wider systemic 
hierarchy in which they are cast aside as their child is taken into the system without 
their blessing.  The analysis also shows how the influence of multiple third parties 
contributes to how parents define and respond to a diagnosis that is still in the process 
of becoming.  
The findings in this chapter connect to the overall thesis as the knowledge of 
parents is central to the wider construction, perpetuation and dissemination of 
knowledge about PBD on multiple levels. The comparison between how understanding 
of the diagnosis, and the new identity of their child is developed and communicated by 
parents in the US as compared to England provides a picture of how what is happening 
on the top-level of the pharmaceutical industry, and the mid-level of clinical 
professionals intersects with the knowledge and experience of those living with, and 
often giving voice to the child. The perspective of parents in these cultural contexts 
offers a sense of how knowledge about PBD has come to be defined and used by those 
closest to the child, and the level to which top-down knowledge is appropriated or not. 
6.2 Analytic procedures and findings 
The purpose of the analysis discussed in this chapter is to provide an empirical 
grounding as evidence for the development of parental representations of PBD. The 
findings presented here are the result of thematic and dialogical analyses, which is 
discussed in further detail in section 3.4.3.  In conducting separate analyses on US and 
English parent data, I sought to develop a coding framework that reflected both the 
content and processes involved in the development of knowledge of PBD, so what was 
being said about PBD, and how it was being said.  Interactions taking place within 
parent’s talk are central to the construction of their thinking about PBD, thus the data 
was coded with an eye towards such interactions. An initial identification of who the 
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significant others were coming up in conversation acted as the organizing themes under 
the global heading of Self-Other. For American participants, this resulted in organizing 
themes of the parental-Self- ‘I’ position followed in frequency by significant others 
coming up:  the child, clinicians, the school, and parental peers. For English parents, In 
addition to the parental-Self- I-position, only two Other’s came up with any frequency, 
resulting in the basic themes of clinicians and the child (See figures 6.1 and 6.2 below). 
Separate coding was undertaken for the US sample of 15 parents, and the English 
sample of 5 parents for a total of 20 interviews. Excerpts of text were coded based on 
who was being addressed, and within that what was being said about PBD. It was in the 
final interpretive stage of analysis, once the coded segments were in place, that a 
dialogical approach to selected segments was undertaken. While the coding and 
resulting thematic framework developed identified the ‘who’ and the ‘what’, the 
dialogical analysis of those coded segments addressed the ‘how’. 
 
Figure 6.1. Themes from analysis of American parents, and position in relation to 
significant others  
 
Parental ‘I’ Position
• Us vs. ‘Them’ experiential knowledge to position 
themselves as experts in relation to multiple Others
• Proactive advocate wanting what’s best for the child
The child
• Control and Unpredictability- True nature of child 
obscured by diagnosis
• Medication as unavoidable necessity
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There was often an overlapping between themes, for example as with medication and 
parental advocacy, which came up in reference to multiple others suggesting how 
intertwined these ideas are with wider parental representation of PBD. For parents in 
the US, the validation and development of their own experiential knowledge in the face 
of multiple other professional knowledges is a key driver in how they arrive at their 
representations of PBD. Among American parents, PBD is seen as something they 
experience alongside their child as a helpful, though not always welcome, diagnosis in 
which medication is viewed as a necessary evil, as does pro-active advocacy.  
 
Figure 6.2. Themes from analysis of English parents, and position in relation to 
significant others 
 
English parents discussed the diagnosis in a way that they were still in the process of 
making sense of it. The focus tended towards personal narratives that incorporated the 
parent’s own subjective experience and their interpretations of what they were facing 
with regards to their child’s behaviour. Interactions with clinicians took up a significant 
amount of space in the interviews, as parents in England, perhaps having less access to 
the cultural openness regarding mental health and mental illness in young people so 
   
Parental ‘I’ Position
• Feel like amateurs
• Ill-informed and lacking support
Clinicians
• Disappointment and frustration
• Faced with reluctance to diagnose a young person
• Comparison with American clinicians
The child
• Lack of certainty over what is normal
• Social pressures as trigger leading to diagnosis
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prevalent in the US, were much more inclined to articulate their own sense of 
confusion and lack of understanding the bipolar could exist in young people. As with 
American parents, those in England discussed feeling cast aside and ignored by 
clinicians, however the hierarchical nature of the health care system in England shown 
through in the lack of control or options parents felt they had. Perhaps stemming from 
a lack of cultural comfort maintaining awareness of mental health issues, English 
parents discussed the child with a sense of confusion, frustration and guilt over their 
own inability to see anything was wrong. An overriding sense of seeing the child’s 
increasingly concerning behaviour was often passed off as normal adolescence, 
something many English parents spent quite a bit of time reflecting on in the 
interviews. The school was not a significant topic of conversation, with only a few 
mentions, nor was there much discussion of parental peers. For English parents, the 
overall tone within the data suggested a sense that they were very much alone in their 
journey, relying on their own upended sense of subjective norms to try and make sense 
of their child’s behaviour, and what the diagnosis of PBD meant for them.  
6.3 Position of Parental Self 
As in the explanation of the ‘reflexive Self’ described in chapter five (cf 5.3) the notion of a 
parental Self here refers to the dominant ‘I’ position coming up in conversation with 
parents- whether through their own overt articulation of how and where they saw 
themselves in the process of coming to understand PBD, or what was interpreted 
through analysis of their talk.  
American parents 
6.3.1 Us v. Them: valuing experiential knowledge as expertise 
One of the most salient themes to come from discussion with American parents was 
the idea of parents feeling that they were constantly coming up against various others in 
their quest to understand what was going on with their child. A sense of ‘Us versus 
Them’, in which the parent positions themselves in alignment with the child and 
counter to others such as clinicians, peers and the school, was present across 
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interactions, likening such attempts at communication as  ‘a battle’ or ‘a constant fight’. 
Reinforcing this position was a process of providing an account of their expertise 
arrived at through experience. Often times, parents were keen to integrate their own 
background with that of their child, for example beginning a discussion by talking about 
their own experiences living with bipolar disorder if they had been previously diagnosed 
as well.  
Well, when we first started going through this, we went to all the little 
psychiatrist doctors up there who were treating her for depression, and I 
was telling them all the other symptoms she was having and they would 
completely ignore it. And I’m like, well this is what I think is going on with 
her. This is what’s happening. I see myself in what’s happening, and I know 
what that feels like, so I know that this is what’s happening with her, and 
nobody wanted to listen to me…because as a parent - these people see 
your kid a couple of days, saying ‘ok this is what’s wrong with them’. You 
see your kid 24 hours a day every day, and you know that it’s much, much 
worse than they say. (USP7) 
 
By locating themselves as a central character in the master narrative of their child’s 
trajectory navigating PBD, American parents find a way to sculpt the uncertainty and 
anxiety they feel into something proactive and meaningful in the face of those who 
doubt their assertions. In the case above, this is illustrated in questioning the assessment 
of a clinician who the parent believes is not capable of seeing, and thus understanding, 
the whole picture. There is a process being made visible of repeated denial and 
perceived indifference from clinicians leading American parents to position themselves 
as experiential experts not only against clinical expertise, but also when considering 
their role as a guiding light to others who may just be at the beginning stages of their 
own journeys with their children. This drive for recognition of their own expertise 
comes out in the way in which parents describe interacting with other parents, 
illuminating the anchoring of their own knowledge of PBD in that of clinicians.  There 
is a need among parents not only to share their experiences of raising a child with PBD, 
but also a desire to educate: 
You get to be an expert- well, you see it in other people that may not 
realize that they have it, and obviously you can’t go up to them and go “you 
know I think your kid might be bipolar” (laughs) you know, it’s not really 
do-able. But there have been people where I have kind of shared my story a 
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little bit and hopefully they would kind of look at it and think “huh. I 
wonder” (USP13) 
 
PBD here has provided an object onto which parents can lay claim to their experience 
as expertise. The parent above positions herself as someone who can see evidence of it 
in other people’s children, suggesting another way in which the diagnosis is perpetuated 
and new frameworks developed through which to view a child’s behaviour: peer 
influence from other parents. There are a number of things at play in the desire to 
impart this knowledge, the first being that the speaker is able to see beyond the surface 
of things. There is a goal underlying the sharing of her experience with unsuspecting 
parents, hoping they will come around. Perhaps if they do, the speaker’s experience can 
be validated in some capacity, and the struggle endured thus far now serves a greater 
purpose-to ‘educate’ others. Feeling needed or appreciated in the face of uncertainty, 
confusion, and dismissal from psychiatrists can prove to be a powerful driving force for 
parents to communicate their subjective expertise:  
I mean there have been a lot of people who have some to me and said, you 
know, I’m seeing XY and Z in my child, what do you think? And I’ve been 
able to talk them through, well do you see this or this. Yes? OK, you may 
want to consider that it could be this. You don’t see that? OK chances are 
it’s not. The way that, and maybe this is the most helpful, I mean people 
always ask “how do you know if your kid has it?” and I say, from what I’ve 
seen (USP5) 
 
Here the parent positions themselves as a clinician-by-proxy, a first point of contact for 
Other anxious parents, perhaps representing a figure she would have felt relieved to 
have in the early stages of trying to figure out her child’s behaviour, and finding solace 
in the notion that her opinion here will be valued. Her child’s diagnosis has provided a 
purpose, a means to connect with others, and a way to demonstrate competence. It is 
not only parents seeking to pass on their knowledge unsolicited, but they are also eager 
to acknowledge that their experience and the awareness that comes with it, is valued by 
some (other anxious parents), even if it is negated by others (psychiatrists).  They are 
proud of being sought out to share what they have seen, and what others might be 
seeing. These excerpts illustrate the diffusion of parental representations of PBD in 
action.  The parent positions themselves as expert, and it is this self-imposed label that 
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acts as a driver to educate others and attempt to steer representations of the child in a 
way as to align with the speaker’s own way of thinking. Perhaps such attempts can be 
read as an attempt to create a solid base of support in anticipation of future struggles to 
validate the diagnosis. 
6.3.2 Proactive advocate wanting what’s best for the child 
For American parents, the demonstration of their experiential expertise comes in the 
form of efforts to advance their understanding of PBD into other spheres of 
knowledge where they may not always feel they are taken seriously: 
I think too often that doctors are looked at as being omniscient and always 
right, and they’re not. They make mistakes. And as a parent you’ve gotta be 
an advocate, that’s the only way things will change too, (USP10) 
 
Referring to oneself in line with a more general sense of ‘being a parent’ suggests 
multiple co-existing value judgments which one must explore in order to fully live 
within that title. Being a parent for the individual above, as opposed to being a doctor, 
means constantly questioning information designed to over-ride a parent’s own coming 
from top-down knowledge systems removed from the experience of the child. In 
suggesting nothing will change unless parents themselves take action, this speaker 
reiterates a theme that came up among several parents that it is a constant battle to 
prove their own position as knowing what is best for their children. One way advocacy 
becomes a beneficial aspect of the child’s diagnosis with PBD is the sense of purpose 
and control it gives to parents who, in the uncertain period prior to a child being 
diagnosed, may have felt overlooked: 
I was ashamed of myself. And being ashamed made it worse. It makes it 
easier now that I know what’s going on and I can talk about it, and people 
are more respective when I say these things about PBD now, and they 
listen more. (USP7) 
 
Here the power of knowledge held and communicated is evident in how it reshapes the 
parent’s own subjective understanding of their relation to others. With respect comes 
the removal of shame, thus the parent now feels they have something to contribute to 
the debate. The fact of their position as parent to a child with PBD renders them 
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worthy of being heard, building up a specific identity with which to share experience, 
influence others and feel a sense of control that comes with being proactive. 
English parents 
6.3.3 Feeling like ‘amateurs’ 
In discussing PBD both as a diagnosis and a process undergone by the family, parents 
in England positioned themselves as amateurs, lacking the sentiment of experiential 
expertise expressed by their American counterparts. For the parents interviewed in 
England, there was a sense of being somewhat lost and trying to make sense of the new 
world that opened up as a result of their child’s ill health. As one parent stated:  “I’m 
not an expert, I just have this ill child and am trying to understand” (UKP 3). With the 
exception of one parent, if the expertise earned as a result of living with a child with 
PBD came up at all, it was later in the narrative, as though discussing their child’s 
trajectory into diagnosis allowed space to incorporate their own, leading to deeper 
reflection of their own place within the wider system.  The positioning of themselves as 
novices in the world of mental illness, making sense of behaviours that presented in the 
child before receiving the diagnosis, however, was murky and confusing: 
We always had this concern that with the family background that she could 
well be bipolar, but she wasn’t exhibiting any of the, what I call “classic” 
traits of bipolar, nor was-- but if you read all the books, we’re really 
amateurs obviously, about how it sort of translates what the symptoms are 
in young people. She didn’t even necessarily have those, but looking back 
on it now, I think we can see there were signs there, but it was just that we 
needed to look a little bit below the surface to see where and actually say 
“well hang on a second, what about that behaviour trait” and so-on. (UKP 
2) 
 
What is salient in this excerpt though is the flat out admission of being amateurs in 
terms of how they as parents are meant to understand what their child’s behaviour 
means through tapping into a wider system of knowledge available. The parent 
discusses the role of books as an entry into the acquisition of knowledge about PBD, 
and it is evident that this knowledge has become internalized in the way the parent 
describes as “classic’ traits of bipolar”. This echo of clinical discourse has been adopted 
by the parent as their own in order gain control over how to approach concern over 
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their child. By stating that they are able to retrospectively see the signs of bipolar in 
their child, immediately after elaborating on what’s been learned from “reading the 
books”, the parent signals how influential the information presented in the literature 
proved to be, and the function this knowledge held for the parent. Behaviours are 
reframed as symptoms and signs as the parent-as-amateur seeks a level of expertise with 
which to take action and move forward. 
With the exception of one, English parents interviewed were unaware that 
bipolar disorder could exist in young people prior to their child’s experience. This can 
be seen as a reflection of both the differing levels of knowledge held by parents in 
England as compared to their counterparts in the US, as well as the wider professional 
standard in England in which young people below the age of 16 are rarely diagnosed 
with severe mental illness:  
I: Did you know it [bipolar] could exist in children before you went 
through this? 
 
R: No, no. I just realised that I could trace it back in me and I began 
looking it up. I have about ten books on it, and I look it up on the internet 
all the time, I contact experts, none in this country! (UKP 1) 
 
 
 I: Did you feel bipolar could exist in young children? 
 
R: No. I don’t know how they would diagnose it, I think it could be quite 
difficult, I mean we’re all born with different personalities, and sometimes 
its maybe more to do with personality, but when I read through the BPD 
information leaflet, to me it seems like sometimes people have ups and 
downs, to me sometimes I feel questioning about whether my daughter 
really is matching with bipolar. Because to me, yes, she does have some 
lows, but her low mood is not very clear. (UKP 3) 
 
In the excerpts above, this lack of knowledge had two different manifestations. For the 
first parent, it is an alignment of the child’s experience with the parent’s own, having 
self-diagnosed as an adult with bipolar (and having been subsequently professionally 
diagnosed bipolar) which led to a drive to obtain the diagnosis for the child.  The 
development of understanding, and validation of this parent’s own suspicion of PBD in 
her daughter comes from books, internet resources, and experts contacted in the US 
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more amenable to recognising bipolar in children. For the second parent, there remains 
a level of denial at play, holding on to an understanding of young people as necessarily 
having mood swings as part of normal development. There is no discussion of seeking 
out more information to support a growing sense of seeing PBD as a possibility, instead 
the information leaflet is positioned as almost an intrusion into a mind set in which 
perhaps the parent doesn’t want to consider that the child really is ill, or that the 
potential is there for their child to have bipolar. In this sense, the parent’s reflexive Self 
might wish to remain an amateur, suggesting as it does a situation that is not yet fully 
formed, and where the outcome, in this case diagnosis, is able to remain distant.  
6.3.4 Ill- informed and cast aside 
The lack of support and information about what was happening to their child was a 
major theme to come from the way in which parents discussed their own position in 
the development of their understanding of PBD.  A perceived lack of control and 
agency resulted, with parents each discussing examples of being ignored, cast aside or 
“removed from the equation” once the psychiatric system of care was put into place. As 
a result, parents felt a lack of clarity in terms of understanding the process and 
prognosis once their child received the diagnosis. As the following parent describes: 
she was put onto a paediatric ward, not a psychiatric ward at all, because it’s 
not a psychiatric hospital, and there was a psychiatrist there, but it was kind 
of a junior one, and of course they didn’t really know what to do with her 
at all, Other than that she needed to be kept in the hospital for her own 
safety. And at this point, as parents we were really taken out of the 
equation. At that point onwards we were told what was going to happen, 
not consulted. Or asked. And although at the time when it looked as if we 
were maybe being sort of consulted, looking back on it in the cold light of 
day, no, we weren’t. At that point I’d say the system took over, and 
effectively took it out of our hands, so we became really passengers in the 
whole process. I have to say, it was the most-- it was unbelievable 
traumatic. (UKP2) 
 
The experience articulated above suggests the power dynamics at play between parents 
and professionals, in which the parent’s perspective suggests little regard for any insight 
they may have as a result of living with the child experiencing difficulties. Instead, there 
is an expectation that they accept what they are told and allow the wider medical system 
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to function as it should. The experience of not being given appointments, not being 
provided relevant information, and not being taken seriously despite the escalation of 
extreme behaviours, such as self-harm, push parents to seek out information from non-
professional sources, in order to at least feel they are gaining some sort of grasp over 
what they are seeing in their child.  A feeling of not being ‘allowed’ to have a say was 
alluded to as well, as illustrated in the following excerpt from the data: 
I: What sorts of things are you telling them [clinicians] when you see them?  
 
R: Well, I’ve bombarded them with my expertise! (laughs). Probably not the 
best way, because I think if I hadn’t done that, it’s possible some 
enlightened person would say “hmm, I wonder if it’s this”, but I think 
because I’ve gone in there and said “I know it’s this”, the tendency is to say 
“no it isn’t”. I don’t know if it’s because I’m not allowed to be an expert, I 
don’t know. You can’t get more of an expert than someone who believes 
they had it as a child and it interferes with everything in life, and I’m not 
going to let my daughter go through that. It’s not going to happen. (UKP 
1) 
 
This parent stood out against the others for being the only one to feel a sense of 
experiential expertise (as discussed in the previous section), which when enacted 
through confrontation with a clinician has sabotaged her chance of obtaining the 
diagnosis of PBD for her daughter. In suggesting that if she had played down her 
understanding a bit, some “enlightened person” would come and give the diagnosis, she 
is highlighting the lack of recognition she feels; a lack of recognition that ultimately 
leads this parent to seek the opinion of experts in the US. For this parent, discussion is 
filled with anticipation of how she is being perceived by the clinicians, however her 
tone is more of defiance as opposed to being beaten down in not being taken seriously. 
The subjective position here is one of a clash of expertise, in which the perception is 
one of professional dismissal, determined to see this parent as nothing more than a 
layperson with outlandish beliefs not in line with their own, or that of wider clinical 
practice in the UK. The more this parent comes up against this attitude, however, the 
more conviction is gained to ensure that she gets what she feels she needs for her 
daughter so that her daughter need not go through what the parent herself went 
through. This positioning of the Self encountering undermining professionals as a 
springboard to action was rare in the few interviews conducted with English parents, 
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however in this instance, the drive was significant and led to a search for a knowledge 
of PBD that was more compatible with the parent’s own. 
 
6.4 The Child 
The position of the child was prominent among both American and English parents, 
however the way they were discussed differed. In the US, the focus was on the true, 
‘gifted’ nature of the child being obscured by the diagnosis, leading discussion to take 
shape around the child not being in control emotionally or behaviourally, and the 
parent then feeling torn about the need for medications. Among parents in England, 
there was more a sense of parents taking on the ‘voice’ of the child through recounting 
examples of interactions they’d had in which parents tried retrospectively to figure out 
of the behaviours seen in their children that were missed as being pathological, but that 
the child themselves were attempting to communicate a sense of something being 
wrong. Understanding the triggers of destructive behaviours was also central. Of 
interest is the gender breakdown between the cultural contexts. The children discussed 
by American parents were boys who had been diagnosed at a younger age while parents 
in England spoke of daughters diagnosed at early adolescence. 
American parents 
6.4.1 True nature of child obscured by diagnosis 
Each and every American parent interviewed made reference to their child as ‘gifted’ in 
some respect; that while they may be outwardly angry and out of control, they had a 
heart of gold.  Among American parents there was frustration over the power the 
diagnosis held in shaping perceptions not only of their parenting, but also how the child 
was viewed by Others. In discussing their children, there was a sense of needing to play 
into wider expectations and: 
You don’t really get to say the great things, you love your child and you 
want to say how smart he is in this area, and how compassionate he is, but 
that doesn’t get you the services that you need, so you have to put these 
labels, and you have talk about the worst of the worst part, and you hate to 
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say all of that because you’re proud of your child, but don’t say that you’re 
afraid to really go there, you’re not going to get the help you need. (USP13) 
 
Ultimately a central aspect of being given this diagnosis is what is opened up to the 
family in terms of available services and accommodations for the child.  The speaker 
above elaborates at the power dynamics at play, in which the parent and child need to 
perform the illness in a sense, matching what is seen to what is expected- a theme 
running through this thesis on many levels. The realignment of expectation on all sides 
in order to make the diagnosis useful has the dual function of making the child 
conform to wider assumptions, while at the same time eclipsing their parents, and their 
own, sense of who they themselves are. This illustrates a point discussed in chapter two 
(cf 2.2) related to the social elaboration of a medical fact in the process of becoming. 
Here we see an illustration of the classification of a child being needed in order to 
access services, but the implication of what is at play once a parent starts to view their 
child through the framework of expectation it the child, in a sense starting to ‘become’ 
their diagnosis. 
6.4.2 Unpredictability and control 
In exploring interactions with the child through discussion with parents, notions of 
unpredictability and control, both in the sense of a child not being able to control their 
brain, and thus their behaviour, but also in terms of agency, were significant in terms of 
how parents were thinking of what PBD meant to them and for their children. Parents 
positioned themselves as almost being at the mercy of their child’s illness, something 
echoed by American clinicians as well (cf. 5.4.3) with one parent noting that it is “the 
person with the diagnosis who is driving the bus “ (USP11), and another suggesting: 
It’s hard to think that what’s happening to them is beyond their control, 
and the behaviours that they’re exhibiting aren’t just them being unruly, or 
just being mean, or just being a bad kid, these are, they’re doing things that 
they really can’t control themselves (USP7) 
 
Assuming that PBD is responsible for unwanted behaviours removes responsibility 
from both the child and the parent. The removal of responsibility plays in to how 
manifestations of the diagnosis are interpreted.  This idea of PBD causing instability, 
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unpredictability and an inability to control one’s own behaviour often lends weight to a 
parent’s decision to medicate the child, suggesting that as a parent, they need to help 
their obviously suffering child- an idea that also plays into the wider discourse 
surrounding what the diagnosis looks like. Reframing the representation of PBD by 
removing responsibility of the parent and the child, putting it squarely in the child’s out 
of control brain make the uncontrollable and unpredictable controllable and 
predictable. 
6.4.3 Medication as an unavoidable necessity  
In chapter five, the pharmaceutical industry was highlighted as a key player shaping 
American clinical representations of PBD. Among parents in the US, frank discussion 
of the industry was less salient, however each and every parent devoted a significant 
portion of the interview discussing the child in relation to the medication they were on. 
The idea of medicating a wide spectrum of behaviours was one that parents were not all 
necessarily on board with initially, but came to see as something of a necessary evil that 
the child needed to survive: 
Every once in a while I would think “hmmm, maybe he is over medicated, 
maybe he is ok” because you start to not know what’s going on anymore, I 
mean, kids are so medicated, you start to wonder what’s under there…it’s 
kind of a reality check when you realise no, he actually can’t go un-
medicated. He’s a sick kid. (USP12) 
 
The parent above is questioning the logic of putting her son on such heavy duty 
medications, lamenting the fact that she no longer knows who he is, and berating 
herself and her skills as a mother in the process. It becomes a vicious cycle of trial and 
error, where it is no longer clear what is being medicated, but without it, the child falls 
apart.  The reality that this parent draws on is one of a sick child who can’t go un-
medicated. Though it pains her to do it, she feels it is the only option, one that she 
succumbs to out of desperation as opposed to any outward motivation related to 
mitigating future risk, or feeling an overt push for present achievement. For this parent, 
medication comes as a result of having a child who is suffering. Underlying what she 
says is an understanding that her job as a parent is to do what she can to ease that 
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suffering. While some saw the use of medication as immediately necessary, others 
required the intervention of a clinician to persuade them to come around to the idea. 
Ultimately all of the American parents interviewed were able to rationalize the use of 
medications as it was deemed a necessary evil that is an unfortunate aspect of this 
diagnosis. Non-pharmaceutical options are not commonly seen as being effective. 
The most important thing is that he gets an education, so if can’t physically 
sit in that seat, he can’t be educated, so the medicine to me, although I 
don’t love that I have to do it either, but it’s a choice you have to make. 
Not on medication means not sleeping, not functioning, not doing well in 
school, not being able to deal with his peers, so it’s a choice you have to 
make, and I feel like you are hurting your child if you don’t give them the advantage of 
being able to learn, and there is no learning in a chaotic brain. There’s no ability to 
learn, so then you end up with a child who’s a mess, who is also 
academically behind. If there was no school, and he didn’t need to be educated and 
we’re just running around in the woods, you know, with animals, ok great. Be as chaotic 
as you want. Climb that tree. Jump off of it. Chase this, chase that, but that’s not 
reality. Reality is, as hard as it is, they have to learn to adapt. You do have to learn how 
to behave in class, and if you need extra help, and that extra help has to come from 
medicine, then that’s what you have to do. (USP13, emphasis added) 
 
The reality for this parent, unlike the previous quote, suggests that it is not only her and 
her son’s subjective reality, but rather the reality of the diagnosis in the wider context of 
social norms, which in the US steers towards academic achievement and sociability with 
peers. Social norms are a player in how this parent sees her son’s behaviour, and the 
medication is necessary here not because she is failing as a parent, as the tone of the 
first parent suggested, but rather the fact that society is what it is, and this parent’s son 
needs to carve out his existence in it and “adapt”. He needs to succeed, and whatever is 
necessary to make that happen is what she, as a proactive parent, must seek out. The 
overlapping influence of the clinician’s voice is present in how parents are shaping their 
own thinking about their children’s behaviour warranting medication: 
I said “I don’t want to put him on Lithium, he’s so young, what’s the 
disadvantage?” and he said “well the problem is, if it blows up, it could ruin 
his life. We don’t know what it would look like. It could be legal trouble, it 
could be physical trouble, it could be suicide, homi- it could be any range 
of things”, but he said “this is what I’m trying to prevent”. (USP6) 
 
As I will discuss in section 6.5 below, this echoing of clinical perspectives embraced and 
incorporated into a parents own thinking, as with the quote above, serves to justify and 
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rationalize what for this parent is a difficult decision; putting their child on Lithium. In 
repeating the words that were said to her, reiterating the risk involved in not treating 
the young person, the parent is able to come around to feeling that it is the responsible 
thing to do, recommended by the professional, and not a negative reflection of her 
decisions made as a parent.  
English parents 
6.4.4 Lack of certainty over what is normal 
Parents in England expressed more bewilderment and continued confusion when 
discussing the child. For three participants, the news of the diagnosis was relatively 
recent, suggesting that there was perhaps less remove the child’s identity pre- and post-
diagnosis. Parents discussed their children in a manner that suggested they were still in 
the process of trying to work out what it all meant, retracing events and symptoms such 
as Self-harm, psychotic hallucinations and suicide attempts, struggling to understand 
how it was possible that they didn’t see this coming. It was in discussing the child that it 
became clear how much of the way parents in England come to understand PBD stems 
from an overwhelming uncertainty over what constitutes normal adolescent behaviour, 
and what indicates something more problematic. Parents discussed feeling something 
wasn’t quite right, but thinking perhaps this was just ‘normal’ adolescent acting out. 
This was often followed by frustration with the clinician once the young person was 
found to be ill, that they themselves were unable to recognize the problems leading up 
to diagnosis. Missing out on what turned out to be ‘symptoms’ led some to turn the 
frustration and guilt from clinicians back onto themselves as parents:  
I: You thought it was just normal teenage angst? 
 
R: Yeah. I didn’t’ deal with it very well. I don’t think I handled it very well 
at all. I don’t think I gave her enough support. As a Chinese parent I would 
think, it’s like “I give her all this and she has to obey”, but she grew up 
here, and she always said to me “you don’t respect me at all” and I was like 
“what? Why should I respect you? You should respect me because I’m your 
mother” But looking back, I think she was right. I didn’t respect her I 
should’ve always listened to her and given her the opportunity to refer to 
herself which I haven’t. (UKP 3) 
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For the parent quoted above, not having a sense of what is normal was tied up in wider 
cultural values in which she felt she dismissed her daughters concern, which the 
diagnosis of PBD has now rendered legitimate. The speaker recreates the interaction 
with her daughter in which the notion of respect and obedience echo the wider social 
norms she equates with being Chinese, and through which the daughter’s behaviour 
was viewed by the parent as deviant as opposed to disordered. Here, the parent’s words 
suggest a retrospective blaming of themselves for holding on to ideas of how she 
initially felt her daughter should behave before there was any idea that the girl was in 
fact psychotic and suicidal. The uncertainty with encountering not just unfamiliar 
behaviour in her child, but also an awareness of wider cultural understandings that are 
at odds with her own parenting and interpretation of her daughter’s behaviour, lead to 
an increased anxiety and confusion over how to understand what is normal versus 
pathological conduct.  
A lack of clarity over what the conduct they were witnessing in their children 
meant led some parents to feel blindsided and ill prepared when a diagnosis of PBD 
was suggested: 
…all of a sudden this consultant who we’d met for 20 minutes, that A. had 
met for an hour, we sat in a room and they said ‘we would give her a 
diagnosis of bipolar’. I felt like I’d been hit across the head with a brick. 
And A. looked at me- she had been saying for about a week ‘oh I think I’ve 
got bipolar’ and we just couldn’t- cos also we were very aware that she- that 
young people- could be very influenced by Other young people when 
they’re in that sort of setting. Um, and you know, and A. did have a 
girlfriend, and she was probably looking at her symptoms, and I wonder if 
she was looking at her or trying to match her symptoms up with Others, so 
we just sort of played it down I suppose. (UKP 4) 
 
There are several interactions taking place in the excerpt above. The parent is caught 
off guard by the seeming abruptness of the diagnosis made by the clinician after such a 
short meeting, however again, as with the parent quoted just previously, there is a sense 
that the daughter was attempting to communicate something she knew to be true about 
herself that the parents weren’t fully hearing, also indicating that she had more 
knowledge of bipolar than did her parents. Parental knowledge of the diagnosis led to 
the assumption that it must be peer influence taking hold, rather than some inborn 
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pathology. This same parent goes on to discuss the daughter’s attitude towards the 
diagnosis as one of relief: 
She said she felt total relief, that she was able to put a name to it, she was 
able to explain to people, and particularly her peers. She immediately came 
home, and within a couple days wanted me to explain to people what’s 
wrong with her, because I think up until that point, she found it really hard 
to explain what was going on, and I think that it was important for her to 
get that diagnosis, and for her to explain to her… because for her, she’s 
also trying to maintain a relationship with her friends as well. So that was 
really good for A. I’m still struggling with the diagnosis though…(UKP4) 
 
The importance of having the diagnosis of PBD is central to the daughter’s ability to 
realign her identity and move forward, however for the parent, this begs the question of 
how the diagnosis impacts their own identity as a parent of a child who is now suffering 
officially with a mental illness. The inability to see the diagnosis coming, of being 
locked into beliefs, or hopes, that the behaviour being exhibited could have been 
normal, leaves the parent blindsided and struggling, unsure of how to move forward 
with her new identity, one which no doubt raises questions of if and how anything 
could have been done differently had there been an awareness or understanding that 
something was wrong and not just adolescent acting out. Unlike their American 
counterpart, discussion of the child among English parent was tied up with their own 
sense of defeat, feeling problematic behaviours had been overlooked as a result of not 
knowing what could be defined as normal adolescent conduct, and what should have 
been approached as something pathological. The context of diagnostic practice in 
England suggests a culture of second opinions, a desire to ‘wait and see’. Perhaps such a 
mentality trickles down to the world of the parent interacting with their child, providing 
a culturally accepted model for how to approach questionable behaviour.  
6.4.5 Social pressures as triggers  
The notion of achievement, which is so prevalent among US parents in conjunction 
with wider cultural pressures favouring enhancement, does not go without mention 
among English parents discussing their children. A difference exists in the way it is 
discussed however. The data from the English sample suggests that achievement is 
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actually seen as a key stressor triggering PBD and the associated behavioural and 
emotional changes that can occur: 
She was very popular when she first went to the senior school she had lots 
of friends, and then from year 8 she began losing these friends and she 
moved friend group and then these problems all started to escalate while 
she was in year 9. She would come back and report on problems with her 
friends or teachers- a lot of complaints, a lot of negativity. So, I didn’t think 
there was anything related to my daughter having mental health 
issues…(UKP 3) 
 
The parent above attributes the stress that came with the changes in friend groups that 
marks many adolescent experiences as a precursor for what eventually led to PBD. 
Again, this is wrapped up in questions surrounding what can be perceived as normal 
behaviour. In hindsight, the strain of adolescence appears to provide a viable 
explanation for the parent as to why her daughter may have tipped towards illness. 
Another parent discusses the changes seen in their daughter after she had achieved her 
goal of becoming ‘head girl’ at her school and began navigating new dynamics within 
her friendship circle: 
She’s always been really bright, really intelligent, that’s sort of her identity, 
she’s been very much known in the family, and extended family “A. she’s 
the bright one”, you know, she’s always gobbled up everything in life, she’s 
always wanted to go on to college and university and do this and do that, 
and she’s always been very mature I suppose. But then we started to see 
some very unusual behaviours in that she was starting to be quite rude to 
us, not wanting to come out of her room very often, but the thing we 
noticed most was that she didn’t seem to have much interest in school 
anymore, she wasn’t doing any revisions, reading any books, she just didn’t 
seem to care, so whenever I would bring this up to her she would say “oh I 
know what I’m doing. You don’t trust me” so was there was a sense of well 
she does know what she’s doing, and she’s very driven, but it just wasn’t 
sitting right with us. (UKP 4) 
 
The confusion is apparent in this parent’s account, where the level to which the parent 
can trust their instincts is shaped in part by aligning new behaviours with the daughter’s 
identity as the ‘good daughter’- bright, intelligent and eager to move on to university- is 
challenged. There is a sense that this parent wanted to believe that her daughter knew 
best what was going on within herself, having always been accomplished, driven and 
successful, however it becomes clear as the parent continues speaking that this identity 
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held by others of the young person was masking underlying pathology. What emerges 
in the interactions recounted here is the degree to which others in the world of this 
young woman relied on her living up to her familiar identity within the family, and 
relying on her to communicate that she is okay even as aspects of her personality began 
to change. The context of the family thus becomes the place where emerging 
behaviours either fit with what is expected, or they don’t. In this case, the severity of 
the girl’s psychosis (as revealed elsewhere in conversation) is overlooked for a time due 
to the daughter’s competence and ‘togetherness’, perhaps combined with a growing 
denial of unsettling behaviours being observed by the parent. 
6.5 Clinicians  
Clinicians maintain a significant presence in the development of parental knowledge 
about PBD, perhaps more so in the US, however English parents used clinical 
interactions as a point of reference in describing their experiences (often negative) in 
making sense of what is happening with their child. The degree to which clinical 
expertise is trusted shapes the development of representations of PBD, with both 
American and English parents expressing dissatisfaction, frustration and in the case of 
American parents, an often flat-out questioning of their expertise.  
American parents 
6.5.1 Feeling ignored, patronised and dismissed 
The level of dismissiveness perceived by American parents either face-to-face, or in the 
form of unreturned phone calls, was cause for incredible frustration, helplessness and 
anger, and very much shaped attitudes towards the clinicians responsible for the care of 
their child: 
They just kind of poo poo you away: “oh no, you don’t know what you’re 
talking about” or “you’re just hysterical”, you know, whatever. And it’s 
hard. It’s really hard. It was easier after we got her diagnosed, but it was 
really, really hard prior to that. It was banging your head into a brick wall. 
I’m trying- why aren’t you people listening to me? Why won’t you people 
help me? Why won’t you people stop looking at each other like “oh, poor 
her”. They just want to pat you on the head and have you go away. “Poo 
poo, bye-bye…” It’s enraging. It’s enraging. (USP6) 
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This was a common tone taken among American parents when discussing their 
trajectory into the world of professionals. No one is interested in listening to them. 
They remain ignored at a time when they feel they are the most desperate. Earlier the 
theme of parents as advocates was discussed, and in examining how parents discussed 
their interactions with clinicians, it became clear that often that advocacy was often the 
result of having to go-it-alone-and not receiving appropriate support from clinicians.  
Parental discussion gives the impression of a type of ‘forced’ advocacy, not in that they 
are being pushed against their own volition to act on what’s best for their child, but 
rather that clinical disengagement leads to a sense of being compelled to develop their 
own expertise. In addition to feeling that they were being dismissed, parents also talked 
of feeling that they were being judged harshly by professionals whom they thought 
should have been more supportive: 
So I went back to (psychiatrist) after my son had been diagnosed PBD by 
another doctor, after he’s been through that, and I had gone back to her 
because I needed to talk to somebody because I was falling apart. She 
actually threw her head back and laughed and said “please don’t tell me that 
he got diagnosed Bipolar” laughing at me, and gave me a huge packet on 
ADHD, and I walked out the door and just fell apart. (USP2) 
 
Such interactions suggest that a growing animosity among parents towards clinicians is 
borne out of not being taken seriously, either on the level of a parent, or on the level of 
an individual. Dismissiveness on the part of clinicians then reinforces the parent’s 
position that they are in a position of ‘us versus them’ with professionals, in which their 
helplessness is channelled into rage and finally a sense of needing to be proactive to 
make sure that their child is actually accounted for and doesn’t suffer the same neglect 
they perceive. 
6.5.2 Questioning clinical expertise 
A compelling aspect to the way American parents discussed the professionals they 
interacted with in the care of their children was just how much frustration was 
apparent. Emerging out of a sense of feeling patronised and ignored was a widespread 
questioning of clinical expertise, often veering between disdain and disbelief over a 
perceived lack of awareness and professionalism on the part of the clinician. Parents felt 
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entitled to question and criticise clinical judgment illustrating a clash of expertise at play 
between what they were being told about the child and what they were experiencing 
first hand: 
I know what a manic episode looks like because I’ve had ‘em. So I knew 
that she was either high, or she was totally in a manic episode. And they 
tested her for drugs and her system was perfectly clean. There was no drugs 
in her system, there was no alcohol in her system. Nothing. So then the 
psychiatrist on duty at the time in the ER and I were discussing what was 
happening with her, and he was the one who finally agreed with me, he was 
like “ok yes, this seems to be, I mean like she is exhibiting signs of having 
bipolar”. (USP7) 
 
As in the excerpt above, several parents inserted their own knowledge and experience 
into recollections of interactions with professionals.  Here the parent is the one driving 
the diagnosis, suggesting a level of understanding that surpasses the clinician’s limited 
knowledge, as the parent here has first-hand experience of a manic episode, thus is able 
to bring the clinician around to acknowledging what she already knows. There is a sense 
of the parent having the higher ground, while the clinicians were not always seen as 
knowing how to best handle the situation: 
The minute he [son] was diagnosed, I forced education, and I never 
allowed the diagnosis to define him, nor I would I allow anyone else 
around him to speak in a way that it would allow the diagnosis to define 
him. We had doctors who would say “shh, he’s sitting right here”. I know 
he’s sitting right here, and you’re going to talk with him sitting right here. 
You are talking about him. Do not talk about him in third person. You 
have to involve the person who is most personally affected. He will help us 
understand how his brain works if you can help him understand how his 
brain works. (USP11)  
 
The parent above speaks to the imagined Other in the form of the clinician, asserting 
her authority and laying claim to her expertise, while at the same time protecting her 
child from what she feels is a secondary, patronizing interaction. In this version of 
events, the parent is left with the last word, commanding authority and respect in the 
retelling, from both herself as an actor, as well as to the listener.  The parent is asserting 
power and control, elevating her son and illustrating the ways in which he is more than 
what the diagnosis suggests he should be. Excerpts such as this highlight the motivation 
involved in shaping a narrative that supports parental representations of the child, in 
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this case an adolescent who is given the position of dominance by his mother. This 
representation of the clinician as somehow lacking the necessary expertise is echoed by 
others as well: 
We told her what was going on and what we saw, and then we went to her 
office, you know, we sat down with her and she said, “right off the bat, I 
need to tell you, I would never medicate a child under the age of six”. I 
said, “Ok, I hear you” I said “I would rather have a glass of water and a 
nap, than take a Tylenol when I have a headache, I hear you. I’m all for the 
least invasive approach first, but my question for you is this, if that doesn’t 
work, how do we survive until he reaches this magical age of six? Right 
now as a family we cannot function”….and she goes “well, I’d really like to 
start with fish oil” and I said “ok, well, by the way, what’s your experience 
with children with paediatric bipolar disorder?” and she goes “oh, well, I’ve 
read a few articles”. (USP5) 
 
In recounting this exchange, again, the anger and sarcasm is palpable as the parent 
communicates to the listener how inept and out of touch the clinician seemed when 
faced with the specific problem that was this parent’s child. At the same time, there is 
desperation present in the voice of the parent. ‘How will we survive?’ living with this 
aggression and uncertainty? Here there is an expectation that is not being met and 
because the clinician is not able to immediately meet that expectation, their knowledge 
is dismissed. The question of when, how, and why knowledge is taken on board and 
internalized or accommodated is central to this thesis overall, but seems especially 
salient here in the examination of an American parent’s subjective recounting of an 
interaction with clinical knowledge. The fact that the information presented doesn’t 
align with a parent’s expectations, isn’t useful in any capacity, causes a reactive 
questioning of that clinician’s true level of expertise. Of interest is the question of when 
clinical knowledge, despite being questioned and challenged, is taken on board by 
parents in their own way. This is to be discussed in the following section. 
6.5.3 Internalisation of clinical expertise 
The level to which professional discourse had been internalised by American parents 
was of particular interest. The adoption of certain terminology and perspectives 
surrounding PBD, despite the sense of distance and neglect that dominated the overall 
negative assessment of their relationship to clinicians, led parents to often refer to their 
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children ‘presenting’ with ‘symptom patterns and clusters’, describing their children as 
manic or hypomanic’, and viewing behaviours through the lens suggestive of 
professional influence: 
 
It worries me sometimes because she’s not as insightful. When she is high 
she just says she’s happy, and ‘I just feel good’, you know, she’ll go to a 
concert and it’s like ‘oh that was the best concert ever’. She likes to go to 
Disneyland, she has a pass and she’s always like “I had the best night of my 
life!” you know, she’s always kind of over the top and doesn’t realize it. Or 
a lot of the Internet texting and, you know, posting a lot of pictures. You 
know it’s a different generation, but you know… I want her to be more 
insightful, you know “do you think you’re a little high?” you know? And 
she doesn’t like that word. She’ll say elevated, but she doesn’t like to say 
“high” you know? (USP9) 
 
In the quote above, the line between what might be construed as normal behaviour has 
the potential to be pathologised, and the parent’s suggestion to her daughter that her 
elated moods might be equivocal with a manic episode illustrates the influence of 
available explanations being drawn on, and wanting her daughter to acknowledge this as 
well by being ‘more insightful’. In appropriating an exploratory framework that moves 
beyond a parent describing their child into something reinforcing the idea of a manic 
episode, the indirect influence of the professional can be seen. The adoption of such 
language and thought processes likely provides a semblance of mastery over the 
diagnosis, further reinforcing a sense of their own parental knowledge so often ignored 
by psychiatrists as being useful and relevant. The influence of clinicians in parental 
discourse also extends into the way parents talk about the need and justification for 
early intervention, adopting the view perpetuating fear and risk for a child’s future so 
often cited by professionals as part of their own dialogue, even as they voice frustration 
at trying to get clinicians to consider PBD as a possibility for their children. The 
justification for early, prodromal diagnosis coming from the parent indicates that a 
certain line of thinking has been absorbed and used in a way that makes sense for the 
parent making sense of their child. What is happening in this parental appropriation of 
clinical discourse refers back to Bakhtin’s (1981) elaboration on the interplay between 
Self-Other which was discussed in section 2.5. Here, it is the parents own experience 
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and intention which has allowed clinical knowledge to be adapted and shaped into an 
idea of what a child with PBD looks like. In this way, clinical influence on parents is 
manifested dialogically. 
English parents 
6.5.4 Disappointment and frustration 
As with their American counterparts, clinicians came up as a significant other in 
interviews with English parents with the dominant theme threading through 
conversation one of feeling defeated and dissatisfied with these interactions. As 
mentioned in the previous section, one reason for this was an absence of information 
being communicated, however a lack of accessibility, professionalism, or ability to 
understand fundamentally what could be wrong with the child were central to how 
parents regarded these communications.  
So to be honest, I noticed a change, and I thought at the time my daughter 
has a mental health problem. So I…approached the GP, and the GP had 
no idea how to assess her, and even though the GP did offer me an 
apology, and in England, the GP knows nothing about mental health (UKP 
3) 
 
This GP as gatekeeper for specialist services is called out for being somewhat inept in 
the parent’s view. Despite concern over the mental wellbeing of the young person, the 
parent is met with a barrier in the form of professional lacking any awareness over how 
to properly assess the child, leaving the responsibility with the parent, and offering not 
much more than apology. This feeling of frustration with the lack of knowledge among 
professionals is echoed by another parent who notes: 
 
I picked up a book and got more out of the first five pages than I did with 
CAMHS. (UKP 1) 
 
The parents speaking in the quotes above exhibit a resignation to the idea that they 
aren’t going to be receiving any guidance, or gaining any information, from the 
clinicians they have interacted with.  The parent in the first quote further indicates the 
perceived incompetence of the clinician in describing how the clinician offered an 
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apology after having no idea how to assess the child with a suspected mental illness. 
The second parent appears further along in the process of dismissing clinical 
knowledge, or lack thereof, having already sought information from outside resources. 
In considering how parents in England acquire and construct knowledge around PBD, 
these feelings around clinical encounters are significant. 
 Disappointment and frustration related to a lack of competence or efficiency 
led parents to feel lost and desiring more information. Parents seeking to gain 
knowledge that makes sense to them often met with clinical understandings not in line 
with their experience. As an example, a parent who is met with a psycho-dynamic 
understanding of the child’s illness:  
She was still seeing and hearing the voices in hospital, she was still 
scratching herself a lot, and then CAMHS came in, the doctor, and they 
said, and this is often said, but they said that she needed to go home, they 
thought that this was an emotional response that she couldn’t tolerate her 
emotions, and that I needed to have much firmer boundaries around her 
emotions, and they described it as a toddler having a tantrum…They were 
saying it was about boundaries, and it was behaviour, and it was about her 
not being able to tolerate her emotions (UKP 4). 
 
Here the parent comes up against an explanation that places some of the responsibility 
for her child’s behaviour on herself, and her supposed inability to impose boundaries 
on the child. Despite the fact that the parent specifically mentions the child’s psychotic 
hallucinations and delusions, they are still encountering the knowledge held by the 
clinician, rooted as it is in less neurochemical explanations that would possibly make 
sense to the parent, but instead something much more psychoanalytic. In recounting 
this interaction, the tone of the parent was one of irritation, as the idea that her 
psychotic daughter was in need of firmer boundaries to sort out her behaviour was a 
ludicrous suggestion not to be taken seriously, and causing her to question not only the 
clinician communicating this, but the wider system as well. 
6.5.5 Faced with professional reluctance to diagnose 
In seeking to arrive at an understanding of what was happening to their child, English 
parents described coming up against clinicians who were hesitant to assign a diagnostic 
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label, even in the case of one parent who was convinced that their child was suffering 
specifically from PBD:  
 
I: So you said you’d already been to CAMHS?  
 
R: We see them, they just won’t believe that it’s PBD. I can say it until I’m 
blue in the face and they just won’t entertain it. In this country I’m 
normally ignored. I don’t get a response at all. Or you get fobbed off, you 
know, “wait until she’s 18”. Well no. I’m not going to wait until she’s 18. 
(UKP 1) 
 
This parent had spoken in the interview about the level of knowledge about PBD 
acquired as a result of searching for answers, which led her to contact consultants in the 
US and parents in online forums. Armed with her understanding of the broader 
spectrum of symptoms favoured in the US, she sought the validation from the CAMHS 
team. As she notes above, she is met with professionals who won’t consider the 
possibility of a child having bipolar. Again, competing knowledges clash in an attempt 
to make sense of a child’s unfamiliar behaviour, with one parent claiming knowledge in 
need of validation, and those in the position to validate her understanding of her 
daughter’s experience refusing to align their way of thinking. The parent here positions 
themselves as frustrated and helpless in the face of clinicians who just won’t listen, 
amidst a system that is not primed to see illness in a young person until they turn 18. 
This ‘refusal to see’ was echoed by another parent: 
I: What sorts of things were you being told by these various professionals? 
Was there an immediate diagnosis of PBD? 
 
R: No. I’d been asking and they said they didn’t want to give the diagnosis 
to someone 14 and under. It’s not best practice. I said to doctor, “I 
understand maybe your practice is to not to give the young people any 
diagnosis because the diagnosis can affect them in the long run”, maybe 
that’s why they hesitate, but I said “I’m open, and but I would like to know 
what I’m dealing with” That’s why he told me it was clear to him that my 
daughter has BPD. (UKP 3)  
 
Here, the parent speaking is a nurse who perhaps feels able to push to get her child 
diagnosed based on her own position as a health professional. In communicating to the 
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clinicians that she is open to the idea of the diagnosis, she is granting permission to the 
clinician, removing some of their fear of being responsible for the implications of the 
diagnosis. For the parent, the need for certainty, and an understanding of what is being 
dealt is the central concern, but from the parent’s perspective, that is not something 
forthcoming unless one knows what to ask for. The way it is presented by the parent 
above, it was clear to the clinicians that their child had PBD, however they weren’t 
going to come out and say it without some sort of tacit understanding with the parent. 
This particular knowledge encounter is coloured by clinical hesitation, leaving the 
parent in limbo.  The suspicion of PBD is present in the clinician, however parental 
permission is implicitly sought out, leading to the question of whether or not action 
would have been withheld had the parent not pushed a bit. As one parent expressed 
over the course of the conversation, sometimes getting out of one’s comfort zone and 
playing the part of the “pushy middle-class parent” is what was required to move 
forward. 
This reluctance takes shape both in the flat out refusal to ‘see’ PBD, as well as 
an approach to diagnosing that favours ‘wait and see’. In the case of one parent, this 
came in the form of a clinician aligning with the more broad-spectrum approach to 
bipolar that is becoming more common in England, but is not yet as widely adopted as 
in the US: 
The psychiatrist she was under then was very keen to emphasize that the 
symptoms if BP in your people are very different to the more “traditional 
signs” as it were that adults share, with the depressive instances and the 
manic cycles. The psychiatrist studied it for a long, long time just by 
observation from a period of 2-3 months, and at a certain point he was 
convinced that my daughter E. did not have PBD, so he effectively sort of 
put that to bed, and so naturally we accepted it, but her problems 
continued and although she was discharged from hospital after 5 months 
there was, we felt, really all that had happened was that she’d been 
stabilized- they hadn’t really gotten to the fundamental route of the 
problem, whatever that fundamental was. (UKP 2) 
 
The quote above illustrates the dynamics at play between a parent with little sense of 
what is happening, and a clinician who is looking for a different set of symptoms from 
what the young person is presenting with. Despite the parent suspecting an illness, the 
clinician remains unconvinced, or unwilling to say anything definitive, thus the parent 
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“naturally” accepts what they are told, as it is the clinician with the expertise in the 
position of authority. The parent is rendered passive despite feeling like the real 
problem has not yet been addressed, while the clinician is perceived to be maintaining 
an aversion to developing an understanding of a child that has been ill enough in the 
parent’s eyes to be in hospital for five months. The final words of the excerpt above 
point to the idea that after all was said and done, no one was any closer to 
understanding what was wrong with their daughter, much to the consternation of the 
parent. 
6.5.6 Perception of American practitioners as more knowledgeable 
A final theme to come from discussion of clinicians among parents in England was the 
sense that parents weren’t only interacting with the clinician as individuals, but that they 
were communicating with a wider system that the clinician was often in a position to 
have to answer to, and parents were secondary to this. This came out in discussion as a 
comparison of health systems, and in particular the US as compared to England, with 
parents feeling that clinicians in the US were part of a system that takes parental 
concerns more seriously:   
I went to every expert in the US that I could think of and it was amazing. 
Every single one of them replied. Janet Wozniak? (author of original paper on 
PBD) She replied. Dimitri what’s his face? (Popolos, author of best-selling book 
The Bipolar Child) He replied. Every single one who I contacted contacted 
me back. In the UK, very few did. And if they did, it was to say “go to 
CAMHS, they can help you” (UKP 1)   
 
The parent quoted above was at wits end attempting to deal with clinicians in England. 
Having suspected bipolar disorder in her child, but unable to get anything validated 
officially, experts in the US were sought out as this parent believed them to be more 
knowledgeable. Perhaps most importantly for this parent, she felt her concerns were 
taken seriously, and significant players in the development of PBD research and the 
dissemination of information in the US were open to communication with her. The way 
in which this is contrasted with the treatment with clinician in England reinforces this 
parents sense that what she is forced to deal with in terms of local expertise and 
CAMHS teams clashes with her own beliefs- beliefs which are backed up in the US, yet 
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she is at the mercy of the system in England, which she associates with a lack of 
knowledge, understanding and competence. While this was the only parent to directly 
seek advice and expertise from those in the US, Other parents echoed the sentiment, 
comparing how they felt they were treated in England with how they perceived the 
situation to be in America: 
 
We have no doubt that the way the US looks at and deals with mental 
health is just streets ahead of the way the UK does it. (UKP2) 
 
So I think the general belief is that the US system is the envy of the world 
(UKP5) 
 
Despite the fact that parents in the US also discussed a feeling of not being heard and 
of being cast off to the side, parents in England held the impression that had they and 
their children been having their experiences in that context, the complex trajectory 
trying to navigate a new mental health diagnosis would have been much more 
straightforward. The professional psychiatric climate in the US was discussed as one 
that was open to understanding pathology in children on a number of levels, while in 
England there was a sense of clinicians not knowing how to interact with, or 
understand, young people potentially suffering from mental illness. As an extension of 
comparison between the two contexts, one English parent noted that young patients 
were treated more like offenders as opposed to adolescents with mental illness in the 
English system.  
They would say to us “E. needs to take responsibility for her behaviour” 
and we’re thinking, “She’s ill!” You know, and they would say “she needs 
to know the consequences of her actions” and they had this horrible term 
they would talk about “we need to punctuate E’s behaviour” in the way 
that they would punctuate involvement by the police. So it was like an 
admission of self-defeat that they were unable themselves to handle the 
young people, so whenever things got tricky, they would call the police. 
(UKP 2) 
 
Criminalisation takes precedence over understanding as this parent recounts 
interactions with the staff at the hospital where their child has been an inpatient. Again, 
for the parent, there is an assumption that clinicians involved that the daughter should 
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be held responsible for her actions, that a lesson should be learned. A removal of 
clinical responsibility takes shape in clinicians faced with not knowing what they are 
dealing with in the young person. Frustration, disbelief and a sense of helplessness 
come up in the tone of the speaker, with a sense, as discussed previously, that a wider 
system has taken over, and the parent is removed from the equation. This was 
counteracted by discussing perceptions of America, where among parents there was 
thought to be a more understanding approach to young people who are mentally ill. 
6.6 Other parents 
For American parents, the perceived attitudes from other parents came up quite a bit in 
discussion, however this was not at all the case among English participants. Other 
parents acted as something of a mirror for parents interviewed, reflecting back their 
own imagined worst fears about how their children’s behaviour and subsequent 
diagnosis would be tied up with their parenting. For parents, negation of their ongoing 
struggle, not being heard, and being blamed for their child’s temperament came to a 
head in their interactions with other parents, either family members, friends, or those 
acquaintances in the wider community. That this was only a significant other among the 
Americans suggests the more open, interwoven projection and enactment of norms and 
expectations, and perhaps more openness in expressing opinion.  
6.6.1 Judgment, conflict, and a lack of support 
The topic of how other parents perceived them was often a sore point for the parents 
interviewed. While I had entered into these conversations thinking that parents would 
find support and solace in learning of other parents’ experiences, often it was the 
opposite, with parents avoiding what support groups were available, noting that there 
was too much complaining involved, and parents felt like the tone was one set to 
inadvertently keep parents in ‘victim’ mode. Stigma and a lack of social support were 
central themes coming up in discussion of how interactions felt with peers about their 
child’s PBD, as was the difficulty eliciting understanding when the child’s diagnosis 
suggests an ‘invisible’ illness as opposed to something such physical disability or cancer: 
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I couldn’t really go to my church and say “oh, could ya’ll bring by some 
food? My daughter’s in the psychiatric hospital because she wanted to kill 
herself” (USP6) 
 
In the hypothetical interaction quoted above, the parent here echoes a sentiment 
expressed by many other parents; that for a stigmatizing mental illness with less obvious 
cues than a physical illness, people are less inclined to offer support. The tone of the 
speaker illustrates the bitter edge this can have, especially when loaded on top of 
perceived neglect from clinicians as well. This feeds into a parent’s sense of having to 
go it alone in isolation in the face of an illness that they know not everyone agrees 
exists. PBD is seen as both an obstacle to support, but perhaps also a motivational 
force pushing the parent to further solidify their position as advocate for their child, 
and for themselves as parents.  
You know, I think people are so willing to assume and judge.  There’s a big 
tendency to suspect the parents. I don’t doubt that there are children who 
are misdiagnosed, that for someone’s convenience they get slapped with a 
label or whatever, and handed a handful of pills, but my experience has 
been, and other parent that I know who have suffered trough this is, none 
of us have us have gone into this lightly, like ‘oh good its bipolar. Throw a 
pill at him’. It’s been painful and excruciating, and very deliberate ok what 
do we do? How do we handle this? How do we manage? How do we help 
our child to live? It bothers me when I think people are so quick to say this 
isn’t real…really? It’s not real? Because my son has been like this since 
birth. Don’t tell me that this is manufactured. See what my life was like for 
the first four years, when he had nothing but love and healthy food and 
exercise. No. I’m sorry. This did not come from nothing. (USP5) 
 
There always remains an undercurrent of being judged by others, and a need to prove 
that as a parent you’re aware of how others might perceive you and your child:  
You know inside they’re thinking “she’s crappy as a mother, she’s not able 
to handle her kid, he’s just a little crying brat” you know, you know it. You 
see the condescending looks at you, like “hmmf. OK”. (USP13)  
 
The eyes of others, and the impressions they are forming, are internalised by parents 
across situations. Here the speaker assumes they know that others are deciding she’s a 
bad mother- an attitude that is no doubt perpetuated on a wider cultural level in the 
debates surrounding children’s mental illness. Parents are not immune to what is said in 
the public sphere, and in recognizing that her son’s behaviour on the ball field is out of 
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line with what would be considered ‘normal’, this parent is drawn to pre-empt what she 
fears others are thinking by acknowledging an awareness that they see her son’s 
behaviour as problematic. Perhaps parents feel their experiential insight into their 
child’s condition is devalued in the face of wider assumptions about parents of difficult 
children that circulate. In response, there is a drive to position themselves as experts 
among peers, utilising the difficulties they have faced after being introduced, voluntarily 
or not, into the world of a controversial diagnosis to render those experiences 
subjectively valuable and useful in some capacity. 
6.7 The School 
Perhaps due to the small sample size of English parents who participated, the position 
of the school as significant other was not as present in conversation as it was for 
American parents, for whom the relevance of schools, teachers, and access to individual 
education plans (IEP’s) was intertwined with how they understood and made meaning 
of PBD in their child. It was in the discussion of the school that the prevailing politics 
of diagnosis could be interpreted, as well as how top-down influence in this sense came 
to shape the development of parental representations not just of PBD, but wider 
cultural norms of how a child should behave.  
6.7.1 Collaborative alliance… 
While American clinicians felt the top-down influence originating from the 
pharmaceutical industry, for American parents, the top-down influence stemmed from 
the power of schools in determining to a large extent how far parents should go in 
order to pursue a diagnosis, or once a diagnosis was obtained, special accommodations 
for their child.  It is in the realm of education where the politics of PBD as a diagnosis 
become most salient. Several parents noted with agitation that special attention and 
support from schools is tied to specific diagnoses, with ADHD and Autism receiving 
priority. Thus, in seeking to obtain an IEP, the negative aspects of the child’s behaviour 
were brought to the fore in order for the child to get the help they need. In this sense, 
the IEP is a driver for diagnosis, as it is this document that requires parents to pinpoint 
certain behaviours and get a label in order for services to be generated. 
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I think it’s more from a school standpoint, now they know they can put a 
label on it, and I think that helps them, although they don’t always like to 
do that, it depends on who you’re dealing with, and it does all turn back in 
terms of the services he gets, but it didn’t change anything except give me a 
little bit of peace of mind that I wasn’t the one with the problem. (USP 12) 
 
In the quote above the parent suggests that the push for diagnosis comes from the 
school, illustrating the conflicting ways in which these two spheres interact. On the one 
hand schools have the upper hand, determining who gets which special accommodation 
and steering certain children towards evaluation for specific diagnoses. On the other 
hand, it is the parent who pushes to make sure that they can get every last bit of help 
they are entitled to as the parent of a special needs child- a position often putting them 
at odds with themselves having to emphasize the more stereotypically ‘bad’ aspects of 
their child’s behaviour. But as the parent quoted above illustrates, there is validation in a 
school’s assessment, reinforcing as it does the subjective sense that it is not her 
parenting to blame for her child’s diagnosis. Positive communication with schools were 
often aligned with how much special accommodation the child gets, and teachers 
described as ‘good’ were those who were most receptive and willing to provide 
specialized treatment: 
My school was just out of this world, awesome. Once they got that 
understanding, the teachers had understanding, the principal had 
understanding, they all listened to me, they let me talk, they let me educate, 
it was just- I can’t even say how good it was. (USP 3)  
 
Here it is the fact that a parent feels heard, that the school has listened to her, let her 
educate them about PBD, and put her in control which has led to a favourable 
interaction, something that was echoed by the few parents who expressed positive 
experiences with schools response to children with PBD. The collaborative alliance at 
play is thus a reflection of the ways in which the parents can help shape the 
consequences of a diagnosis if PBD in their favour through a mutually beneficial 
relationship with the ever-powerful forces that be within the school setting. 
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6.7.2 …but also a constant struggle 
Schools also represent the symbolic fight against a wider system of norms, in which 
what gets played out and manifested through interactions between parents, teachers and 
school officials is indicative of the processes involved in shaping how a child’s 
behaviours should be interpreted and objectified.  Among parents, interactions with 
schools were described as fraught- a battle of wills and clashing expertise in which each 
sought to define problematic behaviour. This desire to demonstrate righteousness and 
persistence comes out in a parent’s desire to use education as a means to influence the 
mechanisms taking shape around the child as well: 
A lot of it for me was educating the teachers. And I was on a mission for 
many years, and every year at the beginning of the school year- I knew I 
was asking a lot of these teachers who were in a group of kids, but I would 
make up a binder, and I would have all these educational materials about 
‘what is bipolar’ and I’d have an introductory letter and I would have a 
picture of P. so I think that’s another important rule for parents, that yes, 
you can try to advocate for your kids and get them the services, but you 
need to educate the teachers, because it is a scary term, and often the only 
context they know it in is in reading about a kid who murdered his parents, 
but of course who wouldn’t be a little bit afraid of that. So I tried to 
humanize it a little bit more and break it down, and of course this was very 
helpful for me as well. (USP10) 
 
The diagnosis represents a reason for parents to make sure that teachers direct their 
attention towards their child, something the speaker above values for the added benefit 
of reducing fear and stigma that teachers may have upon learning they have a student 
with PBD.  Again, the diagnosis represents “a mission” for the parents, not 
comfortable with the idea that the child might alleviate stigma through their own 
interactions with teachers, but rather seeing it as their own prerogative to pave the way, 
to ease the child’s transition into a new setting. As this parent also indicates, 
humanizing the child in the teacher’s eyes is helpful to her as well, as in this sense she 
can build a potential ally. In recounting her ‘mission’, the parent above lapses into 
addressing other parents in her talk, using her own experience as an example they might 
follow thereby illustrating a full circle in which the uncertainty surrounding the child’s 
diagnosis with PBD became a mission undertaken by the parent to gain knowledge, 
validate their experiential expertise and educate others, both parents and teachers. For 
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this parent, the struggle has culminated in a level of confidence and agency shaping a 
developing awareness of their own power as a voice for their child living with PBD. 
6.8 Discussion 
This chapter has taken findings from interviews with American and English parents of 
children with PBD to examine interactions with significant others coming up in 
discussion about the diagnosis. These interactions determine how parental knowledge 
about the condition is constructed, indicating that knowledge encounters with 
professionals and peers shift parental conceptualizations of PBD, and of their child. 
The influence of these others, and the accommodation of this knowledge into the 
parents’ own thinking, suggests the role representational and dialogical processes play in 
the development and transmission of understandings around PBD.  
American parents view themselves as a central character in the master narrative 
of their child’s trajectory navigating PBD, providing a way to validate the decisions they 
have made as they have gone along. Participants spoke of having had previous 
awareness that bipolar could exist in children, and once it became part of their own 
reality, the diagnosis was represented as a phenomenon rendering the parents victim to 
a set of unstable and unpredictable behaviours for which there is no clinical agreement 
on what should be done. Thus, a key finding of this thesis lies in how PBD is 
represented as something requiring first-hand experience to truly understand.  
American parents place a high value on their experiential knowledge, rendering 
themselves as experts- a position that becomes problematic when encountering 
professional knowledge systems where on the one hand the clinician is needed, trusted 
and relied upon, by the parent who then also views these interactions as a source of 
endless frustration, alongside a sense they are not being heard.  Encounters (or lack 
thereof) with clinicians become a springboard for parents to develop both a sense of 
their own knowledge built out of a shared experience with their child, and a clarity of 
purpose with regards to advocacy. An overarching sense of ‘us against them’ takes 
shape in dialogue, further distancing the parental Self from wider professional and 
institutional frameworks to, in a sense, go it alone with the child.  
 
 
 
 
213 
Among American participants, PBD is understood by to be a problem of their 
child’s physical self, a disordered neurochemistry indicating a risk in need of early 
pharmaceutical treatment to prevent the worst future outcomes. While many articulate 
a discomfort with the push for medication that accompanies the diagnosis, an 
acceptance takes shape as parent’s appropriate clinical perspectives into their own 
internal dialogue in order to why it is necessary. As a “physical brain disorder”, 
alignment with physical illness allows for justification of pharmaceutical treatments that 
parents may have been initially resistant to, and removes of some element of shame and 
stigma. This explanatory framework through which American parents consider PBD is 
the result of processes of normalisation, in which clinical knowledge, as well 
expectations of other parents and the school is accommodated. As was discussed in 
chapter three, the accommodation and assimilation of, and conformity to, other 
perspectives is central to the development of parental thinking about PBD as a whole, 
but also the wider normative framework into which they send their child to make their 
way. No frame of reference regarding what is ‘normal’ leaves parents open to influence.  
The more they research on their own, speak to and come into conflict with others, the 
more they begin to rely on their own expertise; an amalgamation of all they have come 
into contact with that makes the most sense for their unique circumstance. Strength and 
control via knowledge and mastery over diagnosis is driven out of a sense of duty to be 
a good parent, and very much based on acknowledging the right of their child to a 
“normal” childhood.  
The data informing this chapter has shown that the key issues framing 
understanding of PBD among English parents involves a lack of information, 
uncertainty, and a reinforcement, both subjectively and based on interactions with 
professionals, of their position as amateurs who are often cast to the side. In discussion 
with English parents, three significant others stood out as being central: the parental 
‘Self’, clinicians, and the child. Discussion of the child and PBD is much more rooted in 
extreme behavioural presentations among English parents, where the boundaries of 
diagnostic criteria hold true to the ‘classical’ bipolar model involving week and month 
long periods of mania, often combined with paranoid delusions and psychotic episodes, 
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episodes four of the five parents interviewed acknowledged as what finally gave them 
cause for action.  
Achievement figured prominently in the talk of English parents, however it was 
almost in a way as to suggest this as a trigger for the psychosis and related behaviours. 
Unlike their American counterparts, there was no sense that PBD could exist in 
children prior to being ushered into their new reality. With the exception of one parent, 
they discussed still not understanding, or wanting to accept, the diagnosis, and that their 
interactions with professionals in charge with their child’s care did little to provide 
comfort or alleviate confusion. A lack of trust in clinical judgement led English parents 
to compare how their circumstances would have played out had they been in the US as 
opposed to England, feeling that the hierarchy in place within the UK system left little 
room for the development of their own understanding, instead fostering a sense of 
helplessness, being side-lined by their position as parents, and at the mercy of a wider 
system. This sense of disconnect between English parents, clinicians, and the wider 
healthcare system stands in stark contrast to the consumer driven system in the US 
which allows parents to feel that they may be capable of having an influence, thus using 
their experiences as a springboard to advocacy, communicating their knowledge about 
PBD to other parents, and clinicians for that matter, ensuring that the diagnosis and 
how it is represented among this group, is perpetuated. 
  Further in depth discussion of American and English parents’ representations 
of PBD, and the dialogical processes shaping these representations, will take place in 
the next and final chapter. A summary and wider discussion of the comparison between 
parents and the significant others referenced, as well as the role the cultural context of 
the US and England play in the development of these representations, will tie this 
empirical chapter in with the two that have come previously, and will also incorporate 
the theoretical framework outlined in chapter two in order to advance a model of how 
representational and dialogical processes, as well as modalities of social influence, 
contribute to the construction of diagnosis. 
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7. Discussion and implications 
It’s the disinhibition or impulsivity of ADHD. It’s the irritability of a 
depressed state, it’s the psychosocial stressor of being unable to sit still in 
the middle of a classroom. Whatever it was, once you start to view it in a 
different way, you could then make the appropriate diagnosis.      
(American clinician on learning to ‘see’ PBD) 
 
7.1 Introduction 
This study has used a social representations approach illustrating processes of 
anchoring, objectification, knowledge encounters and dialogical processes as 
mechanisms involved in shaping the diagnosis of PBD in the US and England. In the 
previous chapters, I have mapped out the representations of different stakeholders in 
the life of the child with PBD, and in this final chapter, these findings will be integrated 
in order to construct a model for how the development of a diagnosis is generated out 
of the sometimes competing, sometimes intersecting perspectives of the pharmaceutical 
industry, clinicians and parents in the US and England. Discussion here will support the 
main finding of this thesis that construction of PBD is extrinsic to the condition itself, 
and instead forged at the interactive meeting points between the three stakeholders. To 
reiterate, the overarching question being asked of this thesis is that of how knowledge 
about PBD is constructed in the US as compared to England. The individual research 
questions are as follows: 
 
1) What are the social representations of PBD held by the pharmaceutical 
Industry, and how has the industry contributed to wider understandings of 
PBD as a diagnostic fact? 
 
1a) What factors shape such representations within the pharmaceutical industry? 
 
2) What are the representations of PBD held by clinicians in the US and 
England, and what psychosocial processes have shaped those representations? 
 
3) What are the representations of PBD held by parents in the US and England, 
and what psychosocial processes have shaped those representations? 
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4) What do the content and processes of representations of PBD among 
Pharma, clinicians, and parents suggest about the construction of the diagnosis 
in the US as compared to England? 
 
What this thesis has shown is that ultimately PBD is made of a patchwork of 
representations about the condition, the child, and the role of different actors. Driving 
these representations are 1) the interaction between the actors, how they understand 
and influence one another, and 2) the pragmatics of cultural background and the 
feelings and interests being accommodated as multiple actors negotiate PBD. This will 
be discussed more in depth in the following sections, beginning with discussion of the 
US and England as distinct cultural contexts and followed by discussion of the child at 
the heart of the debates. Following on from this will be a summary of representations 
held by pharma, clinicians and parents, illustrating the organisational and lay knowledge 
at play in shaping the diagnosis. The psychosocial processes shaping these 
representations will then be expanded upon in a final section that will bring together 
knowledge encounters, and dialogical processes of Self-Other interaction and modalities 
of social influence. The chapter concludes with discussion of implications, limitations 
and future directions for research.  
7.2 Comparison of cultural context: The US and England  
When it comes to developing a line of thinking around children’s mental illness, what 
shapes how a society interprets and categorises emotional, behavioural or cognitive 
aspects of childhood experience? How is individual experience perceived, both 
subjectively and objectively, on a wider cultural level?  Davies (2011) discusses the 
sense-making struggle that comes not only with the generation of a new phenomenon, 
but also the consequences of how a particular phenomenon, such as a new diagnosis, is 
“defined, socially understood, and ultimately managed” (p. 190).  In the preceding 
chapters, I have sought to illustrate this dynamic of constructive processes at play that 
allow individuals and groups to produce, objectify and make sense of a still-emerging 
disorder.  
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Unspoken cultural assumptions shape behaviours in unique ways, as it is 
through the context in which something is said that shapes interpretation 
(Jovchelovitch 2007). In the case of a contested diagnosis such as PBD, in which 
biological behaviours may be present, understanding of these as symptomatic is socially 
and culturally based. Van Bavel and Gaskell (2004) have suggested that societies draw 
on sets of cultural symbols in order to develop explanations for phenomena and events. 
Such symbols instil a believability which allows explanations to make sense, thereby 
increasing acceptance (ibid). To this point, the diagnosis of PBD itself has become a 
cultural symbol, imbued with all of the values, morals and assumptions that lead to its 
enactment as a diagnostic category in the US, while remaining rare in England. 
Jovchelovitch (2007) suggests that the “concrete social conditions within which 
knowledge develops are intrinsic to the process of knowledge formation and shape the 
internal structure of knowledge” (p.167). Thus, in looking to summarise and discuss 
how the pharmaceutical industry, parents and clinicians develop representations of 
PBD, cultural context encompassing diagnostic and parenting understanding and 
practice exists as an actor in its own right. This section will aim to unpack the role of 
cultural context as it pertains to the construction of PBD in order to ground the more 
fine-grained analysis of the processes at work in such construction that has been 
presented in chapters four, five and six.  
As discussed in chapter one, the American healthcare system remains one of the 
most highly regarded in the world, prized for the efficiency and level of care afforded to 
those who have access. Alongside this exists a pressure to stay innovative; an unspoken 
demand driven through being a consumer-driven, for-profit model of healthcare 
delivery, reliant upon third party payers in the form of insurance companies, and the 
ever present influence of the pharmaceutical industry steering research funding. The 
much studied and debated increase in the medicalisation of once ‘normal’ aspects of 
human behaviour represents the less-favourable flipside of innovation. This culture of 
medicalisation in the US is reflected in the widening scope of American clinical and 
parental notions of what behaviours can be included in a definition of PBD. Bipolar 
disorder was at one time a more clearly delineated in patients who manifested the 
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dramatic highs and lows, accompanied by psychosis. This conceptualisation has been 
redefined, indicating wider cultural schemas objectified through practice, taking shape 
as an increasing number of individuals and groups who decide that explanations such as 
rage and irritability, for example, make sense.  
Resilience, moving forward, innovation, and efficiency are often associated as 
American cultural norms; factors that are exemplified in the creation of PBD as a 
separate dialogical entity from established classifications of Bipolar I, II and ‘not 
otherwise specified’ that are used when diagnosing adults. Now, the psychosis and 
extended mood swings that had been defining features of bipolar disorder have been 
adjusted to reduce the duration of mood swings for children, allowing for recognition 
of the broader symptoms of irritability mentioned, as well as ‘rapid cycling’ of a child’s 
temper in one day.  
Added to this definition of PBD developed in the US context is the importance 
that the concept of risk holds in terms of the rationalization and justification of the 
diagnosis in children; a popular understanding is developing suggesting that mental 
illness in younger children looks different than it does in adults or even older children. 
The outcome of the development of the idea of a child as ‘at risk’ is the increased push 
for prodromal diagnosis, in which a diagnosis is made, and treatment started, before any 
symptoms appear. According to the National Institute of Mental Health (NIMH 2009) 
changes in a young person’s body leading to mental illness may start very early, before 
any symptoms present. Thus, the idea has been established that the ability of clinicians 
to help parents and their young children manage difficulties early in life may prevent 
such disorders from developing. Parents and clinicians both adopt the idea of risk 
involved in leaving a child untreated, tapping into both the neurochemical risk of brain 
atrophy that can supposedly result, as well as the social and economic risk in which 
undiagnosed PBD leads to potential criminality and sours any chances at future 
achievement. Despite the fact that “much more research is needed to determine the 
effects and benefits of medications in children of all ages” clinicians and parents are 
asked to “keep in mind that serious untreated mental disorders themselves can harm 
brain development” (NIMH 2009).  It is this aim at preventing the development of 
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disorders that remains controversial given that there is no certainty surrounding these 
assertions. A delay in seeking help, it is claimed, will be detrimental to the child’s future 
mental health. Thus, PBD as an emerging diagnosis is presented as an urgent matter to 
be dealt with as soon as possible, reinforcing the ‘quick fix’ mentality perpetuated by 
the US healthcare system.  
This cultural pressure pushing innovation leaves little incentive to take time to 
explore what lies behind a set of behaviours recast as ‘symptoms’. In England where the 
reluctance to act to quickly can be seen as the result of a ‘culture of second opinions’ 
there is less pressure from above to derive a quick fix. The present research suggests 
that it is a wider cultural comfort with ambiguity as opposed to an American need for 
certitude that drives this difference. One plausible reason lies in a comparison between 
cultural moralities in which the American mind-set, pushing innovation and moving 
forward despite the potential costs being discussed here, come up against an English 
perspective keen to maintain theory and valuing tradition as part of diagnostic and 
treatment practices. The conceptual differences between the US and England were 
illustrated by an American clinician discussing an interaction with the English 
publishers of a textbook that the clinician was writing for:  
We used the phrase ‘paediatric bipolar disorder. They don’t like that 
because it implies that PBD might be different from adult BP. I didn’t 
mean to be, you know, a ‘paediatric specific phenotype’, I was trying to not 
have to say ‘children with bipolar disorder’ sixty times in a chapter, I just 
transferred it to say a word, but they were very concerned about, “well this 
gives the impression that you’re implying that there’s a different type of 
bipolar disorder, or a different standard for kids. (USC6) 
 
This excerpt illustrates the concern of English psychiatry to hold tight to specifics and 
not imply something is present which remains unproven. This is indicative of the level 
of resistance to the broad-spectrum approach to bipolar disorder in children held by 
Americans. For the English, bipolar disorder is bipolar disorder, made up of an 
established set of diagnostic criteria that need rarely be deviated from. The uncertainty 
of the diagnosis’ validity is deemed too risky to apply in a population for whom so 
much is at stake in a potentially stigmatizing label and treatment with heavy 
medications. In discussing the importance of semantics as present in the language of 
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suffering, Brinkmann (2014) notes that specific terminology and vocabulary used to 
articulate an experience frames how that experienced is acted upon. Specific 
vocabularies make possible specific actions, so whether one is reliant on a biomedical, 
religious, existential or political means of explanation impacts how a specific set of 
behaviours is viewed. Ideas and diagnoses cannot be separated from “the institutional 
and material bases from which such ideas arise and influence our understandings; both 
are aspects of social practices, and the linguistic articulations of practices necessarily 
operate within a complex field of social practices with symbolic and embodied aspects” 
(Brinkmann 2014, 634). There is, however, a growing sense that it is only a matter of 
time before PBD becomes a more acceptable diagnosis in England. This ties in with 
Fleck’s (1935/1979) assertion that part of the process of establishing a medical fact is a 
period of debate and questioning, writing that a fact 
…begins with a tentative signal of resistance by the collective, which acts as 
the predisposition for an emergent fact. Through collective interaction, this 
tenuous indication gradually becomes stylised, undergoes consolidation, 
and emerges as accepted fact (Fleck 1979, 157) 
 
Indeed, this consolidation has potentially started to take shape with the publication of 
updated NICE guidelines for bipolar disorder diagnosis and treatment released in 
September 2014.  The mere mention of a new condition in any sort of official guideline 
can act as enough of a spring board just by virtue of planting the idea that the condition 
exists enough as an entity somewhere to warrant mention in a localised guidance or 
protocol. It is the presence of such guidelines which Moncrieff and Timimi (2013) 
suggest can be misleading via the management of contradictory data to support, and 
not jeopardise, the dominant medical discourse suggesting the validity of contentious 
medical conditions, such as ADHD or depression, and the requisite pharmacological 
treatments. Such clinical guidelines are central to the construction of psychiatric 
knowledge, thus, if more ‘official’ mention is made of something like PBD, the more 
familiar the idea becomes, the more it becomes picked up by clinicians and ultimately 
becomes a part of common sense thinking.  
The US and England hold on to different vocabularies, whether in textbooks, 
research, clinical or parental discourse. How these cultural vocabularies are echoed by 
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individuals, becoming part of how they understand something like PBD, are of 
particular interest in the transmission of knowledge about PBD. These cultural 
differences in what language is adopted, what behaviours are sought out and labelled, 
whether to seek treatment, and practices around diagnosis provide insight into the 
cultural comfort each context has with the notion of a ‘disordered child’. 
Representations diffused by larger, powerful industries like that of Big Pharma are 
internalised by the wider professional and lay public, echoing a wider discourse and 
illustrating the internalisation of this discourse made evident in practice. The fact that 
the diagnosis was born in the US makes sense of the trend that sees increasing numbers 
of parents and clinicians no longer uncomfortable with the idea of childhood diagnosis. 
Attention paid to ADHD and autism spectrum disorders have brought discussion of 
children’s mental illness to the fore, often with the element of political advocacy 
shaping them as causes related to a child’s rights, whether to proper schooling or 
beyond that, a proper childhood. Such attention, while not necessarily advocating an 
increase in these diagnoses, nonetheless serves to normalize the idea of them.  What 
constitutes a proper childhood, and how a child should be, are necessarily at the core of 
the development and perpetuation of social representations about PBD and will be 
discussed in the following section. 
7.3 The child at the heart of the debates 
In comparing the knowledge of PBD held by the pharmaceutical industry, clinicians 
and parents in the US and England, a central finding of this thesis was how the 
diagnosis was made up of representations not only of the condition, but also the child 
at the centre of the discussion. In looking at how a diagnosis encompassing very young 
children is represented, it is necessary to consider not just the diagnostic label, but how 
the existence of such disorders ties in to larger presumptions of childhood in general. 
An interesting point that I noticed while conducting interviews with parents in the US 
as compared to England was the seemingly gendered differences inherent in which 
children had the diagnosis. In the US, all but two of the parents I spoke to had younger 
sons with the diagnosis, while the limited number of parents I spoke to in England had 
adolescent daughters. This observation supports other research pointing to gendered 
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notions of ‘deviance’ (see for example Singh 2007) and could work towards explaining 
differing cultural norms in what is acceptable behaviour. 
D’Alessio (1990) explains how adults “maintain and construct the idea of a 
normal child” establishing norms in the process that are then used to make judgments 
and moral assumptions (p. 71). Childhood is presented as an object that is at once 
familiar and distant, making it difficult to distinguish between what is just the child 
acting of their own volition, and what is behaviour that depends on the presence of an 
adult (D’Alessio 1990). As adults seek to familiarise themselves with childhood through 
communicating about, classifying, and representing childhood development, D’Alessio 
(1990) reminds us that children play in active role in shaping the resulting adult 
representations, by being “active participants whose activity provides a source of 
feedback on the adults ideas” (p. 73). It’s a circular process that has children being 
labelled as a result of deviating from a set of normal behaviours, and adults learning to 
see their behaviour in light of those norms. It is striking to note that even after a child 
has been undiagnosed with PBD, the parent often has difficulty not seeing their child as 
still being ill, despite assurances that perhaps their behaviour is developmentally normal, 
but what is developmentally appropriate has been lost in the murkiness of an ever-
changing diagnosis.  
This coincides with Duveen and Lloyd’s (1993) assertion that one characteristic 
of communities made up of adults is that part of the culture will be inclusive of 
expectations for how a child should behave, how they should have developed by a 
certain age, what they should understand, and how competent they should be with 
regards to communication (p. 98). Such assumptions shape representations of the child, 
which then feed into wider understandings about what is normal versus what could be 
seen as on the spectrum of pathology. When societal thinking about such expectations 
is always in flux, it makes seeking certainty through medical explanation a viable option 
for parents to make sense of their child’s behaviour. Adults are the ones who position 
children within a society and whose own representations provide the scaffolding which 
allows the young person to internalise the identity imparted through adult 
representation (Duveen and Lloyd 1993, 92), but the question remains to what extent 
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children and young people accept such representations without resistance. In discussion 
with parents of children with PBD, many talked of their older adolescent’s refusal to 
accept the diagnosis after having lived with it for many years, preferring instead to 
accept as their own brand of normal those aspects of themselves deemed ‘ill’ at a wider 
societal level. Conversely, younger children often tried to communicate to their parents 
that they didn’t feel right, that they thought something was wrong with them and they 
wanted to be more like other kids. How much of these children’s perceptions of 
themselves is the result of adapting to representations held by adults in their world? 
PBD is more than a set of words, or a diagnosis. The label comprises a set of 
expectations of what constitutes ‘normal’ behaviour. Behaviours running contrary to 
that established social norm leads to the possibility of seeing such conduct disordered 
and dis-regulated. It also acts as a flashpoint, highlighting contrasting ideas over what 
childhood should mean and subsequently raising issues surrounding the increasing 
medicalisation of childhood.  
This thesis uncovered the systems involved in this process as a new diagnostic 
category takes shape. Organisational, medical, educational, parental spheres of 
knowledge- all contain reference points determining what ‘normal’ should look like. Of 
particular concern is the question of how such definitions and points of reference 
change through the introduction of new information. Representations become 
powerful through institutionalisation. Knowledge encounters among and between often 
competing systems of knowledge lead to the adoption of ways of seeing the child that 
are useful in some capacity, either as a means to the development of a business goal, or 
an explanation that makes sense and provides a sense of certainty and action to be 
taken. The more aligned what is seen becomes with what an individual or group feels 
should be seen is the result of changing representations of the child and the 
incorporation of these representations into wider practices and common sense 
assumptions about how a child should be. A child’s identity is constructed out of 
socially shaped resources (Campbell and Burgess 2012) leading to the question of what 
function certain representations play in wider social relations. For example, the 
representation of the suffering child used by the pharmaceutical industry as discussed in 
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chapter four allows for the establishment of the child as an ‘unmet need’, which then acts 
as a useful point from which to base marketing campaigns around the definition of 
what this ‘need’ looks like, as well as the treatment available to mollify it. Thus, all of 
the representations and processes discussed below necessarily begin with the child who, 
while unfortunately not a source of data for this thesis, maintains the central position at 
the core of how the key actors around them develop and apply their knowledge about 
PBD. 
7.4 Organisational, professional and ‘lay’ knowledge: pharma, clinicians, 
parents and the representations of a new diagnostic category 
This section presents the key findings from each chapter for the purpose of comparing 
themes across actors and contexts. The construction of PBD takes place at the meeting 
point between these three stakeholders, in which the representations developed of the 
diagnosis extend into representations of the child as well. The content of these 
representations is presented in table 7.1 below and forms the basis of the summaries 
presented in sections 7.4.1- 7.4.5.  
 
Table 7.1  
The making of a diagnosis 1: Social representations of PBD (content) 
  
Pharma 
 
 
Clinicians 
 
 
Parents 
 Global US England US England 
The 
Condition: 
PBD 
 
Adult disorder 
reconfigured for 
childhood 
 
Anchored in 
ADHD 
 
Anchored in 
manic-
depressive 
psychosis, 
schizophrenia 
 
Requires first-
hand experience 
to understand 
 
Requires 
professional 
expertise to 
understand 
  
Anchored in ADHD 
and schizophrenia 
Diagnosis ‘in 
flux’- 
uncertainty 
‘bipolar is 
bipolar’ - rare 
Knowledge of its 
existence in 
young children 
Unaware it 
could exist in 
children 
  
Characterised by rage, 
irritability. Psychosis 
need not be present. 
 
Broad 
spectrum’ 
approach 
more 
 
‘classical 
presentation’ 
more 
accepted 
 
Genetic, 
neurochemical 
explanatory 
framework 
 
Social 
pressures as 
trigger 
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accepted 
  
Treatable. Urgent. 
 
PBD more 
common 
than 
originally 
thought 
 
Uncommon 
in young 
people, 
virtually 
unheard of in 
children 
  
The Child  
Unmet need/market 
opportunity 
 
‘at risk’ : 
prodromal 
treatment 
 
Part of wider 
social context 
 
True nature of 
child obscured 
by diagnosis 
 
Uncertain 
over what is 
‘normal’ 
behaviour. 
 Suffering from 
‘constellation of 
diseases’ 
 
Peripheral in 
discourse 
 
Central 
position in 
discourse 
 
Rage, irritability, 
crying fits main 
symptoms 
 
Psychosis, 
Self-harm, 
suicidality 
main 
symptoms 
   
Cluster of 
symptoms in 
need of 
management 
 
‘voice’ of 
child 
incorporated 
into 
diagnostic 
practice 
 
Lack of control 
or responsibility 
for behaviour 
 
 
While the above table provides an illustration of the content of the representations 
held, a central aspect of this thesis has been to illuminate the role of interactions in 
shaping such representations. Table 7.2 below brings together these interactions by 
focusing on the positioning of the ‘Self’ in relation to significant others. A more in- 
depth discussion of these knowledge encounters, and the processes of influence which 
allow representations of PBD to form in extension, will be elaborated upon in section 
7. 5 below. 
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Table 7.2  
The making of a diagnosis 2: Self-Other interactions shaping development of representations of PBD 
(dialogical process) 
 
  
Pharma 
 
 
Clinicians 
 
 
Parents 
 Global US England US England 
Self: The 
reflexive ‘I’ 
position 
 
Pressured for 
diagnostic expansion 
 
Independent 
 
Interdependent 
 
Expert 
 
Amateur 
  
Driven by 
competitive 
economic forces 
 
Uncertainty 
amidst 
pressures for 
recognition 
Positioned in 
relation to 
American 
colleagues- 
prominent in 
discourse 
Pro-active 
advocate 
wanting what’s 
best for the 
child 
Ill - informed 
and cast aside 
  
 
 
Role of career 
development; 
expertise 
 
Cautious, 
reflective 
expertise 
  
The voice of 
significant 
‘Others’ 
Competitors 
Differentiation via 
accommodation of 
knowledge 
Parents 
Experiential 
experts- co-
producers of 
early 
knowledge 
about PBD; as 
voice for the 
child; as 
victims. 
Parents 
Novice- seekers 
of knowledge; 
alignment with 
child, separate 
from clinician 
Clinicians 
Questioning  
clinical 
expertise; feel 
ignored and 
patronized; 
Direct and 
indirect 
adoption of 
clinical 
perspectives 
Clinicians 
Disappointment 
and frustration; 
faced with 
reluctance to 
diagnose; 
perception of 
US clinicians as 
more 
knowledgeable 
 Clinicians 
Industry alliance: 
shaping opinion 
leaders, sharing 
responsibility 
Pharma. 
Subjective 
values 
compete with 
professional 
reality 
Pharma 
Encroaching 
American 
threat- vested 
interest. Leads 
to trust in 
‘home-grown’ 
research. 
Parental Peers 
Judgement; 
lack of 
support; Desire 
to impart 
expertise 
Parental peers 
No mention 
 Parents 
Notably absent from 
industry discourse  
  The School 
Collaborative 
alliance while 
also a constant 
struggle 
The school 
Minimal 
mention 
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The tables above present the main points of discussion to be expanded upon in the 
remaining chapter, tying empirical findings in with the theoretical framework in order 
to advance a model of social representations and dialogical processes at play in the 
construction of diagnosis. The discussion begins with a summary of representations 
held by the pharmaceutical industry. 
 
7.4.1 The global influence of the pharmaceutical industry 
Chapter four presented the ‘internal’ and ‘external’ voices of the pharmaceutical industry 
through the analysis of internal industry documents and advertisements. 
Representations of PBD were dependent upon the voice that was enacted, as the 
internal voice sought to establish the objectification of a set of symptoms indicative of a 
new type of child into a new diagnosis, while the external voice sought to reify this 
objectification through the suggestion of norms so central to pharmaceutical 
advertisements. Advertisements for the antipsychotics used to treat PBD on the one 
hand incite fear, tapping in to the notion of future-risk affiliated with PBD, as well as 
deep-rooted anxiety and the disintegration of self that comes with mental illness. The 
internal voice of the industry represents the child as an ‘unmet need’ suffering 
unnecessarily, thus existing as a marketing opportunity for future profit. Those 
advertisements for ADHD, the most salient anchor for the diagnosis of PBD in the US, 
promise a highly regulated child who will succeed socially and academically. The 
analysis of representations held by the pharmaceutical industry acted as grounding for 
the remaining empirical chapters, as the representations of PBD developed by Other 
key actors could be said to stem directly from how this industry reshaped 
representations of the child.  
For the pharmaceutical industry seeking to treat an as-yet-unnamed disorder, 
PBD began through a process of anchoring the new condition in more well-known, 
previously established conditions, namely ADHD in the US and illnesses such as more 
established notions of manic-depressive psychosis and schizophrenia in England  
(Figure 7.1). New symptoms to single out as pathological in children were taken from 
older categorical symptoms of schizophrenia (representing severity and urgency of 
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treatment) and ADHD (representing chronicity and treatability) in order to initiate off-
label prescribing. This, combined with the inclusion of broader spectrum criteria such 
as rage and irritability, perpetuated an idea of the child via the new possibility of 
treatments available.  
 
         
Figure 7.1 Pharmaceutical anchoring of PBD 
 
The concept of PBD as developed by the pharmaceutical industry remained vague 
enough to be encompassing of more and more children. Marketing strategies, 
professional education, and the push for sales representatives, and thus prescribing 
clinicians, to anchor PBD in something more ‘treatable’ such as ADHD established a 
new set of criteria on which to draw on, however the development of what behaviours 
are indicative of PBD being developed in concert with sales and marketing model is 
concerning. Clinicians were brought on board, nurtured as ‘opinion leaders, and 
retained for their level of influence both on clinical colleagues, and the parents of their 
young patients. Conveniently, the position of clinician as reliable expert liaison between 
industry and public, also allowed for the industry to shrug off controversy, reassigning 
responsibility when the criticism got too close.  
Dialogical processes shaping the development of pharmaceutical representations 
indicated the unidirectional, top-down nature of Self-Other interactions. The industry 
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‘Self’ was positioned in response to economic pressures from competitors in the field, 
in which pushing to expand diagnostic categories, and the symptoms they encompass, is 
about survival. It was this need for survival in a competitive market that drove the 
accommodation of external threat and need for differentiation in terms of what was 
being offered as new treatment for novel conditions. Industry influence in the form of 
persuasion played on the ego and esteem of practicing clinicians, reifying their expertise 
in the promise of paid speaking engagements and positions as opinion leaders. Also 
being played into was a clinical sense of ‘moral entrepreneurship’ (Becker 1963) in 
which clinicians’ act as ‘rule enforcers’ to the industry’s position as ‘rule creator’ via an 
organisational understanding of clinical perspectives validating the clinician’s role as 
something of a saviour to their patients. The building of trust through the provision of 
answers in the face of uncertainty allows clinicians to succeed in interactions with their 
patients. This will be unpacked further in relation to the wider theoretical issues in 
section 7.5 below. 
7.4.2 Representations of PBD among American clinicians 
PBD represented an initial career opportunity for many of the American clinicians 
interviewed, supporting Fleck’s (1979) assignment to the importance of the role of 
education and indoctrination into an already established thought collective. Among 
those interviewed, there was very much a sense of autonomy of practice, and 
independence from the wider field of practice in the US, in which there is no agreed 
upon understanding of what PBD actually is.  For American clinicians, the closest point 
of reference on which many agree is that PBD is anchored in the existing diagnosis of 
ADHD. The overlap in the two diagnoses often leads to initial mistreatment with 
medications that can end up making things worse, or as some clinicians contend, create 
the problem by initiating a manic episode where none would have occurred organically. 
It is seen as a very different entity to adult bipolar, carrying with it its own unique sets 
of behaviours that do not make up the diagnostic criteria in adults. Characterised by 
rage, irritability and restlessness, American clinicians interviewed note that PBD can be 
present in children as young as three years old. As a diagnosis, PBD is thought to be 
more common than originally thought, due to more adept diagnosis, but yet remains a 
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diagnosis in flux. Despite this, PBD is objectified through its enactment as a diagnostic 
category, and if suspected, the first-line treatment is with antipsychotic medications. 
For American clinicians, parents are collaborative allies shaping PBD as distinct 
from adult bipolar disorder. Based on their lived experience with their children, it is 
parents who were often described as initially focusing clinical attention on specific 
behaviours, which clinicians have then adopted into their representation of a disordered 
child. The behaviours thus become reified as ‘symptoms’ through the process of 
negotiation with parents to log them as symptomatic of this illness. Parents directed 
clinical attention, which clinicians then steered back to parents and, by proxy, onto the 
child. Clinicians, as the Self, engage in this circular process with multiple Others, with 
the child seeming to exist on the periphery. These interactions are taking place as 
clinicians negotiate their position within a social hierarchy that finds them between top-
down pressures from the pharmaceutical industry, and bottom up pressures in the form 
of subjective anxiety based on their own conflicts between values and practice, and 
external anxiety in the form of parental pressure for explanation of their child’s 
behaviour. As discussed in section 7.2, representations of the condition include 
representations of the child, whom American clinicians conceptualize as at risk; a 
cluster of potentially damaging symptoms in need of management.  
Dialogically, there is a tension present between the clinicians’ subjective ‘I’ 
position and professional reality, something which is manifested in the positioning of 
the clinicians as an expert among experts practicing in a healthcare system that leaves 
little space for deliberation, rather emphasizing the immediacy of a quicker fix. Also 
present in this tension is the position of clinical colleagues as a potential threat, and the 
distancing of the child in conversation, perhaps to keep the interactions clinical and 
devoid of emotion, alongside the concurrent alliance with the parent. In attempting to 
build consensus around the development of a more ‘fixed’ set of criteria for PBD, the 
accommodation of parental experience becomes a source of validation of clinical 
perspectives. The privatized, consumer-driven culture of practice in the US places a 
level of power in the patient, in this case the parent, to get a level of care deemed 
worthy of what is being paid for it. Thus, in the development of PBD, the position of 
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clinician as a mid-point between the wider healthcare system and the parent, in which 
top down influence meet bottom up pressures, contributes to the establishment of 
understanding the symptoms and behaviours that make up PBD. 
 
7.4.3 Representations of PBD among English clinicians 
In contrast to their American counterparts, for English clinicians interviewed PBD is 
still considered very rare, is not normally seen in younger children, and is not seen as 
distinctive from bipolar in adults.  As a diagnosis, it remains anchored in schizophrenia 
and manic-depressive psychosis, in which young people diagnosed are often in the 
midst of psychotic delusions or other severe behaviours warranting in-patient 
treatment. The objectification of the diagnosis then comes in the resistance to use of 
the category, instead focusing on more traditional notions of bipolar disorder. There 
was awareness among English clinicians of the broader spectrum approach favoured in 
the US, however the context of the child was central to discussion, and it was the more 
holistic approach to diagnostic practice that was a central finding setting English 
practitioners apart from their American counterparts. English clinicians interviewed 
pointed out that it is rare to see very young children with severe mental health issues, 
and unless stabilization is required, psychopharmacological treatment would not be 
seen as a first line treatment. 
The culture of socialised medicine, as exists in England, has embedded within it 
an established hierarchy among clinicians and patients. English clinicians positioned 
themselves interdependently, as part of wider collective field of practice. Such 
identification with a group of practitioners allows for an alliance with clinical colleagues, 
but also serves to open up the space for influence, in which each practitioner, as a 
member of the group, feels a subjective obligation to maintain consistency of practice, 
illustrating what one clinician referred to as a “culture of second opinions”. Parents are 
seen as seekers, rather than holders of knowledge, thus, parents are positioned 
alongside their child in a dyad. The established hierarchy present within the English 
medical system shapes this distancing between themselves and the parent, in which it is 
the clinician who holds the necessary proficiency to impart sound and uncontested 
 
 
 
 
232 
judgment. With regards to the child, however, intersubjectivity and a desire to 
understand the experience of PBD from the young person’s perspective marked clinical 
practice. While English clinicians identify as being part of a wider network of 
practitioners, it is America, and their American colleagues, which represent a globalized 
Other against which to express opposition. For the English clinicians interviewed, this 
comes in the form of referencing and addressing American clinical colleagues in 
discussion, expressing a conflicted thinking around acceptance and rejection of 
information shared via research and professional settings. On the one hand, there is a 
sense of America as leading with innovation, remaining at the forefront of research and 
practice surrounding children’s mental health. However this is tempered by a lack of 
trust and due to an assumption of American clinicians practicing in a culture of vested 
interests, whether professional, therapeutic, personal or scientific. 
7.4.4 Representations of PBD among American parents 
Parental representations of PBD in the US are very much bound up with how parents 
position themselves in relation to other key significant actors in the life of the child, 
namely clinicians, teachers, and other parents.  When referencing interactions with these 
groups, parents position themselves, across the boards, as experts, no matter the 
position in the professional hierarchy their interlocutor holds. A dynamic of ‘Us versus 
Them’ is a common thread in discussion, in which the child’s diagnosis sets parents up 
for battle with schools and clinicians. PBD is seen as something that requires 
experience to understand, experience which provides them with a level of knowledge 
unlike that of clinicians, but which should be seen as valid. This sense of experiential 
knowledge allows American parents to take an active role in their child’s illness 
trajectory, a role perhaps driven by an understanding of PBD as obscuring the true 
nature of the child, one that needs fighting to preserve. For parents interviewed in the 
US, this contributes to an external locus of control in which a biological or 
neurochemical explanation for behaviour means that associated behaviours are beyond 
their, or their child’s control.  
Dialogical processes incorporating outward resistance to, and internal 
accommodation of, clinical knowledge helps foster a sense of mastery of the diagnosis, 
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as well as interactions with clinicians who are generally found to be dismissive and 
unsupportive. Interactions with schools and parental peers present an opportunity to 
exercise, and feel appreciated for, experiential expertise allowing for the 
communication, perpetuation and dissemination of understanding PBD that may often 
times rival clinical knowledge for those still unfamiliar with the diagnosis. Of interest is 
an apparent mismatch between clinicians and parents, which will be discussed in a final 
section exploring the directionality of influences. While clinicians take on board 
parental experience and remain open to their influence, particularly in the early days of 
PBD, parents don’t recognize this themselves, instead feeling shut out, unheard and 
cast aside. American parents simultaneously challenge clinical expertise, while at the 
same time internalizing clinical perspectives (often indirectly, as through online fora and 
books such as The Bipolar Child) in order to advance their own knowledge of PBD 
through advocacy and sharing with Other parents. 
7.4.5 Representations of PBD among English parents 
For the modest sample of parents interviewed in England, discussion of PBD was 
presented in much more of an uninterrupted narrative, suggesting a pent up desire to 
communicate concerns and be heard. This was consistent with the representations of 
PBD interpreted from analysis pointing to a sense of confusion around the diagnosis, 
and an almost complete lack of awareness that it could exist in young people. English 
parents were caught off guard by their child’s diagnosis, with behaviours misattributed 
to what was thought to be ‘normal adolescence’. Social triggers were suggested as a 
cause, in which high achievement indicated as leading to a level of stress causing 
breakdown. A diagnosis of PBD came only after suicide attempts, psychotic breaks and 
extreme Self-harm.  
The most significant others to come out of conversation with English parents 
were clinicians, who were referenced with disappointment and frustration. Caught up in 
this talk were comparisons of American clinicians, with English parents imagining less 
reluctance getting a diagnosis for their child if they were going through the same 
process in the U.S. With the exception of one, English parents positioned themselves as 
amateurs, perhaps at the mercy of the previously mentioned medical hierarchy in which 
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parents accept what they are told, feeling little sense that they could change anything. 
Both an internal and external locus of control emerges in dialogue, in which internally 
parents feel responsible for having “missed” signs by thinking it was normal adolescent 
at play. This can be seen to tie in with wider cultural explanatory frameworks available 
to parents, in which the context of the U.S. has a more readily available medicalized 
explanation for behaviour, ‘normalizing’ disorder in a sense encouraging parents to pay 
close attentions. English parents raise their children in a setting with a different set of 
cultural, and thus explanatory, norms. Mental illness is not as in the foreground as it is 
with American parents, leaving English parents to feel ill-informed, cast aside by a 
system within which they have little control, and left feeling that there might have been 
more they could do to prevent the suffering that their child now endures. The fact that 
mental illness is not as much of the conversation in England as it is in the U.S. can be 
seen as a contributing factor to the difficulty in accessing parents to speak to. Not only 
is PBD a much rarer diagnosis, but the willingness to openly acknowledge and share the 
experience is one which is still gaining traction. 
7.5 Social representations, dialogical processes and modalities of influence 
shape the emergence of PBD 
This thesis has explored the making of a diagnosis, and its development in two cultural 
contexts, and what has been shown is that such diagnostic construction is a social and 
psychological process. I have shown this process to exist in the interrelation of three 
key actors involved in this condition, while child at the heart of it all is present in their 
voices. The main finding of this project points to how the construction of PBD in the 
US and England is driven by factors extrinsic to the actual condition, or something 
innate in the child, but is rather the result of social representation, dialogical processes 
and modalities of social influence taking place at the meeting point between these three 
groups, and their associated spheres of knowledge production.  
An illustration of what Moscovici (1994) would refer to as the social sharing of 
meaning, the emergence of PBD has been the result of developing criteria based on 
well-established, popularly accepted disorders such as ADHD, schizophrenia and adult 
bipolar disorder, applying them to children who don’t necessarily have the exact 
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symptoms of those illnesses. Rage, aggression and irritability have become three 
defining hallmarks of bipolar disorder in children, despite not having any connection to 
these disorders from which PBD is drawn, illustrating the processes of anchoring at 
work. Actors are thus enabled to construct a condition that can be viewed as less 
contested, less unstable, and more useful. The concepts of anchoring and 
objectification (Moscovici 1961, 1984) are especially important in relation to the way 
PBD has been constructed as a diagnosis because of this power that they have as 
‘meaning-making structures’ (Schmitz et al 2003). As a diagnosis, PBD is itself an 
objectification, the result of the anchoring process, based as it is on a series of 
borrowed representations, rather than possessing any clearly defined diagnostic criteria 
of its own.  Clinicians are then in a position to realign what is being seen what they feel 
should be seen, creating the conditions for a new disorder to be reified as fact. 
The content of these representations are shaped by cultural context, in which 
the salience of pharmaceutical influence, professional hierarchy within differing medical 
systems, and access to parental knowledge contribute to how knowledge about PBD is 
constructed. In the US, PBD is further along in the process of becoming objectified as 
a medical ‘fact’, as Pharma, clinicians and parents have moved closer to what Fleck 
(1979) refers to as a “structurally complete and closed system of opinions consisting of 
many details and relations” which, once established “offers enduring resistance to 
anything that contradicts it” (p.27). English clinicians continue to be both open to new 
research coming from the US, while at the same time priding themselves on a healthy 
scepticism that allows a sense maintaining clinical autonomy in the face of an at times 
overwhelming American influence. Whether there will be a complete recognition on the 
part of English practitioners of the knowledge of PBD coming from America remains 
to be seen, as in order for such knowledge to be observed, “new paradigms, patterns or 
frameworks of thinking have to be recognised and accepted, and theories have to 
change” (Alderson 2013, 5), a process which is still very much underway.  
The psychosocial processes central to development of PBD will be elaborated 
below, beginning with representations of the new idea of PBD as resulting from 
anchoring and objectification, followed by the role of knowledge encounters, Self-
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Other interactions, and culminating in an extension to Sammut and Bauer’s (2011) cycle 
of normalisation, here presented with PBD as a new frame of reference driven by the 
steering psychiatric knowledge via persuasion, accommodating that knowledge in ways 
that are useful, and finally confirming new knowledge and representations via wider 
social validation. 
7.5.1 Anchoring the unfamiliar; objectification via enactment 
In coming to terms with the phenomenon of a new diagnostic category, the act of 
attaching a label and set of characteristics is essential in order to allow it to be discussed 
and communicated more broadly (Wagner et. al., 1999). Biomedical explanations 
provide a tempting certitude given the complex problems faced by many children with 
behavioural difficulties, and the fear among their parents of being somehow labelled as 
“bad” (Harris 2006; Singh 2011). With Americans, and increasingly English, publics 
becoming well versed in the language of childhood mental disorder as a result of the 
emergence of Other illnesses such as ADHD, situating conceptions of a child’s 
threatening behaviour within a label of PBD is in fact attaching unfamiliar conduct to 
something that has been rendered familiar; a diagnostic label and a promise of 
treatment.  
 The anchoring of PBD in more established diagnoses is what leads to 
realignment of what should be seen based on what is being seen, thus one is more likely 
to see and label a child’s conduct pathological if primed by information circulating in 
public sphere. The anchoring of the new is done with much more reluctance in 
England, a culture in which medical practice gives more weight to theory and traditions 
than their American counterparts, perhaps suggesting one explanation for resistance of 
the diagnosis. Findings suggest that the process of anchoring the unfamiliar in the 
familiar is significant both in the development of knowledge around a diagnosis, as well 
as how that knowledge is applied. It illustrates the transformation of expert knowledge 
as being circular in nature, and where there is room for different forms of expertise, 
both professional and experiential. At the dialogical level, the empirical data presented 
here has shown the transmission of knowledge in action, illustrating mechanisms to 
explore how, when, and by whom knowledge is appropriated, accommodated, or 
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resisted via multiple modalities of social influence. In chapter two, Duveen and Lloyd 
(1990) were singled out for proposing that a representation to be anchored before the 
process of objectification takes place. I would argue that PBD as a case study in the 
construction of a diagnosis is an illustration of both processes happening 
simultaneously. In the US, objectification through enactment and application of the 
diagnosis is happening before the diagnostic category has been firmly established, or 
even fully understood. In England, there is a sense of waiting for some certainty from 
the US before accepting the possibility of PBD, thus objectification has yet to take 
place on a wider scale. 
 
7.5.2 Encountering multiple system of knowledge 
The model of knowledge encounters (Jovchelovitch 2007) has been employed in this 
thesis as a means to explore the production of knowledge around a contested diagnosis, 
and the development of new norms, that comes as the result of interaction among and 
between competing knowledge systems. The findings show how expert, experiential 
and market-driven knowledge builds discourse and classification systems on the basis of 
intensely social processes. Thus attempts to stabilise a diagnostic category and establish 
validated criteria are related to a number of psychosocial processes in relation to 
significant others. 
Encounters between diverse representations, such as experts and laypeople, or 
the questioning of one’s own subjective interpretations of behaviour when confronted 
with another type of expert knowledge (America v. England; pharma v. clinician; 
clinician v. parent; parent v. parent; clinician v. colleague) are significant in their 
contribution to the establishment of PBD as an object to be considered and acted 
upon. The direct and indirect interactions between the pharmaceutical industry and 
American clinicians for example, initiated a pushing of boundaries, stretching the 
definition of a category to accommodate the confluence of ‘new’ symptoms, both old 
and new. Or to use another example, a major finding of this thesis, the role of parents 
especially, and their centrality to the expansion of the diagnosis in America, provides an 
illustration for knowledge encounters in action.  
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Healy (2007, 218) notes that clinicians are making diagnoses “not based on 
publicly visible signs in the patients in front of them, or publicly demonstrable public 
tests, but rather on the basis of what third parties, such as parents or teachers say” (p. 
218). On what are these third parties basing their knowledge, and how are different 
meanings asserted and contested? According to Brown (1995) “patients and other lay 
people can be active collaborators in their own medicalisation, although sympathetic 
professionals are usually needed for successful claims-making” (cited in Conrad and 
Potter 2000, p.560). A lack of standardised diagnostic criteria could lead to third parties 
being more influential in shaping clinical decisions of what is best for the child, leading 
to a conflict between, as Markova (2008) writes, “’epistemological priorities’ in which 
on the one hand there exists a knowledge based on common sense versus that which is 
professional knowledge acquired through training” (p.461). Thus the ways clinicians 
produce and objectify PBD is determined by their own positioning in the cultural 
context, and how well they are able to fuse common sense and expert knowledge. 
Parents have taken part in influencing clinicians’ social representations of PBD 
by shaping how clinicians view their children, and their own experiences as victims held 
hostage to the diagnosis, blamed and not taken seriously by peers and other 
psychiatrists. Clinicians are complicit in this however, sourcing parental experience as a 
means to ground their own theories in something real, refining what PBD means to 
them in the process. The extent to which parents are aware of their level of influence in 
the development of the diagnosis that has now become their child’s reality is not 
known, however parental accounts of interactions with clinicians, both in the US and 
England suggest that they feel their experience is ignored. Whatever validation they 
have unknowingly provided clinicians has left parents feeling lost and frustrated, with 
American parents taking it upon themselves to turn to action and advocacy, while those 
in England struggle to make sense of the system they have now been entered into, one 
in which, as parents, they often feel as though they are somehow in the way. In the 
same way clinicians have used parental experience, parents have taken from clinicians 
the language and interpretive frameworks and made it their own, so the influence may 
be unidirectional with regards to what one group is getting specifically from the Other, 
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however both are taking on board new knowledge, and making it their own, as a result 
of their interactions. 
7.5.3 Self-Other-object interaction 
Interaction is at the core of a second framework drawn on in this research, that of 
dialogicality. This idea of encountering, and then appropriating, the knowledge of 
others illustrates processes of poly-vocality and intertextuality (Bakhtin 1984; Linell 
2006) at work. New meaning is created from those that are more established, and are 
adapted and reshaped to make sense among a new set of actors in a different contexts.  
Elements of dialogue are taken from other sources and internalised, accommodated 
into one’s own thinking via the recognition, or lack thereof, of the perspective of the 
Other.  With the emergence of PBD, we can see a shift in the discourses Foucault 
termed ‘discursive orders’, those patterned ways of thinking that shift between 
domination and subordination within a cultural context or community over time (Linell 
2006). As discussed in chapter three, asymmetrical knowledge among actors, and the 
hidden or more open polemics taking place in their actual or implied interaction 
between Self-Other-Object, alter what becomes the dominant way of thinking. In 
discussing the dialogical nature of interaction, and the resulting asymmetries in power, 
authority and knowledge, Marková (2014) introduces the importance of epistemic trust, 
noting that it is where knowledge ends that trust or distrust necessarily comes into play. 
Social representations can be either knowledge-based or belief based and dependent on 
cultural definitions of what constitutes ‘truth’ (Marková 2014).  Those representations 
that are belief (and trust) based develop out of the strength of the relationship between 
Self - Other. I argue here that the dialogical basis for the development of social 
representations of PBD are belief based, as at this point, there is no set ‘truth’ present 
in any aspect of PBD, with the exception perhaps of the representations of condition 
and child perpetuated by the pharmaceutical industry, who have constructed their own 
truth. For the other key actors though, there remains a lack of certainty. Thus, trust 
between Self-Other presents more certainty in the face of an unstable object, while a 
lack of trust leads to resistance, and alignment on the belief and opinions of others in 
order to determine a point of reference that makes sense.  
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This has been illustrated in findings from English clinicians who position 
themselves as a collective in response to American representations of PBD. As 
discussed in section 5.5.3, there is an underlying distrust of America and what it 
represents in terms of vested interest. Among English parents, however, PBD as 
conceptualized in the US represented more of an ‘imagined’ Other, imparting a trust in 
the American system to provide a quick and accurate diagnosis for their child, 
increasing a sense of certainty in what parents were dealing with, and an opportunity to 
take action (cf. 6.5.6). The level to which trust in the knowledge of the Other is 
incorporated into one’s own understanding about PBD is based on modalities of social 
influence in which systems of knowledge compete for dominance in the establishment 
of PBD as a social object, and thus a new normative frame of reference.  
7.5.4 Modalities of social influence 
Social influence was approached here as an extension of the dialogical framework, 
pointing to the role of influence as being borne out of the negotiation and positioning 
that takes place in relation to Self-Other-object. Sammut and Bauer’s (2011) cycle of 
normativity (cf. 2.5.1) was drawn upon as a means to explore how new social norms are 
established, and new reference points made salient. This thesis has found that 
normative frames of reference for PBD remain in flux and contested. Despite two 
decades of clashing over the existence of PBD, it remains in a sort of limbo, at which 
point it may become more established as a diagnosis on its own, or be subsumed into 
other diagnostic categories. The recently established diagnosis of disruptive mood 
dysregulation disorder (DMDD), is one such example, developed to find a ‘diagnostic 
home’ for children who are deemed in need of help, but don’t fit common 
understandings of bipolar disorder. The debates continue, however, and driving the 
degree to which PBD remains a valid diagnostic entity are modalities of persuasion (in 
the assimilation or challenging of institutional, clinical or parental knowledge), 
accommodation of the perspective of the Other (dictated by conformity pressures and 
minority influence), and finally the social validation sought to achieve recognition and 
verification of one’s own level of knowledge about PBD in reference to others.  
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Figure 7.1 below illustrates my variation of the cycle of normativity as it relates 
to the modalities found to be most salient in this study. As discussed in chapter two, such 
processes can lead to a collective decision among individuals to establish a frame of 
reference that makes sense, so as to have a sense of stability in the face of inherently 
unstable social norms (Sherif 1936).  Such a collective decision has not yet taken place 
more broadly, with a lack of consensus among clinicians still dominating in the US, and 
an adherence to the narrower, more classical presentation of bipolar disorder 
maintained in England. 
 
 
 
 
Figure 7.2 modalities of influence central to the development of PBD as a normative 
frame of reference 
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oneself and accept as a possible diagnostic fact, or discard as clinically unsound. What is 
established regardless of position, is an entity, however transient, that allows for action. 
Norms and frames of reference 
The establishment of social norms is especially important with regards to children’s 
mental illness, where the alignment of  ‘badness’ with pathology has been in place for 
decades. Suggestions of norms for how children should conduct themselves have led to 
points of reference against which the medicalisation of children takes shape, requiring 
medication for anything that falls outside of normative boundaries. In discussing the 
power of uncertainty to open up spaces for influence, Moscovici (1976) notes that the 
more ambiguous a “non-social stimulus situation”, the more dependent one is on the 
social reality created through “consultation and agreement among group members on 
the basis of different observations they could make to support their opinions” and thus 
orient themselves (p. 31). Social consensus is central to the development of PBD as a 
diagnostic category, or as is the case in England, rejecting an encroaching idea which 
advances the existence of PBD as a distinct diagnosis to that of adult bipolar.  
Consensus building, either in support of or in response to a new phenomenon, comes 
as a result of ‘processes of normalisation’. As discussed in chapter four, the 
pharmaceutical industry has sought to establish behaviours of rage, irritability and 
restlessness as a reference point for PBD, normalizing the idea of the diagnosis, and its 
recommended treatment, through identification of the disorder in children as more 
common than previously thought, and treatable. Playing upon wider social norms of 
childhood that favour achievement, sociability and staying out of trouble, the industry is 
then able to diffuse this knowledge into the wider sphere of prescribing clinicians. In 
establishing the idea of PBD as a new point of reference, new norms regarding what is 
morally desirable are established through respectable channels: that of the expert 
professional. 
In Chapter five, findings showed how American clinicians interviewed changed 
their own understanding and knowledge about bipolar disorder to fit with these 
evolving norms set out by pharma. What resulted involved American clinicians seeing 
what was in front of them in a different way; the child presenting in their office was 
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now viewed through a framework in which what was being seen was altered to fit with 
what should be seen. For English clinicians the frame of reference remains bipolar 
disorder as found in adults. The wider collective field of practice in the UK unites in 
not adopting PBD as a legitimate category. While positive in that this encourages a 
more deliberative approach to treating young people with mental health issues, one 
critique might be that while no one would advocate moving towards over-diagnosis and 
treatment, there is a fear that in maintaining norms of rarity of mental illness in 
children, legitimate concerns and alternative options may not considered in favor of  
maintaining consensus with colleagues 
For American parents discussed in chapter six, normative frames of  reference are 
murky, and do not necessarily stem from their interactions with professionals. Instead, a 
finding of  this thesis points to the fact that these parents don’t seek out the influence 
of  clinicians to the same degree that clinicians sought out parental influence to validate 
the diagnosis in its early days. While American parents echoed clinical perspectives and 
terminology in their own discourse, indicating the presence of  clinical influence, the 
accommodation of  this thinking was outwardly resisted, despite being internalised. 
Instead, parents placed trust in their own knowledge developed through research, and 
significantly, the book The Bipolar Child which provided parents with a set of  norms on 
which to base their own interpretation of  their child’s behaviour. While the knowledge 
disseminated by the book was often similar to that held by many clinicians, the position 
of  the book as a reference point suggests the degree to which parents in the US often 
lacked trust in clinical knowledge they came into contact with directly. Thus the book, 
combined with peer influence, allowed for an alternative source of  initial knowledge 
about PBD.  
English parents, in comparison, lack any solid frames of  references or sense of  
what is normal. This “lack” is illustrated in the way English parents often referred to 
themselves as amateurs, of  unsure what bipolar meant for their child, and 
acknowledging ignorance that a) the diagnosis could exist in young people, or b) that 
the behaviors they were seeing in their child was anything Other than normal 
adolescent behavior. This despite the fact that for the English parents interviewed, 
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those behaviors were much more severe than their American counterparts, often 
involving paranoia, psychosis, and attempted suicide. For English parents, there was no 
mention, or knowledge of, The Bipolar Child. There was no network of  peers openly 
comparing notes about their own children’s difficulties. Instead, English parents exist in 
a continuous state of  trying to get answers from a system where they feel consistently 
set aside and left in the dark. The following sections will explore the modalities of  
social influence that shape the development and salience of  the normative frames of  
reference for PBD in the US and England, and will show persuasion, accommodation, 
and validation all, to varying degrees in the groups studied here, lead to the acceptance 
or challenging of  PBD as a diagnostic fact. 
 
Steering psychiatric knowledge via persuasion 
In the cycle of  normalization leading to the development of  PBD as a diagnosis, 
persuasion plays a central role in how knowledge takes shape. It is central to the idea of  
social influence as a communicative process as well, in that it relies upon engagement 
with the perspective of  the Other in relation to reshaping understandings of  the social 
object. Findings from chapter four illustrate the degree to which the pharmaceutical 
industry relies upon persuasion as a modality of  influence in order to change previously 
held representations of  bipolar disorder to emphasize the new criteria the industry is 
pushing for to sell medication. Nowhere are these persuasive tactics more present than 
in the interactions with American clinicians. Mechanisms of  soft power and financial 
incentive are used to develop an alliance with clinicians targeted by the industry, 
identifying those willing to come on board to be fostered as opinion leaders, who will 
seek to persuade colleagues. Such alliance with clinicians has the benefit of  validating 
the position of  the pharmaceutical industry while at the same time removing a level of  
responsibility that then becomes shared with the clinician.  
As found in chapter five, American clinicians on the receiving end of  persuasion 
in form of ‘soft power’ from the pharmaceutical industry did in fact reshape their 
representations of  a ‘disordered child’ in line with what was being suggested via 
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targeted education campaigns. Early financial incentives and offers to be an opinion 
leader among colleagues also played into a desire to be held in high esteem by patients 
and colleagues. Thus, persuasion as a modality of  influence extends into seeking to 
persuade colleagues by using parental experience and accounts to back them up, and 
parents through the emphasis on future risk. 
Persuasion here ties in with the idea of ‘moral entrepreneurship’ (Becker 1963) 
mentioned previously, and it is here that it figures in to a wider argument about the role 
of persuasion in the shaping of clinical thinking about PBD.  Becker’s (1963) idea 
positions individuals or groups into two camps; those who have a moral imperative to 
create a new set of rules (or norms)  (‘creators’) and those who have little stake in the 
‘content’ of the rules  (‘enforcers’) and as a result develop their own personal 
assessment of what ideas are worthy of being perpetuated and acted upon accordingly. 
Both the creators and enforcers of norms influence one another, with the creation of 
new notions of what makes up PBD stemming directly from how new sets of norms 
are enforced, with rejection also serving as a form of enforcement.  If this idea is taken 
into the realm of diagnostic practice, in which the pharmaceutical industry represents 
the institutionalisation of rule creation, the rules here become the rules of a diagnostic 
category. They become synonymous with symptoms to be actively sought out and re-
categorised. Clinicians incorporate their own understanding of these norms from what 
has been handed down from the pharmaceutical industry, modified through interaction 
with parents and clinical colleagues, and acted upon accordingly.  
The extent to which the rules/norms differ in the US versus England is thus 
shaped by the level of openness to persuasion, which ultimately stems from the degree 
to which there exists cultural comfort with uncertainty and caution in approaching 
diagnosis. For English clinicians, there is a refusal to assimilate the ‘broad spectrum’ 
idea of PBD, resisting persuasion by remaining actively sceptical that such a  diagnosis 
can be present in very young children, and instead maintaining the more established and 
traditional conceptualisation of bipolar disorder as manic-depressive psychosis.  
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Integrating the knowledge of ‘Other’ through accommodation 
The degree to which unfamiliar meanings are accommodated and incorporated into the 
establishment of new norms is reliant upon influences becoming internalized. In chapter 
four it was shown how the pharmaceutical industry used information from competitors, 
accommodating that knowledge to their own ends instead of seeing the competition as 
a threat. This allowed for the crystallisation of a new way to understand how behaviours 
could be recast as a new diagnostic entity and was thus used as a basis to diffuse this 
understanding to prescribing clinicians. In chapter five, these processes of 
accommodating pharmaceutical knowledge, and the persuasive influence discussed 
above, was illustrated in clinician interviews regarding the new symptoms of bipolar in 
children, echoing what was put forth in education campaigns form pharmaceutical 
representatives. For American clinicians, new ideas of how the diagnosis might present 
also came as a result of taking on board parental knowledge. Parents here represent the 
minority coming into contact with a seemingly more powerful ‘expert’ Other, but in the 
development of clinical representations of PBD in concert with parental influence, 
making concessions to what parent’s saw as a need which has shaped the development 
of a new clinical frame of reference (cf 5.4.3).  
In contrast, the accommodation of knowledge for English clinicians came not 
from parents, but from clinical colleagues, suggesting the value placed on different 
systems of knowledge plays into a wider cultural hierarchy emphasizing the importance 
of an alliance among clinical colleagues, and perhaps not trusting parental experience 
and understanding of their child as enough to steer clinical thinking. Among American 
parents, understandings of PBD came not only directly from interactions with 
professionals (cf 6.5.3), but also through channels such as The Bipolar Child, as well as 
knowledge and recommendations from peers and schools. This ties in with discussion 
in section 7.5.3 in relation to parental development of  representations as a function of  
trust and the strength of relation between Self and Other. For American parents 
interviewed, there was an active lack of trust in clinical guidance, thus clinical 
knowledge, while not discarded, is instead accommodated via more trusted sources. 
English parents’ representations of PBD remain largely unformed due to the efforts of 
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the wider clinical sphere to keep the notion of such a diagnosis in young people rare. As 
a result, English parents hold a murkier understanding than their American 
counterparts, as well as a less established network to draw on. That’s not to say there is 
no influence on their thinking from external sources, however it remains less specific, 
where English parental knowledge is accommodated from a more generalised ‘Other’ in 
the form of American perspectives on PBD gleaned anecdotally, or in the case of one 
parent interviewed (UKP 1), actively seeking out information online and via direct 
contact with American clinicians in order to validate what this parent believed they 
were seeing in their daughter (cf. 6.5.6).   
What determines whether accommodation of the knowledge of another takes 
place?  Findings from this thesis, and particularly those from English clinicians and 
American parents, suggest that unspoken pressures to conform play a key role in the 
degree to which other perspectives are taken on board. For English clinicians, 
conforming to the wider field of practice is understood as a means to maintain 
consensus. Thus, unspoken pressure from colleagues, as discussed in section 5.3.3 for 
example, determines which normative frame of reference will be drawn on- that of the 
American ‘broad spectrum’ approach, or the more established manic-depressive 
psychosis representation held in England, which also play into wider ideas about mental 
illness in children. For American parents, such conformity pressures come from 
interactions with parental peers, schools, wider societal norms closely tied to their 
parenting practices. Lacking in discussion with English parents was any mention of 
school or peer influence that was so present in conversation with American parents. 
Conformity pressures were not as salient among American clinicians, however this may 
be due to the fact that it remains hidden. One clinician interviewed clearly struggled in 
having to cater to the realities of answering to wider institutional systems (cf 5.5.1), 
conforming to their wishes, however this was rarely made explicit.  
 A second determinant shaping whether knowledge of another is internalised, 
and one which stands in contrast to conformity pressures, is the degree to which the 
majority accommodates minority understandings of PBD. A key issue in social 
influence is the psychology of minorities, as minorities have the capacity to bring about 
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innovation through the power of ideas  (Moscovici 2001) in which the power of 
minority influence lies in its inherent challenge to consensus as a means to innovation 
(Moscovici 1976). Central to this is how useful such knowledge is deemed to be. 
Minority influence serves as a challenge to consensus, leading to innovation. As 
discussed in chapter five, the perceived alliance with parents on the part of American 
clinicians allows for the wider diffusion of PBD as a new diagnostic entity, using their 
status as minority as a tool to validate the need for increased attention to this particular 
problem as highlighted by parents. As such, those clinicians who were early proponents 
of PBD, and perhaps in the minority themselves, are able to position themselves as 
innovators at the forefront of a new field of research into children’s mental illness. 
For American parents, it is their position as minorities driving the desire for 
recognition of experience living with their child. A culture of advocacy in which parents 
find comfort, power, and perhaps a decrease in stigma in the support of others lead to 
their increased presence in clinical understanding of PBD. The more American parents 
engage in research, and interact with others, the more they become experts of their 
own, challenging the judgment and opinion of professionals in the field. Strength and 
control via knowledge and mastery over diagnosis stems from a sense of duty to be a 
good parent, awhile acknowledging the right of their child to a normal childhood, 
whatever that may mean for them. Once parents take ownership of professional 
knowledge, the murkiness expressed by clinicians is replaced by a certainty expressed by 
the parents suggesting again that how much a diagnosis proves to be useful shapes its 
staying power. Parents positioning themselves as the real expert leads to a forging of 
their own way when dismissed by clinicians who they feel do not truly value their 
knowledge. Thus, finding solidarity and purpose in advocacy groups, American parents 
are able to take steps to end their ‘silent suffering’ through the education of peers and 
teachers, moving the diagnosis further towards fact.  
It is this persistence that allows a minority to be successful, allowing its own 
perspective to become more familiar to the majority. The last group in this study where 
this can be seen is among English clinicians. While not a minority within the context of 
the UK, in the development of PBD as a diagnostic category, it is the American 
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ideology that has remained dominant. Thus, in challenging consensus through resisting 
the imposition of  American understandings of  PBD (as discussed in section 5.3.4), 
which English clinicians interviewed link to the vested interest of  pharma, English 
clinicians may not necessarily succeed in getting Americans to take on board their 
minority perspective, nonetheless have upheld a culturally situated discourse that 
maintains distance, and remains firm against assimilation to a more dominant 
representation of PBD.  
 
Confirmation through validation 
As discussed in chapter two, the social dependence on Others for validation, and a 
resulting informational dependence leading to influence (Turner 1991, 19) is especially 
salient as a final process in the development of PBD as a normative object. Among 
parents in both the US and England, the world of professional expertise remains 
inaccessible in many capacities, with a lack of resources in both contexts leading to 
shortages of child psychiatrists, putting them at the mercy of whatever information is 
available. For American parents, this results in taking it upon themselves to develop the 
expertise they deem necessary to make informed decisions about their child, often 
relying on peers in support networks to validate what they are seeing. This validation is 
then used to impart knowledge on less informed parents going through a similar 
experience with the child, serving as a means to uphold their own sense of mastery and 
control in the face of uncertainty. In contrast, for English parents interviewed, 
professional validation took precedence over that of peers, suggesting again a lack of 
knowing who else to turn to or where to begin in order to interpret of confirm what 
they were seeing in their child as anything other than normal adolescent behaviour. 
 Both American and English clinicians represent the meeting between lay and 
institutional spheres of  knowledge in which their own subjective values and personal 
judgment can’t be objectively validated, something which may be problematic in a field 
that is based on empirical evidence, but which relies on subjective appraisal of  a 
situation. For clinicians in England, as has been discussed in relation to accommodation 
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and conformity pressures, this validation of  the view of  ‘bipolar as bipolar’ 
disconnected from any separate diagnosis specific to children, came through 
confirmation from clinical colleagues, supporting discussion above related to the nature 
of  diagnostic practice in England specifically, and within a socialized medical 
framework more generally. Among American clinicians it was subjective validation, 
which confirmed their own perspective was correct, utilising parents’ experiential 
knowledge in as much as it held significance and utility in backing up an existing clinical 
agenda.   American clinicians discussing PBD as an uncertain, ambiguous entity allows 
them to create a space in which they might carve out their own niche, demonstrating 
mastery in the face of something so poorly understood, strengthening their individual 
position in the process.   
Finally, the pharmaceutical industry, despite its dominance in shaping 
representations of a broader spectrum bipolar disorder in children, was not immune to 
validation. As was illustrated in analysis of industry documents, there was a definite 
concern around these new behaviours being legitimated, most notably in the eyes of the 
FDA. Thus, validation came via seeking alliance with clinicians, as well as scientific 
validation established through anchoring PBD as a neurochemical problem. 
 
Vectors of social influence 
The mechanisms of  social influence discussed here all exist in different degrees among 
groups and between cultural contexts. Equally as important to the actual mechanisms 
of  influence involved in the cycle of  normalisation shaping construction of  PBD is the 
directionality of  these forms of  influence. For example, these so-called “vectors of 
influence” (Sammut and Bauer 2011) are manifold and multidirectional in the US, 
where channels of influence are quite open between pharma, clinicians and parents.  In 
England, however, they are much more restricted. English clinicians, for example, rely 
on conformity and consensus within the group, and their position within the wiser 
hierarchy of practice, as a means to resist multiple sources of influence. Pressures for 
innovation and staying ahead which are so prevalent in the US, and a regulatory 
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framework encouraging this, allows for an increased openness to influence from one 
another, and other sources as well. 
In contemplating why this might be the case, we need to consider who is taking 
part in the knowledge encounters that render such influence possible. As an example, in 
the US the parents are self-declared experts, whereas in England they define themselves 
as amateurs. As an amateur, the degree of influence you are likely to have on a clinician, 
whether subtle or overt, is likely to be nil. American parents take the pieces of 
knowledge that make sense to them from clinicians, other parents, and their own 
developing expertise to generate their own assumptions of what makes PBD. Such 
belief -based representations are open to change, as the drive towards the truth in 
something unseen is in a state of constant flux. Steering this evolution of representation 
through dialogue and knowledge encounter is the directionality of professional versus 
lay influence. American clinicians cite parents as influential in the development of their 
own early knowledge about PBD, however this is not reciprocated by American 
parents, for whom clinicians are a source of frustration and a lack of trust. The 
consumer-driven nature of the US healthcare system impacts on the doctor patient 
relationship in that the increase in the power of the consumer has caused patients to 
question professional authority, while at the same time allowing clinicians to shed some 
responsibility onto the parent (Lupton 2003).  
In elaborating on the idea of experiential knowledge, Jodelet (2013) asks how, 
within a specific context, are “representations created that incorporate the subjects’ 
history, social belonging and practices while being, at the same time, influenced by 
larger social systems?” (Jodelet 2013, 9.4).  It is in the health sector that the 
development of the idea of experiential knowledge has developed the most, where 
patient experience, or in this case parental experience as proxy for that of their child, is 
given a privileged place for how illness and treatment is dealt with (Jodelet 2013, 9.15).  
There is no consensus among clinicians in either the US or England, with children 
being given the diagnosis of PBD presenting very differently from one another. English 
clinicians use their lack of trust, or wariness of the American influence to govern their 
own practices and development of thinking around the diagnosis, while English parents 
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feel they have no choice but to put their faith in the clinicians treating their child, as 
there are few other options, and the system is one they find hostile and closed to their 
input. 
American clinicians see themselves as innovators, and attempts have been made 
to influence colleagues England, but this has largely been resisted due to English 
clinicians as interdependent consensus builders aligned with the wider profession, and 
engaged in collective resistance to American influence. The degree to which this holds 
in the future is up for debate however, as those few clinicians interviewed who do 
subscribe to aspects of US thinking on PBD are in a position of power and influence in 
their own right.  With regards to the pharmaceutical industry, the degree of influence in 
England is thwarted due to regulatory frameworks in place, whereas the connection is 
much more direct in the US. This research has shown that the pharmaceutical industry 
is a major vector of social influence through the adoption of a number of behaviours 
that influence clinicians and parents. Uncertainty combined with pressure and the 
promise of prestige is used to reshape how clinicians thinks about this disorder, but 
more importantly, how knowledge of what makes up this diagnosis is realigned to make 
sense in children. A psychotic disorder becomes behavioural through persuasion, soft 
power of economic incentives, and the perpetuation of risk, exemplifying the power of 
the industry shape psychiatric knowledge, steering broader social and cultural attitudes 
toward medication (Kirmayer and Raikhel 2009). Overall, the vectors of influence 
between Pharma, clinicians and parents is uninterrupted in the US while in England 
they are more disjointed.  
One of the key issues discussed by Moscovici (1976) was the idea that contrary 
to more traditional views of social influence as a top-down approach, it actually exists as 
a much more multi-directional phenomena. This idea is supported by the findings of 
this thesis, which illustrate the circular nature of influence, supporting Moscovici’s 
assertion that information begins within fields of established expertise before diffusing 
into more wide spread common sense assumptions about bipolar disorder specifically 
and mental illness in children more generally. This view of influence ties in with how 
this thesis presents an added dynamic to early conceptualisation of medicalisation that 
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focused almost exclusively on a clinician’s interaction with a patient. Exploring the 
multiple vectors of influence points to the idea that medicalisation does not just happen 
uni-directionally, nor does it necessarily involve direct interaction with the patient. 
Rather such reshaping of problems can happen with patients-by- proxy, as with parents 
of young children, or even within an individual clinician, the subjective self in 
negotiation with a professional self for example, or the institutional influences shaping 
less direct, but no less salient interactions.  
Social influence has been incorporated here as a communicative practice. At the 
heart of this discussion is the construction and negotiation of a new medical fact via the 
development of a new normative frame of reference, culminating in a new diagnostic 
category. In referring back to the overarching theoretical framework of social 
representations informing this thesis, what has been reiterated is the importance of the 
social group to which one belongs as central to shaping which aspects of socially 
embedded knowledge are drawn upon, providing a map on which to base various 
interpretations and comparisons of what constitutes normal versus pathological 
behaviour (Moscovici 1961). Different forms of knowledge can co-exist, undergoing 
what Jovchelovitch (2007) refers to as “productive transformations” in which 
knowledge is “cross fertilized” based on dialogical encounters (Jovchelovitch 2007, 6). 
It is this culmination of encounters which I have attempted to illustrate below in figure 
7.3, bringing together the multiple frameworks discussed in this chapter into a model 
illustrating PBD as a diagnosis constructed via psychosocial processes.  
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Figure 7.3 psychosocial model of diagnostic construction in the US and England 
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7.6 Implications, limitations and future directions 
 
Exploring the genesis of a new diagnostic category in children from a socio-
psychological approach is meaningful and significant because, as Davies suggests, “how 
we are marked shapes how we feel” (2011, p.190). When children are being ‘marked’ at 
younger and younger ages, they end up somehow removed from determining how they 
feel. Instead, their identity is developed in concert with one that has been imposed on 
them. Social psychology sheds light on those practices allowing for the appropriation of 
knowledge or specific terminology that has found a home in everyday discourse and 
common sense thinking, and understand the impact this might have on the child. There 
is the idea of a ‘looping effect’ that takes shape (Hacking 1995; Brinkman 2014) in 
which behaviours are interpreted, reassigned and acted upon in a way suggesting that 
individuals become their illness, and thus perform as expected. The diagnosis and 
treatment of young children with a mental illness that has no stable base is of great 
concern, and a phenomenon that seems too multifaceted and grounded in social 
processes to be solely left to statistics. This thesis has shown that transformations in the 
representations of PBD are also in fact transformations in representations of childhood. 
In one we see the other. To be considered here are the implications for assigning 
younger and younger children a diagnostic label which carries with it so many 
associations.  
Through the integration of socio-psychological frameworks including social 
representations, knowledge encounters, dialogicality, and modalities of social influence, 
the findings presented offer one explanation of diagnostic construction, and expands 
the socio-cultural psychology of medicalisation. The focus of this study on the 
interaction, transmission and application of organisational, clinical, and parental 
knowledge as related to PBD contributes to the wider scholarship on medicalisation 
and the debates around children’s mental health in that such an exploration goes deeper 
into the processes and social forces determining which aspects of childhood behaviour 
might be deemed pathological, and why.  
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An important point for discussion to come from the findings presented lies in 
potential implications stemming from the meeting of lay and professional systems of 
knowledge. Is it always advisable to enable forms of nonmedical knowledge to push the 
development of medical behaviour and understanding? The importance of local and 
experiential knowledge has been advocated for decades, where the achievements linked 
to empowering patients via the incorporation of lay experience and understanding into 
policy and practice has resulted in positive steps forward, especially with regards to 
awareness and destigmatisation campaigns around mental illness, such as the 
international Hearing Voices Network, and the inclusion of user experience into mental 
health intervention models. It is not my intention here to negate the experience of 
those living with or alongside mental illness, or to suggest it is somehow wrong to 
include such knowledge into policy and practice.  What is being suggested instead is 
space to consider, and be attentive to, any unintended consequences of these multiple 
pressures and anxieties coming together in a focus on the child.  
Oftentimes medicalisation appears as the ultimate remedy for issues that should 
be solved elsewhere, but the confluence of these knowledge encounters is enabling 
multiple medical understandings from both industry and lay spheres, driven by 
dimensions and interests extrinsic to the actual understandings that constitute a mental 
condition. The findings from this thesis indicate diverse anchors for the understanding 
of PBD. The objectification of the diagnosis has taken place quickly in the US, despite 
it only existing as a theoretical assumption. In England, it remains resisted, however this 
could change as those clinicians in a position of power find separating paediatric bipolar 
out as a distinct diagnostic entity to adult bipolar disorder makes sense. Such a shift has 
taken place with ADHD, which, while much more common now, was rare in England 
twenty years ago and was also conceptualised as an American problem.  
Van Bavel and Gaskell (2004) suggest that when it comes to the supposed 
“knowledge deficit” held by the wider public about specialist domains of knowledge, 
what is not understood tends to be resisted. While this might be true in some domains, 
when it comes to navigating unsettled behaviour in children, this thesis has shown this 
to be culturally variant. While a degree of resistance has taken hold in England, in the 
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US, that which is not understood has led to a drive to develop understanding in concert 
with multiple sources of information. The drive to understand has led to an expansion 
of behaviours that could be included in diagnostic criteria, as well as parental advocacy, 
which has been a source of clinical knowledge as well.  
The implications for the merging of multiple knowledges lead to broader 
questions relating to appropriateness of care and systems of clinical practice in which 
shortages of resources are a source of the issues being discussed here. The current 
systems in both the US and England allow for diagnosis and treatment of children by 
medical professionals not formally qualified in psychiatry, treating outside their realm of 
expertise. As such, the reliance on knowledge, and openness to influence from various 
others, could be proposed by many as necessary in the face of diagnostic uncertainty. 
At risk is closing the space within clinical practice to consider of a child’s developing 
identity. Contentious diagnoses in children’s mental health are unlikely to disappear 
anytime soon, however a considered approach incorporating the child’s position, 
focusing on a child’s strengths rather than letting the diagnosis define them, would be a 
step away from seeing child as more broadly ‘disordered’. Social knowledge is very 
much tied to the social and cultural background against which it is produced 
(Jovchelovitch 2001) and while it is true that we are continuously constructing social 
knowledge, we do so “in relation to a reality which permanently escapes from our 
making” (ibid, p. 180). That is, what we know about a diagnosis such as PBD is 
evolving, existing as it does alongside a set of circumstances unique to a particular place 
and time. Thus, what is understood and presented here will no doubt change. However 
it is the attempt to a capture a snapshot of how unstable diagnoses flourish or disappear 
that can be useful in understanding the historical cycle related to the development of 
diagnostic categories.  
 
7.7 Study limitations and areas of further investigation 
This project contributes a small piece of a very large pie. While it would have been ideal 
to be able to study the construction of PBD on a much larger scale, the limitations 
imposed by access restrictions, the time and funding scale of a PhD, and the emergence 
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of possible new angles of study late in the research process all mean that there are many 
areas which I feel would benefit from research attention in the future. Perhaps the most 
significant omission from this thesis is that of the direct voice of the child at the heart 
of the debate. Alderson (2013) emphasizes the necessity for the inclusion of the child’s 
voice in research, criticizing earlier traditions across the social sciences that have 
omitted the child from national statistics and economic policies. Highlighting the 
recognition children should receive as “social agents shaping their own lives and 
influencing the world around them” Alderson (2013) suggests that children should not 
be dismissed as “pre-social and pre-moral entities, or as the mainly passive object of 
adult socialization” but rather as respected potential research participants in their own 
right (p. 34). This was also addressed in Singh’s (2012) work on the ADHD Voices 
study (Voices of Identity, Childhood, Ethics and Stimulants) illustrating the importance 
of having the perspective of young people when discussing issues around their 
diagnosis and treatment that are directly pertinent to them. Alderson and Singh’s 
inclusion of the child is something I would like to have seen for this project, and indeed 
to me this thesis represents the beginning of what I hope will be a much more extensive 
research, one which will seek to include children living with a diagnosis of PBD as 
participants. While inclusion of the child here would be ideal, the child as captured in 
the voices of those interviewed provided a sense of their position in relation to the 
diagnosis constructed around them. A next step would be to speak to young people, 
accessing their understandings and attitudes towards their diagnosis, and how it differs 
between those diagnosed young, with the broad-spectrum diagnosis, and those 
diagnosed as older adolescence. 
A second limitation to my research involves the small sample size of parents 
from England. As discussed previously, the process of accessing these parents was a 
challenge that ultimately resulted in only five interviews. While a frustrating aspect of 
the research process, I think this difficulty, as compared with the relative ease of 
accessing parent-participants in the US, points to wider mechanisms at play in this 
diagnosis. This ‘lack’ can be viewed as a form of data in its own right, with the absence 
serving as a tool with which to refocus attention to what is significant. In the future, a 
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more engaged study incorporating attitudes and experiences of parents in England 
would provide a more in depth account of the similarities and differences between the 
two contexts, as well as providing an interesting longitudinal case-study in the event 
that PBD begins to expand as a diagnosis in the UK over the coming years. 
A final aspect of the present study that could be developed for future research 
is that of seeking out a larger and more varied sample of mental health practitioners, 
particularly non-prescribers, in the US and England. Clinical social workers, 
psychologists, more CAMHS nurses and members of mental health teams who are 
perhaps more often placed on the periphery would provide an interesting and nuanced 
perspective on understanding the development of PBD at many more levels than have 
been accessed here, allowing for a more representative view of how ‘professionals’ 
conceptualize this particular diagnosis.  
Methodologically, the scope of this project was concerned with the 
development of knowledge around a particular diagnosis, and for this the use of semi-
structured interviews was useful.  Given that this project is so closely bound up with the 
idea of interaction and dialogical processes, however, future research might incorporate 
evidence of ‘interaction in action’ via focus groups,  an approach that was not a feasible 
option for this project given the constraints of  very tight clinician schedules, and the 
scattered locations of parent- participants. The use of surveys to glean much more 
wide-scale assumptions and attitudes towards PBD as compared to other diagnoses 
would provide interesting insight as well, allowing perhaps for a much more wide-scale 
comparative study across multiple contexts. 
As mentioned in chapter one, clinical literature suggests that diagnostic practice, as 
opposed to epidemiological prevalence rates that is central to the increase in PBD in 
the US as compared to England.  The reports and studies suggesting this were not in a 
position to delve into greater detail to processes shaping diagnostic practice, however, 
as the emphasis was (necessarily) on the hard data. It is in this respect, getting ‘behind’ 
the data that a social psychological approach can contribute to the clinical literature, as 
well as wider research on medicalisation of children. The hard data is of obvious 
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importance, but qualitative studies lend valuable and necessary insight into the why and 
the how questions at the heart of social phenomena, as has hopefully been shown here. 
Reshaping how something is seen is ingrained within the diagnostic process, 
however with a condition is as unstable as PBD, calling attention to wider cultural 
processes that shape thinking, whether they be the roles of gendered norms, 
breakthroughs in the ever-present quest to find a biomarker for mental illness, or even 
the politics of globalisation leading to lifestyle changes such as job loss, and poverty, 
provide a more nuances way to understand the development and representation of the 
child. The treatment of a child is reflective of larger societal forces, in a sense, the child 
acts as a mirror, absorbing the wider anxieties and cultural concerns at play around 
them. Thus, a focus on who is present in the life of a child, and who they are interacting 
with, allows for deeper consideration of processes shaping how a diagnosis emerges, is 
defined, and thus accepted or challenged as valid. In contexts where PBD remains 
something of a peripheral notion, there is an opportunity present through which we can 
learn what drivers are in play influencing how certain sets of behaviours become 
synonymous with disorder. Such understanding might enable greater scrutiny of 
broader cultural systems and socio-psychological mechanisms shaping conceptions of 
the child, and childhood more generally, before advocating diagnosis and treatment of 
something that remains poorly understood. 
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Appendices 
Appendix 1: NHS ethical approval  
 
 
 
 
 
 
 
262 
 
 
 
 
 
 
 
 
 
 
263 
 
 
 
 
 
 
 
 
 
 
264 
  
Appendix 2: Participant information sheet- parents, England 
 
 
 
                                                            London school of Economics and Political 
Science 
Department of Social Psychology 
St. Clements Building 
Houghton Street 
London WC2A 2AE 
       Tel:  020 7955 
7712 
    Fax: 020 7955 7565 
 
 
Information about the Research for Potential Participants 
Paediatric Bipolar Disorder in the US vs. UK (REC Ref No: 13/EM/0313) 
 
 
As a parent of a young person living with the diagnosis of bipolar disorder, I would like to invite you to take part in a 
research study. Before you decide I would like you to understand why the research is being done and what it would involve for 
you. I would ask you to go through this information sheet and should you have any questions contact me and I will answer 
them as thoroughly as possible. Please talk to others about the study if you wish in order to help you decide.  
 
Purpose of the study: 
 
Over the course of the last ten years in North America, the diagnosis of bipolar disorder in children has 
been made more and more frequently. This has happened against a backdrop in which many mental 
health professionals did not think such disorders could exist in younger children and adolescents. In 
contrast, there seems to be more reluctance among psychiatrists in the UK towards making the diagnosis, 
with some arguing that while children may have symptoms that suggest bipolar disorder, they are not 
convinced that there is enough evidence from research to support its wider use as a common diagnostic 
category. Part of this reluctance stems from a fear of misdiagnosis, and possible over- medication of 
children; issues that are very much a part of the conversation in the US.  
 
This leads to the purpose of my research, undertaken as part of my PhD in social psychology at the 
London School of Economics, which is to explore why paediatric bipolar disorder (PBD) has become  
much more common in the US while remaining less so in the UK. As part of the research, I have already 
spoken to 20 American parents. In order to explore similarities and differences in the two cultural 
contexts, I’m hoping to speak to 15-20 parents in England as well. My interest lies in investigating this 
apparent difference in prevalence, and I want to understand your (parental) perspective on your own 
initial sources of knowledge about pediatric bipolar, experiences negotiating the period before they had 
an official diagnosis (such as interactions with various professionals), issues related to accessing support 
(both professional and social) and treatment post-diagnosis, and perceptions of stigma. I hope to get a 
sense of how PBD is understood and communicated by different groups. 
 
Why you have been invited to participate: 
 
You have been invited to participate as the parent of a child up to the age of 18 who has been given the 
diagnosis of bipolar disorder. It is completely up to you to decide to join the study. If you do agree to 
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take part, I will then ask you to sign a consent form. You are free to withdraw at any time, without giving 
a reason and this would not in any way affect the care you or your child receives.  
 
Details of your involvement: 
 
This project is based on interviews with participants. If you decide to participate, we would go through 
any further questions you may have about the research in general, or my project in particular, and then 
discuss the informed consent sheet that has been provided. We would then decide if you were able to 
meet in person, or if a telephone interview would be preferable. Pending your consent, the interview will 
be recorded and last from 45 minutes to one hour. There would be no expectation to answer all of the 
questions, and you would be free to stop the interview at any time.  
 
Questions asked would be related to how you first heard about the PBD, what kind of treatments have 
been made available and how you feel about them, how much you knew about PBD before your family’s 
own experience, and your experiences accessing support from Other parents, schools and mental health 
professionals. At the close of the interview, you will be invited to receive a copy of both the final report, 
as well as the written transcription of our conversation to see if there is anything you would want to be 
further anonymised, or omitted altogether.  
 
There would be no expectation of a follow up, however I am happy to stay in touch and provide updates 
on the research, or answer further questions. If the decision was made to withdraw before any formal 
write up or publication, the transcription of your interview would be destroyed and any included 
quotations omitted. If you decide to withdraw after a piece has been submitted for publication, data 
collected prior to withdrawal will need to be included, though quotes will be removed and data destroyed 
prior to any future inclusion. 
 
Risks and benefits to participation: 
 
As this can be a difficult and private topic, there is a risk that when asked to reflect on your experiences 
about your child’s diagnosis you may feel upset. It is my aim to be sensitive to this and not ask too 
personal, probing questions. If this should happen in the course of conversation, you should feel free to 
stop answering at any time. I will of course move on to a different topic. I am also happy to provide a list 
of resources available offering parental support. 
 
The benefit would be contributing your experience to the debate surrounding PBD. In addition, though 
sharing your story you can raise awareness, offer hope and decrease stigma with others parents who may 
be just starting this journey. 
 
What if there is a problem: 
 
If you have a concern about any aspect of this study, you can contact me directly at 07954 210294 and I 
will do my best to answer your questions. If you remain unhappy and wish to complain formally, there 
are several options. 
 
First, you may contact my academic supervisor, Professor Sandra Jovchelovitch: 020 7955 6863 
 
If you wish to make a complaint to my university, you may contact the director of the LSE research 
division, David Coombe: 020 7955 7114 
 
Finally, if you wish to complain to the NHS about an aspect of this research, you may contact the 
complaints manager for the Oxford Health patient liaison officer via email: PALS@oxfordhealth.nhs.uk 
or by phone at 0800 328 7971. 
 
Confidentiality: 
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All information that is collected about you during the course of the research will be kept strictly 
confidential, and any information about you that leaves the CAMHS site will have your name and address 
removed so that you cannot be recognised. I will be the sole individual responsible for collecting, 
recording and transcribing the interviews that make up the data for this project. Participants will be 
anonymised at the point of transcription, and identifying details of the individual or the location will 
likewise not be included. Instead of using names, participants will be referred to by a unique number 
code. 
 
Immediately following the interview, the recording will be uploaded to the secure LSE server that only I 
have access to via remote desktop where the data will be kept secure. Anonymous transcripts of our 
interview will only be accessible to myself and my academic supervisor for purposes of monitoring the 
progress of the research. Additionally, if you allow it, anonymous quotes from our interview may be used 
in future publications or presentations.  
 
The interview transcripts will be retained for a period of five years to allow for the completion of the 
PhD and related publications. While I intend to finish within the suggested three-year time frame, the 
publication and dissemination of findings to take place after the period of analysis means the data will 
need to be stored for a period of longer than three years. Following Medical Research Council guidelines, 
the data will be held for five years after which time I will be responsible for destroying it. 
 
What will happen to the results of the research study? 
 
The results will be written up as part of my PhD thesis. In addition, results may be included in academic 
journal articles and conference presentations. 
 
Who has reviewed this study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given a favourable opinion by 
Derby Research Ethics Committee. In addition, the research ethics committee in the Institute of Social 
Psychology, London School of Economics and Political Science has approved the project. 
 
Further Information and Contact Details: 
 
General information about research:                                                                                                         
Oxford Health Patient Advice Liaison Service (PALS): 0800 328 7971 or PALS@oxfordhealth.nhs.uk 
Specific information about this research project: 
Jane Roberts (researcher): +44 (0)7954 210294                                                                 
 j.roberts7@lse.ac.uk 
As a participant in this research, you will be given a copy of this form to keep, along with a signed copy 
of the attached informed consent. 
Thank you for your consideration. 
Jane Roberts, MSc 
PhD Candidate 
Department of Social Psychology 
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Appendix 3: Recruitment letters to Young Minds- English Parents 
 
 
    
    
YoungMinds 
Suite 11, Baden Place 
Crosby Row, 
London, SE1 1YM 
 
1st March, 2013 
 
To Whom It May Concern, 
I recently contacted YoungMinds regarding my research looking at the diagnosis of bipolar 
disorder in children in the US as compared to the UK. As part of the project I am looking to 
interview parents (as well as child psychiatrists) about their experiences. I understand that 
this is a sensitive topic, and I understand the importance of confidentiality, so I suggested 
that I might put together a pamphlet about the project with my contact information in the 
event that anyone was interested. The Parent’s Helpline Advisor who responded 
mentioned I might send you the pamphlets to be included with information to be sent out 
to parents requesting information. I have enclosed some of these and wonder if this might 
be possible? 
Please don’t hesitate to contact me with any questions.  
 
Yours Sincerely, 
 
Jane Roberts                                                                                                            
MPhil/PhD Candidate 
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Institute of Social Psychology 
London School of Economics and Political Science 
Houghton Street 
London 
WC2A 2AE 
J.Roberts7@lse.ac.uk         
 
                                                                                                                                                                                                              
 
     
    
                                                    Paediatric bipolar research 
Hello, 
I am currently a PhD candidate in the Institute of Social Psychology at the LSE 
where I’m in the initial stages of research looking at the diagnosis of bipolar 
disorder in children in the US as compared to the UK. In the last twenty years, the 
diagnosis has become increasingly common in the US, while here in the UK there 
seems to be a resistance to the diagnosis, at least  on a clinical level,  despite an 
increase in parents seeking treatment for their children who are suffering with 
what they feel is more than just depression or anxiety. I’m interested in exploring 
why there is such a big difference between these two countries.  As part of my 
research I will be looking to interview both parents and child psychiatrists in the US 
and UK about individual experiences, and to get a sense of various factors at play in 
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knowledge surrounding bipolar in children generally, as well as attitudes 
surrounding available treatment options. 
As someone who has contacted the YoungMinds parent helpline, I wanted to pass 
this pamphlet on to you in the event that you might consider participating. Even if 
your child hasn’t been formally diagnosed, I would be interested in hearing what 
your experience has been so far.  
This project has been approved by the ethics committee at the Institute of Social 
Psychology at LSE and, in accordance with those standards, all contact will be 
confidential and any record of conversation anonymised. If interested, I would be 
looking to conduct an interview lasting about 45 minutes, either in person (if in the 
vicinity of London) or over the telephone. 
Please feel free to contact me with any questions or for more information via email 
at: J.roberts7@lse.ac.uk 
Yours Sincerely, 
Jane Roberts 
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Appendix 4: Recruitment letter to MD Junction- English parents 
Submitted via online form 
 
April 23, 2013 
To Whom it may Concern: 
I was recently in touch with one of the bipolar forum group leaders who suggested I 
contact you directly. I am currently a doctoral candidate in Social Psychology at The London 
School of Economics where my research is looking at comparisons in the diagnosis of 
childhood bipolar disorder between the US and UK. For my research, I have been 
interviewing psychiatrists in both contexts, but I think it is important to get the perspective 
of parents as well, as they are the ones living with the unfamiliar behaviour and are 
responsible for negotiating health care systems in search of appropriate information and 
treatment for their children. It is my understanding that the experience of parents in these 
two cultural contexts is quite different, with parents in the UK encountering a higher level 
of clinical resistance to the idea of the diagnosis, making it difficult to begin treatment in 
children under 18. In speaking to parents, I would seek to understand similarities or 
differences in accessing care and types of treatment, as well as understanding cultural 
differences related to levels of social support and acceptance for their child’s diagnosis. 
I am writing to request permission to make one- time posts on both the UK BP forum page, 
as well as the more general BP forum. It is not my intention to contact users directly, rather 
I am seeking permission to post a description of the project along with my contact 
information and leave it to the parents to decide if they want to make contact with me. 
The project has full ethical approval of the governing body at The Institute of Social 
Psychology at LSE, and in accordance with this, all information from those interviewed will 
be confidential and anonymous. 
Thank you for your consideration, and I look forward to hearing from you. 
With Best Wishes, 
Jane 
Jane Roberts, MSc 
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Appendix 5: Participant Information sheet- parents, United States 
 
 
The London School of Economics and Political Science 
 
                                                                                                  Institute of Social Psychology 
St. Clements Building 
Houghton Street 
London WC2A 2AE 
       Tel:  020 7955 7712 
    Fax: 020 7955 7565 
 
 
18 June 2013 
 
 
To Potential Participants: 
 
I'm currently a first-year PhD candidate in the Institute of Social Psychology at The London School of Economics 
and Political Science (LSE) where my research is looking at the diagnosis of pediatric bipolar disorder in the US as 
compared to the UK. Central to my research are questions surrounding why it has expanded so rapidly in the context 
of the US, while there seems to be a level of resistance, at least on a clinical level, here in the UK, this despite 
increasing frustration on the part of parents unable to get the disorder recognised in their children. In trying to 
understand factors contributing to such a disparity, I hope to get a sense of how the disorder is understood and 
communicated by different groups in these contexts and, and that conversations with those who are directly involved 
with PBD, whether as family, clinicians, or researchers may shed some light on the phenomenon and the personal 
experiences behind the debates. 
 
As part of the research I’m hoping to speak to parents in the US and UK about their own initial sources of 
knowledge about pediatric bipolar, as well as experiences negotiating the period before they had an official diagnosis 
(such as interactions with various professionals), and issues related to accessing support and treatment post-
diagnosis. Interviews would be conducted over the phone or in person if you were willing.  Pending your consent at 
the start of the interview, the interview will be recorded and last around 45 minutes. There would be no expectation 
to answer all of the questions, and you would be free to terminate the interview at any time. Anonymity and 
maintaining confidentiality are of the utmost importance. For this reason any identifying details such as names, 
locations, schools etc. will be anonymized when transcribing the interview, and participants will be referred to by 
code, for example the first parent I speak to in the US would be USP01, and so on. The recordings are destroyed 
after being transcribed, and the remaining anonymous data is to be stored on the secure servers at LSE which is 
password protected, and only I have access to. Similarly, consent forms will be stored in a locked cabinet in a locked 
office at LSE, which again, only I have access to. 
 
I will be in the US from Tuesday June 25th through Friday August 9th. While there, I can be reached by phone at 773-
396-8318.  
I will be in the UK after the 9th of August and can be reached by phone at 011+44+ (0) 7954210294. I can be 
reached via email at all times: j.roberts7@lse.ac.uk . 
 
I invite any you to contact me with any questions you may have prior to deciding whether or not to participate. 
The project has received ethical approval from the committee within the Institute of Social Psychology at LSE. 
 
Thank you for your consideration, and Best Wishes, 
 
Jane 
 
Jane Roberts, MSc 
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Appendix 6: Informed consent 
                                           The London School of Economics and Political Science 
 
 Department of Social Psychology 
St. Clements Building 
Houghton Street 
London WC2A 2AE 
       Tel:  020 7955 
7712 
    Fax: 020 7955 7565 
 
Participant Identification code:  
5th November 2014: Version 4 
REC Ref No: 13/EM/0313 
 
CONSENT FORM 
 
Title of Project: Paediatric Bipolar Disorder in the US vs. UK 
 
Name of Researcher: Jane Roberts (j.roberts7@lse.ac.uk) 
 
Academic Supervisor: Professor Sandra Jovchelovitch (s.jovchelovitch@lse.ac.uk) 
 
Please initial box 
 
 
1. I confirm that I have read and understand the information sheet for the above study. 
I have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without mine or my child’s medical care or legal 
rights being affected.  
 
3. I understand that data collected during the study may be looked at by individuals 
from the London School of Economics where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to this data. 
 
4. I agree to allow the researcher to audio record the interview and allow use of 
anonymised quotes in presentations and publications. 
 
5. I agree to take part in the above study. 
 
 
 
______________________  _________ ___________          
Name of Participant   Date Signature 
 
 
______________________  _________ ____________ 
Researcher    Date  Signature 
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When completed, 1 for participant; 1 for researcher site file 
 
Please provide contact information below if you would like to receive a copy of the 
transcription or final report: 
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Appendix 7: Interview schedule- parents 
 
Project Title: Paediatric Bipolar Disorder in the US vs. UK 
 
Interview Schedule 
 
Introduction and developing rapport: 
 
I want to thank you again for agreeing to participate and share your experiences.  
Just in terms if a time frame, I anticipate this interview lasting for about 45 minutes. 
Will this work for you today? 
 
I know you’ve had a look at the information sheet and consent form already, but I 
thought I would begin by just telling you a bit more about the research, what I’ve done 
so far, and why I’m glad I can talk to you today (discussion) 
 
Do you have any questions for me at all before we begin?  
 
Body: 
I’d like to ask you some questions about your experiences related to the time leading up 
to your child’s diagnosis, as well as how things have been since that time. Maybe I 
could begin by asking how old your son/daughter was when they were first diagnosed 
with bipolar. 
 
Can you describe what it was like for you and your family before your child received 
the diagnosis? 
Did you have a sense of what was wrong? 
What sorts of things were you being told? 
 
Had you heard of Paediatric bipolar disorder prior to your family’s own experience 
with it?   
If not, how was it described to you? 
If so, where had you heard about it? 
 
Can you talk about how you felt on learning of the diagnosis?   
 
How would you say things changed after they were diagnosed? 
 
Transition 
 
Can you tell me a bit about your experiences seeking help and accessing services for 
your child? 
 GP/psychiatrists 
 Teachers  
 Other mental health professionals 
 
Can you describe the treatments that have been made available to your child and how 
effective you find them? 
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 Psychosocial interventions- focus on the child or heavy family involvement? 
 Feelings about medication? 
 
Do you feel you’ve had access to positive social support?  
If so, where have you found it? (e.g. peer support groups, online, family) 
  
Do you feel your child (if old enough) has the support he/she needs? 
If not, what would you like to see? 
 
What are your thoughts generally on stigma surrounding children’s mental health in the 
US/UK, and PBD in particular? 
 
If you were to hazard a guess, how do you imagine things are different for parents in 
the US/UK (country Other than where participant is from)? 
 
Transition 
 
I know this is a bit broad, but if you were to try and describe childhood bipolar to 
someone who had never heard of it before, what would you say? (you can be as specific 
or abstract as you wish) 
 
What tips might you have for parents encountering this for the first time? 
 
 
Conclusion: 
 
I don’t have any more questions, but I’m wondering if there is anything I may not have 
touched on that you would like to add? 
 
I want to thank you again for being so generous with your time. I’ll be in touch soon 
with a copy of this transcription (if requested) which you can review. That way if you 
come across anything that you would like further anonymised you can let me know. 
Otherwise, feel free to be in touch generally with any questions. 
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Appendix 8: Interview schedule- clinicians 
 
Introduction and developing rapport: 
 
I want to thank you again for agreeing to participate and share your experiences.  
Just in terms if a time frame, I anticipate this interview lasting for about 45 minutes. 
Will this work for you today? 
 
I know you’ve had a look at the information sheet and consent form already, but I 
thought I would begin by just telling you a bit more about the research, what I’ve done 
so far, and why I’m glad I can talk to you today (discussion) 
 
Do you have any questions for me at all before we begin?  
 
 
Body: 
 
I’d like to ask you some questions about your experiences related to the …Maybe I 
could begin by asking you just to tell me a bit of what you do here at xxx? 
 
 
In your practice do you see kids w/ PBD? 
 General ages? 
 
 
What sorts of changes have you noticed regarding mental health in children over the 
course of your career? 
 
When/ how did you first start hearing about PBD? 
 
What do you think causes PBD? 
 
How do your young patients arrive in your office?  
 Parent/teacher/GP concern? 
 
Are you often the source of initial knowledge about the disorder, or do the parents 
have some understanding already? 
 
 Where do you think their knowledge come from? 
 
Are you able to tell me how parents, or children if they’re old enough, react to the 
diagnosis? 
 
What are some of your approaches to treatment? 
 Attitudes towards medication? 
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Brief discussion of verbal vignette presented in which a child’s behavior (taken from parental account of 
child with bipolar) is described and clinician asked to reflect on how they would respond to such a child 
in their office. 
 
In your opinion, why is it so contested a diagnosis? 
 
What do you think it is that drives this difference of opinion? 
 
Do you have any ideas about why it might be more recognised in US but not UK?  
 
Any sense of how your professional colleagues in the US/UK think about PBD? 
 
Conclusion: 
 
I don’t have any more questions, but I’m wondering if there is anything I may not have 
touched on that you would like to add? 
 
I want to thank you again for being so generous with your time. I’ll be in touch soon 
with a copy of this transcription (if requested) which you can review. That way if you 
come across anything that you would like further anonymised you can let me know. 
Otherwise, feel free to be in touch generally with any questions. 
 
 
Appendix 9: Coding frame- pharmaceutical industry internal documents 
 
        
CODES 
BASIC THEMES 
ORGANISIN
G THEMES 
GLOBAL 
THEMES 
High cost of hospitalization       
mental illness a drain on 
resources 
1.1.1  
Pressure to expand indications 
for     
stagnant mkt for antipsychotics 
medications in face of  
competition and economic 
pressure     
medication's benefit to society 
 
1.1 The voice 
of Pharma 1. SELF 
context of US marketplace   ('I' position)   
European market       
Medicaid -Medicare       
external economic pressure       
FDA as a potential threat       
goal of expanding market to 
children       
Increase awareness to increase 
prescription rates       
off label prescribing-defense of 1.1.2  
Need for use of indirect 
marketing practices     
off-label promotion denial of to 'get the word out' about PBD 
as a diagnostic category     
off-label promotion pushing 
 
    
strategic collaboration with 
clinicians       
Advocacy groups to influence       
education of primary care 
phys.and psychiatrists       
influence and persuasion of sales  
reps        
influence and persuasion from 
reps to clinicians       
development of 
opinion/knowledge leaders       
education of pharma reps       
sell symptoms not disease states       
publications and presentations to 
validate and influence       
advisory committees to educate 
and influenced       
focus on symptoms not diagnosis       
incentives to promote PBD in 
children       
aggressive treatment warranted to 
reduce future risk       
expansion of approved indication       
threat-Seroquel/Astra Zeneca       
threat- Risperdal / Johnson & 
Johnson 
2.1.1 
Other companies and their 
2.1 Industry 
Competitors   
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medications a constant threat 
threat-Zyprexa /Lilly 
 
    
industry-wide competition       
perceptions on industry       
perceptions of medications       
Maintain credibility through 
message of dependable 
medication      
2. 
OTHERS 
Expand approved indications of 
medications       
incentives to promote PBD in 
children 
2.1.2  
Need for differentiation from 
competition     
focus on symptoms not diagnosis       
strategic collaboration       
potential as paid speaker as 
incentive to prescribe 
2.2.1  
Essential to have on board as 
'opinion leaders'     
education about symptoms for wider validation of diagnosis 
of PBD     
instil confidence in  idea of 
diagnosing and prescribing   2.2 Clinicians   
reassurance they are doing what's 
best for patient       
development of diagnostic fact       
defining PBD       
parents need validity to accept 
diagnosis       
Increase awareness to increase 
Rx       
Manipulation of trial data       
justification and defence of off 
label practices 
2.2.2  
Relied on for knowing how best 
to     
PBD as a "difficult condition" diagnose and treat PBD     
focus on symptoms not diagnosis       
promote notion of reassurance 
from Rd. to patient       
bipolar in kids easy to miss       
business and marketing trumps 
science and research 
2.3.1  
Unmet need and opportunity     
expansion of sales       
bipolar behaviours increasing 
occurrence in physicians offices       
Increase awareness to increase 
prescription   2.3 The child   
Manipulation of trial data       
paediatrics as 'fastest growing 
market'       
ADHD anchors PBD       
Conduct disorder anchors PBD 2.3.2  
suffering from debilitating 
disorder made up of     
rage, irritability, aggression as "constellation of diseases"     
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main symptoms in kids 
psychosis need not be present       
focus on symptoms not diagnosis       
misdiagnosis and uncertainty       
No previous history of depression 
needed       
 
 
 
 
 
 
 
 
 
Appendix 10: Coding frame and sample analysis, pharmaceutical advertisement 
 
                           Variable                              Value 
1. Image type 1.1 photo 
1.2 illustration (drawing) 
1.3 cartoon 
 
2. Social distance 2.1 intimate 
2.2 close personal 
2.3 far personal 
2.4 close social 
2.5 far social 
2.6 public 
3. Pictorial elements 3.1 bright 
3.2 muted 
3.3 dark 
3.4 size 
4. Age 
 
4.1 child 
4.2 adult 
4.3 elderly 
5. Gender 5.1 male 
5.2 female 
6. Role represented 6.1 parent 
6.2 teacher 
6.3 student 
6.4 son/daughter 
6.5 patient  
6.6 Unknown sufferer 
7. Individual manner 7.1 physical poses 
7.2 expression 
8. Setting 8.1 home 
8.2 school 
8.3 unknown/not indicated 
9.  Text 9.1 content/tone 
9.2 position 
9.3 size 
9.4 prominence 
10.  Appeals 10.1 emotional 
10.2 factual/ scientific 
10.3 aspirational 
11. Normative values 11. 1 achievement 
11.2 social belonging 
11.3 control (Self or clinical) 
11.4 active 
11.5 obedient 
(Template as presented by Bell 2001) 
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                           Variable                              Value 
1. Image type 1.2 illustration (drawing)- artistic, dark 
 
2. Social distance 2.2 close, personal 
 
3. Pictorial elements 3.2 muted 
3.3 dark 
3.4 size- double page spread 
4. Age 
 
Not clear- young adult?? 
5. Gender 5.2 female 
6. Role represented Self as delusion - half woman-half dog 
7. Individual manner 7.1 physical poses- woman morphing into 
a dog, crouching low to the ground. 
 
7.2 expression- eyes closed, unaware, out 
of it, removed. 
8. Setting 8.3 unknown/not indicated 
9.  Text 9.1 content/tone- blurb about the 
character, Amelia, and her delusions- a 
window for clinicians into Amelia’s mind. 
The blurb serves to reinforce the slogan at 
the bottom, about relapses being a living 
nightmare. 
 
9.2 position- tiny font at top so you really 
have to get up close to read about 
Amelia’s delusions. Prescribing info off to 
the side and easy to ignore. 
 
9.3 size/ prominence- unobtrusive 
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10.  Appeals 10.1 emotional- very much in the image. 
Fear, depth of pain that delusions must 
bring. Text attempts to bring viewer in to 
a shared experience. Aimed at prescribing 
clinician viewer- get inside the experience 
10.2 factual/ scientific- none 
11. Normative values Losing control; antisocial behavior driven 
by fear;  
 
 
This is a very dramatic ad, presented almost as a work of art. The text at the top 
of the ad: “Amelia, virtually housebound through fear, believes that when she 
goes out she’s followed by a menacing black dog. And that the dog and her 
coalesce.” Is presented in a very small font, inviting the viewer in close, perhaps 
suggesting they get close to her delusion. An invitation to share her fear. The 
premise of this ad is that relapses are a living nightmare, though it’s never 
specified what the relapse refers to- schizophrenia? Something else? The 
overall tenor of the ad is unsettling, fear, going deep into wild delusions, a living 
nightmare. The woman appears to be young, her expression one of remove, 
perhaps lost in her delusion, unaware of the world around her. The ad is edgy 
and alternative and relies on the image and cryptic text to make its case with 
very view other indicators. Dark, foreboding. This time the light in the image 
appears to be a hazy glow coming from below. Mythology- shapeshifting- 
confinement and restraint- metamorphosis- horror.  
              
 
 Associations: extreme otherness; uneasiness;  
 Addressivity: clinician/ viewer. Vague 
 Cultural knowledges required? Equating otherness/ delusion with fear. 
This is not a culturally universal approach, therefore this ad plays on the 
assumption that this image, and connotations will have effect of wanting 
to ‘fix’ the delusion. 
 
 
 
 
 
 
 
Appendix 11: Coding frame, US clinicians 
 
CODES 
BASIC THEMES 
ORGANISING 
THEMES 
GLOBAL 
THEMES 
early career influences and 
opportunities       
fear of missing something       
better at diagnosing; previously 
under-recognised 
1.1.1  
Uncertainty surrounding 
diagnostic     
cautious and reasonable in 
approach to diagnosis 
criteria  leads  to increased 
recognition 1.1 'I' position-   
acknowledging the controversy   US clinical Self 1. SELF 
same symptoms, different 
diagnoses by Other clinicians       
what do we call this?'       
clinician duty of care 
1.1.2  
The importance of expertise     
 helpful to the parent, teaching 
parenting skills etc.       
 understanding of what is being 
seen       
risk if left untreated       
Disengagement with the 
controversy       
Justification for medication        
Working in conjunction with 
parent       
parental diaries/logs relied on       
Parents asking about diagnosis 
2.1.1 
 Parents as co-constructors 
of knowledge     
what parents see as a need   2.1 On parents   
BP parent not wanting same thing 
for the child 
2.1.2  
Parents as voice for the 
child     
accounts of behaviour at home       
Relief at diagnosis        
 explanation for child’s behaviour       
child lacks appropriate  
vocabulary        
Parent-child mismatch  
2.1.3 
 Parents as victims 'held 
hostage' to diagnosis     
beaten down     2. OTHERS 
repercussions of illness without a 
name       
At the mercy of  child’s behaviour        
confused, misinformed       
judged by Others       
rage, irritability       
emotionally and behaviourally 
dysregulated. 
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clinical distance 
2.2.1  
child as a cluster of 
symptoms     
symptom overlap with ADHD 
  
2.2 On the 
child   
Parental accounts of behaviour       
sadness/depression       
Same behaviours seen in a 
different way       
social risks       
cognitive risks 
2.2.2  
at risk and in need of early 
intervention     
‘emotional lability’       
in best interest of the child to treat 
early        
Role of parent significant       
management of early symptoms       
behaviours as symptoms       
As a threat       
Defensive   
  
2.3 on clinical 
colleagues   
doing disservice to child 
2.3.1 
 lack of consensus, unity of 
field     
clinical mastery       
what's at stake       
disagreement over symptoms and 
presentation       
forced to justify own position        
pharma as a necessary evil       
 hands are tied       
Caught in middle 
2.4.1  
subjective values up against 
professional 2.4 on Pharma   
Clinical distancing reality     
strong influence needed for 
funding       
rationalization through suffering 
child       
justification for medications       
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Appendix 12: Coding frame, English clinicians 
CODES 
BASIC THEMES 
ORGANISING 
THEMES 
GLOBAL 
THEMES 
nervous about making the 
diagnosis       
stigma through labelling 1.1.1  
Interdependence and 
caution     
second opinion       
risk   
1.1  
Reflexive clinical 
'Self' among 1. SELF 
reflection on practice   colleagues   
position as educator       
clinical mastery       
 wider community of practice       
caution with regards to labelling 
a young person       
Judgement of colleagues        
perception of US feeling UK is  
behind       
US as source of knowledge 
about PBD 
1.1.2  
Positioned against 
American colleagues     
awareness/recognition of PBD 
 
    
differing prevalence prevalence 
rates       
broad spectrum v. classical 
presentation       
Stereotypes       
US is drug company led       
 over reliant on medication       
 English scepticism       
conflicted attitudes towards US       
sceptical of parents seeking the 
diagnosis       
seeking reassurance/removal of 
blame 
2.1.1  
Parents as seekers  of 
knowledge 2.1 On parents   
level of knowledge about PBD 
not deep       
parental investment in medical 
explanation        
parent seeing child as  ill 
2.1.2  
clinician distanced from 
parent-child dyad   2. OTHERS 
psychoeducation for both parent 
and young person 
 
    
 parent/child interaction a factor 
in behaviour       
pharma a 'pernicious' influence 
2.2.1 
 Encroaching threat, 
vested interest     
fatalism and inevitability       
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active resistance   
2.2  
On the 
pharmaceutical 
industry   
link w/ American colleagues       
dominance of US led research       
UK:  space for non-pharma 
treatment 
2.2.2 
Trusting the familiar, 
resisting the unfamiliar     
drug company financed research                 
openly sceptical       
pharmacotherapy in children 
very recent phenomenon       
social adversity       
multiple factors shaping a child's 
behaviour 
2.3.1  
Child as part of a wider 
social context     
desire to understand "the whole 
child"       
hidden factors contributing to 
behaviour    2.3 On the child   
        
age of child       
uncertainty 
2.3.2 
 PBD not distinct from 
adult BP     
manic-depressive psychosis       
Self-harm/ suicide attempts       
severity       
classic presentation       
psychosocial approach before 
medication 
2.3.3  
Giving child  a voice     
hopes and fears         
feelings about medications       
experiences with friends       
move beyond control of 
symptoms       
recast Self-image       
unpacking narrative, meaning       
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Appendix 13: Coding frame, US parents 
CODES 
BASIC THEMES 
ORGANISING 
THEMES 
GLOBAL 
THEMES 
knowledge as leverage       
shared experience with child 1.1.1  
'Us v. them': Valuing 
experiential knowledge and  
expertise     
integration of subjective 
experience into child's illness 
trajectory                
parents know best 
  
1.1 Position of the 
American parental 
‘Self’ 1. SELF 
development of  knowledge 
essential   
 
  
need for mastery, control       
need to be taken seriously       
power struggles with 
professionals       
need to be a pushy parent       
education of others 1.1.2  
Proactive advocate     
what's best for child       
sense of purpose       
need for a solution       
gradual acceptance after initial 
discomfort       
validation of decisions made on 
behalf of child       
"gifted" child       
angry child with a heart of gold 
2.1.1  
True nature of child obscured 
by diagnosis 2.1 The child   
caring and affectionate 
underneath it all       
have to perform illness       
diagnosis to access assistance       
never know what you're going 
to get       
fear       
child in control 
2.1.2  
Unpredictability and 
control     
no sense of what is normal     
2. 
OTHERS 
removal of responsibility        
medication is a choice you 
have to make       
wish it wasn't needed but its 
reality 
2.1.3  
Medication as an 
unavoidable necessity     
not in control of their brain       
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 help child who is suffering       
treat now to prevent future risk       
fall apart when off medication       
ashamed       
"at a loss"       
multiple clinicians consulted to 
find right 'fit'       
lacking support 
2.2.1  
Feeling ignored, patronized, 
dismissed     
unreturned phone calls       
dismissive attitude       
feel judged by professional       
disdain       
on our own'       
enraged       
nobody would help us   2.2 Clinicians   
professionals nothing more 
than prescription fillers 
2.2.2  
Questioning clinical expertise     
 lack of professionalism       
clash of expertise       
desperate for answers       
lack of recognition of child's 
behaviour as 
problematic/illness       
 lack appropriate 
awareness/knowledge       
use of professional terminology 
2.2.3 
 Internalization of clinical 
expertise     
need/justification for early 
intervention       
establishment of workshops to 
educate Others        
increased certainty       
blamed for bad parenting 
2.3.1  
Judgement, conflict and a 
lack of support     
parents of non-BP kids can't 
understand- naïve   
2.3 Other parents 
(peers)   
parents of BP kids in support 
groups too 'victim' oriented       
Need for education of other 
parents       
perpetuation of stigma 
stemming from fear       
feeling isolated from other 
parents, family       
Difference of opinion with father 
of child       
good teacher is a receptive 
teacher       
reliance on school/teacher to 
monitor child 
2.4.1   
Collaborative alliance     
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need to educate teachers   2.4 The school   
accommodation- Indiv. 
education plans       
scholastic attention tied to 
specific diagnoses       
need to pushy to get child the 
help they need 
2.4.2  
Constant struggle     
constitutional right to education'       
school shirking duties       
 BP child is 'tarnishing' school's 
reputation       
 emphasis on negative to 
access services       
don't take responsibility       
no appropriate structures in 
place to deal with BP kids       
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Appendix 14: Coding frame, English parents 
 
CODES BASIC THEMES 
ORGANISING 
THEMES 
GLOBAL 
THEMES 
eager to hear Other's 
experiences       
guilt 1.1.1 Feeling like amateurs     
Self-blame       
overlooked early symptoms   
1.1 The voice of 
English Parents  1. SELF 
not an expert        ('I') position   
trying to understand       
every decision is the wrong 
decision       
not allowed to be an expert       
desire for certainty       
little understanding of mental 
illness 
1.1.2 Ill- informed and lacking 
support     
not enough done to inform 
parents       
Need to act like 'pushy middle 
class parent'       
BP the same as 
Schizophrenia?       
no prior knowledge of BP in 
kids       
GP unsure how to assess       
GP assured everything was 
fine       
not allowed to be an expert 
2.1.1 Disappointment and 
frustration 
2.1 Interacting with 
clinicians   
forced to go private to get 
adequate support       
lack of information       
lack of appropriate resources       
professionals unsure how to 
handle child       
GP not supportive       
    nobody would listen       
Parents have no control       
lack of consultation with 
parents-'system' took over     
2. 
OTHERS 
GP didn't delve deep enough       
symptoms not  thought of as 
being BP       
pos. interactions equate 
w/being heard       
refusal to validate what parent 
is seeing       
power dynamics 
2.1.2 Faced with a 
reluctance to diagnose     
CAMHS wouldn't consider BP       
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in a child 
public v. private treatment       
age of child a factor in what is 
seen       
take PBD seriously       
US approach to mental health 
envy of the world 
2.1.3 Perception of 
American clinicians as      
open to understanding MI in 
children more knowledgeable     
criminalization of MI in UK       
denial that child is mentally ill       
symptoms of paranoia 
2.2.1 Lack of certainty 
over what is normal     
normal adolescent behaviour?       
quick shift- normal to severe 
psychosis   
2.2 Interaction 
with voice    
thought child too young to be 
diagnosed   of the child   
personal v. professional ideas 
of what is wrong       
Dx reason for decline in 
interest in school       
stressful family dynamics as 
trigger 
 2.2.2 Social pressures as 
triggers leading to     
bullying as a trigger            diagnosis     
change in friend groups       
high achiever       
 Appendix 15: Sample excerpt, dialogical analysis 
 
I had a child under my care who I had diagnosed with BPD. Teenager. And I was 
treating him with medications for BPD, and he had a relapse and overdosed on one of 
his medicines, went to the hospital, was hospitalized at a local psychiatric hospital, and 
the doctor there said “well, this is a boy that’s depressed, but I don’t see the bipolar” 
and I said, “well he’s not manic now. He’s depressed now. He has a history of mania”. 
(Doctor:)”I heard that history and I don’t think it sounds like bipolar disorder”. And so 
the doctor told the patient and the mother “I don’t believe Dr. (Interviewee) has the 
correct diagnosis. I think you should take an antidepressant. Here’s Prozac.” And they 
discharged him on Prozac. That was February. It’s now July. I decreased the Prozac 
dose because after several months he started to seem more agitated and irritable, and 
last week, and now he’s smoking marijuana every day, so his drug use has picked up, 
and so he went to the emergency room. He wanted help, because he goes nights 
without sleep, he’s very agitated, he’s exploding with his mother, he’s been making odd 
sexual comments to her. Well what is that? He’s got bipolar disorder. So, they tried to 
rehospitalize him, he didn’t want to stay, so he left after a day, and the doctor there said 
“I don’t think you have BP disorder, I think you have depression” Well how - aren’t 
they hearing these same facts?! (USC7) 
 
Representational processes at work  
 Knowledge encounters 
 Self-other positioning 
 Other dr. anchoring in depression 
 USC 7 objectifying PBD in ‘fact’ 
 Negotiation 
 Validation of position with listener; validation through illustration of child 
suffering from lack of appropriate treatment 
 
 Self-Other positions   
 USC 7- Clinical Self- as voice of reason; expert; intermediary caught 
in middle 
 Other- child as suffering the result of clinical disagreement 
 Other- doctor as stubborn, not fully informed, jeopardizing health of 
young person; causing confusion; positioned as threat 
 
Who is being addressed? 
 Researcher/interviewer 
 Clinician-Self 
 Doctor-Other 
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 Child and parent indirectly 
 
Functions 
 Speaker undermined, seeking alliance of listener; conspiratorial; invitation 
to take sides 
  legitimisation  
 validation 
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Appendix 16 Excerpt from interview transcript 
 
USP5 
July 2nd, 2013 
Duration: 54:31 
 
Can you describe what it was like for you and your family before your child 
received the diagnosis. I know you said in your email that he’s 14 now, but that 
he was diagnosed when he was three, is that correct? 
 
Just before his 4th birthday, yeah. Well for us, we’ve got a really strong family history on 
both sides. My father has BPD and my father in law had it as well, so we knew 
genetically speaking our deck was pretty well stacked, so we knew that we needed to 
keep an eye out for that, but neither my husband nor I have ever been diagnosed with 
BP or any of those correlated illnesses, I guess you could say. Um, so when, A. is our 
first, and I don’t know if you have kids, but when it’s your first, you don’t know 
anything! You don’t know if this normal, if it’s not normal, are they going to grow out 
of this, are they not. In retrospect, there were a lot of things that were very clearly not 
normal. Even when he was in the womb, he was very, like you could watch him get 
agitated, like he would fling himself from one side of my stomach to the other, we were 
like wow! OK, how ‘bout that! When he was born he had a very normal childbirth, 
nothing out of the ordinary, no trauma or anything else, and then I think he was 
probably about 7 months old before he slept through the night at all. Hang on just a sec  
 
(conversation interrupted by child asking to buy a video game online).  
 
Sorry, that’s the youngest of five. So he didn’t sleep through the night at all until he was 
7 months old, so we were like “oh you know, it’s your first, it’s how babies are” really, 
really sensitive to noise. When we moved to Illinois from Utah when he was a baby, as 
I was packing boxes I would do the tape gun, you know just stretch out the packing 
tape and whatever, and he would howl like someone was stabbing him. We would be 
sitting around the table and one of us would burst out laughing, and he’d cry, really 
sensitive to noise. And then when he got more into toddler phase, when everybody 
else’s kids were kind of growing out of the biting thing, his was getting worse, we were 
like “ok, this isn’t so great”. When he was two, I think one of our first, in retrospect, 
clearest indicators when he was just barely two, he had to have steroids for croupe, and 
they made him hallucinate. He was seeing, like, spiders in the air, and, like, big bugs- he 
was trying to catch them and stomp them, and they weren’t there! Something tells you 
 
 
 
 
296 
something when you have a hallucinating 2 year old. Again, in retrospect, I know 
steroids are contraindicated for a lot of people with BPD because it can make them 
hyper-manic. Which, for him, it also made him hallucinate So as he got older and we 
had other children, just the behaviour we were seeing- I mean he would just rage times 
four, ten times a day, 30 minutes at a crack, he would try to rip my hair out of the scalp, 
he would try to gouge my eyes out, and we’re a very non-violent house. I mean the 
most violent input he was getting was Sesame Street, so it’s not like he was watching 
WWF and acting something out. It was all very, very internal. I remember when he was 
three I had cut up a credit card and had put it in the trash, you know, throwing it away. 
He went and found the sharpest piece he could find and hidden it, and then the next 
time he went into a rage he went and got that piece of credit card and was slashing at 
me with it. 
 
Oh my gosh. 
Yeah, it was, it was something. So after three, three and a half years of that, we finally 
said ‘you know what, nothing that we’re doing is helping’ You know, of course we’re 
hearing all the parents saying “he needs more discipline, he needs less discipline, he 
needs a good spanking, if he bites you, bite him back”, you know, all of these things, 
but nothing worked. And we just said, we knew our deck was pretty heavily stacked, if 
it looks like a zebra, and smells like a zebra and eats the same things a zebra eats, maybe 
we need to be concerned that we have a zebra. There’s something going on, so that was 
what led us to seek out professional help. 
 
So you had actually considered that this could be the case given your family 
history when you sought out help. Did you tell them that you thought this might 
be bipolar? 
 
Absolutely, absolutely.  
And can you tell me about the reaction of the psychiatrist- was it a psychiatrist 
that you went to initially? 
 
It was. The very first one we went to, and again, you’re very much tied by who’s in 
network with your insurance, who’s accepting new patients, who’s accepting patients as 
young as your kid, so we went to the first doctor that we could find who fit all of those 
criteria, it was still a good 50 minute drive from us, which, you know, whatever, we 
needed to go somewhere. We told her what was going on and what we saw, and then 
we went to her office, you know, we sat down with her and she said, “right off the bat, 
I need to tell you, I would never medicate a child under the age of six”. I said, “Ok, I 
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hear you” I said “I would rather have a glass of water and a nap, than take a Tylenol 
when I have a headache, I hear you. I’m all for the least invasive approach first, but my 
question for you is this, if that doesn’t work, how do we survive until he reaches this 
magical age of six? Right now as a family we cannot function”. And, you know, he was 
raging, so he couldn’t even take swim lessons. You know he would just sit and glower 
and scowl, he couldn’t even do a lot of the most basic things because he was so 
incapacitated, and she goes “well, I’d really like to start with fish oil” and I said “ok, 
well, by the way, what’s your experience with children with paediatric bipolar disorder?” 
and she goes “oh, well, I’ve read a few articles”. Ok, but remember this was 10 or 11 
years ago, PBD wasn’t being as readily diagnosed back then. I think back then it was 
running about 50/50. 50% of psychiatrists said yeah this is a legitimate occurrence, the 
other half said this is something else, children cannot have BPD, which is maybe what 
you’re seeing in the UK, I don’t know. So she said “well I’d like to do fish oil”. Ok, 
fine. So she had recommended this kind, and after the fact I found out that in general 
with fish oil there’d been- and I don’t know if you know much about fish oil… 
 
I hadn’t heard about it for this particular diagnosis. 
 
Sure, um. In fish oil there are two main components, EPA and DHA and I found out 
later that for BPD, I think the ratio that you want for EPA to DHA is like 7:2 or 7:3 or 
something like that. The one that she had recommended to us was flipped and it was a 
lot higher in DHA than EPA, so we put A. on it and he went hyper manic. I mean, 
much more raging, much more violent, whatever else. I’m going crazy, I’m sobbing, I’m 
trying to call this doctor to get her to call me back, she’s not returning my phone calls. 
I’m now totally in crisis. I called the insurance company in tears saying ‘I need a 
different doctor, this one’s not calling me back, she prescribed the wrong thing’ And at 
this time I have a child that’s one, so it’s not like it’s just him that I’m dealing with. So 
the insurance company then recommended us to a different doctor who, from 
everything I could research at the time, that was his thing. He was really working with 
depression and bipolar disorder, specifically in children and adolescents, so we had 
videotaped A. in one of his rages, because that was another thing, he’s gonna white 
knuckle it if he’s in an environment where he doesn’t feel secure, and he’s going to be 
calm, and he’s going to be, you know, perfect, and wonderful and presentable, so we 
had videotaped one of his rages for multiple reasons, one so we could show the doctor, 
and two, if any neighbours heard yelling, things being thrown and whatever else, and 
reported it, we could show he video and say, ok this is what’s going on, this is what it 
looks like, we’re not beating him, we’re not, we’re not throwing furniture, that would be 
him. So we went to this second doctor, we took him the video, we showed him what it 
looked like, we told him what we’d been through, and this is what we think it is and he 
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said “I agree”. He then made the actual diagnosis, you know “yes, I would consider this 
to be paediatric bipolar disorder” and then started him on meds.  
 
In terms of these rages, would he have them at school or pre-school, or was it 
exclusively in the home?  
 
He started pre- school a month or two after he was diagnosed, ‘cause he was three, he 
had just turned four, but he had turned four like, he’s a September birthday, so he had 
turned four after the start of the school year, so he was fully the oldest kid in his class, 
because if he had been born six days earlier, he would’ve started school a year earlier. It 
was really- I mean it is, and has been, a really long road, and we were with that 
psychiatrist, if memory serves, I think we were that psychiatrist for two years, maybe 
three, and he was clinically good, but his bedside manner was horrible. His last name 
was xxx, but behind his back and to each other we called him grumpyxxx. He was, you 
know, I would call him in crisis and he would just be very curt, and very dry and very 
direct, which, that’s ok but we all felt that we needed a more holistic approach than 
“here’s the pill, goodbye’  
 
So after that we sought out another doctor, and he was almost the opposite, you know 
he was very kind and patient, bedside manner was fantastic, but we felt that he was 
throwing darts. You know, when things would fire up and it was clear that whatever 
meds we were using weren’t balanced or weren’t the right ones, we felt like he would 
throw a dart and go ‘OK, let’s try “plink”… this one!”. One time he had prescribed, I 
think it was Prozac, and I was like, you don’t give antidepressants to people who are 
clearly bipolar, you boost their mania through the roof when you do that! So at that 
point we were frustrated. I think A. was probably 8 or 9 and we said, you know, 
however far we have to drive, we need to go to an expert. We need to go somewhere 
where they’re on the cutting edge of this, where they know what they’re doing, they 
know that they know what they’re doing, and they can really give us a clear cut path, 
because we were just so tired of the “well let’s try this. Oh that didn’t work? Well let’s 
try this! Let’s try that, well how about this!”  
 
So we ended up going to xxx with Rd. P so that was a long drive, but that was really 
worth it. I mean, we went down there 5 or 6 times, and she, he had been on Depakote 
ever since that first diagnosis, and then they kind of played around with a couple other 
things like Pylectol  and a couple other things here and there. She took him off the 
Depakote and said ‘this isn’t working, obviously he’s not working. We’re taking him off 
completely and we’re gonna put him on Risperdal” and we were like, well we’ve already 
tried Risperdal, and I don’t remember if that was the one that didn’t seem to have an 
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effect at all, or if it was one of the ones that made him lethargic, and she said “you 
know, I can’t promise you anything, but if I could, I will come as close to promising 
you as I can that this is going to make a difference” and she said “we’ve got the 
research to back it, we’ve got the data to back it, this is going to make a difference” and 
it did. Ever since then, he has been what I would call medically stable, I’d say 95% of 
the time. I mean, he still has his issues, you know, he’s never going to function as 
normal. He has a lot of Asperger’s type social issues that can’t be medicated out, that 
they’re just part of how his brain functions, but you know, the violence, the rages, the 
massive ups, the depression, they’ve pretty much levelled. I mean he’s very, like I said 
he’s got Asperger’s like social issues, he’s still sensitive to noise a little bit here and 
there, but by and large he can function as a human being. 
 
When he was first diagnosed was there ever any attempt to bring you as the 
parent in to do more psychosocial interventions. 
 
You know, every time we would talk, the doctor would ask, well “what do you do about 
this, and what do you about that, and how do you handle this and how do you handle 
that”. Every single one across the board said, “Wow, I don’t really have anything to tell 
you, you’re doing it already”. We never really got the impression that we should be 
doing this, or we should be doing that, and, you know, I read a lot. So I’ve read The 
Explosive Child and the  book The Bipolar Child, and you know, reading as much as I 
could and trying as many things as I could, just trying to do whatever we could to 
address what he had going on. But I was never- nobody thought that that was ever part 
of the problem. 
 
In terms of social support for either you or for your son, have you found it easy 
to access support? 
 
No. 
 
No? Can you tell me a bit about that? 
 
There aren’t, especially 10 years ago, there was this doubt as to whether or not  children 
could have PBD, so there was a lot of “well maybe its ADHD, maybe it’s this, maybe 
it’s that”, so I didn’t find that there were  a lot of things out there where people were 
saying ‘this is what they need’. I think- I think bipolar disorder kind of became the 
diagnosis du jour after ADHD, and I think now BP is kind of fading out a bit, and now 
its Asperger’s that’s kind of coming in to everybody’s common language, and “oh it’s 
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on the Dateline special”, you know, and there’s a lot more awareness and misdiagnosis I 
would say as well, there just wasn’t much of anything. The only place I found that 
would help sometimes was I was on the board at, it’s called Balanced Mind now, but 
whatever it was before, CABF (child and adolescent BP foundation) which is where we 
heard about your study, there were groups there, but unfortunately what it seemed to 
be a lot of the time was a lot of people getting together and going “oh my gosh, it’s so 
terrible what do we do, oh my gosh it’s so terrible” and, when you’re in crisis, you don’t 
want to hear this, that everybody else is having a terrible time too, you want to hear that 
there’s hope, and I think back then the diagnosis was still fairly new, there weren’t a lot 
of people who could say yeah my child was diagnosed with this 15 years ago and now 
he’s a successful college student or whatever, it was just a bunch of us in crisis going 
“boy, this is terrible”.  
 
Have you found yourself having to defend his diagnosis in conversation with 
people or met anybody who’s openly challenged that? 
 
Oh sure. The biggest issue we had, I would say was the school. He, let me thinking, he 
went to pre -school. He was diagnosed right before he started pre-school, and we 
decided not to say anything. We thought, this is a new diagnosis we kind of suspected 
this, but we don’t want there to be a stigma if there doesn’t have to be. We’re just going 
to keep our mouth shut and do it on a need-to-know basis. Well, he punched his 
teacher in the eye on the first day. It was like ‘ok, I guess that need to know basis is 
right about now’.  So we talked with her about it and she was all ‘oh, I really wish you 
had told me and this, that and the other’ um, he went there for a year. He finished one 
full year and had started the second year when the director pulled me aside and said 
‘we’re very sorry, but he’s not allowed to attend here anymore’. It was a mixed age 
classroom and so the second year he was obviously now the oldest of two ages of kids. 
It was a two year program, but they mix the ages of the kids, and he was very OCD at 
the time. He would get obsessed by odd things like paperclips, or insects, and that 
would be the only thing he would think about, the only thing he would want to do. So 
between that and his outbursts and whatnot, they didn’t feel that it was a safe 
environment for the other kids. At that time we were moving to a different school 
district anyway, and they said, you know ‘we’ll give you all the recommendations you 
need, have him evaluated for special ed. Obviously we’ve seen him now for over a year, 
we will heartily say that he needs services’ whatever.  
 
So when we moved to the different district he did half a year at their pre-K program, 
and then in Kindergarten he went to the regular classroom in the morning and then the 
special-ed kindergarten I the afternoon and continues that through first, second third 
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and fourth grade. But I found that the school was very…it wasn’t that they challenged 
that he had bipolar disorder verbally or outright, but the way that they treated the 
problems that he had really demonstrated that there wasn’t a lot of understanding. 
When he was in first grade, he would hide under the teacher’s desk because it was quiet 
over there and nobody would bother him, but they would send him to the office for it. 
So after, I think this was in first grade, again, he was getting sent to the office all the 
time, his teacher was one year away from retirement, very old school, very “my way or 
the highway” and I remember being called into the principal’s office and her saying 
“well, you know, he’s very manipulative. He gets himself sent to the office on purpose” 
and I said, “you know, I’m not disagreeing with you, I agree it’s probably on purpose, 
but did you ask yourself the next question, the next question is why? Why would he get 
himself sent to the office? Why would he do that? Because it’s quiet? Nobody bothers 
him? He’s not distracted? And if he wants to lay his head down and rest for a few 
minutes? He can do that”.  
 
(interruption in conversation).  
 
So I said, yeah, he’s doing it on purpose behind it. He has a need and it’s not being met. 
He’s smart enough to try and get himself the kind of environment that he needs. So 
there was just a lot of, I mean he was getting suspended him all the time. I mean, some 
kid would jostle him in line, and with his very hypersensitive fear of harm kind of thing, 
you know ‘I’m being threatened’ he would hit the kid and because there’s zero 
tolerance, you’re suspended. Ok, but why?! Why did that happen and what could you 
have structure to prevent it? If you’d structured it so he could walk inside from recess 
two minutes earlier than everyone else. So they would suspend him all the way up to the 
legal limit where they would have to re-evaluate his educational placement, and then the 
clock would reset every January and it would be the same thing, they would suspend 
him, suspend him, suspend him, and then the assistant principal, one of the other times 
he was suspended, she’s sitting there, and of course she’s glowering and whatever and 
she says “young man I want you to come in tomorrow with a totally different attitude!” 
and it was all I could do not to say to her “I would like you to come in tomorrow fifty 
pounds lighter!...because you obviously have a problem. Fix it! Isn’t that what you’re 
telling him?” 
 
So, I really, really, really struggled with the school. I still remember there was this one 
day with the social worker, she called me up, she was in tears she said (name), I finally 
understand. And I said ‘what do you mean?’ and she had been wrestling him to the 
ground and this that and the other, and I told her, if you have to do that then do that, 
but ask yourself how he’s going to feel when you’re done? He’s going to feel horrible. 
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‘cause she’s like ‘I’m just going to let him hit me. I’m just going to let him do it’. I said 
‘you can choose that if you want, but if you do that, he’s going to feel that kind of 
remorse and feel horrible that he did it. You might want to consider avoiding that some 
other way, or addressing that some other way’. And she called me up and she goes “I 
get it now. You’re right” She goes’ I finally told him fine you wanna hit me, hit me” He 
did it, and then he felt the next hour crying because he felt so bad. And I said “thank 
you” and from then on, she was my ally, because she had finally seen for herself that 
this was not a kid that was trying to be horrible. This was a kid who literally couldn’t 
help it. He literally could not help it.  And no amount of carrot or stick was going to 
make that change. 
 
If I’m being generous I would say they did the best they could. We don’t live in a high 
income area. We’re not low income, you know, we’re pretty solidly upper middle class, 
but we have a lot of poor areas within our school district, we have a lot of second 
language learners, we have a lot of kids who are reading at maybe the 10th to 25th 
percentile, they have a lot on their plate, and I get that. There’s a lot of policy that they 
don’t necessarily get to decide themselves, like ‘zero tolerance’. To me that’s a 
community based reaction to things. They want to know ‘it’s zero tolerance if a kid 
does this’. I get that, but I really think in a lot of ways they have their hands full. And 
what do you do with a kid that’s violent? You have to protect the other kids. I get that. 
I would never say that they shouldn’t, but U felt that they were really lacking in 
compassion. They really wanted somebody to blame, and unfortunately that’s not really 
helpful. He always had- I think from second, maybe third grade on, he always had the 
special ed classroom for things like math. He processed things slower academically, 
where he could handle the thinking part of it, but just the processing, or just the 
mechanics of writing were a lot slower, so he would go to a special ed classroom for 
that. He had a one to one aid, I think from 3rd grade on, maybe 2nd grade, I can’t 
remember for sure. So he had a one to on aid, and I really feel like they felt, there’s 
nothing more we can do, and maybe there wasn’t. I don’t think school was meant to be 
the end all, be all fix every problem a parent has with a child, but like I said, I think 
really what was lacking was compassion. I don’t think having a lot of problems should 
be mutually exclusive to also having compassion. 
 
If you were to try and describe PBD to someone who had never heard of it 
before, or someone in the UK who was seeing threatening behaviours in their 
child, what would you tell them? 
 
Grip the wheel and hold on tight, ‘cause it’s going to be a long bumpy ride! I wouldn’t 
even know what to say, I mean there have been a lot of people who have some to me 
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and said, you know, I’m seeing XY and Z in my child, what do you think? And I’ve 
been able to talk them through, well do you see this or this. Yes? OK, you may want to 
consider that it could be this. You don’t see that? OK chances are it’s not. The way 
that, and maybe this is the most helpful, I mean people always ask “how do you know if 
your kid has it?” and I say, from what I’ve seen, not just in A. but in my other kids, I 
would describe full on BP disorder as say 10 switches, and maybe those switches are 
rage, being easily irritated, being sensitive to noise, hyper sexuality, whatever, an whole 
panorama of what BP can be. Picture those each being their own switch. Full on BP is 
10 switches being all turned on. Now A. at certain times in his life I would say he was 9 
or 10 switches all turned on, now with medication, with growing older, with time, 
maybe he’s only got 7 switches turned on. I have a daughter that when she was 6, I’d 
say she also had about 5 switches turned on. Never was on meds, never had to go to a 
psychiatrist or anything else. As she grew into herself and becoming the person she is, I 
think she maybe got one switch flipped on. I wouldn’t even think she has BPD, because 
it’s only 1 dimension of her life. And one that she’s able to manage without anything 
else, so at what point do you say ‘yes this is BPD’ or ‘no it isn’t’, I don’t know. 
 
And the thing that I think gets complex is, there are a lot of factors, and maybe this is 
part of why it’s different in the UK, I don’t know, but over here, there’s a lot of talk 
about ingredients in foods and vaccines and things like that, so a lot of people I see on 
some of these boards are like ‘oh my god, I took red dye out my kid’s diet and he’s 
been wonderful!’. I don’t doubt that there are kids who have BP type symptoms in 
response to food additives or sensitivities, or a vaccine reaction, or something. I don’t 
discredit what they’ve experienced with their own children, but I also don’t think that 
that is the cause for every person that has those symptoms, and I think that’s where you 
get those people saying “oh you should never medicate a child!” I get that. There are 
some kids that their cause is something else, but that to me does a discredit to the 
people who say, you know what we’ve tried everything and its still happening. Don’t 
assume that they are doing something wrong, or they’re not doing enough, because 
their experience is different from yours. There’s a big tendency of suspect the parents. 
The parents what the meds, or the parents what this, or the parents want the meds, or 
the parents are disciplining incorrectly, or the parents aren’t providing healthy enough 
food. Whatever it is, know what? Sometimes the crappy universe answer is, yeah, this 
stinks, and he’s got a disorder. It just is, like anything else, sometimes it just is.  
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